0001396814-24-000045.txt : 20240507 0001396814-24-000045.hdr.sgml : 20240507 20240507160247 ACCESSION NUMBER: 0001396814-24-000045 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 24921681 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 10-Q 1 pcrx-20240331.htm 10-Q - PCRX - 3.31.2024 pcrx-20240331
000139681412/312024Q1FALSEP0D0.953.013932430111232929436000013968142024-01-012024-03-3100013968142024-05-06xbrli:shares00013968142024-03-31iso4217:USD00013968142023-12-31iso4217:USDxbrli:shares0001396814us-gaap:ProductMember2024-01-012024-03-310001396814us-gaap:ProductMember2023-01-012023-03-310001396814us-gaap:RoyaltyMember2024-01-012024-03-310001396814us-gaap:RoyaltyMember2023-01-012023-03-3100013968142023-01-012023-03-310001396814us-gaap:CommonStockMember2023-12-310001396814us-gaap:AdditionalPaidInCapitalMember2023-12-310001396814us-gaap:RetainedEarningsMember2023-12-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001396814us-gaap:CommonStockMember2024-01-012024-03-310001396814us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001396814us-gaap:RetainedEarningsMember2024-01-012024-03-310001396814us-gaap:CommonStockMember2024-03-310001396814us-gaap:AdditionalPaidInCapitalMember2024-03-310001396814us-gaap:RetainedEarningsMember2024-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001396814us-gaap:CommonStockMember2022-12-310001396814us-gaap:AdditionalPaidInCapitalMember2022-12-310001396814us-gaap:RetainedEarningsMember2022-12-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100013968142022-12-310001396814us-gaap:CommonStockMember2023-01-012023-03-310001396814us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001396814us-gaap:RetainedEarningsMember2023-01-012023-03-310001396814us-gaap:CommonStockMember2023-03-310001396814us-gaap:AdditionalPaidInCapitalMember2023-03-310001396814us-gaap:RetainedEarningsMember2023-03-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100013968142023-03-310001396814pcrx:TermLoanBFacilityMember2024-01-012024-03-310001396814pcrx:TermLoanBFacilityMember2023-01-012023-03-310001396814pcrx:TermLoanAFacilityMember2024-01-012024-03-310001396814pcrx:TermLoanAFacilityMember2023-01-012023-03-310001396814us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-03-31pcrx:productpcrx:segment0001396814us-gaap:CustomerConcentrationRiskMember2024-01-012024-03-31pcrx:customer0001396814pcrx:LargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-31xbrli:pure0001396814pcrx:LargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001396814pcrx:SecondLargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001396814pcrx:SecondLargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001396814us-gaap:SalesRevenueNetMemberpcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001396814us-gaap:SalesRevenueNetMemberpcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001396814pcrx:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001396814pcrx:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001396814srt:MinimumMember2024-01-012024-03-310001396814srt:MaximumMember2024-01-012024-03-310001396814pcrx:EXPARELMember2024-01-012024-03-310001396814pcrx:EXPARELMember2023-01-012023-03-310001396814pcrx:ZILRETTAMember2024-01-012024-03-310001396814pcrx:ZILRETTAMember2023-01-012023-03-310001396814pcrx:IoveraMember2024-01-012024-03-310001396814pcrx:IoveraMember2023-01-012023-03-310001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2024-01-012024-03-310001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2023-01-012023-03-310001396814us-gaap:MachineryAndEquipmentMember2024-03-310001396814us-gaap:MachineryAndEquipmentMember2023-12-310001396814us-gaap:LeaseholdImprovementsMember2024-03-310001396814us-gaap:LeaseholdImprovementsMember2023-12-310001396814pcrx:ComputerEquipmentAndSoftwareMember2024-03-310001396814pcrx:ComputerEquipmentAndSoftwareMember2023-12-310001396814us-gaap:FurnitureAndFixturesMember2024-03-310001396814us-gaap:FurnitureAndFixturesMember2023-12-310001396814us-gaap:ConstructionInProgressMember2024-03-310001396814us-gaap:ConstructionInProgressMember2023-12-310001396814us-gaap:MachineryAndEquipmentMember2024-01-012024-03-310001396814us-gaap:ConstructionInProgressMember2024-01-012024-03-310001396814us-gaap:ConstructionInProgressMember2023-01-012023-03-310001396814srt:EuropeMemberus-gaap:LeaseholdImprovementsMember2024-03-310001396814srt:EuropeMemberus-gaap:LeaseholdImprovementsMember2023-12-31pcrx:lease0001396814us-gaap:DevelopedTechnologyRightsMember2024-03-310001396814us-gaap:DevelopedTechnologyRightsMember2024-01-012024-03-310001396814us-gaap:CustomerRelationshipsMember2024-03-310001396814us-gaap:CustomerRelationshipsMember2024-01-012024-03-310001396814us-gaap:InProcessResearchAndDevelopmentMember2024-03-310001396814us-gaap:DevelopedTechnologyRightsMember2023-12-310001396814us-gaap:DevelopedTechnologyRightsMember2023-01-012023-12-310001396814us-gaap:CustomerRelationshipsMember2023-12-310001396814us-gaap:CustomerRelationshipsMember2023-01-012023-12-310001396814us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-12-310001396814pcrx:ConvertibleSeniorNotesDue2025Member2024-03-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Member2024-03-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Member2023-12-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2024Member2024-03-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2024Member2023-12-310001396814pcrx:SecuredAndUnsecuredDebtMember2024-03-310001396814pcrx:SecuredAndUnsecuredDebtMember2023-12-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-03-312023-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-06-302023-06-300001396814pcrx:TermLoanAFacilityDueMarch2028Membersrt:ScenarioForecastMemberus-gaap:SecuredDebtMember2025-03-312025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Membersrt:ScenarioForecastMemberus-gaap:SecuredDebtMember2028-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Member2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2024-01-012024-03-31pcrx:day0001396814srt:MinimumMemberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:BaseRateMember2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:BaseRateMembersrt:MaximumMember2024-03-310001396814srt:MinimumMemberpcrx:TermLoanAFacilityDueMarch2028Memberpcrx:SecuredOvernightFinancingRateSOFRMember2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Membersrt:MaximumMemberpcrx:SecuredOvernightFinancingRateSOFRMember2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2023-01-012023-12-310001396814pcrx:TermLoanBFacilityDueDecember2026Memberus-gaap:SecuredDebtMember2021-12-310001396814pcrx:TermLoanBFacilityDueDecember2026Memberus-gaap:SecuredDebtMember2021-12-012021-12-310001396814pcrx:TermLoanBFacilityDueDecember2026Memberus-gaap:SecuredDebtMember2023-01-012023-03-310001396814pcrx:TermLoanBFacilityDueDecember2026Memberus-gaap:SecuredDebtMember2023-03-312023-03-310001396814pcrx:TermLoanBFacilityDueDecember2026Memberus-gaap:SecuredDebtMember2023-03-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Member2020-07-310001396814us-gaap:UnsecuredDebtMemberpcrx:DebtRedemptionTermsPriorToFebruary32023Memberpcrx:ConvertibleSeniorNotesDue2025Member2020-07-012020-07-31pcrx:trading_day0001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Member2020-07-012020-07-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Member2024-01-012024-03-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberpcrx:DebtRedemptionTermsOnOrAfterAugust12023Member2023-08-010001396814pcrx:ConvertibleSeniorNotesDue2025Memberpcrx:DebtRedemptionTermsOnOrAfterAugust12023Member2023-08-012023-08-010001396814us-gaap:UnsecuredDebtMemberpcrx:FlexionTherapeuticsIncMemberpcrx:ConvertibleSeniorNotesDue2024Member2017-05-020001396814pcrx:ConvertibleSeniorNotesDue2024Member2021-12-062022-01-060001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2024Member2022-01-070001396814us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310001396814us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2024-03-310001396814us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2024-03-310001396814us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001396814us-gaap:CarryingReportedAmountFairValueDisclosureMemberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMember2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:SecuredDebtMember2024-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SecuredDebtMember2024-03-310001396814us-gaap:FairValueInputsLevel3Memberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMember2024-03-310001396814us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Member2024-03-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2024-03-310001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2024-03-310001396814us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001396814us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDue2024Member2024-03-310001396814us-gaap:UnsecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberpcrx:ConvertibleSeniorNotesDue2024Member2024-03-310001396814us-gaap:UnsecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberpcrx:ConvertibleSeniorNotesDue2024Member2024-03-310001396814us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberpcrx:ConvertibleSeniorNotesDue2024Member2024-03-310001396814srt:MaximumMemberpcrx:ConvertibleSeniorNotesDue2025Member2024-01-012024-03-310001396814us-gaap:EquitySecuritiesMember2022-12-310001396814pcrx:ConvertibleNotesReceivableMember2022-12-310001396814us-gaap:EquitySecuritiesMember2023-01-012023-12-310001396814pcrx:ConvertibleNotesReceivableMember2023-01-012023-12-3100013968142023-01-012023-12-310001396814us-gaap:EquitySecuritiesMember2023-12-310001396814pcrx:ConvertibleNotesReceivableMember2023-12-310001396814us-gaap:EquitySecuritiesMember2024-01-012024-03-310001396814pcrx:ConvertibleNotesReceivableMember2024-01-012024-03-310001396814us-gaap:EquitySecuritiesMember2024-03-310001396814pcrx:ConvertibleNotesReceivableMember2024-03-310001396814pcrx:FlexionAndMyoScienceAcquisitionMember2024-03-310001396814pcrx:FlexionAndMyoScienceAcquisitionMember2023-12-310001396814pcrx:FlexionMember2021-11-300001396814pcrx:FlexionMember2022-08-300001396814pcrx:FlexionMember2021-11-012021-11-300001396814pcrx:FlexionMember2024-01-012024-03-310001396814pcrx:FlexionMember2023-01-012023-03-310001396814us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:WeightedAverageMemberpcrx:ContingentConsiderationMemberpcrx:FlexionMember2024-03-310001396814srt:MinimumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberpcrx:ContingentConsiderationMemberpcrx:FlexionMember2024-03-310001396814us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberpcrx:ContingentConsiderationMemberpcrx:FlexionMember2024-03-310001396814srt:MinimumMemberus-gaap:FairValueInputsLevel3Memberpcrx:MeasurementInputExpectedMilestonePaymentMemberpcrx:ContingentConsiderationMemberpcrx:FlexionMember2024-03-310001396814pcrx:ContingentConsiderationMember2022-12-310001396814pcrx:ContingentConsiderationMember2023-01-012023-12-310001396814pcrx:ContingentConsiderationMember2023-12-310001396814pcrx:ContingentConsiderationMember2024-01-012024-03-310001396814pcrx:ContingentConsiderationMember2024-03-310001396814us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:CorporateBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:USTreasuryBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:USTreasuryBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:USTreasuryBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2024-03-310001396814us-gaap:FairValueInputsLevel1Member2024-03-310001396814us-gaap:FairValueInputsLevel2Member2024-03-310001396814us-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:USTreasuryBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:USTreasuryBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:USTreasuryBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2023-12-310001396814us-gaap:AssetBackedSecuritiesMemberpcrx:LongTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberpcrx:LongTermInvestmentsMember2023-12-310001396814us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberpcrx:LongTermInvestmentsMember2023-12-310001396814pcrx:LongTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel1Memberpcrx:LongTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel2Memberpcrx:LongTermInvestmentsMember2023-12-310001396814us-gaap:FairValueInputsLevel1Member2023-12-310001396814us-gaap:FairValueInputsLevel2Member2023-12-31pcrx:wholesaler0001396814us-gaap:AccountsReceivableMemberpcrx:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001396814us-gaap:AccountsReceivableMemberpcrx:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001396814us-gaap:AccountsReceivableMemberpcrx:MajorCustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001396814us-gaap:AccountsReceivableMemberpcrx:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001396814us-gaap:AccountsReceivableMemberpcrx:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001396814us-gaap:AccountsReceivableMemberpcrx:MajorCustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001396814pcrx:IoveraMember2024-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001396814us-gaap:SubsequentEventMember2024-05-070001396814us-gaap:CostOfSalesMember2024-01-012024-03-310001396814us-gaap:CostOfSalesMember2023-01-012023-03-310001396814us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001396814us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001396814pcrx:AcquisitionRelatedChargesImpairmentAndOtherMember2024-01-012024-03-310001396814pcrx:AcquisitionRelatedChargesImpairmentAndOtherMember2023-01-012023-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2023-12-310001396814us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2024-03-310001396814us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001396814us-gaap:EmployeeStockMember2024-01-012024-03-31pcrx:offeringPeriod0001396814us-gaap:AccountingStandardsUpdate202006Member2024-01-012024-03-310001396814us-gaap:AccountingStandardsUpdate202006Member2023-01-012023-03-310001396814us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001396814us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001396814us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001396814us-gaap:SeniorNotesMember2024-01-012024-03-310001396814us-gaap:SeniorNotesMember2023-01-012023-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001396814us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001396814us-gaap:EmployeeStockMember2024-01-012024-03-310001396814us-gaap:EmployeeStockMember2023-01-012023-03-310001396814us-gaap:SeniorNotesMemberus-gaap:AccountingStandardsUpdate202006Member2023-01-012023-03-310001396814pcrx:FlexionTherapeuticsIncMember2024-01-012024-03-310001396814pcrx:FlexionTherapeuticsIncMember2023-01-012023-03-310001396814pcrx:AcquisitionRelatedFeesMember2024-01-012024-03-310001396814pcrx:AcquisitionRelatedFeesMember2023-01-012023-03-310001396814pcrx:EXPARELMember2024-02-012024-02-290001396814us-gaap:OneTimeTerminationBenefitsMember2024-01-012024-03-310001396814us-gaap:EmployeeSeveranceMember2023-12-310001396814us-gaap:ContractTerminationMember2023-12-310001396814us-gaap:EmployeeSeveranceMember2024-01-012024-03-310001396814us-gaap:ContractTerminationMember2024-01-012024-03-310001396814us-gaap:EmployeeSeveranceMember2024-03-310001396814us-gaap:ContractTerminationMember2024-03-310001396814pcrx:FortisMember2020-10-012020-10-3100013968142023-08-080001396814pcrx:GeneQuineMemberpcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMemberpcrx:FlexionTherapeuticsIncMember2017-02-280001396814pcrx:GeneQuineMemberpcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMemberpcrx:FlexionTherapeuticsIncMember2017-02-012017-02-280001396814pcrx:LaurenRikerMember2024-01-012024-03-310001396814pcrx:KristenWilliamsMember2024-01-012024-03-310001396814pcrx:JonathanSloninMember2024-01-012024-03-310001396814pcrx:PaulHastingsMember2024-01-012024-03-310001396814pcrx:PaulHastingsMember2024-03-310001396814pcrx:DarylGauglerMember2024-01-012024-03-310001396814pcrx:DarylGauglerMember2024-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2024

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from     to
Commission File Number: 001-35060

pacirabiosciencesa05.jpg

PACIRA BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware51-0619477
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
 Identification No.)

5401 West Kennedy Boulevard, Suite 890
Tampa, Florida 33609
(Address and Zip Code of Principal Executive Offices)
(813) 553-6680
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes  ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) ☒ Yes  ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes  ☒ No

As of May 6, 2024, 46,546,148 shares of the registrant’s common stock, $0.001 par value per share, were outstanding.

PACIRA BIOSCIENCES, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2024

TABLE OF CONTENTS
  Page #
 
 
 
 
 
 
   
 

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 3
PART I — FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS (Unaudited)
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
March 31,
2024		December 31,
2023
ASSETS
Current assets:  
     Cash and cash equivalents$184,052 $153,298 
     Short-term available-for-sale investments141,838 125,283 
     Accounts receivable, net101,639 105,556 
     Inventories, net96,782 104,353 
     Prepaid expenses and other current assets18,802 21,504 
          Total current assets543,113 509,994 
Noncurrent available-for-sale investments— 2,410 
Fixed assets, net171,804 173,927 
Right-of-use assets, net58,626 61,020 
Goodwill163,243 163,243 
Intangible assets, net468,936 483,258 
Deferred tax assets141,057 144,485 
Investments and other assets36,542 36,049 
          Total assets$1,583,321 $1,574,386 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
     Accounts payable$8,982 $15,698 
     Accrued expenses66,818 64,243 
     Lease liabilities9,003 8,801 
     Current portion of convertible senior notes, net8,641 8,641 
          Total current liabilities93,444 97,383 
Convertible senior notes, net399,210 398,594 
Long-term debt, net112,477 115,202 
Lease liabilities52,446 54,806 
Contingent consideration20,892 24,698 
Other liabilities12,690 13,573 
          Total liabilities691,159 704,256 
Commitments and contingencies (Note 15)
Stockholders’ equity:  
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023
— — 
Common stock, par value $0.001; 250,000,000 shares authorized; 46,517,410 and 46,481,174 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
47 46 
     Additional paid-in capital989,780 976,633 
     Accumulated deficit(97,817)(106,796)
     Accumulated other comprehensive income152 247 
          Total stockholders’ equity892,162 870,130 
          Total liabilities and stockholders’ equity$1,583,321 $1,574,386 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 4
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
March 31,
 20242023
Revenues:  
Net product sales$165,824 $159,431 
Royalty revenue1,293 910 
          Total revenues167,117 160,341 
Operating expenses:  
Cost of goods sold47,416 49,020 
Research and development18,238 17,140 
Selling, general and administrative72,026 70,843 
Amortization of acquired intangible assets14,322 14,322 
Contingent consideration (gains) charges, restructuring charges and other1,903 12,107 
          Total operating expenses153,905 163,432 
Income (loss) from operations13,212 (3,091)
Other income (expense):  
Interest income3,903 3,142 
Interest expense(3,316)(9,589)
Loss on early extinguishment of debt— (16,926)
Other, net(159)(10)
          Total other income (expense), net428 (23,383)
Income (loss) before income taxes13,640 (26,474)
Income tax (expense) benefit(4,661)6,938 
Net income (loss)$8,979 $(19,536)
Net income (loss) per share:  
Basic and diluted net income (loss) per common share$0.19 $(0.43)
Weighted average common shares outstanding:
     Basic46,499 45,949 
     Diluted52,193 45,949 
 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 5
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)
Three Months Ended
March 31,
 20242023
Net income (loss)$8,979 $(19,536)
Other comprehensive income (loss):  
Net unrealized (loss) gain on investments, net of tax(108)251 
Foreign currency translation adjustments13 (8)
Total other comprehensive (loss) income(95)243 
Comprehensive income (loss)$8,884 $(19,293)
 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 6
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(In thousands)
(Unaudited)

 Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Income		 
 SharesAmountTotal
Balance at December 31, 202346,481 $46 $976,633 $(106,796)$247 $870,130 
Vested restricted stock units36 1 — — — 1 
Common stock withheld for employee withholding tax liabilities on vested restricted stock units— — (4)— — (4)
Stock-based compensation— — 13,151 — — 13,151 
Other comprehensive loss (Note 10)— — — — (95)(95)
Net income— — — 8,979 — 8,979 
Balance at March 31, 202446,517 $47 $989,780 $(97,817)$152 $892,162 
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Loss
SharesAmountTotal
Balance at December 31, 202245,928 $46 $924,095 $(148,751)$(380)$775,010 
Exercise of stock options12 — 334 — — 334 
Vested restricted stock units30 — — — — — 
Stock-based compensation— — 11,990 — — 11,990 
Other comprehensive income (Note 10)— — — — 243 243 
Net loss— — — (19,536)— (19,536)
Balance at March 31, 202345,970 $46 $936,419 $(168,287)$(137)$768,041 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 7
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (In thousands)
(Unaudited)
Three Months Ended
March 31,
 20242023
Operating activities:  
Net income (loss)$8,979 $(19,536)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:  
Deferred taxes3,463 (7,342)
Depreciation of fixed assets and amortization of intangible assets18,426 19,602 
Amortization of debt issuance costs681 937 
Amortization of debt discount24 675 
Loss on early extinguishment of debt— 16,926 
Stock-based compensation13,151 11,990 
Changes in contingent consideration(3,806)11,618 
Other net losses (gains)73 (23)
Changes in operating assets and liabilities:  
Accounts receivable, net3,917 5,192 
Inventories, net7,572 3,086 
Prepaid expenses and other assets897 (1,926)
Accounts payable(6,976)2,628 
Accrued expenses and income taxes payable3,471 (25,120)
Other liabilities(771)421 
Net cash provided by operating activities49,101 19,128 
Investing activities:  
Purchases of fixed assets(2,836)(6,565)
Purchases of available-for-sale investments(56,055)(49,497)
Sales of available-for-sale investments43,361 126,245 
Purchases of debt investments— (4,000)
Net cash (used in) provided by investing activities(15,530)66,183 
Financing activities:  
Proceeds from exercises of stock options— 333 
Payment of employee withholding taxes on restricted stock unit vests(4)— 
Proceeds from Term loan A facility— 149,550 
Repayment of Term loan B facility— (296,875)
Repayment of Term loan A facility(2,813)— 
Debt extinguishment costs— (5,750)
Payment of debt issuance and financing costs— (1,163)
Net cash used in financing activities(2,817)(153,905)
Net increase (decrease) in cash and cash equivalents30,754 (68,594)
Cash and cash equivalents, beginning of period153,298 104,139 
Cash and cash equivalents, end of period$184,052 $35,545 
Supplemental cash flow information: 
Cash paid for interest$3,969 $17,634 
Net cash (received) paid for income taxes$(245)$201 
Non-cash investing and financing activities:  
Fixed assets included in accounts payable and accrued liabilities$607 $2,252 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 8
PACIRA BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
NOTE 1—DESCRIPTION OF BUSINESS
Business Overview
Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) is the therapeutic area leader in non-opioid pain management with a stated corporate mission of providing non-opioid pain management options to as many patients as possible and redefining the role of opioids for rescue therapy only. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the “Flexion Acquisition”), and added ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. In April 2019, the Company added iovera°® to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience (the “MyoScience Acquisition”). The iovera° system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to targeted nerves.
Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.
The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker—manages and allocates resources at a consolidated level. Effective January 2, 2024, the Company appointed a new Chief Executive Officer. Consistent with the Company’s predecessor chief operating decision maker, the Company views its business as one reportable operating segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.
NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”), for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”).
The condensed consolidated financial statements at March 31, 2024, and for the three-month periods ended March 31, 2024 and 2023, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2023 is derived from the audited consolidated financial statements included in the Company’s 2023 Annual Report. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.
The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 9
Concentration of Major Customers
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual physicians. The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented:
Three Months Ended
March 31,
20242023
 Largest wholesaler36%32%
 Second largest wholesaler23%24%
 Third largest wholesaler20%23%
     Total79%79%
Recent Accounting Pronouncements Not Adopted as of March 31, 2024
In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The ASU amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The new segment disclosure requirements apply for entities with a single reportable segment. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023 and interim periods thereafter, with early adoption permitted. The ASU amendment will require adoption on a retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The ASU amendment addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.
NOTE 3—REVENUE
Revenue from Contracts with Customers
The Company’s net product sales consist of (i) EXPAREL in the U.S., the European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and (iv) sales of its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of its bupivacaine liposome injectable suspension for veterinary use. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA.
Net Product Sales
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.
Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 10
value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.
Chargebacks for fees and discounts to qualified government healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified Department of Veteran Affairs hospitals, participating GPO members and 340B entities at prices lower than the list prices charged to other customers. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers charge the Company for the difference between the product payment and the statutory selling price to the qualified entity. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are generally determined at the time of sale to the qualified government healthcare provider by customers, and the Company generally issues credits for such amounts within weeks of the customer’s notification to the Company of the sale. Reserves for chargebacks consist of credits that the Company expects to issue for units that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.
The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.
Accounts Receivable
The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from zero to four months from the date of the transaction, and accordingly, there is no significant financing component.
Performance Obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.
Disaggregated Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Three Months Ended
March 31,
20242023
Net product sales:
   EXPAREL$132,430 $130,408 
   ZILRETTA25,839 24,334 
   iovera°5,030 4,001 
   Bupivacaine liposome injectable suspension2,525 688 
      Total net product sales$165,824 $159,431 
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 11
NOTE 4—INVENTORIES
The components of inventories, net are as follows (in thousands):
March 31,December 31,
20242023
Raw materials$51,608 $54,099 
Work-in-process18,764 31,215 
Finished goods26,410 19,039 
     Total$96,782 $104,353 
NOTE 5—FIXED ASSETS
Fixed assets, net, summarized by major category, consist of the following (in thousands):
March 31,December 31,
20242023
Machinery and equipment (1)
$106,670 $121,773 
Leasehold improvements58,835 61,826 
Computer equipment and software17,223 17,186 
Office furniture and equipment2,543 2,543 
Construction in progress106,987 105,905 
        Total292,258 309,233 
Less: accumulated depreciation (1)
(120,454)(135,306)
        Fixed assets, net$171,804 $173,927 
(1) During the three months ended March 31, 2024, the Company disposed of $19.0 million of fully depreciated machinery and equipment associated with its 45-liter EXPAREL manufacturing process at the Thermo Fisher Scientific Pharma Services facility located in Swindon, England. The Company continues to operate its 200-liter EXPAREL manufacturing process at the same facility.
For the three months ended March 31, 2024 and 2023, depreciation expense was $4.1 million and $5.3 million, respectively. For the three months ended March 31, 2024 and 2023, there was $0.7 million and $1.4 million of capitalized interest on the construction of manufacturing sites, respectively.
At March 31, 2024 and December 31, 2023, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located in Europe in the amount of $34.3 million and $36.8 million, respectively.
As of March 31, 2024 and December 31, 2023, the Company had asset retirement obligations of $3.9 million and $4.3 million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.
NOTE 6—LEASES
The Company leases all of its facilities, including its EXPAREL and iovera° handpiece manufacturing facility at its Science Center Campus in San Diego, California. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees has been allocated to the lease components based on a relative fair value basis.
Since July 2022 and February 2023, the Company has been recognizing sublease income for laboratory space leased in Woburn, Massachusetts and a portion of office space leased in Burlington, Massachusetts, respectively, from leases that were assumed as part of the Flexion Acquisition. In February 2024, the lease and sublease term concluded for the laboratory space in Woburn, Massachusetts.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 12
The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):
Three Months Ended
March 31,
20242023
Fixed lease costs$3,497 $3,628 
Variable lease costs494 567 
Sublease income(131)(153)
Total$3,860 $4,042 
Supplemental cash flow information related to operating leases is as follows (in thousands):
Three Months Ended
March 31,
20242023
Cash paid for operating lease liabilities, net of lease incentives$3,219 $3,763 
The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.
The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:
March 31,
20242023
Weighted average remaining lease term5.81 years6.61 years
Weighted average discount rate7.01 %7.03 %
Maturities of the Company’s operating lease liabilities are as follows (in thousands):
YearAggregate Minimum
Payments Due
2024 (remaining nine months)$9,777 
202512,775 
202612,814 
202712,587 
202810,925 
Thereafter16,426 
   Total future lease payments75,304 
   Less: imputed interest(13,855)
   Total operating lease liabilities$61,449 
NOTE 7—GOODWILL AND INTANGIBLE ASSETS
Goodwill
The Company’s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. (the Company’s California operating subsidiary) from SkyePharma Holding, Inc. (now Vectura Group Limited, a subsidiary of Philip Morris International, Inc.) in 2007, the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. The goodwill balance at each of March 31, 2024 and December 31, 2023 was $163.2 million.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 13
Intangible Assets
Intangible assets, net, consists of the in-process research and development, or IPR&D, and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):
March 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(155,975)$434,025 10 years, 5 months
Customer relationships90 (45)45 10 years
     Total finite-lived intangible assets, net590,090 (156,020)434,070 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(156,020)$468,936 
December 31, 2023Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(141,655)$448,345 10 years, 5 months
Customer relationships90 (43)47 10 years
     Total finite-lived intangible assets, net590,090 (141,698)448,392 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(141,698)$483,258 
Amortization expense on intangible assets was $14.3 million for both the three months ended March 31, 2024 and 2023.
Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $43.0 million for the remaining nine months of 2024, $57.3 million each year from 2025 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.
NOTE 8—DEBT
The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):
March 31,December 31,
20242023
Term loan A facility maturing March 2028$112,477 $115,202 
0.750% Convertible senior notes due August 2025
399,210 398,594 
3.375% Convertible senior notes due May 2024 (1)
8,641 8,641 
     Total$520,328 $522,437 
(1) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.
2028 Term Loan A Facility
On March 31, 2023, the Company entered into a credit agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders, to refinance the indebtedness outstanding under the Company’s then-existing TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of the Company’s and any subsidiary guarantor’s assets. Subject to certain conditions, the Company may, at any time, on one or more occasion, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the TLA Term Loan were approximately $149.6 million after deducting an original issue discount of $0.4 million.

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 14
The total debt composition of the TLA Term Loan is as follows (in thousands):
March 31,December 31,
20242023
Term loan A facility maturing March 2028$113,750 $116,563 
Deferred financing costs(924)(988)
Discount on debt(349)(373)
     Total debt, net of debt discount and deferred financing costs$112,477 $115,202 
The TLA Term Loan matures on March 31, 2028 and the TLA Credit Agreement requires quarterly repayments of principal in the amount of $2.8 million which commenced on June 30, 2023, increasing to $3.8 million commencing March 31, 2025, with a remaining balloon payment of approximately $85.3 million due at maturity. Due to voluntary principal prepayments made, the Company is not required to make further principal payments until March 2026, although the Company retains the option to do so.
The TLA Credit Agreement requires the Company to, among other things, maintain (i) a Senior Secured Net Leverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no greater than 3.00 to 1.00 and (ii) a Fixed Charge Coverage Ratio (as defined in the Credit Agreement), determined as of the last day of each fiscal quarter, of no less than 1.50 to 1.00. The TLA Credit Agreement requires the Company to maintain an unrestricted cash and cash equivalents balance of at least $500.0 million less any prepayments of the 2025 Notes (as defined below) at any time from 91 days prior to the maturity date through the earlier of (i) the latest maturity date of the 2025 Notes and (ii) the date on which there is no outstanding principal amount of the 2025 Notes. The TLA Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of March 31, 2024, the Company was in compliance with all financial covenants under the TLA Credit Agreement.
The Company may elect to borrow either (i) alternate base rate borrowings or (ii) term benchmark borrowings or daily simple SOFR (as defined in the TLA Credit Agreement) borrowings. Each term loan borrowing that is an alternate base rate borrowing bears interest at a rate per annum equal to (i) the Alternate Base Rate (as defined in the TLA Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 2.00% to 2.75%. Each term loan borrowing that is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. During the three months ended March 31, 2024, the Company made a $2.8 million voluntary principal prepayment. During the year ended December 31, 2023, the Company made a scheduled principal payment of $2.8 million as well as $30.6 million of voluntary principal prepayments. As of March 31, 2024, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 8.41%.
2026 Term Loan B Facility
In December 2021, the Company entered into a term loan credit agreement (the “TLB Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the TLB Credit Agreement (the “TLB Term Loan”) was issued at a 3.00% discount and allowed for a single-advance term loan B facility in the principal amount of $375.0 million, which was secured by substantially all of the Company’s and each subsidiary guarantor’s assets. The net proceeds of the TLB Term Loan were approximately $363.8 million after deducting an original issue discount of $11.2 million.
During the three months ended March 31, 2023, the Company repaid the outstanding $296.9 million principal on the TLB Term Loan, which resulted in a $16.9 million loss on early extinguishment of debt.
On March 31, 2023, the Company used the $149.6 million of net borrowings under the TLA Credit Agreement and cash on hand to repay the indebtedness outstanding under the TLB Credit Agreement and concurrently terminated the TLB Credit Agreement. The Company incurred a prepayment fee of 2.00% of the outstanding principal balance of the TLB Term Loan in connection with the termination.

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 15
Convertible Senior Notes Due 2025
In July 2020, the Company completed a private placement of $402.5 million in aggregate principal amount of its 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1st and August 1st of each year. The 2025 Notes mature on August 1, 2025.
The total debt composition of the 2025 Notes is as follows (in thousands):
March 31,December 31,
20242023
0.750% convertible senior notes due August 2025
$402,500 $402,500 
Deferred financing costs(3,290)(3,906)
     Total debt, net of deferred financing costs$399,210 $398,594 
Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only if certain circumstances are met, including if during the previous calendar quarter, the last reported sales price of the Company’s common stock was greater than 130% of the conversion price then applicable for at least 20 out of the last 30 consecutive trading days of the quarter. During the quarter ended March 31, 2024, the conditions for conversion were not met.
On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.
Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company’s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.
As of March 31, 2024, the 2025 Notes had a market price of $953 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $402.5 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company’s option).
Since August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40th scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company’s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a “make-whole fundamental change” (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.
While the 2025 Notes are currently classified on the Company’s condensed consolidated balance sheet at March 31, 2024 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company’s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 16
Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition
Prior to the Flexion Acquisition, in May 2017, Flexion issued an aggregate of $201.3 million principal amount of 3.375% convertible senior notes due 2024 (the “Flexion 2024 Notes”), pursuant to the indenture, dated as of May 2, 2017 (the “Original Flexion Indenture”), between Flexion and Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), as trustee (the “Flexion Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the “First Supplemental Flexion Indenture” and, together with the Original Flexion Indenture, the “Flexion Indenture”). The Flexion 2024 Notes had a maturity date of May 1, 2024, were unsecured, and accrued interest at a rate of 3.375% per annum, payable semi-annually on May 1st and November 1st of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company.
As a result of the Flexion Acquisition, and in connection with a Fundamental Change Company Notice and Offer to Purchase (the “Notice”) to the holders of the Flexion 2024 Notes in accordance with the Flexion Indenture, holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights. On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, the Company offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to 100% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder’s Flexion 2024 Notes under the Flexion Indenture as well as the right to receive interest payments on the Flexion 2024 Notes.
On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6 million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. At March 31, 2024, the remaining principal outstanding was $8.6 million, which was repaid upon its maturity on May 1, 2024.
Interest Expense
The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):
Three Months Ended
March 31,
20242023
Contractual interest expense$3,311 $9,350 
Amortization of debt issuance costs681 937 
Amortization of debt discount24 675 
Capitalized interest (Note 5)
(700)(1,373)
        Total$3,316 $9,589 
Effective interest rate on total debt2.96 %5.36 %
NOTE 9—FINANCIAL INSTRUMENTS
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:
•Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
•Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company’s convertible
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 17
senior notes and its TLA Term Loan are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either an impairment or upward or downward adjustments based on observable transactions.
At March 31, 2024, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):
Carrying ValueFair Value Measurements Using
Level 1Level 2Level 3
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Financial Assets:
Equity investments$15,877 $— $— $15,877 
Convertible notes receivable$12,030 $— $— $12,030 
Financial Liabilities:
   Acquisition-related contingent consideration$20,892 $— $— $20,892 
Financial Liabilities Measured at Amortized Cost:
Term loan A facility due March 2028$112,477 $— $113,181 $— 
   0.750% convertible senior notes due 2025 (1)
$399,210 $— $383,381 $— 
   3.375% convertible senior notes due 2024 (2)
$8,641 $— $8,641 $— 
(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $29.22 per share at March 31, 2024 compared to a conversion price of $71.78 per share. At March 31, 2024, as the conversion price was above the stock price, the requirements for conversion have not been met. The maximum conversion premium that could have been due on the 2025 Notes is 5.6 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.
(2) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Equity and Convertible Note Investments
The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):
Equity InvestmentsConvertible Notes ReceivableTotal
Balance at December 31, 2022
$15,877 $5,315 $21,192 
   Purchases— 6,758 6,758 
   Foreign currency adjustments— 61 61 
Balance at December 31, 2023
15,877 12,134 28,011 
   Foreign currency adjustments— (104)(104)
Balance at March 31, 2024
$15,877 $12,030 $27,907 
Acquisition-Related Contingent Consideration
The Company has recognized contingent consideration related to the Flexion Acquisition in the amount of $20.9 million and $24.7 million as of March 31, 2024 and December 31, 2023, respectively. The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 18
Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts.
In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3 million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5 million prior to the Company’s September 2022 decision to formally discontinue further development of Flexion’s product candidate, PCRX-301. The Company’s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended March 31, 2024, the Company recorded a gain of $3.8 million primarily due to an adjustment reflecting the probability of achieving the remaining regulatory milestone by December 31, 2030, the expiration date. During the three months ended March 31, 2023, the Company recorded a charge of $11.6 million, which was due to a decrease to the assumed discount rate based on a significant improvement in the Company’s incremental borrowing rate resulting from the TLA Credit Agreement entered into in March 2023. These adjustments were recorded within contingent consideration (gains) charges, restructuring charges and other in the condensed consolidated statements of operations. At March 31, 2024, the weighted average discount rate was 8.6%.
The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:
Assumption
Ranges
Utilized as of
March 31, 2024
Discount rates
8.0% to 9.3%
Probability of payment for remaining regulatory milestone
0%
The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):
Contingent Consideration
Fair Value
Balance at December 31, 2022
$28,122 
Fair value adjustments and accretion(3,424)
Balance at December 31, 2023
24,698 
   Fair value adjustments and accretion(3,806)
Balance at March 31, 2024
$20,892 
Available-for-Sale Investments
Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency and government bonds with maturities greater than three months, but less than one year. Noncurrent investments consist of asset-backed securities collateralized by credit card receivables and contain maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company’s short-term investments are reported in other comprehensive income (loss). At March 31, 2024 and December 31, 2023, all of the Company’s short-term and noncurrent investments are classified as available-for-sale investments and are determined to be Level 2 instruments, with the exception of U.S. government bonds, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an “A” or better rating by Standard & Poor’s. 
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 19
The following summarizes the Company’s short-term and noncurrent available-for-sale investments at March 31, 2024 and December 31, 2023 (in thousands):
March 31, 2024 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 1)		Fair Value
(Level 2)
Current:
Asset-backed securities$25,345 $— $(38)$— $25,307 
Commercial paper94,138 28 (51)— 94,115 
Corporate bonds7,984 — (6)— 7,978 
U.S. federal agency bonds9,479 — (10)— 9,469 
U.S. government bonds4,974 — (5)4,969 — 
          Total$141,920 $28 $(110)$4,969 $136,869 
December 31, 2023 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 1)		Fair Value
(Level 2)
Current:
Asset-backed securities$9,539 $1 $— $— $9,540 
Commercial paper77,941 103 — — 78,044 
U.S. federal agency bonds22,849 — (29)— 22,820 
U.S. government bonds14,899 — (20)14,879 — 
Subtotal125,228 104 (49)14,879 110,404 
Noncurrent:
Asset-backed securities2,403 7 — — 2,410 
Subtotal2,403 7 — — 2,410 
          Total$127,631 $111 $(49)$14,879 $112,814 
At March 31, 2024, there were no investments available for sale that were materially less than their amortized cost.
The Company elects to recognize its interest receivable separate from its available-for-sale investments. At March 31, 2024 and December 31, 2023, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.1 million and $0.4 million, respectively.
Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.
 As of March 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 39%, 19% and 16%. At December 31, 2023, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 37%, 19% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of March 31, 2024, there were $0.1 million of allowances for credit losses on its accounts receivable associated with iovera°. As of December 31, 2023, the Company did not deem any allowances for credit losses on its accounts receivable necessary.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 20
NOTE 10—STOCKHOLDERS’ EQUITY
Accumulated Other Comprehensive Income (Loss)
The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Income
Balance at December 31, 2023
$124 $123 $247 
   Net unrealized loss on investments, net of tax(1)
(108)— (108)
   Foreign currency translation adjustments— 13 13 
Balance at March 31, 2024
$16 $136 $152 
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Loss
Balance at December 31, 2022
$(523)$143 $(380)
   Net unrealized gain on investments, net of tax (1)
251 — 251 
   Foreign currency translation adjustments— (8)(8)
Balance at March 31, 2023
$(272)$135 $(137)
(1) Net of a nominal tax benefit and $0.2 million tax expense for the three months ended March 31, 2024 and 2023, respectively.
Share Repurchase Program
On May 7, 2024, the Company announced that its Board of Directors has approved a new share repurchase program, effective immediately, which authorizes the Company to purchase up to an aggregate of $150.0 million of the Company’s outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.
NOTE 11—STOCK PLANS
Stock-Based Compensation
The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):
Three Months Ended
March 31,
20242023
Cost of goods sold$1,128 $1,724 
Research and development1,803 1,875 
Selling, general and administrative7,985 8,391 
Contingent consideration (gains) charges, restructuring charges and other2,235 — 
        Total$13,151 $11,990 
Stock-based compensation from:
    Stock options$6,729 $6,464 
    Restricted stock units6,210 5,250 
    Employee stock purchase plan212 276 
        Total$13,151 $11,990 
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 21
Equity Awards
The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2024:
Stock Options Number of
Stock Options		 Weighted Average Exercise Price (Per Share)
 Outstanding at December 31, 2023
7,079,748 $49.40 
     Granted900,995 31.95 
     Forfeited(155,397)46.84 
     Expired(245,082)50.23 
 Outstanding at March 31, 2024
7,580,264 47.35 
Restricted Stock Units Number of
Restricted
Stock Units		 Weighted Average Grant Date Fair Value (Per Share)
Unvested at December 31, 2023
1,364,618 $47.66 
     Granted196,974 31.53 
     Vested(36,395)53.97 
     Forfeited(102,206)47.71 
Unvested at March 31, 2024
1,422,991 45.26 
The weighted average fair value of stock options granted during the three months ended March 31, 2024 was $13.65 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:
Black-Scholes Weighted Average AssumptionThree Months Ended March 31, 2024
Expected dividend yieldNone
Risk-free interest rate3.92%
Expected volatility40.94%
Expected term of options5.28 years
Employee Stock Purchase Plan
The Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1 to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is lesser. During the three months ended March 31, 2024, no shares were purchased and issued through the ESPP.

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 22
NOTE 12—NET INCOME (LOSS) PER SHARE
Basic and diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.
Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and the purchase of shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible notes are treated under the if-converted method, adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible debt on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible debt on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.
Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive.
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2024 and 2023 (in thousands, except per share amounts):
Three Months Ended
March 31,
20242023
Numerator:
   Net income (loss)—basic$8,979 $(19,536)
ASU 2020-06 convertible notes if-converted method adjustment1,029 — 
   Adjusted net income (loss)—diluted$10,008 $(19,536)
Denominator:
   Weighted average common shares outstanding—basic46,499 45,949 
Computation of diluted securities:
ASU 2020-06 convertible notes if-converted method adjustment5,608 — 
   Dilutive effect of stock options1 — 
   Dilutive effect of RSUs85 — 
   Weighted average common shares outstanding—diluted52,193 45,949 
Net income (loss) per share:
   Basic and diluted net income (loss) per common share$0.19 $(0.43)
The following table summarizes the outstanding stock options, RSUs, ESPP purchase options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):
Three Months Ended
March 31,
20242023
Weighted average number of stock options7,662 6,362 
Convertible senior notes (1)
— 5,608 
Weighted average number of RSUs1,230 1,137 
Weighted average ESPP purchase options52 55 
      Total8,944 13,162 
(1) The convertible senior notes were antidilutive for the three months ended March 31, 2023, in conjunction with a $1.0 million if-converted method adjustment to the numerator that adds back the interest expense associated with the convertible senior notes on a post-tax basis.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 23
NOTE 13—INCOME TAXES
Income (loss) before income taxes and income tax expense (benefit) are as follows (dollar amounts in thousands):
Three Months Ended
March 31,
20242023
Income (loss) before income taxes:
   Domestic$13,657 $(27,773)
   Foreign(17)1,299 
Total income (loss) before income taxes$13,640 $(26,474)
Income tax expense (benefit)$4,661 $(6,938)
Effective tax rate34 %26 %
The Company’s income tax expense (benefit) represents the estimated annual effective tax rate applied to the year-to-date domestic operating results adjusted for certain discrete tax items.
The Company’s effective tax rate for the three months ended March 31, 2024 include costs related to non-deductible stock-based compensation and non-deductible executive compensation, partially offset by tax credits and a fair value adjustment for Flexion contingent consideration. The Company’s effective tax rate for the three months ended March 31, 2023 includes costs for a fair value adjustment to Flexion contingent consideration and a valuation allowance recorded against non-U.S. results, partially offset by tax credits and stock-based compensation benefits.
As of March 31, 2024 and December 31, 2023, the Company has an income tax payable balance of $1.0 million that is included in other liabilities within the condensed consolidated balance sheets.
NOTE 14—CONTINGENT CONSIDERATION (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER
Contingent consideration (gains) charges, restructuring charges and other for the three months ended March 31, 2024 and 2023 summarized below (in thousands):
Three Months Ended
March 31,
20242023
Flexion contingent consideration$(3,806)$11,618 
Restructuring charges5,535 — 
Acquisition-related fees174 489 
Total contingent consideration (gains) charges, restructuring charges and other$1,903 $12,107 
Flexion Acquisition Contingent Consideration
During the three months ended March 31, 2024, the Company recognized a $3.8 million contingent consideration gain. During the three months ended March 31, 2023, the Company recorded a $11.6 million contingent consideration charge. See Note 9, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.
Restructuring Charges
In February 2024, the Company initiated a restructuring plan to ensure it is well positioned for long-term growth. The restructuring plan includes: (i) reshaping the Company’s executive team, (ii) reallocating efforts and resources from the Company’s ex-U.S. and certain early-stage development programs to its commercial portfolio in the U.S. market and (iii) reprioritizing investments to focus on commercial readiness for the implementation of separate Medicare reimbursement for EXPAREL at average sales price plus 6 percent in outpatient settings beginning in January 2025 and broader commercial initiatives in key areas, such as strategic national accounts, marketing and market access and reimbursement. The Company recognized $5.5 million of restructuring charges for the three months ended March 31, 2024 related to employee termination benefits, such as the acceleration of share-based compensation, severance, and, to a lesser extent, other employment-related
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 24
termination costs, as well as contract termination costs. The Company’s restructuring charges as of March 31, 2024, including the beginning and ending liability balances, are summarized below (in thousands):
Employee Termination Benefits (1)
Contract Termination CostsTotal
Balance at December 31, 2023$— $— $— 
Charges incurred2,567 733 3,300 
Cash payments made / settled(386)— (386)
Balance at March 31, 2024$2,181 $733 $2,914 
(1) During the three months ended March 31, 2024, there was $2.2 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.
Acquisition-Related Fees
The Company recognized acquisition-related costs of $0.2 million and $0.5 million during the three months ended March 31, 2024 and 2023, respectively, primarily related to vacant and underutilized Flexion leases that were assumed from the Flexion Acquisition.
NOTE 15—COMMITMENTS AND CONTINGENCIES
From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to its patents and intellectual property, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.
MyoScience Milestone Litigation
In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (“Pacira CryoTech”), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (“Fortis”), solely in its capacity as representative for the former securityholders of MyoScience, and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the “MyoScience Merger Agreement”), specifically related to the achievement of certain milestone payments under the MyoScience Merger Agreement. In addition, the Company and Pacira CryoTech sought general, special and compensatory damages against the other defendants related to breach of fiduciary duties in connection with the purported achievement of milestone payments under the MyoScience Merger Agreement, and breach of the MyoScience Merger Agreement and certain other agreements with the defendants. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the MyoScience Merger Agreement. The total remaining value of these milestones is $30.0 million, plus attorneys’ fees.
A trial was conducted in September 2023, and a decision is expected in the coming months. The Company is unable to predict the outcome of this action at this time.
eVenus Pharmaceutical Laboratories Litigations
In October 2021, the Company received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application, or ANDA with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the ‘495 patent).
In November 2021, the Company filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the ‘495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA which expires on July 1, 2024. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the ‘495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in eVenus’s ANDA submission.
In December 2021, the Company received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the ‘495 patent. In the second Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 25
Patent No. 11,179,336 (the ‘336 patent). eVenus further alleges in the Notice Letter that both the ‘495 patent and the ‘336 patent are invalid and/or not infringed.
In February 2022, the Company filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the ‘495 and ‘336 patents and that the 266 mg/20 mL ANDA product will infringe the ‘336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product which expires on July 1, 2024. The first and second patent infringement suits were consolidated.
In February 2023, eVenus filed its first amended answer to the first amended complaint, alleging patent invalidity, non-infringement and inequitable conduct. The Company has denied the allegations in eVenus’s first amended answer. The Company has subsequently voluntarily dismissed its claims with respect to the ‘336 Patent. The trial on the remaining claim was conducted in February 2024 with a decision expected in the coming months.
In April 2023, the Company filed a third patent infringement suit against eVenus, its parent company, and Fresenius Kabi USA, LLC, in the U.S. District Court for the District of New Jersey (23-cv-2367) asserting that the 133 mg/10 mL and 266 mg/20 mL ANDA products will infringe U.S. Patent No. 11,426,348 (the ‘348 patent). In July 2023, eVenus filed its answer with claims for declaratory judgment, alleging patent invalidity, non-infringement and inequitable conduct with respect to the ‘348 patent as well as the Company’s other patents, U.S. Patent Nos. 11,278,494; 11,304,904; 11,311,486; 11,357,727 and 11,452,691. The parties have subsequently dismissed all patents other than the ‘348 patent from this litigation.
The Company is unable to predict the outcome of these litigations at this time.
Research Development Foundation
Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company’s ‘495 patent was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company’s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of its U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that the Company owes no royalties to RDF with respect to its EXPAREL product after December 24, 2021.
On August 8, 2023, the U.S. District Court, District of Nevada, granted the Company’s motion for partial summary judgment in respect to the Company’s claim for a declaration that it no longer owes royalties for EXPAREL made under the 45-liter manufacturing process as of December 24, 2021. As a result, the Company expects to receive $14.5 million from RDF, representing the royalties that the Company paid to RDF under protest after December 24, 2021 for EXPAREL made from the 45-liter manufacturing process. Once it becomes probable that the settlement amount will be received, the Company will record a settlement gain within other operating income (expense), net in the condensed consolidated statement of operations. In November 2023, the U.S. District Court, District of Nevada conducted a mediation that did not result in a settlement. During the pendency of the remaining lawsuit, the Company will continue to pay royalties associated with the 200-liter EXPAREL manufacturing process to RDF under protest. A trial is currently scheduled for September 2024. The Company is unable to predict the outcome of this action at this time.
Other Commitments and Contingencies
Pediatric Trial Commitments
The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL for infiltration and as a brachial plexus block in pediatric patients. The Company was granted deferrals for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the E.U. Despite the U.K.’s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.
The Company received notification from the FDA in October 2023 that its pediatric studies requirement had been waived for the indication of brachial plexus interscalene nerve block to produce postsurgical regional analgesia in pediatric patients. The Company is still working with the FDA, EMA and Medicines and Healthcare Regulatory Agency (MHRA) to finalize the regulatory pathways for its remaining pediatric commitments.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 26
Contingent Milestone Payments
Refer to Note 9, Financial Instruments, for information on potential contingent milestone payments related to the Flexion Acquisition.
PCRX-201
PCRX-201, a novel, intra-articular gene therapy product candidate that produces the anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) treating OA pain in the knee, was added to the Company’s portfolio as part of the Flexion Acquisition in November 2021. Prior to the Flexion Acquisition, in February 2017, Flexion entered into an agreement with GQ Bio Therapeutics GmbH to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0 million of payments could become due upon the achievement of certain development and regulatory milestones, including up to $4.5 million through initiation of a Phase 2 proof of concept clinical trial and, following successful proof of concept, up to an additional $51.5 million in development and global regulatory approval milestone payments.
In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 for the treatment of OA pain of the knee.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 27
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and in accordance with the rules and regulations of the United States Securities and Exchange Commission, or SEC.
This Quarterly Report on Form 10-Q and certain other communications made by us contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, patent terms, development of products, strategic alliances and intellectual property and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We often use the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” “will,” “would” and similar expressions to help identify forward-looking statements. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the integration of our new chief executive officer; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States, or U.S., economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) and iovera°®; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration, or FDA, supplemental New Drug Applications, or sNDAs, and premarket notification 510(k)s; the related timing and success of European Medicines Agency, or EMA, Marketing Authorization Applications, or MAAs; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome, or pMVL, drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the ability to successfully integrate any future acquisitions into our existing business; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; and the anticipated funding or benefits of our share repurchase program.

Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on the forward-looking statements as representing our views as of any date subsequent to the date of the filing of this Quarterly Report on Form 10-Q.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include items mentioned herein and the matters discussed and referenced in Part I-Item 1A. “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”) and in other reports as filed with the SEC.

Unless the context requires otherwise, references to “Pacira,” the “Company,” “our,” “us” and “we” in this Quarterly Report on Form 10-Q refer to Pacira BioSciences, Inc. and its subsidiaries.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 28
Overview
Pacira is the therapeutic area leader in non-opioid pain management with a stated corporate mission of providing non-opioid pain management options to as many patients as possible and redefining the role of opioids for rescue therapy only. Our long-acting, local analgesic EXPAREL® (bupivacaine liposome injectable suspension) utilizes our unique pMVL drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In the U.S., EXPAREL is a long-acting, non-opioid option proven to manage postsurgical pain. EXPAREL is the only product indicated for local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and adductor canal block in adults. In Europe, EXPAREL is approved as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults and children aged six years and older. Since its initial approval in 2011, more than 14 million patients have been treated with EXPAREL. We drop-ship EXPAREL directly to end-users based on orders placed to wholesalers or directly to us, and there is no product held by wholesalers. With the acquisition of Flexion Therapeutics, Inc., or Flexion, in November 2021 (the “Flexion Acquisition”), we acquired ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular, or IA, therapy that can provide major relief for osteoarthritis, or OA, knee pain for three months and has the potential to become an alternative to hyaluronic acid, platelet rich plasma injections or other early intervention treatments. With the acquisition of MyoScience, Inc., or MyoScience, in April 2019 (the “MyoScience Acquisition”), we acquired iovera°®, a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to targeted nerves, which we sell directly to end users. EXPAREL, ZILRETTA and iovera° are highly complementary products as long-acting, non-opioid therapies that alleviate pain.
We expect to continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera° in additional procedures; progress our earlier-stage product candidate pipeline; advance regulatory activities for EXPAREL, ZILRETTA, iovera°, PCRX-201 and our other product candidates; invest in sales and marketing resources for EXPAREL, ZILRETTA and iovera°; expand and enhance our manufacturing capacity for EXPAREL, ZILRETTA and iovera°; invest in products, businesses and technologies; and support legal matters.
Global Economic Conditions
Direct and indirect effects of global economic conditions have in the past, and may continue to, negatively impact our business, financial condition and results of operations. Such impacts may include the effect of prolonged periods of inflation which could, among other things, result in higher costs for labor, raw materials and services; cause patients to defer or cancel medical procedures, thereby adversely impacting our revenues; and negatively impact our suppliers which could result in longer lead-times or the inability to secure a sufficient supply of materials. The current macroeconomic environment remains dynamic and subject to rapid and possibly material changes. Additional negative impacts may also arise that we are unable to foresee. The nature and extent of such impacts will depend on future developments, which are highly uncertain and cannot be predicted.

Recent Highlights

•In February 2024, the FDA approved our sNDA for a 200-liter EXPAREL manufacturing suite at our Science Center Campus in San Diego, California. We expect to start selling commercial product manufactured in this 200-liter suite later this year, which could help drive a more favorable cost of commercial product sold and benefit EXPAREL gross margins over time.
•In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy, or RMAT, designation to PCRX-201 (enekinragene inzadenovec), our novel IA helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra) for the treatment of OA pain of the knee. The RMAT application was supported by the preliminary safety and efficacy findings from a Phase 1 open-label, proof-of-concept, single ascending dose trial that enrolled 72 patients in two three-dose cohorts: a co-administered IA steroid cohort and a cohort that did not receive a steroid. PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts. Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the development and review processes for promising therapies—including genetic therapies—that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates that the drug or therapy has the potential to address an unmet medical need.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 29
•In March 2024, the United States Patent and Trademark Office issued Patent No. 11,925,706 (the ‘706 patent) claiming composition of matter, Patent No. 11,918,565 (the ‘565 patent) claiming method of use as a sciatic nerve block in the popliteal fossa and Patent No. 11,931,459 (the ‘459 patent) claiming method of use in pediatric patients. Each of these EXPAREL patents are listed in the FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations” (the “Orange Book”). The ‘706 patent has an expiration date of January 22, 2041 and the ‘459 and ‘565 patents have expiration dates of March 17, 2042 and February 2, 2043, respectively.
•In April 2024, investigators presented encouraging preliminary results from a 72-patient study of PCRX-201 data at the Osteoarthritis Research Society International, or OARSI, 2024 World Congress in Vienna, Austria. The data showed that a single IA injection of PCRX-201 demonstrated sustained clinical effect as assessed by patient-reported outcomes at all dose levels for at least one-year post-injection. Importantly, PCRX-201 was shown to be well-tolerated with a favorable safety profile. We expect to submit updated data demonstrating PCRX-201’s effectiveness through two years for presentation at a medical meeting in the second half of 2024.
•On May 7, 2024, we announced that the Board of Directors has approved a new share repurchase program—effective immediately—which authorizes us to purchase up to an aggregate of $150.0 million of our outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026. We expect to fund the share repurchase program using a combination of existing cash reserves and future cash flows.

EXPAREL

In the U.S., EXPAREL is currently indicated for local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block in adults. Safety and efficacy have not been established in other nerve blocks. In Europe, EXPAREL is approved as a brachial plexus block or femoral nerve block for treatment of post-operative pain in adults, and as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds in adults and children aged six years and older.

EXPAREL Label Activities

•Launching EXPAREL in two new lower extremity nerve block indications. In February 2024, we launched EXPAREL in two key lower extremity nerve blocks—namely an adductor canal block and a sciatic nerve block in the popliteal fossa. We believe these two key nerve blocks provide the opportunity to significantly expand EXPAREL utilization within surgeries of the knee, lower leg, and foot and ankle procedures. The launch is supported by two successful head-to-head Phase 3 studies in which EXPAREL demonstrated four days of superiority to bupivacaine.

•Pediatrics. We are launching a Phase 1 pharmacokinetic study of EXPAREL as a single-dose post-surgical infiltration administration in patients under six years of age. If successful, we expect this study, followed by a Phase 3 registration study, will support expansion of the EXPAREL labels in the U.S. and E.U. We are also discussing with the FDA, EMA and Medicines and Healthcare Products Regulatory Agency (MHRA) our regulatory strategy for EXPAREL administered as a nerve block in the pediatric setting. We received notification from the FDA in October 2023 that our pediatric studies requirement had been waived for the indication of brachial plexus interscalene nerve block to produce postsurgical regional analgesia in pediatric patients.

•Stellate ganglion block. Planning is underway for a multicenter EXPAREL Phase 3 registration program as a stellate ganglion block for preventing postoperative atrial fibrillation after cardiothoracic surgery. We worked with a steering committee of Key Opinion Leaders, or KOLs, in regional anesthesia and stellate ganglion blocks to design our program and we are awaiting FDA feedback on study design. We believe a stellate ganglion block utilizing EXPAREL will be critical in an unmet need with post-operative atrial fibrillation, or POAF. POAF is a common and costly complication after cardiothoracic surgery, occurring after up to 40% of cardiac procedures and 20% of thoracic procedures, and often results in an extended intensive care unit and/or hospital stay, as well as higher long-term risk. A stellate ganglion block is a sympathetic nerve block which can stabilize the heart. Since POAF typically occurs around the third day after surgery, a long-acting block with EXPAREL provided at the time of surgery may enhance current prophylactic measures.

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 30
EXPAREL Clinical Benefits

We believe EXPAREL can replace the use of bupivacaine delivered via elastomeric pumps as the foundation of a multimodal regimen for long-acting postsurgical pain management. Based on our clinical data, EXPAREL:
•provides long-lasting local or regional analgesia;
•is a ready-to-use formulation;
•expands easily with saline or lactated Ringer’s solution to reach a desired volume;
•can be administered for local analgesia via infiltration and for regional analgesia via field block, as well as brachial plexus nerve block, sciatic nerve block in the popliteal fossa and adductor canal block; and
•facilitates treatment of a variety of surgical sites.
We believe EXPAREL is a key component of long-acting postsurgical pain management regimens that reduce the need for opioids. Based on the clinical data from our Phase 3 and Phase 4 clinical studies as well as data from retrospective health outcomes studies, EXPAREL significantly reduces opioid usage while improving postsurgical pain management.
ZILRETTA

ZILRETTA is the first and only extended-release, intra-articular therapy for OA knee pain. ZILRETTA employs a proprietary microsphere technology combining triamcinolone acetonide, or TA, a commonly administered, immediate-release corticosteroid, with a poly lactic-co-glycolic acid, or PLGA, matrix to provide extended pain relief. PLGA is a proven extended-release delivery vehicle that is metabolized to carbon dioxide and water as it releases drug in the intra-articular space and is used in other approved drug products and surgical devices. The ZILRETTA microspheres slowly and continuously release triamcinolone acetonide into the knee to provide significant pain relief for 12 weeks, with some people experiencing pain relief through 16 weeks. ZILRETTA was approved by the FDA in October 2017 and launched in the U.S. shortly thereafter.

We believe ZILRETTA’s extended-release profile may also provide effective treatment for OA pain of the shoulder.

ZILRETTA Clinical Benefits

ZILRETTA combines TA, a commonly administered steroid, with a proprietary, extended-release microsphere technology to administer extended therapeutic concentrations in the joint and persistent analgesic effect.

Based on the strength of its pivotal and other clinical trials, we believe that ZILRETTA represents an important treatment option for the millions of patients in the U.S. in need of safe and effective extended relief from OA knee pain. The pivotal Phase 3 trial showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through 16 weeks. We believe that ZILRETTA holds the potential to become the corticosteroid of choice given its safety and efficacy profile, and the fact that it is the first and only extended-release corticosteroid on the market. In September 2021, the American Association of Orthopaedic Surgeons, or AAOS, updated its evidence-based clinical practice guidelines, finding ZILRETTA can improve patient outcomes over traditional immediate-release corticosteroids.

In 2024, we launched a Phase 3 registration study to evaluate the safety and efficacy of ZILRETTA for the management of OA pain of the shoulder. If the study is successful, we plan to seek approval to expand the ZILRETTA label to include OA pain of the shoulder.

iovera°

The iovera° system is a non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature to targeted nerves. It is FDA 510(k) cleared in the U.S., has a CE mark in the E.U. and is cleared for marketing in Canada for the blocking of pain. We believe the iovera° system is highly complementary to EXPAREL and ZILRETTA as a non-opioid therapy that alleviates pain using a non-pharmacological nerve block to disrupt pain signals being transmitted to the brain from the site of injury or surgery. It is also indicated for the relief of pain and symptoms associated with arthritis of the knee for up to 90 days.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 31
iovera° Clinical Benefits

There is a growing body of clinical data demonstrating success with iovera° treatment for a wide range of chronic pain conditions. Some of our strongest data relates directly to the improvement of OA pain of the knee. Surgical intervention is typically a last resort for patients suffering from OA pain of the knee. In one study, the majority of the patients suffering from OA pain of the knee experienced pain relief up to 150 days after being treated with iovera°.
Preliminary findings demonstrated reductions in opioids, including:
•The daily morphine equivalent consumption in the per protocol group analysis was significantly lower at 72 hours (p<0.05), 6 weeks (p<0.05) and 12 weeks (p<0.05).
•Patients who were administered iovera° were far less likely to take opioids six weeks after surgery. The number of patients taking opioids six weeks after total knee arthroplasty, or TKA, in the control group was three times the number of patients taking opioids in the cryoanalgesia group (14 percent vs. 44 percent, p<0.01).
•Patients in the iovera° group demonstrated a statistically significant reduction in pain scores from their baseline pain scores at 72 hours (p<0.05) and at 12 weeks (p<0.05).
We believe these data validate iovera° as a clinically meaningful non-opioid alternative for patients undergoing TKA, and that iovera° offers the opportunity to provide patients with non-opioid pain control well in advance of any necessary surgical intervention through a number of key product attributes:
•iovera° is safe and effective with immediate pain relief that can last for months as the nerve regenerates over time;
•iovera° is repeatable, with no diminishing effectiveness over time and repeat use;
•The iovera° technology does not risk damage to the surrounding tissue;
•iovera° is a convenient handheld device with a single-use procedure-specific Smart Tip; and
•iovera° can be delivered precisely using ultrasound guidance or an anatomical landmark.
A study published in 2021 that included 267 patients (169 who underwent cryoneurolysis with iovera° compared to 98 patients who did not receive iovera° treatment) showed that patients who were treated with iovera° had 51% lower daily morphine milligram equivalents during their hospital stay and a 22% lower mean pain score versus those who were not. In addition, the iovera° group had greater function at discharge, a shorter length of hospital stay and received significantly fewer opioids, including discharge prescriptions at week 2 and week 6 after surgery.
In September 2021, the AAOS updated its evidence-based clinical practice guidelines, reporting that denervation therapy—including cryoneurolysis—may reduce knee pain and improve function in patients with symptomatic OA of the knee.

The Osteoarthritis Market

OA is the most common form of arthritis. It is also called degenerative joint disease and occurs most frequently in the hands, hips and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and worsen over time. OA can cause pain, stiffness and swelling. In some cases, it also causes reduced function and disability—some people are no longer able to do daily tasks or work. According to the Centers for Disease Control and Prevention (CDC), OA affects over 32.5 million adults in the U.S.

The lifetime risk of developing symptomatic knee OA is 45 percent according to the Arthritis Foundation. The prevalence of symptomatic knee OA increases with each decade of life, with the annual incidence of knee OA being highest between age 55 and 64 years old. There are 14 million individuals in the U.S. who have symptomatic knee OA, and nearly two million are under the age of 45. Surgical intervention is typically a last resort for patients suffering from OA of the knee.

With ZILRETTA, we now offer clinicians the flexibility to individualize OA knee pain treatment with either ZILRETTA or a drug-free nerve block with iovera° based on patient factors and preference, physician training, site of care and reimbursement considerations.


Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 32
Clinical Development Programs

PCRX-201

PCRX-201 was added to our product development portfolio as part of the Flexion Acquisition. PCRX-201 is a novel, helper-dependent adenoviral vector expressing interleukin-1 receptor antagonist (IL-1Ra). After injection, the vector enters joint cells and turns them into factories to produce sustained therapeutic levels of IL-1Ra and inhibit the IL-1 pathway to manage pain and mitigate OA-related joint damage while remaining localized to the joint space. In a Phase 1 proof-of-concept study of patients with moderate to severe OA of the knee, PCRX-201 was well tolerated with improvements in knee pain observed across all doses. In February 2024, the FDA granted PCRX-201 an RMAT designation. Our RMAT application was supported by the preliminary safety and efficacy findings from a Phase 1 open-label, proof-of-concept, single ascending dose trial that enrolled 72 patients in two three-dose cohorts: a co-administered IA steroid cohort and a cohort that did not receive a steroid. PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts. The highest level of efficacy was achieved in the co-administered steroid group, which showed a greater percentage of patients with at least a 50% improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and stiffness scores, as well as a meaningful improvement in (Knee Injury and Osteoarthritis Outcomes Score) KOOS functional assessment. The 52-week data were presented at the Osteoarthritis Research Society International (OARSI) 2024 World Congress in April 2024 and we expect to submit the 104-week efficacy and safety data for presentation at a medical meeting later this year.

pMVL-Based Clinical Program

Given the proven safety, flexibility and customizability of our pMVL drug delivery technology platform for acute, sub-acute and chronic pain applications, we have another pMVL-based product in clinical development. Following data readouts from preclinical and feasibility studies, we initiated a second Phase 1 study of EXPAREL for intrathecal analgesia in June 2023.

External Innovation

In parallel to our internal clinical programs, we are pursuing innovative acquisition targets that are complementary to EXPAREL, ZILRETTA and iovera° and are of great interest to the surgical and anesthesia audiences we are already calling on today. We are using a combination of strategic investments, in-licensing and acquisition transactions to buildout a pipeline of innovation to improve patients’ journeys along the neural pain pathway. The strategic investments we have made to support promising early-stage platforms are summarized below:

CompanyDevelopment StageDescription of Platform TechnologyPotential Therapeutic Areas
CarthroniX, Inc.Phase 1-ReadyCX-011, a small molecule modulator of gp130 formulated as an IA injection designed to slow joint degeneration by mediating IL-6 cytokinesKnee OA
Genascence CorporationPhase 1b
Adeno-associated virus (AAV) based gene therapy engineered to deliver Interleukin-1 Receptor Antagonist (IL-1Ra) to target cells in joint(s)
Knee OA
GQ Bio Therapeutics GmbHPreclinical
High-capacity adenovirus (HCAd) based gene therapy engineered to deliver DNA to target cells in joint(s) and intervertebral disc(s)
Knee OA and degenerative disc disease (DDD)
Spine BioPharma, LLCPhase 3
SB-01, a 7-amino acid chain peptide that binds to and induces down regulation of transforming growth factor, beta 1 (TGFβ1)
Degenerative disc disease (DDD)

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 33
Product Portfolio and Internal Pipeline

Our current product portfolio and internal product candidate pipeline, along with anticipated milestones over the next 12 to 18 months, are summarized in the table below:

Product Pipeline Q1 2024.jpg

Pacira Training Facilities

We maintain and operate two Pacira Innovation and Training, or PIT, facilities—one in Tampa, Florida and one in Houston, Texas. These sites were constructed with a singular goal in mind: to advance education on best practice techniques to effectively manage acute pain while reducing or eliminating the need for opioids. These facilities provide clinicians with flexible, state-of-the-art environments for interactive, hands-on instruction on the latest and most innovative local, regional and field block approaches for managing pain, improving patient care and enabling patient migration to the 23-hour stay environment. Each of our PIT facilities feature distinct training spaces, including simulation labs equipped with ultrasound scanning stations; lecture halls that feature liquid crystal display video walls to support live, virtual and global presentations; and green-screen broadcast studios to livestream content with single or multiple hosts. The PIT of Houston has both wet and dry lab space for cadaver and other interactive workshops. The PIT of Tampa also houses our principal executive offices and corporate headquarters.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 34
Results of Operations
Comparison of the Three Months Ended March 31, 2024 and 2023
Revenues
Net product sales consist of sales of (i) EXPAREL in the U.S., E.U., and U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and (iv) sales of our bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of our bupivacaine liposome injectable suspension for veterinary use.
The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
Net product sales:
EXPAREL$132,430 $130,408 2%
ZILRETTA25,839 24,334 6%
iovera°5,030 4,001 26%
Bupivacaine liposome injectable suspension2,525 688 100% +
Total net product sales165,824 159,431 4%
Royalty revenue1,293 910 42%
Total revenues$167,117 $160,341 4%
EXPAREL revenue increased 2% in the three months ended March 31, 2024 versus 2023. Components of the increase included a 3% increase in gross vial volume, which was offset by a shift in product mix. EXPAREL revenue was also impacted by a 2% increase in selling price per unit related to a January 2024 price increase, which was partially offset by sales related allowances as a result of group purchasing organization contracting.
ZILRETTA revenue increased 6% in the three months ended March 31, 2024 versus 2023 primarily due to a 7% increase in net selling price per unit related to increases of gross selling price per unit and favorable sales related allowances, partially offset by a 1% decrease in kit volume.
Net product sales of iovera° increased 26% in the three months ended March 31, 2024 versus 2023 primarily due to an increase of 34% in Smart Tip volume, partially offset by a 2% decrease in selling price per Smart Tip due to increased sales to clinics.
Bupivacaine liposome injectable suspension revenue increased more than 100% in the three months ended March 31, 2024 versus 2023 and its related royalties increased 42% primarily due to the sales mix of vial sizes and the timing of orders placed for veterinary use.
The following tables provide a summary of activity with respect to our sales related allowances and accruals related to EXPAREL and ZILRETTA for the three months ended March 31, 2024 and 2023 (in thousands):
March 31, 2024Returns
Allowances		Prompt
Payment
Discounts		Service
Fees		Volume
Rebates and
Chargebacks		Government
Rebates		Total
Balance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 
Provision76 3,057 4,771 25,800 636 34,340 
Payments / Adjustments(175)(3,087)(5,064)(26,320)(333)(34,979)
Balance at March 31, 2024$1,769 $1,278 $3,404 $5,350 $1,478 $13,279 
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 35
March 31, 2023Returns
Allowances		Prompt
Payment
Discounts		Service
Fees		Volume
Rebates and
Chargebacks		Government
Rebates		Total
Balance at December 31, 2022$1,691 $1,187 $3,193 $5,452 $786 $12,309 
Provision465 2,938 4,277 22,549 412 30,641 
Payments / Adjustments(328)(2,921)(4,162)(22,689)(396)(30,496)
Balance at March 31, 2023$1,828 $1,204 $3,308 $5,312 $802 $12,454 
Total reductions of gross product sales from sales-related allowances and accruals were $34.3 million and $30.6 million, or 17.1% and 16.2% of gross product sales, for the three months ended March 31, 2024 and 2023, respectively. The overall 0.9% increase in sales-related allowances and accruals as a percentage of gross product sales was primarily related to accruals as a result of higher chargeback-related allowances from expanded contracting efforts.
Cost of Goods Sold
Cost of goods sold primarily relates to the costs to produce, package and deliver our products to customers. These expenses include labor, raw materials, manufacturing overhead and occupancy costs, depreciation of facilities, royalty payments, quality control and engineering.
The following table provides information regarding our cost of goods sold and gross margin during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
 Cost of goods sold$47,416$49,020(3)%
 Gross margin72 %69 %
Gross margin increased three percentage-points in the three months ended March 31, 2024 versus 2023 primarily due to lower EXPAREL product cost and lower royalty expense as discussed below, partially offset by higher inventory reserves.
On August 8, 2023, the U.S. District Court, District of Nevada, concluded we were no longer obligated to pay royalties to the Research and Development Foundation for EXPAREL made under the 45-liter manufacturing process. For more information, see Note 15, Commitments and Contingencies, to our condensed consolidated financial statements included herein.
Research and Development Expenses
Research and development expenses primarily consist of costs related to clinical trials and related outside services, product development and other research and development costs, including trials that we are conducting to generate new data for EXPAREL, ZILRETTA and iovera° and stock-based compensation expense. Clinical and preclinical development expenses include costs for clinical personnel, clinical trials performed by third-parties, toxicology studies, materials and supplies, database management and other third-party fees. Product development and manufacturing capacity expansion expenses include development costs for our products, which include personnel, research equipment, materials and contractor costs for process development and product candidates, development costs related to significant scale-ups of our manufacturing capacity and facility costs for our research space. Regulatory and other expenses include regulatory activities related to unapproved products and indications, medical information expenses, registry expenses and related personnel. Stock-based compensation expense relates to the costs of stock option grants, awards of restricted stock units, or RSUs, and our employee stock purchase plan, or ESPP.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 36
The following table provides a breakout of our research and development expenses during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
Clinical and preclinical development$6,346$5,26121%
Product development and manufacturing capacity expansion7,3957,672(4)%
Regulatory and other2,6942,33216%
Stock-based compensation1,8031,875(4)%
Total research and development expense$18,238$17,1406%
 % of total revenues11 %11 %
Total research and development expense increased 6% in the three months ended March 31, 2024 versus 2023.
Clinical and preclinical development expense increased 21% in the three months ended March 31, 2024 versus 2023 due to the start-up and enrollment in a ZILRETTA shoulder trial and an EXPAREL pediatric trial, and start-up activities in an iovera° spasticity trial. These increases were partially offset by the winding down of a PCRX-201 Phase 1 study for knee OA as follow-up visits of subjects were completed in November 2023, and the completion of toxicology studies for product candidates.
Product development and manufacturing capacity expansion expense decreased 4% in the three months ended March 31, 2024 versus 2023, primarily attributable to the near-completion of pre-commercial scale-up activities of our EXPAREL manufacturing capacity at our Science Center Campus in San Diego, California. The FDA approved an sNDA for our 200-liter EXPAREL manufacturing suite in February 2024. This decrease is partially offset by ongoing product development costs related to PCRX-201 and an iovera° medial branch Smart Tip.
Regulatory and other expense increased 16% in the three months ended March 31, 2024 versus 2023 due to increased enrollment and additional sites related to an observational registry study which tracks patients’ symptoms and experience with pain management related to OA of the knee.
Stock-based compensation decreased 4% in the three months ended March 31, 2024 versus 2023 primarily due to the impact of a February 2024 restructuring program which resulted in accelerated stock-based compensation for those impacted being recorded in contingent consideration (gains) charges, restructuring charges and other.
Selling, General and Administrative Expenses
Sales and marketing expenses primarily consist of compensation and benefits for our sales force and personnel that support our sales, marketing, medical and scientific affairs operations, expenses related to communicating the health outcome benefits of our products, investments in provider-level market access and patient reimbursement support and educational programs for our customers. General and administrative expenses consist of compensation and benefits for legal, finance, regulatory activities related to approved products and indications, compliance, information technology, human resources, business development, executive management and other supporting personnel. It also includes professional fees for legal, audit, tax and consulting services. Stock-based compensation expense relates to the costs of stock option grants, RSU awards and our ESPP.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 37
The following table provides information regarding our selling, general and administrative expenses during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
 Sales and marketing$39,435$41,579(5)%
 General and administrative24,60620,87318%
 Stock-based compensation7,9858,391(5)%
Total selling, general and administrative expense$72,026$70,8432%
 % of total revenues43 %44 %
Total selling, general and administrative expense increased 2% in the three months ended March 31, 2024 versus 2023.
Sales and marketing expense decreased 5% in the three months ended March 31, 2024 versus 2023, which is attributable to the impact of a February 2024 restructuring program. These measures involved reallocating resources and prioritizing investing in programs to drive awareness and education for our customers and enhance our marketing, market access and reimbursement teams and value creation for the implementation of separate Medicare reimbursement for EXPAREL at average sales price plus 6 percent in outpatient settings beginning in January 2025. We expect investments in these programs to increase in the remaining nine months of 2024.
General and administrative expense increased 18% in the three months ended March 31, 2024 versus 2023 primarily driven by legal fees primarily attributable to ongoing litigation. We also incurred compensatory costs associated with the transition to our new Chief Executive Officer effective January 2, 2024, which include compensation related to the current Chief Executive Officer and to the former Chief Executive Officer who remains employed by the Company in an advisory role, and, to a lesser extent, third-party consulting. For more information on our ongoing litigation, see Note 15, Commitments and Contingencies, to our condensed consolidated financial statements included herein.
Stock-based compensation decreased 5% for the three months ended March 31, 2024 versus 2023 primarily due to the impact from the February 2024 restructuring program which resulted in accelerated stock-based compensation for those impacted being recorded in contingent consideration (gains) charges, restructuring charges and other.
Amortization of Acquired Intangible Assets
The following table provides a summary of the amortization of acquired intangible assets during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
Amortization of acquired intangible assets$14,322 $14,322 —%
As part of the Flexion Acquisition and the MyoScience Acquisition, we acquired intangible assets consisting of developed technology intangible assets and customer relationships, with estimated useful lives between 9 and 14 years. For more information, see Note 7, Goodwill and Intangible Assets, to our condensed consolidated financial statements included herein.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 38
Contingent Consideration Charges (Gains), Restructuring Charges and Other
The following table provides a summary of the costs related to the contingent consideration, acquisition-related charges and restructuring charges during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
Flexion contingent consideration$(3,806)$11,618 N/A
Restructuring charges5,535 — N/A
Acquisition-related fees174 489 (64)%
Total contingent consideration (gains) charges, restructuring charges and other$1,903 $12,107 (84)%
Total contingent consideration (gains) charges, restructuring charges and other decreased 84% in the three months ended March 31, 2024 versus 2023.
During the three months ended March 31, 2024, we recognized a contingent consideration gain of $3.8 million primarily due to an adjustment reflecting the probability of achieving the remaining Flexion regulatory milestone by December 31, 2030, the expiration date.
During the three months ended March 31, 2023, we recognized a contingent consideration charge of $11.6 million, which was due to a decrease to the assumed discount rate based on a significant improvement in our incremental borrowing rate resulting from the TLA Credit Agreement (as defined below) entered into in March 2023.
During the three months ended March 31, 2024, we recognized restructuring charges of $5.5 million related to employee termination benefits, such as the acceleration of share-based compensation, severance, and, to a lesser extent, other employment-related termination costs, as well as contract termination costs.
For more information, see Note 9, Financial Instruments and Note 14, Contingent Consideration Charges (Gains), Restructuring Charges and Other, to our condensed consolidated financial statements included herein.
Other Income (Expense), Net
The following table provides information regarding other income (expense), net during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
 Interest income$3,903 $3,142 24%
 Interest expense(3,316)(9,589)(65)%
 Loss on early extinguishment of debt— (16,926)(100)%
 Other, net(159)(10)100% +
Total other income (expense), net$428 $(23,383)N/A
Total other income, net was $0.4 million in the three months ended March 31, 2024. Total other expense, net was $23.4 million in the three months ended March 31, 2023.
The 24% increase in interest income in the three months ended March 31, 2024 versus 2023 was due to higher interest rates and overall investment balances.
The 65% decrease in interest expense during the three months ended March 31, 2024 versus 2023 was primarily driven by lower principal outstanding associated with the TLA Term Loan (as defined below) that was entered into on March 31, 2023 which replaced our then-outstanding TLB Term Loan (as defined below) that had a higher principal balance and interest rates.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 39
In conjunction with the entry into the TLA Credit Agreement, we incurred a $16.9 million loss on early extinguishment of debt recognized as a result of the retirement of $287.5 million aggregate principal of our TLB Term Loan (as defined below) in the three months ended March 31, 2023. For more information, see Note 8, Debt, to our condensed consolidated financial statements included herein.
Income Tax Expense (Benefit)
The following table provides information regarding our income tax expense (benefit) during the periods indicated, including percent changes (dollar amounts in thousands):
Three Months Ended
March 31,		% Increase / (Decrease)
20242023
 Income tax expense (benefit)$4,661 $(6,938)N/A
 Effective tax rate 34 %26 %
The effective tax rates were 34% and 26% for the three months ended March 31, 2024 and 2023, respectively. Income tax expense represents the estimated annual effective tax rate applied to the year-to-date domestic operating results adjusted for certain discrete tax items.
The effective tax rate for the three months ended March 31, 2024 include costs related to non-deductible stock-based compensation and non-deductible executive compensation, partially offset by tax credits and a fair value adjustment for the Flexion contingent consideration. The effective tax rate for the three months ended March 31, 2023 includes costs for a fair value adjustment to Flexion contingent consideration, and a valuation allowance recorded against non-U.S. results, offset by tax credits and stock-based compensation benefits.
Liquidity and Capital Resources
Since our inception in 2006, we have devoted most of our cash resources to manufacturing, research and development and selling, general and administrative activities related to the development and commercialization of EXPAREL. In addition, we acquired ZILRETTA as part of the Flexion Acquisition in November 2021 and iovera° as part of the MyoScience Acquisition in April 2019. We are primarily dependent on the commercial success of EXPAREL and ZILRETTA. We have financed our operations primarily with the proceeds from the sale of convertible senior notes and other debt, common stock, product sales and collaborative licensing and milestone revenue. As of March 31, 2024, we had an accumulated deficit of $97.8 million, cash and cash equivalents and available-for-sale investments of $325.9 million and working capital of $449.7 million.
We expect that our cash and cash equivalents and available-for-sale investments on hand will be adequate to cover our short-term liquidity needs, and that we would be able to access other sources of financing should the need arise.
Summary of Cash Flows
The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated (in thousands):
Three Months Ended
March 31,
Condensed Consolidated Statements of Cash Flows Data:20242023
 Net cash provided by (used in):
 Operating activities$49,101 $19,128 
 Investing activities(15,530)66,183 
 Financing activities(2,817)(153,905)
Net increase (decrease) in cash and cash equivalents$30,754 $(68,594)
Operating Activities
During the three months ended March 31, 2024, net cash provided by operating activities was $49.1 million, compared to $19.1 million during the three months ended March 31, 2023. The increase of $30.0 million was attributable to increased revenue, lower interest paid and a $13.0 million payment made in the prior year for a termination fee relating to a licensing agreement.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 40
Investing Activities
During the three months ended March 31, 2024, net cash used in investing activities was $15.5 million, which reflected $12.7 million of outflows from available-for-sale investment purchases (net of sales), as well as $2.8 million of capital expenditures for manufacturing product fill lines and for an EXPAREL capacity expansion project at our Science Center Campus in San Diego, California.
During the three months ended March 31, 2023, net cash provided by investing activities was $66.2 million, which reflected proceeds from $76.7 million of available-for-sale investment sales (net of purchases), partially offset by purchases of fixed assets of $6.6 million for fill lines for our products and equipment for an EXPAREL capacity expansion project at our Science Center Campus in San Diego, California and purchases of equity and debt investments of $4.0 million.
Financing Activities
During the three months ended March 31, 2024, net cash used in financing activities was $2.8 million for a voluntary prepayment of TLA Term Loan principal. See Note 8, Debt, to our condensed consolidated financial statements included herein for further discussion on the TLA Term Loan.
During the three months ended March 31, 2023, net cash used in financing activities was $153.9 million, which primarily consisted of a $296.9 million repayment of TLB Term Loan principal as well as a $5.8 million prepayment penalty, partially offset by the net proceeds from the TLA Term Loan of $149.6 million.
Debt
2028 Term Loan A Facility
On March 31, 2023, we entered into a credit agreement (the “TLA Credit Agreement”) to refinance the indebtedness outstanding under our TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of our and any subsidiary guarantor’s assets and matures on March 31, 2028. We may elect to borrow either (i) alternate base rate borrowings or (ii) term benchmark borrowings or daily simple SOFR (as defined in the TLA Credit Agreement) borrowings. Each term loan borrowing which is an alternate base rate borrowing bears interest at a rate per annum equal to (i) the Alternate Base Rate (as defined in the TLA Credit Agreement), plus (ii) a spread based on our Senior Secured Net Leverage Ratio ranging from 2.00% to 2.75%. Each term loan borrowing which is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the TLA Credit Agreement), plus (ii) a spread based on our Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. During the three months ended March 31, 2024, we made a voluntary principal prepayment of $2.8 million. Due to voluntary principal prepayments made, we are not required to make further principal payments for the year ended December 31, 2024, although we retain the option to do so. As of March 31, 2024, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 8.41%.
The TLA Credit Agreement requires us to, among other things, maintain (i) a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), determined as of the last day of each fiscal quarter, of no greater than 3.00 to 1.00 and (ii) a Fixed Charge Coverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no less than 1.50 to 1.00. The TLA Credit Agreement requires us to maintain an unrestricted cash and cash equivalents balance of at least $500.0 million less any prepayments of the 2025 Notes (as defined below) at any time from 91 days prior to the maturity date through the earlier of (i) the latest maturity date of the 2025 Notes and (ii) the date on which there is no outstanding principal amount of the 2025 Notes, which we expect to accomplish. The TLA Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of March 31, 2024, we were in compliance with all financial covenants under the TLA Credit Agreement. See Note 8, Debt, to our condensed consolidated financial statements included herein for further discussion.
2025 Convertible Senior Notes
In July 2020, we completed a private placement of $402.5 million in aggregate principal amount of our 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per annum, payable semiannually in arrears on February 1st and August 1st of each year. The 2025 Notes mature on August 1, 2025. At March 31, 2024, the outstanding principal on the 2025 Notes was $402.5 million. See Note 8, Debt, to our condensed consolidated financial statements included herein for further discussion.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 41
Future Capital Requirements
We believe that our existing cash and cash equivalents, available-for-sale investments and cash received from product sales will be sufficient to enable us to fund our operating expenses, capital expenditure requirements and payment of the interest and principal on our TLA Term Loan and 2025 Notes through the next 12 months. Our future use of operating cash and capital requirements will depend on many forward-looking factors, including, but not limited to:
•the cost and timing of the potential milestone payments to former Flexion stockholders, which could be up to an aggregate of $372.3 million if certain regulatory and commercial milestones are met. See Note 9, Financial Instruments, to our condensed consolidated financial statements included herein for more information;
•the impact of global economic conditions—including the impact of inflation—on our product, material and labor costs, supply chain, longer lead-times, an inability to secure a sufficient supply of materials, our operating expenses and our business strategy;
•the timing of and extent to which the holders of our 2025 Notes elect to convert their 2025 Notes, the timing of principal and interest payments on our TLA Term Loan and the timing and impact of increases to the variable interest rate on our TLA Term Loan borrowings in accordance with the terms of the TLA Credit Agreement;
•the costs and our ability to successfully continue to expand the commercialization of EXPAREL, ZILRETTA and iovera°;
•the cost and timing of expanding and maintaining our manufacturing facilities;
•the cost and timing of additional strategic investments, including additional investments under existing agreements;
•the costs related to legal and regulatory matters;
•the costs of performing additional clinical trials for our products, including the additional pediatric trials required by the FDA and EMA as a condition of the approval of EXPAREL;
•the costs for the development and commercialization of other product candidates;
•the costs and timing of future payments under our employee benefit plans, including but not limited to our cash long-term incentive plan and non-qualified deferred compensation plan; and
•the extent to which we acquire or invest in products, businesses and technologies.
We may require additional debt or equity financing to meet our future operating and capital requirements. We have no committed external sources of funds, and additional equity or debt financing may not be available on acceptable terms, if at all. In particular, capital market disruptions or negative economic conditions may hinder our access to capital.

Critical Accounting Estimates
For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to our 2023 Annual Report. There have been no significant changes to our critical accounting policies nor any recently issued accounting pronouncements that are expected to have a material impact on our financial results since December 31, 2023.

Contractual Obligations
There have been no material changes in our contractual obligations relating to our indebtedness, lease obligations and purchase obligations from those reported in our 2023 Annual Report. For more information on our contractual obligations and commercial commitments, see Part II, Item 7 in our 2023 Annual Report.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 42
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The primary objective of our cash equivalents and investment activities is to preserve principal while at the same time maximizing the income that we receive from our investments without significantly increasing risk. We invest in corporate bonds, commercial paper, asset-backed securities and U.S. Treasury and other government agency notes for purposes other than trading which are reported at fair value. These securities are subject to interest rate risk and credit risk. This means that a change in prevailing interest rates may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, we expect that the fair value of our investment will decline. A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at March 31, 2024 by approximately $0.6 million.
The fair value of our 2025 Notes is impacted by both the fair value of our common stock and interest rate fluctuations. As of March 31, 2024, the estimated fair value of the 2025 Notes was $953 per $1,000 principal amount. See Note 8, Debt, to our condensed consolidated financial statements included herein for further discussion of our 2025 Notes, which bear interest at a fixed rate. At March 31, 2024, all $402.5 million of principal remains outstanding on the 2025 Notes and $8.6 million of principal remained outstanding on the Flexion 2024 Notes, which was subsequently repaid at maturity on May 1, 2024.
The TLA Term Loan provides for a single-advance term loan in the principal amount of $150.0 million and is scheduled to mature on March 31, 2028. Each term loan borrowing that is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the TLA Credit Agreement), plus (ii) a spread based on our Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. At March 31, 2024, the outstanding principal on the TLA Term Loan was $113.8 million. As of March 31, 2024, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 8.41%. A hypothetical 100 basis point increase in interest rates would increase interest expense over the next 12 months by approximately $1.1 million, based on the balance outstanding for these borrowings as of March 31, 2024.
We have agreements with certain vendors and partners that operate in foreign jurisdictions. The more significant transactions are primarily denominated in the U.S. Dollar, subject to an annual adjustment based on changes in currency exchange rates.
Additionally, our accounts receivable are primarily concentrated with four large wholesalers of pharmaceutical products. In the event of non-performance or non-payment, there may be a material adverse impact on our financial condition, results of operations or net cash flow.
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) under the Exchange Act, our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. As defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, disclosure controls and procedures are controls and other procedures which are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2024.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including the Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 43
system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II — OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

For information related to Item 1. Legal Proceedings, refer to Note 15, Commitments and Contingencies, to our
condensed consolidated financial statements included herein.

Item 1A. RISK FACTORS

You should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our 2023 Annual Report, which could materially affect our business, financial condition, cash flows or future results. There have been no material changes in our risk factors included in our 2023 Annual Report. The risks described in our 2023 Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 44
Item 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2024. No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2024.
Trading Arrangement
Name and PositionActionDateRule 10b5-1*Non-Rule
10b5-1**		Total Number of
Shares to be Sold		Expiration
Date
Lauren Riker
Principal Accounting Officer
Adopt3/5/2024x
To Be Determined (1)
12/31/2024
Kristen Williams
Chief Administrative Officer and Secretary
Adopt3/8/2024x
To Be Determined (1)
6/28/2024
Jonathan Slonin
Chief Medical Officer
Adopt3/8/2024x
To Be Determined (1)
1/31/2025
Paul Hastings
Director
Adopt3/12/2024x1,77512/31/2024
Daryl Gaugler
Chief Operating Officer
Adopt3/12/2024x2,5003/7/2025
* Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).

(1) The aggregate number of shares to be sold pursuant to each trading arrangement listed above is dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 45
Item 6. EXHIBITS

The exhibits listed below are filed or furnished as part of this report.

Exhibit NumberDescription
Executive Employment Agreement, dated May 4, 2020, between the Registrant and Jonathan Slonin.(1) ***
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
  
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
  
101
The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss); (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.*
104Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith.
**Furnished herewith.
***Denotes management contract or compensatory plan or arrangement.
(1)Incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed on May 4, 2022.
Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 46
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Date:May 7, 2024By: /s/ FRANK D. LEE
Frank D. Lee
Chief Executive Officer and Director
(Principal Executive Officer)
Date:May 7, 2024By:/s/ CHARLES A. REINHART, III
Charles A. Reinhart, III
Chief Financial Officer
(Principal Financial Officer)

Pacira BioSciences, Inc. | Q1 2024 Form 10-Q | Page 47
 EX-31.1 2 pcrx-3312024xex311.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATION
 
I, Frank D. Lee, certify that:
 
1.I have reviewed this quarterly report on Form 10-Q of Pacira BioSciences, Inc. (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 
Date: May 7, 2024/s/ FRANK D. LEE
 Frank D. Lee
 Chief Executive Officer and Director
 (Principal Executive Officer)


 EX-31.2 3 pcrx-3312024xex312.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATION
 
I, Charles A. Reinhart, III, certify that:
 
1.I have reviewed this quarterly report on Form 10-Q of Pacira BioSciences, Inc. (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 
Date: May 7, 2024/s/ CHARLES A. REINHART, III
 Charles A. Reinhart, III
 Chief Financial Officer
 (Principal Financial Officer)


 EX-32.1 4 pcrx-3312024xex321.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
Pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that this Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira BioSciences, Inc. at the dates and for the periods indicated.


 
Date: May 7, 2024/s/ FRANK D. LEE
 Frank D. Lee
 Chief Executive Officer and Director
 (Principal Executive Officer)


Date: May 7, 2024/s/ CHARLES A. REINHART, III
 Charles A. Reinhart, III
 Chief Financial Officer
 (Principal Financial Officer)


 EX-101.SCH 5 pcrx-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - STOCK PLANS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - NET INCOME (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - STOCK PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - REVENUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - REVENUE - Schedule of Disaggregated Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - FIXED ASSETS - Schedule of Major Categories (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - FIXED ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - DEBT - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - DEBT - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Available-For-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - STOCK PLANS - Schedule of Stock Based Compensation Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - STOCK PLANS - Schedule of Stock Based Compensation Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - STOCK PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - STOCK PLANS - Schedule of Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - NET INCOME (LOSS) PER SHARE - Schedule of Computation of EPS (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - NET INCOME (LOSS) PER SHARE- Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Acquisition Related Charges (Gains) and Other (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Schedule of Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 pcrx-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 pcrx-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 pcrx-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Fair value adjustments and accretion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued expenses Accrued Liabilities, Current Range [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Major Customer Two Major Customer Two [Member] Represents the major customer of the entity. Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Equity Award [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Unvested at beginning of period (in shares) Unvested at end of period in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number DEBT Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Short-Term and Noncurrent Available-for-Sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Total other income (expense), net Nonoperating Income (Expense) Probability of payment for remaining regulatory milestone Measurement Input, Expected Milestone Payment [Member] Measurement Input, Expected Milestone Payment [Member] Commitments and contingencies (Note 15) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS' EQUITY Equity [Text Block] Geographical [Axis] Geographical [Axis] INCOME TAXES Income Tax Disclosure [Text Block] Number of embedded leases Number Of Leases Number Of Leases Expected dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Total contingent consideration (gains) charges, restructuring charges and other Contingent Consideration Gain (Loss), Restructuring Charges and Other Contingent Consideration Gain (Loss), Restructuring Charges and Other Vested restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Jonathan Slonin [Member] Jonathan Slonin Concentration Risk [Line Items] Concentration of Major Customers Concentration Risk [Line Items] Stock options Compensation expense from stock options, employees Compensation expense from stock options (employee and board of director awards) Major Customers [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value (Per Share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Amortization expense, seventh period Finite-Lived Intangible Asset, Expected Amortization, Year Seven Finite-Lived Intangible Asset, Expected Amortization, Year Seven Diluted net income (loss) per common share (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Secured and Unsecured Debt Secured and Unsecured Debt [Member] Secured and Unsecured Debt Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Current portion of convertible senior notes, net Convertible Debt, Current Cash payments made / settled Payments for Reinsurance Outstanding beginning of period (in shares) Outstanding end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol U.S. federal agency bonds US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net income (loss) Net income (loss) Net income (loss) Net income (loss)—basic Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Discount rate Debt Instrument, Discount Rate Debt Instrument, Discount Rate Company Selected Measure Name Company Selected Measure Name Machinery and equipment Machinery and Equipment [Member] LEASES Lessee, Operating Leases [Text Block] Corporate bonds Corporate Bond Securities [Member] Gross Carrying Value Intangible Assets, Gross (Excluding Goodwill) Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Amortization of debt discount Amortization of Debt Discount (Premium) Weighted average ESPP purchase options Employee Stock [Member] Contingent Consideration Contingent Consideration [Member] Contingent Consideration [Member] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Executive Category: Executive Category [Axis] Weighted-Average Useful Lives Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Investments without Readily Determinable Fair Value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Number of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Financial Liabilities: Financial Liabilities Fair Value Disclosure [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Carrying Value Reported Value Measurement [Member] Purchases of available-for-sale investments Payments to Acquire Short-Term Investments Goodwill Goodwill recorded in connection with the acquisition Goodwill Schedule of Fixed Assets Summarized by Major Category Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses and income taxes payable Increase (Decrease) in Accrued Liabilities Measurement Basis [Axis] Measurement Basis [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Amortization expense, fourth period Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast Forecast [Member] ESPP purchasing period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Selling, general and administrative Selling, General and Administrative Expenses [Member] Accounts Receivable Accounts Receivable [Member] Adjusted net income (loss)—diluted Net Income (Loss) Attributable to Parent, Diluted Net unrealized (loss) gain on investments, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Lease liabilities Operating Lease, Liability, Noncurrent Restricted Stock Units (RSUs) Dilutive effect of RSUs Weighted average number of RSUs Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Number of major customers Number of Major Customers Represents the number of major customers of the reporting entity. Depreciation expense Depreciation Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Purchases of debt investments Payments to Acquire Long-Term Investments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Common stock withheld for employee withholding tax liabilities on vested restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Stock-based compensation from: Share-Based Payment Arrangement, Noncash Expense [Abstract] Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Europe Europe [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Operating Lease Expense and Other Operating Lease Information Lease, Cost [Table Text Block] Inventories, net Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Beginning balance Ending balance Restructuring Reserve Acquisition-related fees Business Combination, Acquisition Related Costs Number of offering periods for ESPP Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods Fortis Fortis [Member] Fortis Antidilutive effects of including these potential shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Investment Categorization [Axis] Investment Categorization [Axis] Investment Categorization Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Debt extinguishment costs Payment for Debt Extinguishment or Debt Prepayment Cost Non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Contract Termination Costs Contract Termination [Member] Interest expense Total Interest Expense Fixed assets included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Loss on early extinguishment of debt Loss on early extinguishment of debt Loss on early extinguishment of debt Gain (Loss) on Extinguishment of Debt Total Property, Plant and Equipment, Gross Amortization expense, remainder of fiscal year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Measurement input, contingent consideration Business Combination, Contingent Consideration, Liability, Measurement Input Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Net income (loss) per share: Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Debt instrument, unamortized discount Discount on debt Debt Instrument, Unamortized Discount Discount rates Measurement Input, Discount Rate [Member] Lease liabilities Operating Lease, Liability, Current Net Unrealized Gain (Loss) From Available-For-Sale Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Common stock issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Amortization of acquired intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Noncurrent available-for-sale investments Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Intangible Assets, Net Finite-Lived Intangible Assets, Net FIXED ASSETS Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements Not Adopted as of March 31, 2024 New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Days prior maturity date Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents, Days Prior To Maturity Date Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents, Days Prior To Maturity Date Amortization expense, eighth period Finite-Lived Intangible Asset, Expected Amortization, Year Eight Finite-Lived Intangible Asset, Expected Amortization, Year Eight Contingent consideration (gains) charges, restructuring charges and other Acquisition-Related Charges, Impairment And Other [Member] Acquisition-Related Charges, Impairment And Other Counterparty Name [Domain] Counterparty Name [Domain] ASU 2020-06 convertible notes if-converted method adjustment Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Periodic payment, principal Debt Instrument, Periodic Payment, Principal Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Kristen Williams [Member] Kristen Williams Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Payment term Contingent Consideration, Payment Term Contingent Consideration, Payment Term 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Convertible senior notes Debt Instrument, Fair Value Disclosure Schedule of Income (Loss) Before Income Taxes and Income Tax Expense (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Variable lease costs Variable Lease, Cost Fixed lease costs Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Convertible notes receivable Notes Receivable, Fair Value Disclosure Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Long-term debt Total debt, net of deferred financing costs Long-Term Debt Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Dilutive effect of stock options Weighted average number of stock options Employee Stock Option [Member] Unrealized Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Total operating expenses Costs and Expenses Maximum Maximum Maximum [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Largest wholesaler Largest Customer [Member] Represents the largest customer of the entity. Schedule of Restructuring Charges Restructuring and Related Costs [Table Text Block] Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Type of Adoption [Domain] Accounting Standards Update [Domain] Entity Address, Address Line One Entity Address, Address Line One Concentration of products (in products) Concentration Risk, Number Of Products Concentration Risk, Number Of Products Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] 0.750% Convertible senior notes due August 2025 Convertible Senior Notes Due 2025 [Member] Convertible Senior Notes Due 2025 Weighted Average Exercise Price (Per Share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Financial Assets: Receivables, Fair Value Disclosure [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Measurements Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Convertible senior notes, net Convertible Debt, Noncurrent Amount of allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Convertible Notes Receivable Convertible Notes Receivable [Member] Convertible Notes Receivable Subsequent Event Subsequent Event [Member] Concentration Risk By Major Customer Customer Concentration Risk [Member] Expect to receive partial summary judgment Litigation Settlement, Amount Expected To Be Awarded from Other Party Litigation Settlement, Amount Expected To Be Awarded from Other Party Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Net leverage ratio Debt Instrument, Covenant, Net Leverage Ratio Debt Instrument, Covenant, Net Leverage Ratio Sublease income Sublease Income Other net losses (gains) Provision for Other Losses Gross Carrying Value Intangible Assets, Net Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Unvested at beginning of period (in dollars per share) Unvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Balloon payment to be paid Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Unrealized gain (loss) on investments, tax expense OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax FINANCIAL INSTRUMENTS Financial Instruments Disclosure [Text Block] Entity Tax Identification Number Entity Tax Identification Number Inventories, net Total Inventory, Net Total Lease, Cost Range [Axis] Statistical Measurement [Axis] Amortization expense, ninth period Finite-Lived Intangible Asset, Expected Amortization, Year Nine Finite-Lived Intangible Asset, Expected Amortization, Year Nine Financial Instrument [Axis] Financial Instrument [Axis] Contractual interest expense Interest Expense, Debt, Excluding Amortization Entity Interactive Data Current Entity Interactive Data Current Interest receivable Interest Receivable Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Asset retirement obligation Asset Retirement Obligation Total Shareholder Return Amount Total Shareholder Return Amount Net product sales Total net product sales Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Leverage ratio, maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Stock Incentive Plans Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Repayment of debt principal Debt Instrument, Repaid, Principal Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Debt instrument, percentage of principal amount for computation of redemption price Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Sales of available-for-sale investments Proceeds from Sale of Short-Term Investments Debt instrument, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Noncurrent: Long-Term Investments [Member] Long-Term Investments [Member] Leases [Abstract] Leases [Abstract] Contingent consideration (gains) charges, restructuring charges and other Acquisition-Related (Gain) Loss, Charges, Impairment And Other Acquisition-Related (Gain) Loss, Charges, Impairment And Other Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] EARNINGS PER SHARE Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Amortization expense, first period Finite-Lived Intangible Asset, Expected Amortization, Year One Cash paid for operating lease liabilities, net of lease incentives Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Initial conversion price of notes into common stock (in dollars per share) Debt Instrument, Convertible, Conversion Price Initial conversion rate of common stock per $1,000 of principal amount of Notes Debt Instrument, Convertible, Conversion Ratio PEO PEO [Member] Threshold percentage stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Income tax payable Taxes Payable Name of Major Customer [Domain] Customer [Domain] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Number of Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Achievement of Milestone [Axis] Achievement of Milestone [Axis] Information by categories of milestones achieved. Debt Instrument [Axis] Debt Instrument [Axis] Maximum milestone payment to be received Collaborative Arrangement, Milestone Payments to be Received, Maximum Collaborative Arrangement, Milestone Payments to be Received, Maximum Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate (in percent) Effective Income Tax Rate Reconciliation, Percent Repayments of debt Repayments of Debt Total operating lease liabilities Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Daryl Gaugler [Member] Daryl Gaugler Total liabilities Liabilities Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount FIXED ASSETS Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Net income (loss) per share: Earnings Per Share [Abstract] Common stock, par value $0.001; 250,000,000 shares authorized; 46,517,410 and 46,481,174 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Convertible senior notes Senior Notes [Member] Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of Consolidation [Policy Text Block] Disclosure of accounting policy for basis of presentation and principles of consolidation. Total current assets Assets, Current Schedule of Carrying Amount and Fair Value of the Long-Term Debt Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Equity Investments Equity Securities [Member] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability Schedule of Percentage of Revenue Comprised of the Three Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Prepayment fee percentage Debt Instrument, Prepayment Fee, Percent Debt Instrument, Prepayment Fee, Percent Cash Flow, Operating Activities, Lessee [Abstract] Cash Flow, Operating Activities, Lessee [Abstract] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Other, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Long-term debt, net Secured Long-Term Debt, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Aggregate purchase Stock Repurchase Program, Authorized Amount GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] PEO Name PEO Name Percentage of revenue from customers to total revenue (in percent) Concentration risk (as a percent) Concentration Risk, Percentage Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Term Loan A Facility Term Loan A Facility [Member] Term Loan A Facility Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Schedule of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Acquisition-related fees Acquisition Related Fees [Member] Acquisition Related Fees Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Amortization expense, fifth period Finite-Lived Intangible Asset, Expected Amortization, Year Five Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Asset-backed securities Asset-Backed Securities [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Acquisition-Related Charges (Gain), Restructuring Charges and Other COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block] COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block] Contingent consideration Contingent Consideration, Noncurrent Contingent Consideration, Noncurrent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] ASU 2020-06 convertible notes if-converted method adjustment (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Amortization expense, sixth period Finite-Lived Intangible Asset, Expected Amortization, Year Six Finite-Lived Intangible Asset, Expected Amortization, Year Six Product Concentration Risk Product Concentration Risk [Member] Depreciation of fixed assets and amortization of intangible assets Depreciation, Depletion and Amortization Office furniture and equipment Furniture and Fixtures [Member] Concentration of Major Customers Major Customers, Policy [Policy Text Block] Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Bupivacaine liposome injectable suspension Bupivacaine Liposome Injectable Suspension [Member] Bupivacaine Liposome Injectable Suspension Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Balance at beginning of period Balance at ending of period Equity, Attributable to Parent Commercial paper Commercial Paper [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Key Assumptions used in the Valuation of Contingent Consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] EXPAREL EXPAREL [Member] EXPAREL/bupivacaine liposome injectable suspension [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term of options (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest U.S. government bonds US Treasury Bond Securities [Member] Equity investments Equity Securities without Readily Determinable Fair Value, Amount Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Lauren Riker [Member] Lauren Riker Investments and other assets Equity Method Investments and Other Assets Equity Method Investments and Other Assets Entity Emerging Growth Company Entity Emerging Growth Company 3.375% Convertible senior notes due May 2024 (1) 3.375% convertible senior notes due 2024 Convertible Senior Notes Due 2024 [Member] Convertible Senior Notes Due 2024 Deferred financing costs Debt Issuance Costs, Net Paul Hastings [Member] Paul Hastings Investment Categorization [Domain] Investment Categorization [Domain] Investment Categorization [Domain] Intangible assets, net Intangible Assets, Net Intangible Assets, Net (Excluding Goodwill) Schedule of Available-for-sale Securities [Table] Schedule of Short-Term and Noncurrent Available-For-Sale Investments [Table] Schedule of Short-Term and Noncurrent Available-For-Sale Investments GeneQuine GeneQuine [Member] GeneQuine Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Payment of debt issuance and financing costs Payment of Financing and Stock Issuance Costs Document Fiscal Period Focus Document Fiscal Period Focus Threshold trading days Debt Instrument, Convertible, Threshold Trading Days 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Outstanding beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Total Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Repurchase amount Debt Instrument, Repurchase Amount Common Stock Common Stock [Member] Term loan A facility maturing March 2028 Term Loan A Facility Due March 2028 [Member] Term Loan A Facility Due March 2028 Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Royalty revenue Royalty [Member] Repayment of Term loan B facility Repayments of Secured Debt Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Minimum Minimum [Member] Weighted average common shares outstanding: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Fixed assets, net Fixed assets, net Property, Plant and Equipment, Net Schedule of the Company's Stock Option Activity and Restricted Stock Unit Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Third largest wholesaler Third Largest Customer [Member] Represents the third largest customer of the entity. Debt Redemption Terms Prior to February 3, 2023 Debt Redemption Terms Prior to February 3, 2023 [Member] Debt Redemption Terms Prior to February 3, 2023 Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Three Largest Customers [Member] Three Largest Customers Term Loan B Facility Due December 2026 Term Loan B Facility Due December 2026 [Member] Term Loan B Facility Due December 2026 Capitalized interest Interest Costs Capitalized Payment of employee withholding taxes on restricted stock unit vests Payment, Tax Withholding, Share-Based Payment Arrangement Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash (received) paid for income taxes Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Disposals Property, Plant and Equipment, Disposals COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Developed technologies Developed Technology Rights [Member] Accumulated Deficit Retained Earnings [Member] Schedule of Recognized Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Cost Debt Securities, Available-for-Sale, Amortized Cost Other income (expense): Nonoperating Income (Expense) [Abstract] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Debt Redemption Terms on or After August 1, 2023 Debt Redemption Terms on or after August 1, 2023 [Member] Debt Redemption Terms on or after August 1, 2023 STOCK PLANS Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block] Risk free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Term Loan B Facility Term Loan B Facility [Member] Term Loan B Facility Basic net income (loss) per common share (in dollars per share) Earnings Per Share, Basic Right-of-use assets, net Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] One-time Termination Benefits One-time Termination Benefits [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Restructuring charges Restructuring Costs Flexion And MyoScience Acquisition Flexion And MyoScience Acquisition [Member] Flexion And MyoScience Acquisition Balance of unrestricted cash and cash equivalents Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] 2024 (remaining nine months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Estimate of restructuring costs, once probable Restructuring and Related Cost, Expected Cost Arrangement Duration Trading Arrangement Duration Maximum conversion premium (in shares) Debt Instrument, Convertible, Conversion Premium, Shares Debt Instrument, Convertible, Conversion Premium, Shares Acquired IPR&D In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Restricted stock units Restricted Stock or Unit Expense Debt issued in private placement Proceeds from Issuance of Debt Charges incurred Restructuring Charges Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Unsecured Debt Unsecured Debt [Member] Termination Date Trading Arrangement Termination Date Achievement of Milestone [Domain] Achievement of Milestone [Domain] Different categories of achievement of milestones. Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Debt Securities, Available-for-Sale Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Current: Short-Term Investments [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Long-term debt Long-Term Debt, Gross Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Flexion Flexion [Member] Flexion ZILRETTA ZILRETTA [Member] ZILRETTA All Adjustments to Compensation All Adjustments to Compensation [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from exercises of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Amortization expense, third period Finite-Lived Intangible Asset, Expected Amortization, Year Three Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Market price of principal amount of notes Debt Instrument, Market Price Debt market price, per $1,000 principal amount. Insider Trading Arrangements [Line Items] Achievement of Development and Regulatory Milestones Achievement of Development and Regulatory Milestones [Member] Achievement of Development and Regulatory Milestones AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Closing sale price (in dollars per share) Share Price Accounts receivable, payment terms Accounts Receivable, Payment Terms Accounts Receivable, Payment Terms Employee termination benefits related to share-based compensation Employee Benefit and Share-Based Payment Arrangement, Noncash Debt Conversion and Redemption Terms [Axis] Debt Conversion and Redemption Terms [Axis] Information regarding the conversion and redemption terms of the debt instruments. Settlement period - convertible debt conversion request Settlement Period - Convertible Debt Conversion Request The number of trading days in a settlement period for convertible debt conversion requests. Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Dilutive effect of share based compensation arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Weighted average interest rate, at point in time Long-Term Debt, Weighted Average Interest Rate, at Point in Time Amortization expense, second period Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of goods sold Cost of Sales [Member] Changes in contingent consideration Flexion contingent consideration Contingent consideration gain Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Employee Termination Benefits Employee Severance [Member] CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block] Leverage ratio, minimum Debt Instrument, Covenant, Leverage Ratio, Minimum Debt Instrument, Covenant, Leverage Ratio, Minimum Document Period End Date Document Period End Date iovera° iovera° [Member] iovera° [Member] Proceeds from Term loan A facility Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Vested restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Scheduled trading day Debt Instrument, Convertible, Redemption, Trading Days From Maturity Debt Instrument, Convertible, Redemption, Trading Days From Maturity Entity Central Index Key Entity Central Index Key Total Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Value Finite-Lived Intangible Assets, Gross Income tax (expense) benefit Income tax expense (benefit) Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Debt Conversion and Redemption Terms [Domain] Debt Conversion and Redemption Terms [Domain] Identification of the conversion and redemption terms of the debt instruments. Sales Revenue Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Total other comprehensive (loss) income Other comprehensive loss (Note 10) Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Fair Value Measurements Debt Securities, Available-for-Sale [Line Items] INVENTORIES Inventory Disclosure [Text Block] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Second largest wholesaler Second Largest Customer [Member] Represents the second largest customer of the entity. Total revenues Total net product sales Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate (in percent) Operating Lease, Weighted Average Discount Rate, Percent Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Loss contingency, damages sought Loss Contingency, Damages Sought, Value Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Leasehold improvements Leasehold Improvements [Member] Major Customer Three Major Customer Three [Member] Represents the major customer of the entity. Diluted (in shares) Weighted average number of shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Operating expenses: Operating Expenses [Abstract] REVENUE Revenue from Contract with Customer [Text Block] Purchases of fixed assets Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Computation of diluted securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Lease, Cost [Abstract] Lease, Cost [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Capitalized interest (Note 5) Interest Costs Capitalized Adjustment Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover page. Cover [Abstract] Number of customers Concentration Risk, Number of Customers Concentration Risk, Number of Customers Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs EXPAREL at average sales price margin Average Sales Price, Margin Percentage Average Sales Price, Margin Percentage Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Effective interest rate on total debt (in percent) Debt Instrument, Interest Rate During Period Other liabilities Other Liabilities, Noncurrent Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Schedule of Total Interest Expense Recognized Related to the Notes Schedule of Interest Expense [Table Text Block] Tabular disclosure of the amount of interest rate expenses related to convertible notes. Non-NEOs Non-NEOs [Member] Total future lease payments Lessee, Operating Lease, Liability, to be Paid Short-term available-for-sale investments Short-Term Investments Construction in progress Construction in Progress [Member] Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Investments Without Readily Determinable Fair Value Roll Forward [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Convertible debt, premium on common stock Debt Instrument, Conversion Obligation Premium on Common Stock Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument. Term Loan Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Foreign currency adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Gain (Loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Gain (Loss) Purchase price of common stock, ESPP (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Scenario [Axis] Scenario [Axis] Debt Instrument [Line Items] DEBT AND FINANCING OBLIGATIONS Debt Instrument [Line Items] Basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Major Customer One Major Customer One [Member] Represents the major customer of the entity. Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Income (loss) from operations Operating Income (Loss) Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Revenues: Revenues [Abstract] Cost of goods sold Cost of Revenue Flexion Flexion Therapeutics, Inc. [Member] Flexion Therapeutics, Inc. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Employee stock purchase plan Compensation Expense From Employee Stock Purchase Plan Compensation Expense From Employee Stock Purchase Plan Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Statement [Line Items] Fair Value Measurements Using Estimate of Fair Value Measurement [Member] Concentration Risk [Table] Concentration Risk [Table] Computer equipment and software Computer Equipment and Software [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems. Scenario, Unspecified [Domain] Scenario [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Composition of the Company's Debt and Financing Obligations Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] Income (loss) before income taxes: Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] EX-101.PRE 9 pcrx-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 pcrx-20240331_g1.jpg PACIRA BIOSCIENCES LOGO begin 644 pcrx-20240331_g1.jpg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pcrx-20240331_g2.jpg PRODUCT PIPELINE begin 644 pcrx-20240331_g2.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
May 06, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-35060  
Entity Registrant Name PACIRA BIOSCIENCES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 51-0619477  
Entity Address, Address Line One 5401 West Kennedy Boulevard, Suite 890  
Entity Address, City or Town Tampa  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33609  
City Area Code 813  
Local Phone Number 553-6680  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol PCRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   46,546,148
Entity Central Index Key 0001396814  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 184,052 $ 153,298
Short-term available-for-sale investments 141,838 125,283
Accounts receivable, net 101,639 105,556
Inventories, net 96,782 104,353
Prepaid expenses and other current assets 18,802 21,504
Total current assets 543,113 509,994
Noncurrent available-for-sale investments 0 2,410
Fixed assets, net 171,804 173,927
Right-of-use assets, net 58,626 61,020
Goodwill 163,243 163,243
Intangible assets, net 468,936 483,258
Deferred tax assets 141,057 144,485
Investments and other assets 36,542 36,049
Total assets 1,583,321 1,574,386
Current liabilities:    
Accounts payable 8,982 15,698
Accrued expenses 66,818 64,243
Lease liabilities 9,003 8,801
Current portion of convertible senior notes, net 8,641 8,641
Total current liabilities 93,444 97,383
Convertible senior notes, net 399,210 398,594
Long-term debt, net 112,477 115,202
Lease liabilities 52,446 54,806
Contingent consideration 20,892 24,698
Other liabilities 12,690 13,573
Total liabilities 691,159 704,256
Commitments and contingencies (Note 15)
Stockholders’ equity:    
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023 0 0
Common stock, par value $0.001; 250,000,000 shares authorized; 46,517,410 and 46,481,174 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 47 46
Additional paid-in capital 989,780 976,633
Accumulated deficit (97,817) (106,796)
Accumulated other comprehensive income 152 247
Total stockholders’ equity 892,162 870,130
Total liabilities and stockholders’ equity $ 1,583,321 $ 1,574,386
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 46,517,410 46,481,174
Common stock, shares outstanding (in shares) 46,517,410 46,481,174
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Total revenues $ 167,117 $ 160,341
Operating expenses:    
Cost of goods sold 47,416 49,020
Research and development 18,238 17,140
Selling, general and administrative 72,026 70,843
Amortization of acquired intangible assets 14,322 14,322
Contingent consideration (gains) charges, restructuring charges and other 1,903 12,107
Total operating expenses 153,905 163,432
Income (loss) from operations 13,212 (3,091)
Other income (expense):    
Interest income 3,903 3,142
Interest expense (3,316) (9,589)
Loss on early extinguishment of debt 0 (16,926)
Other, net (159) (10)
Total other income (expense), net 428 (23,383)
Income (loss) before income taxes 13,640 (26,474)
Income tax (expense) benefit (4,661) 6,938
Net income (loss) $ 8,979 $ (19,536)
Net income (loss) per share:    
Basic net income (loss) per common share (in dollars per share) $ 0.19 $ (0.43)
Diluted net income (loss) per common share (in dollars per share) $ 0.19 $ (0.43)
Weighted average common shares outstanding:    
Basic (in shares) 46,499 45,949
Diluted (in shares) 52,193 45,949
Net product sales    
Revenues:    
Total revenues $ 165,824 $ 159,431
Royalty revenue    
Revenues:    
Total revenues $ 1,293 $ 910
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income (loss) $ 8,979 $ (19,536)
Other comprehensive income (loss):    
Net unrealized (loss) gain on investments, net of tax (108) 251
Foreign currency translation adjustments 13 (8)
Total other comprehensive (loss) income (95) 243
Comprehensive income (loss) $ 8,884 $ (19,293)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2022   45,928,000      
Balance at beginning of period at Dec. 31, 2022 $ 775,010 $ 46 $ 924,095 $ (148,751) $ (380)
Increase (Decrease) in Stockholders' Equity          
Exercise of stock options (in shares)   12,000      
Exercise of stock options 334   334    
Vested restricted stock units (in shares)   30,000      
Stock-based compensation 11,990   11,990    
Other comprehensive loss (Note 10) 243       243
Net income (loss) (19,536)     (19,536)  
Ending balance (in shares) at Mar. 31, 2023   45,970,000      
Balance at ending of period at Mar. 31, 2023 $ 768,041 $ 46 936,419 (168,287) (137)
Beginning balance (in shares) at Dec. 31, 2023 46,481,174 46,481,000      
Balance at beginning of period at Dec. 31, 2023 $ 870,130 $ 46 976,633 (106,796) 247
Increase (Decrease) in Stockholders' Equity          
Vested restricted stock units (in shares)   36,000      
Vested restricted stock units 1 $ 1      
Common stock withheld for employee withholding tax liabilities on vested restricted stock units (4)   (4)    
Stock-based compensation 13,151   13,151    
Other comprehensive loss (Note 10) (95)       (95)
Net income (loss) $ 8,979     8,979  
Ending balance (in shares) at Mar. 31, 2024 46,517,410 46,517,000      
Balance at ending of period at Mar. 31, 2024 $ 892,162 $ 47 $ 989,780 $ (97,817) $ 152
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating activities:    
Net income (loss) $ 8,979 $ (19,536)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Deferred taxes 3,463 (7,342)
Depreciation of fixed assets and amortization of intangible assets 18,426 19,602
Amortization of debt issuance costs 681 937
Amortization of debt discount 24 675
Loss on early extinguishment of debt 0 16,926
Stock-based compensation 13,151 11,990
Changes in contingent consideration (3,806) 11,618
Other net losses (gains) 73 (23)
Changes in operating assets and liabilities:    
Accounts receivable, net 3,917 5,192
Inventories, net 7,572 3,086
Prepaid expenses and other assets 897 (1,926)
Accounts payable (6,976) 2,628
Accrued expenses and income taxes payable 3,471 (25,120)
Other liabilities (771) 421
Net cash provided by operating activities 49,101 19,128
Investing activities:    
Purchases of fixed assets (2,836) (6,565)
Purchases of available-for-sale investments (56,055) (49,497)
Sales of available-for-sale investments 43,361 126,245
Purchases of debt investments 0 (4,000)
Net cash (used in) provided by investing activities (15,530) 66,183
Financing activities:    
Proceeds from exercises of stock options 0 333
Payment of employee withholding taxes on restricted stock unit vests (4) 0
Proceeds from Term loan A facility 0 149,550
Debt extinguishment costs 0 (5,750)
Payment of debt issuance and financing costs 0 (1,163)
Net cash used in financing activities (2,817) (153,905)
Net increase (decrease) in cash and cash equivalents 30,754 (68,594)
Cash and cash equivalents, beginning of period 153,298 104,139
Cash and cash equivalents, end of period 184,052 35,545
Supplemental cash flow information:    
Cash paid for interest 3,969 17,634
Net cash (received) paid for income taxes (245) 201
Non-cash investing and financing activities:    
Fixed assets included in accounts payable and accrued liabilities 607 2,252
Term Loan B Facility    
Financing activities:    
Repayment of Term loan B facility 0 (296,875)
Term Loan A Facility    
Financing activities:    
Repayment of Term loan B facility $ (2,813) $ 0
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DESCRIPTION OF BUSINESS
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
Business Overview
Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) is the therapeutic area leader in non-opioid pain management with a stated corporate mission of providing non-opioid pain management options to as many patients as possible and redefining the role of opioids for rescue therapy only. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the “Flexion Acquisition”), and added ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. In April 2019, the Company added iovera°® to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience (the “MyoScience Acquisition”). The iovera° system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to targeted nerves.
Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.
The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker—manages and allocates resources at a consolidated level. Effective January 2, 2024, the Company appointed a new Chief Executive Officer. Consistent with the Company’s predecessor chief operating decision maker, the Company views its business as one reportable operating segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”), for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”).
The condensed consolidated financial statements at March 31, 2024, and for the three-month periods ended March 31, 2024 and 2023, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2023 is derived from the audited consolidated financial statements included in the Company’s 2023 Annual Report. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.
The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.
Concentration of Major Customers
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual physicians. The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented:
Three Months Ended
March 31,
20242023
 Largest wholesaler36%32%
 Second largest wholesaler23%24%
 Third largest wholesaler20%23%
     Total79%79%
Recent Accounting Pronouncements Not Adopted as of March 31, 2024
In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The ASU amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The new segment disclosure requirements apply for entities with a single reportable segment. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023 and interim periods thereafter, with early adoption permitted. The ASU amendment will require adoption on a retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The ASU amendment addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
Revenue from Contracts with Customers
The Company’s net product sales consist of (i) EXPAREL in the U.S., the European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and (iv) sales of its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of its bupivacaine liposome injectable suspension for veterinary use. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA.
Net Product Sales
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.
Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected
value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.
Chargebacks for fees and discounts to qualified government healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified Department of Veteran Affairs hospitals, participating GPO members and 340B entities at prices lower than the list prices charged to other customers. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers charge the Company for the difference between the product payment and the statutory selling price to the qualified entity. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are generally determined at the time of sale to the qualified government healthcare provider by customers, and the Company generally issues credits for such amounts within weeks of the customer’s notification to the Company of the sale. Reserves for chargebacks consist of credits that the Company expects to issue for units that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.
The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.
Accounts Receivable
The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from zero to four months from the date of the transaction, and accordingly, there is no significant financing component.
Performance Obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.
Disaggregated Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Three Months Ended
March 31,
20242023
Net product sales:
   EXPAREL$132,430 $130,408 
   ZILRETTA25,839 24,334 
   iovera°5,030 4,001 
   Bupivacaine liposome injectable suspension2,525 688 
      Total net product sales$165,824 $159,431 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
The components of inventories, net are as follows (in thousands):
March 31,December 31,
20242023
Raw materials$51,608 $54,099 
Work-in-process18,764 31,215 
Finished goods26,410 19,039 
     Total$96,782 $104,353 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FIXED ASSETS
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
FIXED ASSETS FIXED ASSETS
Fixed assets, net, summarized by major category, consist of the following (in thousands):
March 31,December 31,
20242023
Machinery and equipment (1)
$106,670 $121,773 
Leasehold improvements58,835 61,826 
Computer equipment and software17,223 17,186 
Office furniture and equipment2,543 2,543 
Construction in progress106,987 105,905 
        Total292,258 309,233 
Less: accumulated depreciation (1)
(120,454)(135,306)
        Fixed assets, net$171,804 $173,927 
(1) During the three months ended March 31, 2024, the Company disposed of $19.0 million of fully depreciated machinery and equipment associated with its 45-liter EXPAREL manufacturing process at the Thermo Fisher Scientific Pharma Services facility located in Swindon, England. The Company continues to operate its 200-liter EXPAREL manufacturing process at the same facility.
For the three months ended March 31, 2024 and 2023, depreciation expense was $4.1 million and $5.3 million, respectively. For the three months ended March 31, 2024 and 2023, there was $0.7 million and $1.4 million of capitalized interest on the construction of manufacturing sites, respectively.
At March 31, 2024 and December 31, 2023, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located in Europe in the amount of $34.3 million and $36.8 million, respectively.
As of March 31, 2024 and December 31, 2023, the Company had asset retirement obligations of $3.9 million and $4.3 million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
LEASES LEASES
The Company leases all of its facilities, including its EXPAREL and iovera° handpiece manufacturing facility at its Science Center Campus in San Diego, California. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees has been allocated to the lease components based on a relative fair value basis.
Since July 2022 and February 2023, the Company has been recognizing sublease income for laboratory space leased in Woburn, Massachusetts and a portion of office space leased in Burlington, Massachusetts, respectively, from leases that were assumed as part of the Flexion Acquisition. In February 2024, the lease and sublease term concluded for the laboratory space in Woburn, Massachusetts.
The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):
Three Months Ended
March 31,
20242023
Fixed lease costs$3,497 $3,628 
Variable lease costs494 567 
Sublease income(131)(153)
Total$3,860 $4,042 
Supplemental cash flow information related to operating leases is as follows (in thousands):
Three Months Ended
March 31,
20242023
Cash paid for operating lease liabilities, net of lease incentives$3,219 $3,763 
The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.
The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:
March 31,
20242023
Weighted average remaining lease term5.81 years6.61 years
Weighted average discount rate7.01 %7.03 %
Maturities of the Company’s operating lease liabilities are as follows (in thousands):
YearAggregate Minimum
Payments Due
2024 (remaining nine months)$9,777 
202512,775 
202612,814 
202712,587 
202810,925 
Thereafter16,426 
   Total future lease payments75,304 
   Less: imputed interest(13,855)
   Total operating lease liabilities$61,449 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill
The Company’s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. (the Company’s California operating subsidiary) from SkyePharma Holding, Inc. (now Vectura Group Limited, a subsidiary of Philip Morris International, Inc.) in 2007, the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. The goodwill balance at each of March 31, 2024 and December 31, 2023 was $163.2 million.
Intangible Assets
Intangible assets, net, consists of the in-process research and development, or IPR&D, and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):
March 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(155,975)$434,025 10 years, 5 months
Customer relationships90 (45)45 10 years
     Total finite-lived intangible assets, net590,090 (156,020)434,070 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(156,020)$468,936 
December 31, 2023Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(141,655)$448,345 10 years, 5 months
Customer relationships90 (43)47 10 years
     Total finite-lived intangible assets, net590,090 (141,698)448,392 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(141,698)$483,258 
Amortization expense on intangible assets was $14.3 million for both the three months ended March 31, 2024 and 2023.
Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $43.0 million for the remaining nine months of 2024, $57.3 million each year from 2025 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):
March 31,December 31,
20242023
Term loan A facility maturing March 2028$112,477 $115,202 
0.750% Convertible senior notes due August 2025
399,210 398,594 
3.375% Convertible senior notes due May 2024 (1)
8,641 8,641 
     Total$520,328 $522,437 
(1) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.
2028 Term Loan A Facility
On March 31, 2023, the Company entered into a credit agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders, to refinance the indebtedness outstanding under the Company’s then-existing TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of the Company’s and any subsidiary guarantor’s assets. Subject to certain conditions, the Company may, at any time, on one or more occasion, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the TLA Term Loan were approximately $149.6 million after deducting an original issue discount of $0.4 million.
The total debt composition of the TLA Term Loan is as follows (in thousands):
March 31,December 31,
20242023
Term loan A facility maturing March 2028$113,750 $116,563 
Deferred financing costs(924)(988)
Discount on debt(349)(373)
     Total debt, net of debt discount and deferred financing costs$112,477 $115,202 
The TLA Term Loan matures on March 31, 2028 and the TLA Credit Agreement requires quarterly repayments of principal in the amount of $2.8 million which commenced on June 30, 2023, increasing to $3.8 million commencing March 31, 2025, with a remaining balloon payment of approximately $85.3 million due at maturity. Due to voluntary principal prepayments made, the Company is not required to make further principal payments until March 2026, although the Company retains the option to do so.
The TLA Credit Agreement requires the Company to, among other things, maintain (i) a Senior Secured Net Leverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no greater than 3.00 to 1.00 and (ii) a Fixed Charge Coverage Ratio (as defined in the Credit Agreement), determined as of the last day of each fiscal quarter, of no less than 1.50 to 1.00. The TLA Credit Agreement requires the Company to maintain an unrestricted cash and cash equivalents balance of at least $500.0 million less any prepayments of the 2025 Notes (as defined below) at any time from 91 days prior to the maturity date through the earlier of (i) the latest maturity date of the 2025 Notes and (ii) the date on which there is no outstanding principal amount of the 2025 Notes. The TLA Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of March 31, 2024, the Company was in compliance with all financial covenants under the TLA Credit Agreement.
The Company may elect to borrow either (i) alternate base rate borrowings or (ii) term benchmark borrowings or daily simple SOFR (as defined in the TLA Credit Agreement) borrowings. Each term loan borrowing that is an alternate base rate borrowing bears interest at a rate per annum equal to (i) the Alternate Base Rate (as defined in the TLA Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 2.00% to 2.75%. Each term loan borrowing that is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. During the three months ended March 31, 2024, the Company made a $2.8 million voluntary principal prepayment. During the year ended December 31, 2023, the Company made a scheduled principal payment of $2.8 million as well as $30.6 million of voluntary principal prepayments. As of March 31, 2024, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 8.41%.
2026 Term Loan B Facility
In December 2021, the Company entered into a term loan credit agreement (the “TLB Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the TLB Credit Agreement (the “TLB Term Loan”) was issued at a 3.00% discount and allowed for a single-advance term loan B facility in the principal amount of $375.0 million, which was secured by substantially all of the Company’s and each subsidiary guarantor’s assets. The net proceeds of the TLB Term Loan were approximately $363.8 million after deducting an original issue discount of $11.2 million.
During the three months ended March 31, 2023, the Company repaid the outstanding $296.9 million principal on the TLB Term Loan, which resulted in a $16.9 million loss on early extinguishment of debt.
On March 31, 2023, the Company used the $149.6 million of net borrowings under the TLA Credit Agreement and cash on hand to repay the indebtedness outstanding under the TLB Credit Agreement and concurrently terminated the TLB Credit Agreement. The Company incurred a prepayment fee of 2.00% of the outstanding principal balance of the TLB Term Loan in connection with the termination.
Convertible Senior Notes Due 2025
In July 2020, the Company completed a private placement of $402.5 million in aggregate principal amount of its 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1st and August 1st of each year. The 2025 Notes mature on August 1, 2025.
The total debt composition of the 2025 Notes is as follows (in thousands):
March 31,December 31,
20242023
0.750% convertible senior notes due August 2025
$402,500 $402,500 
Deferred financing costs(3,290)(3,906)
     Total debt, net of deferred financing costs$399,210 $398,594 
Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only if certain circumstances are met, including if during the previous calendar quarter, the last reported sales price of the Company’s common stock was greater than 130% of the conversion price then applicable for at least 20 out of the last 30 consecutive trading days of the quarter. During the quarter ended March 31, 2024, the conditions for conversion were not met.
On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.
Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company’s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.
As of March 31, 2024, the 2025 Notes had a market price of $953 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $402.5 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company’s option).
Since August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40th scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company’s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a “make-whole fundamental change” (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.
While the 2025 Notes are currently classified on the Company’s condensed consolidated balance sheet at March 31, 2024 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company’s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.
Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition
Prior to the Flexion Acquisition, in May 2017, Flexion issued an aggregate of $201.3 million principal amount of 3.375% convertible senior notes due 2024 (the “Flexion 2024 Notes”), pursuant to the indenture, dated as of May 2, 2017 (the “Original Flexion Indenture”), between Flexion and Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), as trustee (the “Flexion Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the “First Supplemental Flexion Indenture” and, together with the Original Flexion Indenture, the “Flexion Indenture”). The Flexion 2024 Notes had a maturity date of May 1, 2024, were unsecured, and accrued interest at a rate of 3.375% per annum, payable semi-annually on May 1st and November 1st of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company.
As a result of the Flexion Acquisition, and in connection with a Fundamental Change Company Notice and Offer to Purchase (the “Notice”) to the holders of the Flexion 2024 Notes in accordance with the Flexion Indenture, holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights. On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, the Company offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to 100% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder’s Flexion 2024 Notes under the Flexion Indenture as well as the right to receive interest payments on the Flexion 2024 Notes.
On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6 million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. At March 31, 2024, the remaining principal outstanding was $8.6 million, which was repaid upon its maturity on May 1, 2024.
Interest Expense
The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):
Three Months Ended
March 31,
20242023
Contractual interest expense$3,311 $9,350 
Amortization of debt issuance costs681 937 
Amortization of debt discount24 675 
Capitalized interest (Note 5)
(700)(1,373)
        Total$3,316 $9,589 
Effective interest rate on total debt2.96 %5.36 %
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:
•Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
•Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company’s convertible
senior notes and its TLA Term Loan are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either an impairment or upward or downward adjustments based on observable transactions.
At March 31, 2024, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):
Carrying ValueFair Value Measurements Using
Level 1Level 2Level 3
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Financial Assets:
Equity investments$15,877 $— $— $15,877 
Convertible notes receivable$12,030 $— $— $12,030 
Financial Liabilities:
   Acquisition-related contingent consideration$20,892 $— $— $20,892 
Financial Liabilities Measured at Amortized Cost:
Term loan A facility due March 2028$112,477 $— $113,181 $— 
   0.750% convertible senior notes due 2025 (1)
$399,210 $— $383,381 $— 
   3.375% convertible senior notes due 2024 (2)
$8,641 $— $8,641 $— 
(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $29.22 per share at March 31, 2024 compared to a conversion price of $71.78 per share. At March 31, 2024, as the conversion price was above the stock price, the requirements for conversion have not been met. The maximum conversion premium that could have been due on the 2025 Notes is 5.6 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.
(2) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Equity and Convertible Note Investments
The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):
Equity InvestmentsConvertible Notes ReceivableTotal
Balance at December 31, 2022
$15,877 $5,315 $21,192 
   Purchases— 6,758 6,758 
   Foreign currency adjustments— 61 61 
Balance at December 31, 2023
15,877 12,134 28,011 
   Foreign currency adjustments— (104)(104)
Balance at March 31, 2024
$15,877 $12,030 $27,907 
Acquisition-Related Contingent Consideration
The Company has recognized contingent consideration related to the Flexion Acquisition in the amount of $20.9 million and $24.7 million as of March 31, 2024 and December 31, 2023, respectively. The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments.
Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts.
In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3 million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5 million prior to the Company’s September 2022 decision to formally discontinue further development of Flexion’s product candidate, PCRX-301. The Company’s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended March 31, 2024, the Company recorded a gain of $3.8 million primarily due to an adjustment reflecting the probability of achieving the remaining regulatory milestone by December 31, 2030, the expiration date. During the three months ended March 31, 2023, the Company recorded a charge of $11.6 million, which was due to a decrease to the assumed discount rate based on a significant improvement in the Company’s incremental borrowing rate resulting from the TLA Credit Agreement entered into in March 2023. These adjustments were recorded within contingent consideration (gains) charges, restructuring charges and other in the condensed consolidated statements of operations. At March 31, 2024, the weighted average discount rate was 8.6%.
The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:
Assumption
Ranges
Utilized as of
March 31, 2024
Discount rates
8.0% to 9.3%
Probability of payment for remaining regulatory milestone
0%
The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):
Contingent Consideration
Fair Value
Balance at December 31, 2022
$28,122 
Fair value adjustments and accretion(3,424)
Balance at December 31, 2023
24,698 
   Fair value adjustments and accretion(3,806)
Balance at March 31, 2024
$20,892 
Available-for-Sale Investments
Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency and government bonds with maturities greater than three months, but less than one year. Noncurrent investments consist of asset-backed securities collateralized by credit card receivables and contain maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company’s short-term investments are reported in other comprehensive income (loss). At March 31, 2024 and December 31, 2023, all of the Company’s short-term and noncurrent investments are classified as available-for-sale investments and are determined to be Level 2 instruments, with the exception of U.S. government bonds, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an “A” or better rating by Standard & Poor’s. 
The following summarizes the Company’s short-term and noncurrent available-for-sale investments at March 31, 2024 and December 31, 2023 (in thousands):
March 31, 2024 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 1)		Fair Value
(Level 2)
Current:
Asset-backed securities$25,345 $— $(38)$— $25,307 
Commercial paper94,138 28 (51)— 94,115 
Corporate bonds7,984 — (6)— 7,978 
U.S. federal agency bonds9,479 — (10)— 9,469 
U.S. government bonds4,974 — (5)4,969 — 
          Total$141,920 $28 $(110)$4,969 $136,869 
December 31, 2023 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 1)		Fair Value
(Level 2)
Current:
Asset-backed securities$9,539 $1 $— $— $9,540 
Commercial paper77,941 103 — — 78,044 
U.S. federal agency bonds22,849 — (29)— 22,820 
U.S. government bonds14,899 — (20)14,879 — 
Subtotal125,228 104 (49)14,879 110,404 
Noncurrent:
Asset-backed securities2,403 7 — — 2,410 
Subtotal2,403 7 — — 2,410 
          Total$127,631 $111 $(49)$14,879 $112,814 
At March 31, 2024, there were no investments available for sale that were materially less than their amortized cost.
The Company elects to recognize its interest receivable separate from its available-for-sale investments. At March 31, 2024 and December 31, 2023, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.1 million and $0.4 million, respectively.
Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.
 As of March 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 39%, 19% and 16%. At December 31, 2023, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 37%, 19% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of March 31, 2024, there were $0.1 million of allowances for credit losses on its accounts receivable associated with iovera°. As of December 31, 2023, the Company did not deem any allowances for credit losses on its accounts receivable necessary.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Accumulated Other Comprehensive Income (Loss)
The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Income
Balance at December 31, 2023
$124 $123 $247 
   Net unrealized loss on investments, net of tax(1)
(108)— (108)
   Foreign currency translation adjustments— 13 13 
Balance at March 31, 2024
$16 $136 $152 
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Loss
Balance at December 31, 2022
$(523)$143 $(380)
   Net unrealized gain on investments, net of tax (1)
251 — 251 
   Foreign currency translation adjustments— (8)(8)
Balance at March 31, 2023
$(272)$135 $(137)
(1) Net of a nominal tax benefit and $0.2 million tax expense for the three months ended March 31, 2024 and 2023, respectively.
Share Repurchase Program
On May 7, 2024, the Company announced that its Board of Directors has approved a new share repurchase program, effective immediately, which authorizes the Company to purchase up to an aggregate of $150.0 million of the Company’s outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK PLANS
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
STOCK PLANS STOCK PLANS
Stock-Based Compensation
The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):
Three Months Ended
March 31,
20242023
Cost of goods sold$1,128 $1,724 
Research and development1,803 1,875 
Selling, general and administrative7,985 8,391 
Contingent consideration (gains) charges, restructuring charges and other2,235 — 
        Total$13,151 $11,990 
Stock-based compensation from:
    Stock options$6,729 $6,464 
    Restricted stock units6,210 5,250 
    Employee stock purchase plan212 276 
        Total$13,151 $11,990 
Equity Awards
The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2024:
Stock Options Number of
Stock Options		 Weighted Average Exercise Price (Per Share)
 Outstanding at December 31, 2023
7,079,748 $49.40 
     Granted900,995 31.95 
     Forfeited(155,397)46.84 
     Expired(245,082)50.23 
 Outstanding at March 31, 2024
7,580,264 47.35 
Restricted Stock Units Number of
Restricted
Stock Units		 Weighted Average Grant Date Fair Value (Per Share)
Unvested at December 31, 2023
1,364,618 $47.66 
     Granted196,974 31.53 
     Vested(36,395)53.97 
     Forfeited(102,206)47.71 
Unvested at March 31, 2024
1,422,991 45.26 
The weighted average fair value of stock options granted during the three months ended March 31, 2024 was $13.65 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:
Black-Scholes Weighted Average AssumptionThree Months Ended March 31, 2024
Expected dividend yieldNone
Risk-free interest rate3.92%
Expected volatility40.94%
Expected term of options5.28 years
Employee Stock Purchase Plan
The Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1 to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is lesser. During the three months ended March 31, 2024, no shares were purchased and issued through the ESPP.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME (LOSS) PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
NET INCOME (LOSS) PER SHARE NET INCOME (LOSS) PER SHARE
Basic and diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.
Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and the purchase of shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible notes are treated under the if-converted method, adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible debt on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible debt on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.
Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive.
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2024 and 2023 (in thousands, except per share amounts):
Three Months Ended
March 31,
20242023
Numerator:
   Net income (loss)—basic$8,979 $(19,536)
ASU 2020-06 convertible notes if-converted method adjustment1,029 — 
   Adjusted net income (loss)—diluted$10,008 $(19,536)
Denominator:
   Weighted average common shares outstanding—basic46,499 45,949 
Computation of diluted securities:
ASU 2020-06 convertible notes if-converted method adjustment5,608 — 
   Dilutive effect of stock options1 — 
   Dilutive effect of RSUs85 — 
   Weighted average common shares outstanding—diluted52,193 45,949 
Net income (loss) per share:
   Basic and diluted net income (loss) per common share$0.19 $(0.43)
The following table summarizes the outstanding stock options, RSUs, ESPP purchase options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):
Three Months Ended
March 31,
20242023
Weighted average number of stock options7,662 6,362 
Convertible senior notes (1)
— 5,608 
Weighted average number of RSUs1,230 1,137 
Weighted average ESPP purchase options52 55 
      Total8,944 13,162 
(1) The convertible senior notes were antidilutive for the three months ended March 31, 2023, in conjunction with a $1.0 million if-converted method adjustment to the numerator that adds back the interest expense associated with the convertible senior notes on a post-tax basis.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
Income (loss) before income taxes and income tax expense (benefit) are as follows (dollar amounts in thousands):
Three Months Ended
March 31,
20242023
Income (loss) before income taxes:
   Domestic$13,657 $(27,773)
   Foreign(17)1,299 
Total income (loss) before income taxes$13,640 $(26,474)
Income tax expense (benefit)$4,661 $(6,938)
Effective tax rate34 %26 %
The Company’s income tax expense (benefit) represents the estimated annual effective tax rate applied to the year-to-date domestic operating results adjusted for certain discrete tax items.
The Company’s effective tax rate for the three months ended March 31, 2024 include costs related to non-deductible stock-based compensation and non-deductible executive compensation, partially offset by tax credits and a fair value adjustment for Flexion contingent consideration. The Company’s effective tax rate for the three months ended March 31, 2023 includes costs for a fair value adjustment to Flexion contingent consideration and a valuation allowance recorded against non-U.S. results, partially offset by tax credits and stock-based compensation benefits.
As of March 31, 2024 and December 31, 2023, the Company has an income tax payable balance of $1.0 million that is included in other liabilities within the condensed consolidated balance sheets.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER CONTINGENT CONSIDERATION (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER
Contingent consideration (gains) charges, restructuring charges and other for the three months ended March 31, 2024 and 2023 summarized below (in thousands):
Three Months Ended
March 31,
20242023
Flexion contingent consideration$(3,806)$11,618 
Restructuring charges5,535 — 
Acquisition-related fees174 489 
Total contingent consideration (gains) charges, restructuring charges and other$1,903 $12,107 
Flexion Acquisition Contingent Consideration
During the three months ended March 31, 2024, the Company recognized a $3.8 million contingent consideration gain. During the three months ended March 31, 2023, the Company recorded a $11.6 million contingent consideration charge. See Note 9, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.
Restructuring Charges
In February 2024, the Company initiated a restructuring plan to ensure it is well positioned for long-term growth. The restructuring plan includes: (i) reshaping the Company’s executive team, (ii) reallocating efforts and resources from the Company’s ex-U.S. and certain early-stage development programs to its commercial portfolio in the U.S. market and (iii) reprioritizing investments to focus on commercial readiness for the implementation of separate Medicare reimbursement for EXPAREL at average sales price plus 6 percent in outpatient settings beginning in January 2025 and broader commercial initiatives in key areas, such as strategic national accounts, marketing and market access and reimbursement. The Company recognized $5.5 million of restructuring charges for the three months ended March 31, 2024 related to employee termination benefits, such as the acceleration of share-based compensation, severance, and, to a lesser extent, other employment-related
termination costs, as well as contract termination costs. The Company’s restructuring charges as of March 31, 2024, including the beginning and ending liability balances, are summarized below (in thousands):
Employee Termination Benefits (1)
Contract Termination CostsTotal
Balance at December 31, 2023$— $— $— 
Charges incurred2,567 733 3,300 
Cash payments made / settled(386)— (386)
Balance at March 31, 2024$2,181 $733 $2,914 
(1) During the three months ended March 31, 2024, there was $2.2 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.
Acquisition-Related Fees
The Company recognized acquisition-related costs of $0.2 million and $0.5 million during the three months ended March 31, 2024 and 2023, respectively, primarily related to vacant and underutilized Flexion leases that were assumed from the Flexion Acquisition.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to its patents and intellectual property, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.
MyoScience Milestone Litigation
In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (“Pacira CryoTech”), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (“Fortis”), solely in its capacity as representative for the former securityholders of MyoScience, and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the “MyoScience Merger Agreement”), specifically related to the achievement of certain milestone payments under the MyoScience Merger Agreement. In addition, the Company and Pacira CryoTech sought general, special and compensatory damages against the other defendants related to breach of fiduciary duties in connection with the purported achievement of milestone payments under the MyoScience Merger Agreement, and breach of the MyoScience Merger Agreement and certain other agreements with the defendants. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the MyoScience Merger Agreement. The total remaining value of these milestones is $30.0 million, plus attorneys’ fees.
A trial was conducted in September 2023, and a decision is expected in the coming months. The Company is unable to predict the outcome of this action at this time.
eVenus Pharmaceutical Laboratories Litigations
In October 2021, the Company received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application, or ANDA with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the ‘495 patent).
In November 2021, the Company filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the ‘495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA which expires on July 1, 2024. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the ‘495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in eVenus’s ANDA submission.
In December 2021, the Company received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the ‘495 patent. In the second Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S.
Patent No. 11,179,336 (the ‘336 patent). eVenus further alleges in the Notice Letter that both the ‘495 patent and the ‘336 patent are invalid and/or not infringed.
In February 2022, the Company filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the ‘495 and ‘336 patents and that the 266 mg/20 mL ANDA product will infringe the ‘336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product which expires on July 1, 2024. The first and second patent infringement suits were consolidated.
In February 2023, eVenus filed its first amended answer to the first amended complaint, alleging patent invalidity, non-infringement and inequitable conduct. The Company has denied the allegations in eVenus’s first amended answer. The Company has subsequently voluntarily dismissed its claims with respect to the ‘336 Patent. The trial on the remaining claim was conducted in February 2024 with a decision expected in the coming months.
In April 2023, the Company filed a third patent infringement suit against eVenus, its parent company, and Fresenius Kabi USA, LLC, in the U.S. District Court for the District of New Jersey (23-cv-2367) asserting that the 133 mg/10 mL and 266 mg/20 mL ANDA products will infringe U.S. Patent No. 11,426,348 (the ‘348 patent). In July 2023, eVenus filed its answer with claims for declaratory judgment, alleging patent invalidity, non-infringement and inequitable conduct with respect to the ‘348 patent as well as the Company’s other patents, U.S. Patent Nos. 11,278,494; 11,304,904; 11,311,486; 11,357,727 and 11,452,691. The parties have subsequently dismissed all patents other than the ‘348 patent from this litigation.
The Company is unable to predict the outcome of these litigations at this time.
Research Development Foundation
Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company’s ‘495 patent was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company’s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of its U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that the Company owes no royalties to RDF with respect to its EXPAREL product after December 24, 2021.
On August 8, 2023, the U.S. District Court, District of Nevada, granted the Company’s motion for partial summary judgment in respect to the Company’s claim for a declaration that it no longer owes royalties for EXPAREL made under the 45-liter manufacturing process as of December 24, 2021. As a result, the Company expects to receive $14.5 million from RDF, representing the royalties that the Company paid to RDF under protest after December 24, 2021 for EXPAREL made from the 45-liter manufacturing process. Once it becomes probable that the settlement amount will be received, the Company will record a settlement gain within other operating income (expense), net in the condensed consolidated statement of operations. In November 2023, the U.S. District Court, District of Nevada conducted a mediation that did not result in a settlement. During the pendency of the remaining lawsuit, the Company will continue to pay royalties associated with the 200-liter EXPAREL manufacturing process to RDF under protest. A trial is currently scheduled for September 2024. The Company is unable to predict the outcome of this action at this time.
Other Commitments and Contingencies
Pediatric Trial Commitments
The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL for infiltration and as a brachial plexus block in pediatric patients. The Company was granted deferrals for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the E.U. Despite the U.K.’s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.
The Company received notification from the FDA in October 2023 that its pediatric studies requirement had been waived for the indication of brachial plexus interscalene nerve block to produce postsurgical regional analgesia in pediatric patients. The Company is still working with the FDA, EMA and Medicines and Healthcare Regulatory Agency (MHRA) to finalize the regulatory pathways for its remaining pediatric commitments.
Contingent Milestone Payments
Refer to Note 9, Financial Instruments, for information on potential contingent milestone payments related to the Flexion Acquisition.
PCRX-201
PCRX-201, a novel, intra-articular gene therapy product candidate that produces the anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) treating OA pain in the knee, was added to the Company’s portfolio as part of the Flexion Acquisition in November 2021. Prior to the Flexion Acquisition, in February 2017, Flexion entered into an agreement with GQ Bio Therapeutics GmbH to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0 million of payments could become due upon the achievement of certain development and regulatory milestones, including up to $4.5 million through initiation of a Phase 2 proof of concept clinical trial and, following successful proof of concept, up to an additional $51.5 million in development and global regulatory approval milestone payments.
In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 for the treatment of OA pain of the knee.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net income (loss) $ 8,979 $ (19,536)
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
Rule 10b5-1 Trading Plans

The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2024. No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2024.
Trading Arrangement
Name and PositionActionDateRule 10b5-1*Non-Rule
10b5-1**		Total Number of
Shares to be Sold		Expiration
Date
Lauren Riker
Principal Accounting Officer
Adopt3/5/2024x
To Be Determined (1)
12/31/2024
Kristen Williams
Chief Administrative Officer and Secretary
Adopt3/8/2024x
To Be Determined (1)
6/28/2024
Jonathan Slonin
Chief Medical Officer
Adopt3/8/2024x
To Be Determined (1)
1/31/2025
Paul Hastings
Director
Adopt3/12/2024x1,77512/31/2024
Daryl Gaugler
Chief Operating Officer
Adopt3/12/2024x2,5003/7/2025
* Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).

(1) The aggregate number of shares to be sold pursuant to each trading arrangement listed above is dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Lauren Riker [Member]  
Trading Arrangements, by Individual  
Name Lauren Riker
Title Principal Accounting Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 3/5/2024
Arrangement Duration 112 days
Kristen Williams [Member]  
Trading Arrangements, by Individual  
Name Kristen Williams
Title Chief Administrative Officer and Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date 3/8/2024
Arrangement Duration 301 days
Jonathan Slonin [Member]  
Trading Arrangements, by Individual  
Name Jonathan Slonin
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 3/8/2024
Arrangement Duration 329 days
Paul Hastings [Member]  
Trading Arrangements, by Individual  
Name Paul Hastings
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 3/12/2024
Arrangement Duration 294 days
Aggregate Available 1,775
Daryl Gaugler [Member]  
Trading Arrangements, by Individual  
Name Daryl Gaugler
Title Chief Operating Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 3/12/2024
Arrangement Duration 360 days
Aggregate Available 2,500
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation
These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”), for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”).
The condensed consolidated financial statements at March 31, 2024, and for the three-month periods ended March 31, 2024 and 2023, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2023 is derived from the audited consolidated financial statements included in the Company’s 2023 Annual Report. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.
The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.
Concentration of Major Customers
Concentration of Major Customers
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual physicians.
Recent Accounting Pronouncements Not Adopted as of March 31, 2024
Recent Accounting Pronouncements Not Adopted as of March 31, 2024
In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures. The ASU amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The new segment disclosure requirements apply for entities with a single reportable segment. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023 and interim periods thereafter, with early adoption permitted. The ASU amendment will require adoption on a retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The ASU amendment addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Percentage of Revenue Comprised of the Three Largest Customers The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented:
Three Months Ended
March 31,
20242023
 Largest wholesaler36%32%
 Second largest wholesaler23%24%
 Third largest wholesaler20%23%
     Total79%79%
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Three Months Ended
March 31,
20242023
Net product sales:
   EXPAREL$132,430 $130,408 
   ZILRETTA25,839 24,334 
   iovera°5,030 4,001 
   Bupivacaine liposome injectable suspension2,525 688 
      Total net product sales$165,824 $159,431 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
The components of inventories, net are as follows (in thousands):
March 31,December 31,
20242023
Raw materials$51,608 $54,099 
Work-in-process18,764 31,215 
Finished goods26,410 19,039 
     Total$96,782 $104,353 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FIXED ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Fixed Assets Summarized by Major Category
Fixed assets, net, summarized by major category, consist of the following (in thousands):
March 31,December 31,
20242023
Machinery and equipment (1)
$106,670 $121,773 
Leasehold improvements58,835 61,826 
Computer equipment and software17,223 17,186 
Office furniture and equipment2,543 2,543 
Construction in progress106,987 105,905 
        Total292,258 309,233 
Less: accumulated depreciation (1)
(120,454)(135,306)
        Fixed assets, net$171,804 $173,927 
(1) During the three months ended March 31, 2024, the Company disposed of $19.0 million of fully depreciated machinery and equipment associated with its 45-liter EXPAREL manufacturing process at the Thermo Fisher Scientific Pharma Services facility located in Swindon, England. The Company continues to operate its 200-liter EXPAREL manufacturing process at the same facility.
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Operating Lease Expense and Other Operating Lease Information Total operating lease expense, net is as follows (in thousands):
Three Months Ended
March 31,
20242023
Fixed lease costs$3,497 $3,628 
Variable lease costs494 567 
Sublease income(131)(153)
Total$3,860 $4,042 
Supplemental cash flow information related to operating leases is as follows (in thousands):
Three Months Ended
March 31,
20242023
Cash paid for operating lease liabilities, net of lease incentives$3,219 $3,763 
The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:
March 31,
20242023
Weighted average remaining lease term5.81 years6.61 years
Weighted average discount rate7.01 %7.03 %
Schedule of Maturities of Operating Lease Liabilities
Maturities of the Company’s operating lease liabilities are as follows (in thousands):
YearAggregate Minimum
Payments Due
2024 (remaining nine months)$9,777 
202512,775 
202612,814 
202712,587 
202810,925 
Thereafter16,426 
   Total future lease payments75,304 
   Less: imputed interest(13,855)
   Total operating lease liabilities$61,449 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination
Intangible assets, net, consists of the in-process research and development, or IPR&D, and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):
March 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(155,975)$434,025 10 years, 5 months
Customer relationships90 (45)45 10 years
     Total finite-lived intangible assets, net590,090 (156,020)434,070 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(156,020)$468,936 
December 31, 2023Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(141,655)$448,345 10 years, 5 months
Customer relationships90 (43)47 10 years
     Total finite-lived intangible assets, net590,090 (141,698)448,392 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(141,698)$483,258 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Instruments
The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):
March 31,December 31,
20242023
Term loan A facility maturing March 2028$112,477 $115,202 
0.750% Convertible senior notes due August 2025
399,210 398,594 
3.375% Convertible senior notes due May 2024 (1)
8,641 8,641 
     Total$520,328 $522,437 
(1) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.
Schedule of Composition of the Company's Debt and Financing Obligations
The total debt composition of the TLA Term Loan is as follows (in thousands):
March 31,December 31,
20242023
Term loan A facility maturing March 2028$113,750 $116,563 
Deferred financing costs(924)(988)
Discount on debt(349)(373)
     Total debt, net of debt discount and deferred financing costs$112,477 $115,202 
The total debt composition of the 2025 Notes is as follows (in thousands):
March 31,December 31,
20242023
0.750% convertible senior notes due August 2025
$402,500 $402,500 
Deferred financing costs(3,290)(3,906)
     Total debt, net of deferred financing costs$399,210 $398,594 
Schedule of Total Interest Expense Recognized Related to the Notes
The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):
Three Months Ended
March 31,
20242023
Contractual interest expense$3,311 $9,350 
Amortization of debt issuance costs681 937 
Amortization of debt discount24 675 
Capitalized interest (Note 5)
(700)(1,373)
        Total$3,316 $9,589 
Effective interest rate on total debt2.96 %5.36 %
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Carrying Amount and Fair Value of the Long-Term Debt
At March 31, 2024, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):
Carrying ValueFair Value Measurements Using
Level 1Level 2Level 3
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Financial Assets:
Equity investments$15,877 $— $— $15,877 
Convertible notes receivable$12,030 $— $— $12,030 
Financial Liabilities:
   Acquisition-related contingent consideration$20,892 $— $— $20,892 
Financial Liabilities Measured at Amortized Cost:
Term loan A facility due March 2028$112,477 $— $113,181 $— 
   0.750% convertible senior notes due 2025 (1)
$399,210 $— $383,381 $— 
   3.375% convertible senior notes due 2024 (2)
$8,641 $— $8,641 $— 
(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $29.22 per share at March 31, 2024 compared to a conversion price of $71.78 per share. At March 31, 2024, as the conversion price was above the stock price, the requirements for conversion have not been met. The maximum conversion premium that could have been due on the 2025 Notes is 5.6 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.
(2) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.
Schedule of Investments without Readily Determinable Fair Value The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):
Equity InvestmentsConvertible Notes ReceivableTotal
Balance at December 31, 2022
$15,877 $5,315 $21,192 
   Purchases— 6,758 6,758 
   Foreign currency adjustments— 61 61 
Balance at December 31, 2023
15,877 12,134 28,011 
   Foreign currency adjustments— (104)(104)
Balance at March 31, 2024
$15,877 $12,030 $27,907 
Schedule of Key Assumptions used in the Valuation of Contingent Consideration
The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:
Assumption
Ranges
Utilized as of
March 31, 2024
Discount rates
8.0% to 9.3%
Probability of payment for remaining regulatory milestone
0%
Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements
The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):
Contingent Consideration
Fair Value
Balance at December 31, 2022
$28,122 
Fair value adjustments and accretion(3,424)
Balance at December 31, 2023
24,698 
   Fair value adjustments and accretion(3,806)
Balance at March 31, 2024
$20,892 
Schedule of Short-Term and Noncurrent Available-for-Sale Investments
The following summarizes the Company’s short-term and noncurrent available-for-sale investments at March 31, 2024 and December 31, 2023 (in thousands):
March 31, 2024 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 1)		Fair Value
(Level 2)
Current:
Asset-backed securities$25,345 $— $(38)$— $25,307 
Commercial paper94,138 28 (51)— 94,115 
Corporate bonds7,984 — (6)— 7,978 
U.S. federal agency bonds9,479 — (10)— 9,469 
U.S. government bonds4,974 — (5)4,969 — 
          Total$141,920 $28 $(110)$4,969 $136,869 
December 31, 2023 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 1)		Fair Value
(Level 2)
Current:
Asset-backed securities$9,539 $1 $— $— $9,540 
Commercial paper77,941 103 — — 78,044 
U.S. federal agency bonds22,849 — (29)— 22,820 
U.S. government bonds14,899 — (20)14,879 — 
Subtotal125,228 104 (49)14,879 110,404 
Noncurrent:
Asset-backed securities2,403 7 — — 2,410 
Subtotal2,403 7 — — 2,410 
          Total$127,631 $111 $(49)$14,879 $112,814 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Accumulated Other Comprehensive Loss
The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Income
Balance at December 31, 2023
$124 $123 $247 
   Net unrealized loss on investments, net of tax(1)
(108)— (108)
   Foreign currency translation adjustments— 13 13 
Balance at March 31, 2024
$16 $136 $152 
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Loss
Balance at December 31, 2022
$(523)$143 $(380)
   Net unrealized gain on investments, net of tax (1)
251 — 251 
   Foreign currency translation adjustments— (8)(8)
Balance at March 31, 2023
$(272)$135 $(137)
(1) Net of a nominal tax benefit and $0.2 million tax expense for the three months ended March 31, 2024 and 2023, respectively.
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK PLANS (Tables)
 3 Months Ended
Mar. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Recognized Stock-Based Compensation Expense
The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):
Three Months Ended
March 31,
20242023
Cost of goods sold$1,128 $1,724 
Research and development1,803 1,875 
Selling, general and administrative7,985 8,391 
Contingent consideration (gains) charges, restructuring charges and other2,235 — 
        Total$13,151 $11,990 
Stock-based compensation from:
    Stock options$6,729 $6,464 
    Restricted stock units6,210 5,250 
    Employee stock purchase plan212 276 
        Total$13,151 $11,990 
Schedule of the Company's Stock Option Activity and Restricted Stock Unit Activity
The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2024:
Stock Options Number of
Stock Options		 Weighted Average Exercise Price (Per Share)
 Outstanding at December 31, 2023
7,079,748 $49.40 
     Granted900,995 31.95 
     Forfeited(155,397)46.84 
     Expired(245,082)50.23 
 Outstanding at March 31, 2024
7,580,264 47.35 
Restricted Stock Units Number of
Restricted
Stock Units		 Weighted Average Grant Date Fair Value (Per Share)
Unvested at December 31, 2023
1,364,618 $47.66 
     Granted196,974 31.53 
     Vested(36,395)53.97 
     Forfeited(102,206)47.71 
Unvested at March 31, 2024
1,422,991 45.26 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:
Black-Scholes Weighted Average AssumptionThree Months Ended March 31, 2024
Expected dividend yieldNone
Risk-free interest rate3.92%
Expected volatility40.94%
Expected term of options5.28 years
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME (LOSS) PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share
The following table sets forth the computation of basic and diluted net income (loss) per common share for the three months ended March 31, 2024 and 2023 (in thousands, except per share amounts):
Three Months Ended
March 31,
20242023
Numerator:
   Net income (loss)—basic$8,979 $(19,536)
ASU 2020-06 convertible notes if-converted method adjustment1,029 — 
   Adjusted net income (loss)—diluted$10,008 $(19,536)
Denominator:
   Weighted average common shares outstanding—basic46,499 45,949 
Computation of diluted securities:
ASU 2020-06 convertible notes if-converted method adjustment5,608 — 
   Dilutive effect of stock options1 — 
   Dilutive effect of RSUs85 — 
   Weighted average common shares outstanding—diluted52,193 45,949 
Net income (loss) per share:
   Basic and diluted net income (loss) per common share$0.19 $(0.43)
Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Loss Per Share
The following table summarizes the outstanding stock options, RSUs, ESPP purchase options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):
Three Months Ended
March 31,
20242023
Weighted average number of stock options7,662 6,362 
Convertible senior notes (1)
— 5,608 
Weighted average number of RSUs1,230 1,137 
Weighted average ESPP purchase options52 55 
      Total8,944 13,162 
(1) The convertible senior notes were antidilutive for the three months ended March 31, 2023, in conjunction with a $1.0 million if-converted method adjustment to the numerator that adds back the interest expense associated with the convertible senior notes on a post-tax basis.
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES (Tables)
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income (Loss) Before Income Taxes and Income Tax Expense (Benefit)
Income (loss) before income taxes and income tax expense (benefit) are as follows (dollar amounts in thousands):
Three Months Ended
March 31,
20242023
Income (loss) before income taxes:
   Domestic$13,657 $(27,773)
   Foreign(17)1,299 
Total income (loss) before income taxes$13,640 $(26,474)
Income tax expense (benefit)$4,661 $(6,938)
Effective tax rate34 %26 %
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Acquisition-Related Charges (Gain), Restructuring Charges and Other
Contingent consideration (gains) charges, restructuring charges and other for the three months ended March 31, 2024 and 2023 summarized below (in thousands):
Three Months Ended
March 31,
20242023
Flexion contingent consideration$(3,806)$11,618 
Restructuring charges5,535 — 
Acquisition-related fees174 489 
Total contingent consideration (gains) charges, restructuring charges and other$1,903 $12,107 
Schedule of Restructuring Charges The Company’s restructuring charges as of March 31, 2024, including the beginning and ending liability balances, are summarized below (in thousands):
Employee Termination Benefits (1)
Contract Termination CostsTotal
Balance at December 31, 2023$— $— $— 
Charges incurred2,567 733 3,300 
Cash payments made / settled(386)— (386)
Balance at March 31, 2024$2,181 $733 $2,914 
(1) During the three months ended March 31, 2024, there was $2.2 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DESCRIPTION OF BUSINESS (Details)
 3 Months Ended
Mar. 31, 2024
product
segment
Concentration Risk [Line Items]  
Number of reportable segments | segment 1
Sales Revenue | Product Concentration Risk  
Concentration Risk [Line Items]  
Concentration of products (in products) | product 3
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Concentration Risk By Major Customer - customer
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Concentration of Major Customers    
Number of customers 3  
Sales Revenue | Largest wholesaler    
Concentration of Major Customers    
Percentage of revenue from customers to total revenue (in percent) 36.00% 32.00%
Sales Revenue | Second largest wholesaler    
Concentration of Major Customers    
Percentage of revenue from customers to total revenue (in percent) 23.00% 24.00%
Sales Revenue | Third largest wholesaler    
Concentration of Major Customers    
Percentage of revenue from customers to total revenue (in percent) 20.00% 23.00%
Sales Revenue | Total    
Concentration of Major Customers    
Percentage of revenue from customers to total revenue (in percent) 79.00% 79.00%
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
Minimum  
Disaggregation of Revenue [Line Items]  
Accounts receivable, payment terms 0 days
Maximum  
Disaggregation of Revenue [Line Items]  
Accounts receivable, payment terms 4 months
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total net product sales $ 167,117 $ 160,341
EXPAREL    
Disaggregation of Revenue [Line Items]    
Total net product sales 132,430 130,408
ZILRETTA    
Disaggregation of Revenue [Line Items]    
Total net product sales 25,839 24,334
iovera°    
Disaggregation of Revenue [Line Items]    
Total net product sales 5,030 4,001
Bupivacaine liposome injectable suspension    
Disaggregation of Revenue [Line Items]    
Total net product sales 2,525 688
Total net product sales    
Disaggregation of Revenue [Line Items]    
Total net product sales $ 165,824 $ 159,431
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 51,608 $ 54,099
Work-in-process 18,764 31,215
Finished goods 26,410 19,039
Total $ 96,782 $ 104,353
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FIXED ASSETS - Schedule of Major Categories (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
FIXED ASSETS      
Total $ 292,258   $ 309,233
Less: accumulated depreciation (120,454)   (135,306)
Fixed assets, net 171,804   173,927
Depreciation expense 4,100 $ 5,300  
Machinery and equipment      
FIXED ASSETS      
Total 106,670   121,773
Disposals 19,000    
Leasehold improvements      
FIXED ASSETS      
Total 58,835   61,826
Computer equipment and software      
FIXED ASSETS      
Total 17,223   17,186
Office furniture and equipment      
FIXED ASSETS      
Total 2,543   2,543
Construction in progress      
FIXED ASSETS      
Total $ 106,987   $ 105,905
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FIXED ASSETS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
FIXED ASSETS      
Depreciation expense $ 4,100 $ 5,300  
Fixed assets, net 171,804   $ 173,927
Asset retirement obligation 3,900   4,300
Construction in progress      
FIXED ASSETS      
Capitalized interest 700 $ 1,400  
Leasehold improvements | Europe      
FIXED ASSETS      
Fixed assets, net $ 34,300   $ 36,800
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Narrative (Details)
Mar. 31, 2024
lease
Leases [Abstract]  
Number of embedded leases 2
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Lease, Cost [Abstract]    
Fixed lease costs $ 3,497 $ 3,628
Variable lease costs 494 567
Sublease income (131) (153)
Total 3,860 4,042
Cash Flow, Operating Activities, Lessee [Abstract]    
Cash paid for operating lease liabilities, net of lease incentives $ 3,219 $ 3,763
Weighted average remaining lease term (in years) 5 years 9 months 21 days 6 years 7 months 9 days
Weighted average discount rate (in percent) 7.01% 7.03%
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Leases [Abstract]  
2024 (remaining nine months) $ 9,777
2025 12,775
2026 12,814
2027 12,587
2028 10,925
Thereafter 16,426
Total future lease payments 75,304
Less: imputed interest (13,855)
Total operating lease liabilities $ 61,449
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill recorded in connection with the acquisition $ 163,243   $ 163,243
Amortization of acquired intangible assets 14,322 $ 14,322  
Amortization expense, remainder of fiscal year 43,000    
Amortization expense, first period 57,300    
Amortization expense, second period 57,300    
Amortization expense, third period 57,300    
Amortization expense, fourth period 57,300    
Amortization expense, fifth period 57,300    
Amortization expense, sixth period 57,300    
Amortization expense, seventh period 37,400    
Amortization expense, eighth period 7,900    
Amortization expense, ninth period $ 2,200    
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 590,090 $ 590,090
Accumulated Amortization (156,020) (141,698)
Intangible Assets, Net 434,070 448,392
Gross Carrying Value 624,956 624,956
Intangible Assets, Net 468,936 483,258
Developed technologies    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 590,000 590,000
Accumulated Amortization (155,975) (141,655)
Intangible Assets, Net $ 434,025 $ 448,345
Weighted-Average Useful Lives 10 years 5 months 10 years 5 months
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 90 $ 90
Accumulated Amortization (45) (43)
Intangible Assets, Net $ 45 $ 47
Weighted-Average Useful Lives 10 years 10 years
Acquired IPR&D    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 34,866 $ 34,866
Intangible Assets, Net $ 34,866 $ 34,866
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Schedule of Long-Term Debt Instruments (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Jul. 31, 2020
Secured and Unsecured Debt      
Debt Instrument [Line Items]      
Long-term debt $ 520,328 $ 522,437  
Term loan A facility maturing March 2028 | Term Loan      
Debt Instrument [Line Items]      
Long-term debt $ 112,477 115,202  
0.750% Convertible senior notes due August 2025      
Debt Instrument [Line Items]      
Stated interest rate (as a percent) 0.75%    
0.750% Convertible senior notes due August 2025 | Unsecured Debt      
Debt Instrument [Line Items]      
Long-term debt $ 399,210 398,594  
Stated interest rate (as a percent) 0.75%   0.75%
3.375% Convertible senior notes due May 2024 (1) | Unsecured Debt      
Debt Instrument [Line Items]      
Long-term debt $ 8,641 $ 8,641  
Stated interest rate (as a percent) 3.375%    
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
Aug. 01, 2023
trading_day
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jan. 06, 2022
Dec. 31, 2021
USD ($)
Jul. 31, 2020
USD ($)
trading_day
$ / shares
Mar. 31, 2024
USD ($)
day
$ / shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2028
USD ($)
Jan. 07, 2022
USD ($)
May 02, 2017
USD ($)
DEBT AND FINANCING OBLIGATIONS                          
Proceeds from Term loan A facility               $ 0 $ 149,550,000        
Loss on early extinguishment of debt               $ 0 $ 16,926,000        
Closing sale price (in dollars per share) | $ / shares               $ 29.22          
Term loan A facility maturing March 2028                          
DEBT AND FINANCING OBLIGATIONS                          
Leverage ratio, maximum               3.00          
Leverage ratio, minimum               1.50          
Weighted average interest rate, at point in time               8.41%          
Term loan A facility maturing March 2028 | Minimum | Base Rate                          
DEBT AND FINANCING OBLIGATIONS                          
Net leverage ratio               2.00%          
Term loan A facility maturing March 2028 | Minimum | Secured Overnight Financing Rate (SOFR)                          
DEBT AND FINANCING OBLIGATIONS                          
Net leverage ratio               3.00%          
Term loan A facility maturing March 2028 | Maximum | Base Rate                          
DEBT AND FINANCING OBLIGATIONS                          
Net leverage ratio               2.75%          
Term loan A facility maturing March 2028 | Maximum | Secured Overnight Financing Rate (SOFR)                          
DEBT AND FINANCING OBLIGATIONS                          
Net leverage ratio               3.75%          
0.750% Convertible senior notes due August 2025                          
DEBT AND FINANCING OBLIGATIONS                          
Stated interest rate (as a percent)               0.75%          
Initial conversion price of notes into common stock (in dollars per share) | $ / shares               $ 71.78          
0.750% Convertible senior notes due August 2025 | Debt Redemption Terms on or After August 1, 2023                          
DEBT AND FINANCING OBLIGATIONS                          
Threshold percentage stock price trigger   130.00%                      
Threshold trading days | trading_day   20                      
Threshold consecutive trading days | trading_day   30                      
Scheduled trading day | trading_day   40                      
Debt instrument, percentage of principal amount for computation of redemption price   100.00%                      
3.375% convertible senior notes due 2024                          
DEBT AND FINANCING OBLIGATIONS                          
Debt instrument, percentage of principal amount for computation of redemption price         100.00%                
Term Loan | Term loan A facility maturing March 2028                          
DEBT AND FINANCING OBLIGATIONS                          
Discount rate       0.30%         0.30%        
Debt instrument, face amount       $ 150,000,000         $ 150,000,000        
Proceeds from Term loan A facility       149,600,000                  
Debt instrument, unamortized discount       400,000       $ 349,000 400,000 $ 373,000      
Periodic payment, principal     $ 2,800,000             2,800,000      
Balance of unrestricted cash and cash equivalents               $ 500,000,000          
Days prior maturity date | day               91          
Repayments of debt               $ 2,800,000   30,600,000      
Long-term debt               $ 112,477,000   115,202,000      
Term Loan | Term loan A facility maturing March 2028 | Forecast                          
DEBT AND FINANCING OBLIGATIONS                          
Periodic payment, principal $ 3,800,000                        
Balloon payment to be paid                     $ 85,300,000    
Term Loan | Term Loan B Facility Due December 2026                          
DEBT AND FINANCING OBLIGATIONS                          
Discount rate           3.00%              
Debt instrument, face amount           $ 375,000,000              
Proceeds from Term loan A facility           363,800,000              
Debt instrument, unamortized discount           $ 11,200,000              
Repayments of debt       $ 149,600,000                  
Repayment of debt principal                 296,900,000        
Loss on early extinguishment of debt                 $ 16,900,000        
Prepayment fee percentage       2.00%         2.00%        
Unsecured Debt | 0.750% Convertible senior notes due August 2025                          
DEBT AND FINANCING OBLIGATIONS                          
Debt instrument, face amount             $ 402,500,000            
Stated interest rate (as a percent)             0.75% 0.75%          
Debt issued in private placement               $ 402,500,000          
Settlement period - convertible debt conversion request             40 days            
Initial conversion rate of common stock per $1,000 of principal amount of Notes               0.0139324          
Initial conversion price of notes into common stock (in dollars per share) | $ / shares             $ 71.78            
Convertible debt, premium on common stock             32.50%            
Closing sale price (in dollars per share) | $ / shares             $ 54.17            
Market price of principal amount of notes               0.953          
Long-term debt               $ 399,210,000   398,594,000      
Unsecured Debt | 0.750% Convertible senior notes due August 2025 | Debt Redemption Terms Prior to February 3, 2023                          
DEBT AND FINANCING OBLIGATIONS                          
Threshold percentage stock price trigger             130.00%            
Threshold trading days | trading_day             20            
Threshold consecutive trading days | trading_day             30            
Unsecured Debt | 3.375% convertible senior notes due 2024                          
DEBT AND FINANCING OBLIGATIONS                          
Stated interest rate (as a percent)               3.375%          
Repurchase amount                       $ 192,600,000  
Long-term debt               $ 8,641,000   $ 8,641,000      
Unsecured Debt | 3.375% convertible senior notes due 2024 | Flexion                          
DEBT AND FINANCING OBLIGATIONS                          
Debt instrument, face amount                         $ 201,300,000
Stated interest rate (as a percent)                         3.375%
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Schedule of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Jul. 31, 2020
0.750% Convertible senior notes due August 2025        
Debt Instrument [Line Items]        
Stated interest rate (as a percent) 0.75%      
Term Loan | Term loan A facility maturing March 2028        
Debt Instrument [Line Items]        
Long-term debt $ 113,750 $ 116,563    
Deferred financing costs (924) (988)    
Discount on debt (349) (373) $ (400)  
Total debt, net of deferred financing costs $ 112,477 115,202    
Unsecured Debt | 0.750% Convertible senior notes due August 2025        
Debt Instrument [Line Items]        
Stated interest rate (as a percent) 0.75%     0.75%
Long-term debt $ 402,500 402,500    
Deferred financing costs (3,290) (3,906)    
Total debt, net of deferred financing costs $ 399,210 $ 398,594    
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT - Schedule of Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Debt Disclosure [Abstract]    
Contractual interest expense $ 3,311 $ 9,350
Amortization of debt issuance costs 681 937
Amortization of debt discount 24 675
Capitalized interest (Note 5) (700) (1,373)
Total $ 3,316 $ 9,589
Effective interest rate on total debt (in percent) 2.96% 5.36%
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
 3 Months Ended
Mar. 31, 2024
Jul. 31, 2020
Financial Liabilities:    
Closing sale price (in dollars per share) $ 29.22  
0.750% Convertible senior notes due August 2025    
Financial Liabilities:    
Stated interest rate (as a percent) 0.75%  
Initial conversion price of notes into common stock (in dollars per share) $ 71.78  
0.750% Convertible senior notes due August 2025 | Maximum    
Financial Liabilities:    
Maximum conversion premium (in shares) 5.6  
0.750% Convertible senior notes due August 2025 | Unsecured Debt    
Financial Liabilities:    
Stated interest rate (as a percent) 0.75% 0.75%
Closing sale price (in dollars per share)   $ 54.17
Initial conversion price of notes into common stock (in dollars per share)   $ 71.78
3.375% convertible senior notes due 2024 | Unsecured Debt    
Financial Liabilities:    
Stated interest rate (as a percent) 3.375%  
Carrying Value    
Financial Assets:    
Equity investments $ 15,877  
Convertible notes receivable 12,030  
Financial Liabilities:    
Acquisition-related contingent consideration 20,892  
Carrying Value | Term loan A facility maturing March 2028 | Term Loan    
Financial Liabilities:    
Convertible senior notes 112,477  
Carrying Value | 0.750% Convertible senior notes due August 2025 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 399,210  
Carrying Value | 3.375% convertible senior notes due 2024 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 8,641  
Fair Value Measurements Using | Level 1    
Financial Assets:    
Equity investments 0  
Convertible notes receivable 0  
Financial Liabilities:    
Acquisition-related contingent consideration 0  
Fair Value Measurements Using | Level 1 | Term loan A facility maturing March 2028 | Term Loan    
Financial Liabilities:    
Convertible senior notes 0  
Fair Value Measurements Using | Level 1 | 0.750% Convertible senior notes due August 2025 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 0  
Fair Value Measurements Using | Level 1 | 3.375% convertible senior notes due 2024 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 0  
Fair Value Measurements Using | Level 2    
Financial Assets:    
Equity investments 0  
Convertible notes receivable 0  
Financial Liabilities:    
Acquisition-related contingent consideration 0  
Fair Value Measurements Using | Level 2 | Term loan A facility maturing March 2028 | Term Loan    
Financial Liabilities:    
Convertible senior notes 113,181  
Fair Value Measurements Using | Level 2 | 0.750% Convertible senior notes due August 2025 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 383,381  
Fair Value Measurements Using | Level 2 | 3.375% convertible senior notes due 2024 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 8,641  
Fair Value Measurements Using | Level 3    
Financial Assets:    
Equity investments 15,877  
Convertible notes receivable 12,030  
Financial Liabilities:    
Acquisition-related contingent consideration 20,892  
Fair Value Measurements Using | Level 3 | Term loan A facility maturing March 2028 | Term Loan    
Financial Liabilities:    
Convertible senior notes 0  
Fair Value Measurements Using | Level 3 | 0.750% Convertible senior notes due August 2025 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes 0  
Fair Value Measurements Using | Level 3 | 3.375% convertible senior notes due 2024 | Unsecured Debt    
Financial Liabilities:    
Convertible senior notes $ 0  
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Investments Without Readily Determinable Fair Value Roll Forward [Abstract]    
Beginning balance $ 28,011 $ 21,192
Purchases   6,758
Foreign currency adjustments (104) 61
Ending balance 27,907 28,011
Equity Investments    
Investments Without Readily Determinable Fair Value Roll Forward [Abstract]    
Beginning balance 15,877 15,877
Purchases   0
Foreign currency adjustments 0 0
Ending balance 15,877 15,877
Convertible Notes Receivable    
Investments Without Readily Determinable Fair Value Roll Forward [Abstract]    
Beginning balance 12,134 5,315
Purchases   6,758
Foreign currency adjustments (104) 61
Ending balance $ 12,030 $ 12,134
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2021
USD ($)
Mar. 31, 2024
USD ($)
wholesaler
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
wholesaler
Aug. 30, 2022
USD ($)
Concentration Risk [Line Items]          
Flexion contingent consideration   $ 3,806,000 $ (11,618,000)    
Interest receivable   $ 100,000   $ 400,000  
Number of major customers | wholesaler   3   3  
Amount of allowance for doubtful accounts       $ 0  
iovera°          
Concentration Risk [Line Items]          
Amount of allowance for doubtful accounts   $ 100,000      
Accounts Receivable | Concentration Risk By Major Customer | Major Customer One          
Concentration Risk [Line Items]          
Concentration risk (as a percent)   39.00%   37.00%  
Accounts Receivable | Concentration Risk By Major Customer | Major Customer Two          
Concentration Risk [Line Items]          
Concentration risk (as a percent)   19.00%   19.00%  
Accounts Receivable | Concentration Risk By Major Customer | Major Customer Three          
Concentration Risk [Line Items]          
Concentration risk (as a percent)   16.00%   16.00%  
Flexion And MyoScience Acquisition          
Concentration Risk [Line Items]          
Acquisition-related contingent consideration   $ 20,900,000   $ 24,700,000  
Flexion          
Concentration Risk [Line Items]          
Acquisition-related contingent consideration $ 372,300,000       $ 425,500,000
Payment term 60 days        
Flexion contingent consideration   $ 3,800,000 $ (11,600,000)    
Flexion | Weighted Average | Contingent Consideration | Level 3 | Discount rates          
Concentration Risk [Line Items]          
Measurement input, contingent consideration   0.086      
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details) - Fair Value, Inputs, Level 3 - Flexion - Contingent Consideration
Mar. 31, 2024
Minimum | Discount rates  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input, contingent consideration 0.080
Minimum | Probability of payment for remaining regulatory milestone  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input, contingent consideration 0
Maximum | Discount rates  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Measurement input, contingent consideration 0.093
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details) - Contingent Consideration - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 24,698 $ 28,122
Fair value adjustments and accretion (3,806) (3,424)
Ending balance $ 20,892 $ 24,698
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FINANCIAL INSTRUMENTS - Schedule of Available-For-Sale Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Fair Value Measurements    
Cost $ 141,920 $ 127,631
Gross Unrealized Gains 28 111
Gross Unrealized Losses (110) (49)
Level 1    
Fair Value Measurements    
Fair Value 4,969 14,879
Level 2    
Fair Value Measurements    
Fair Value 136,869 112,814
Current:    
Fair Value Measurements    
Cost   125,228
Gross Unrealized Gains   104
Gross Unrealized Losses   (49)
Current: | Level 1    
Fair Value Measurements    
Fair Value   14,879
Current: | Level 2    
Fair Value Measurements    
Fair Value   110,404
Noncurrent:    
Fair Value Measurements    
Cost   2,403
Gross Unrealized Gains   7
Gross Unrealized Losses   0
Noncurrent: | Level 1    
Fair Value Measurements    
Fair Value   0
Noncurrent: | Level 2    
Fair Value Measurements    
Fair Value   2,410
Asset-backed securities | Current:    
Fair Value Measurements    
Cost 25,345 9,539
Gross Unrealized Gains 0 1
Gross Unrealized Losses (38) 0
Asset-backed securities | Current: | Level 1    
Fair Value Measurements    
Fair Value 0 0
Asset-backed securities | Current: | Level 2    
Fair Value Measurements    
Fair Value 25,307 9,540
Asset-backed securities | Noncurrent:    
Fair Value Measurements    
Cost   2,403
Gross Unrealized Gains   7
Gross Unrealized Losses   0
Asset-backed securities | Noncurrent: | Level 1    
Fair Value Measurements    
Fair Value   0
Asset-backed securities | Noncurrent: | Level 2    
Fair Value Measurements    
Fair Value   2,410
Commercial paper | Current:    
Fair Value Measurements    
Cost 94,138 77,941
Gross Unrealized Gains 28 103
Gross Unrealized Losses (51) 0
Commercial paper | Current: | Level 1    
Fair Value Measurements    
Fair Value 0 0
Commercial paper | Current: | Level 2    
Fair Value Measurements    
Fair Value 94,115 78,044
Corporate bonds | Current:    
Fair Value Measurements    
Cost 7,984  
Gross Unrealized Gains 0  
Gross Unrealized Losses (6)  
Corporate bonds | Current: | Level 1    
Fair Value Measurements    
Fair Value 0  
Corporate bonds | Current: | Level 2    
Fair Value Measurements    
Fair Value 7,978  
U.S. federal agency bonds | Current:    
Fair Value Measurements    
Cost 9,479 22,849
Gross Unrealized Gains 0 0
Gross Unrealized Losses (10) (29)
U.S. federal agency bonds | Current: | Level 1    
Fair Value Measurements    
Fair Value 0 0
U.S. federal agency bonds | Current: | Level 2    
Fair Value Measurements    
Fair Value 9,469 22,820
U.S. government bonds | Current:    
Fair Value Measurements    
Cost 4,974 14,899
Gross Unrealized Gains 0 0
Gross Unrealized Losses (5) (20)
U.S. government bonds | Current: | Level 1    
Fair Value Measurements    
Fair Value 4,969 14,879
U.S. government bonds | Current: | Level 2    
Fair Value Measurements    
Fair Value $ 0 $ 0
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
May 07, 2024
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period $ 870,130,000 $ 775,010,000  
Other comprehensive (loss) income (95,000) 243,000  
Balance at ending of period 892,162,000 768,041,000  
Unrealized gain (loss) on investments, tax expense 0 200,000  
Subsequent Event      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Aggregate purchase     $ 150,000,000
Net Unrealized Gain (Loss) From Available-For-Sale Investments      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period 124,000 (523,000)  
Other comprehensive (loss) income (108,000) 251,000  
Balance at ending of period 16,000 (272,000)  
Unrealized Foreign Currency Translation      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period 123,000 143,000  
Other comprehensive (loss) income 13,000 (8,000)  
Balance at ending of period 136,000 135,000  
Accumulated Other Comprehensive Loss      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period 247,000 (380,000)  
Other comprehensive (loss) income (95,000) 243,000  
Balance at ending of period $ 152,000 $ (137,000)  
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK PLANS - Schedule of Stock Based Compensation Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-Based Compensation    
Total $ 13,151 $ 11,990
Stock-based compensation from:    
Stock options 6,729 6,464
Restricted stock units 6,210 5,250
Employee stock purchase plan 212 276
Total 13,151 11,990
Cost of goods sold    
Share-Based Compensation    
Total 1,128 1,724
Research and development    
Share-Based Compensation    
Total 1,803 1,875
Selling, general and administrative    
Share-Based Compensation    
Total 7,985 8,391
Contingent consideration (gains) charges, restructuring charges and other    
Share-Based Compensation    
Total $ 2,235 $ 0
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK PLANS - Schedule of Stock Based Compensation Activity (Details)
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Number of Stock Options  
Outstanding beginning of period (in shares) | shares 7,079,748
Granted (in shares) | shares 900,995
Forfeited (in shares) | shares (155,397)
Expired (in shares) | shares (245,082)
Outstanding end of period (in shares) | shares 7,580,264
Weighted Average Exercise Price (Per Share)  
Outstanding beginning of period (in dollars per share) | $ / shares $ 49.40
Granted (in dollars per share) | $ / shares 31.95
Forfeited (in dollars per share) | $ / shares 46.84
Expired (in dollars per share) | $ / shares 50.23
Outstanding at end of period (in dollars per share) | $ / shares $ 47.35
Restricted Stock Units (RSUs)  
Number of Restricted Stock Units  
Unvested at beginning of period (in shares) | shares 1,364,618
Granted (in shares) | shares 196,974
Vested (in shares) | shares (36,395)
Forfeited (in shares) | shares (102,206)
Unvested at end of period in shares) | shares 1,422,991
Weighted Average Grant Date Fair Value (Per Share)  
Unvested at beginning of period (in dollars per share) | $ / shares $ 47.66
Granted (in dollars per share) | $ / shares 31.53
Vested (in dollars per share) | $ / shares 53.97
Forfeited (in dollars per share) | $ / shares 47.71
Unvested at end of period (in dollars per share) | $ / shares $ 45.26
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK PLANS - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
offeringPeriod
$ / shares
shares
Stock Incentive Plans  
Weighted average fair value (in dollars per share) | $ / shares $ 13.65
Purchase price of common stock, ESPP (as a percent) 85.00%
Common stock issued under employee stock purchase plan (in shares) | shares 0
Weighted average ESPP purchase options  
Stock Incentive Plans  
Number of offering periods for ESPP | offeringPeriod 2
ESPP purchasing period 6 months
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK PLANS - Schedule of Valuation Assumptions (Details) - Employee Stock Option
 3 Months Ended
Mar. 31, 2024
Stock Incentive Plans  
Expected dividend yield (as a percent) 0.00%
Risk free interest rate (as a percent) 3.92%
Expected volatility (as a percent) 40.94%
Expected term of options (in years) 5 years 3 months 10 days
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME (LOSS) PER SHARE - Schedule of Computation of EPS (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator:    
Net income (loss)—basic $ 8,979 $ (19,536)
Adjusted net income (loss)—diluted $ 10,008 $ (19,536)
Denominator:    
Weighted average common shares outstanding - basic (in shares) 46,499 45,949
Computation of diluted securities:    
Weighted average number of shares outstanding - diluted (in shares) 52,193 45,949
Net income (loss) per share:    
Basic net income (loss) per common share (in dollars per share) $ 0.19 $ (0.43)
Diluted net income (loss) per common share (in dollars per share) $ 0.19 $ (0.43)
Accounting Standards Update 2020-06    
Numerator:    
ASU 2020-06 convertible notes if-converted method adjustment $ 1,029 $ 0
Computation of diluted securities:    
ASU 2020-06 convertible notes if-converted method adjustment (in shares) 5,608 0
Dilutive effect of stock options    
Computation of diluted securities:    
Dilutive effect of share based compensation arrangements (in shares) 1 0
Dilutive effect of RSUs    
Computation of diluted securities:    
Dilutive effect of share based compensation arrangements (in shares) 85 0
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET INCOME (LOSS) PER SHARE- Schedule of Antidilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
EARNINGS PER SHARE    
Antidilutive effects of including these potential shares (in shares) 8,944 13,162
Weighted average number of stock options    
EARNINGS PER SHARE    
Antidilutive effects of including these potential shares (in shares) 7,662 6,362
Convertible senior notes    
EARNINGS PER SHARE    
Antidilutive effects of including these potential shares (in shares) 0 5,608
Convertible senior notes | Accounting Standards Update 2020-06    
EARNINGS PER SHARE    
Antidilutive effects of including these potential shares (in shares)   1,000
Weighted average number of RSUs    
EARNINGS PER SHARE    
Antidilutive effects of including these potential shares (in shares) 1,230 1,137
Weighted average ESPP purchase options    
EARNINGS PER SHARE    
Antidilutive effects of including these potential shares (in shares) 52 55
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Income (loss) before income taxes:      
Domestic $ 13,657 $ (27,773)  
Foreign (17) 1,299  
Income (loss) before income taxes 13,640 (26,474)  
Income tax expense (benefit) $ 4,661 $ (6,938)  
Effective tax rate (in percent) 34.00% 26.00%  
Income tax payable $ 1,000   $ 1,000
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Acquisition Related Charges (Gains) and Other (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]    
Changes in contingent consideration $ (3,806) $ 11,618
Restructuring charges 5,535 0
Total contingent consideration (gains) charges, restructuring charges and other 1,903 12,107
Flexion    
Restructuring Cost and Reserve [Line Items]    
Changes in contingent consideration (3,806) 11,618
Acquisition-related fees 200 500
Acquisition-related fees    
Restructuring Cost and Reserve [Line Items]    
Acquisition-related fees $ 174 $ 489
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Feb. 29, 2024
Mar. 31, 2024
Mar. 31, 2023
Business Acquisition [Line Items]      
Contingent consideration gain   $ 3,806 $ (11,618)
Charges incurred   3,300  
EXPAREL      
Business Acquisition [Line Items]      
EXPAREL at average sales price margin 6.00%    
One-time Termination Benefits      
Business Acquisition [Line Items]      
Charges incurred   5,500  
Flexion      
Business Acquisition [Line Items]      
Contingent consideration gain   3,806 (11,618)
Acquisition-related fees   200 500
Flexion      
Business Acquisition [Line Items]      
Contingent consideration gain   $ 3,800 $ (11,600)
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Schedule of Restructuring Charges (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning balance $ 0
Charges incurred 3,300
Cash payments made / settled (386)
Ending balance 2,914
Employee Termination Benefits  
Restructuring Reserve [Roll Forward]  
Beginning balance 0
Charges incurred 2,567
Cash payments made / settled (386)
Ending balance 2,181
Employee termination benefits related to share-based compensation 2,200
Contract Termination Costs  
Restructuring Reserve [Roll Forward]  
Beginning balance 0
Charges incurred 733
Cash payments made / settled 0
Ending balance $ 733
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Oct. 31, 2020
Feb. 28, 2017
Mar. 31, 2024
Aug. 08, 2023
Loss Contingencies [Line Items]        
Expect to receive partial summary judgment       $ 14,500
Charges incurred     $ 3,300  
Fortis        
Loss Contingencies [Line Items]        
Loss contingency, damages sought $ 30,000      
GeneQuine | Flexion | Achievement of Development and Regulatory Milestones        
Loss Contingencies [Line Items]        
Maximum milestone payment to be received   $ 56,000    
Estimate of restructuring costs, once probable   4,500    
Charges incurred   $ 51,500    
EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 86 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 272 335 1 false 97 0 false 12 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.pacira.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://www.pacira.com/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - REVENUE Sheet http://www.pacira.com/role/REVENUE REVENUE Notes 10 false false R11.htm 0000011 - Disclosure - INVENTORIES Sheet http://www.pacira.com/role/INVENTORIES INVENTORIES Notes 11 false false R12.htm 0000012 - Disclosure - FIXED ASSETS Sheet http://www.pacira.com/role/FIXEDASSETS FIXED ASSETS Notes 12 false false R13.htm 0000013 - Disclosure - LEASES Sheet http://www.pacira.com/role/LEASES LEASES Notes 13 false false R14.htm 0000014 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 14 false false R15.htm 0000015 - Disclosure - DEBT Sheet http://www.pacira.com/role/DEBT DEBT Notes 15 false false R16.htm 0000016 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 16 false false R17.htm 0000017 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.pacira.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 17 false false R18.htm 0000018 - Disclosure - STOCK PLANS Sheet http://www.pacira.com/role/STOCKPLANS STOCK PLANS Notes 18 false false R19.htm 0000019 - Disclosure - NET INCOME (LOSS) PER SHARE Sheet http://www.pacira.com/role/NETINCOMELOSSPERSHARE NET INCOME (LOSS) PER SHARE Notes 19 false false R20.htm 0000020 - Disclosure - INCOME TAXES Sheet http://www.pacira.com/role/INCOMETAXES INCOME TAXES Notes 20 false false R21.htm 0000021 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER Sheet http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHER CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER Notes 21 false false R22.htm 0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 26 false false R27.htm 9954473 - Disclosure - REVENUE (Tables) Sheet http://www.pacira.com/role/REVENUETables REVENUE (Tables) Tables http://www.pacira.com/role/REVENUE 27 false false R28.htm 9954474 - Disclosure - INVENTORIES (Tables) Sheet http://www.pacira.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.pacira.com/role/INVENTORIES 28 false false R29.htm 9954475 - Disclosure - FIXED ASSETS (Tables) Sheet http://www.pacira.com/role/FIXEDASSETSTables FIXED ASSETS (Tables) Tables http://www.pacira.com/role/FIXEDASSETS 29 false false R30.htm 9954476 - Disclosure - LEASES (Tables) Sheet http://www.pacira.com/role/LEASESTables LEASES (Tables) Tables http://www.pacira.com/role/LEASES 30 false false R31.htm 9954477 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS 31 false false R32.htm 9954478 - Disclosure - DEBT (Tables) Sheet http://www.pacira.com/role/DEBTTables DEBT (Tables) Tables http://www.pacira.com/role/DEBT 32 false false R33.htm 9954479 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSTables FINANCIAL INSTRUMENTS (Tables) Tables http://www.pacira.com/role/FINANCIALINSTRUMENTS 33 false false R34.htm 9954480 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.pacira.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.pacira.com/role/STOCKHOLDERSEQUITY 34 false false R35.htm 9954481 - Disclosure - STOCK PLANS (Tables) Sheet http://www.pacira.com/role/STOCKPLANSTables STOCK PLANS (Tables) Tables http://www.pacira.com/role/STOCKPLANS 35 false false R36.htm 9954482 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables) Sheet http://www.pacira.com/role/NETINCOMELOSSPERSHARETables NET INCOME (LOSS) PER SHARE (Tables) Tables http://www.pacira.com/role/NETINCOMELOSSPERSHARE 36 false false R37.htm 9954483 - Disclosure - INCOME TAXES (Tables) Sheet http://www.pacira.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.pacira.com/role/INCOMETAXES 37 false false R38.htm 9954484 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER (Tables) Sheet http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER (Tables) Tables http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHER 38 false false R39.htm 9954485 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails DESCRIPTION OF BUSINESS (Details) Details http://www.pacira.com/role/DESCRIPTIONOFBUSINESS 39 false false R40.htm 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 40 false false R41.htm 9954487 - Disclosure - REVENUE - Narrative (Details) Sheet http://www.pacira.com/role/REVENUENarrativeDetails REVENUE - Narrative (Details) Details 41 false false R42.htm 9954488 - Disclosure - REVENUE - Schedule of Disaggregated Revenue (Details) Sheet http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails REVENUE - Schedule of Disaggregated Revenue (Details) Details 42 false false R43.htm 9954489 - Disclosure - INVENTORIES (Details) Sheet http://www.pacira.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.pacira.com/role/INVENTORIESTables 43 false false R44.htm 9954490 - Disclosure - FIXED ASSETS - Schedule of Major Categories (Details) Sheet http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails FIXED ASSETS - Schedule of Major Categories (Details) Details 44 false false R45.htm 9954491 - Disclosure - FIXED ASSETS - Narrative (Details) Sheet http://www.pacira.com/role/FIXEDASSETSNarrativeDetails FIXED ASSETS - Narrative (Details) Details 45 false false R46.htm 9954492 - Disclosure - LEASES - Narrative (Details) Sheet http://www.pacira.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 46 false false R47.htm 9954493 - Disclosure - LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details) Sheet http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details) Details 47 false false R48.htm 9954494 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) Sheet http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) Details 48 false false R49.htm 9954495 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 49 false false R50.htm 9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details) Sheet http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details) Details 50 false false R51.htm 9954497 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details) Sheet http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails DEBT - Schedule of Long-Term Debt Instruments (Details) Details 51 false false R52.htm 9954498 - Disclosure - DEBT - Narrative (Details) Sheet http://www.pacira.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 52 false false R53.htm 9954499 - Disclosure - DEBT - Schedule of Debt (Details) Sheet http://www.pacira.com/role/DEBTScheduleofDebtDetails DEBT - Schedule of Debt (Details) Details 53 false false R54.htm 9954500 - Disclosure - DEBT - Schedule of Interest Expense (Details) Sheet http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails DEBT - Schedule of Interest Expense (Details) Details 54 false false R55.htm 9954501 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details) Details 55 false false R56.htm 9954502 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details) Details 56 false false R57.htm 9954503 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails FINANCIAL INSTRUMENTS - Narrative (Details) Details 57 false false R58.htm 9954504 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details) Details 58 false false R59.htm 9954505 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details) Details 59 false false R60.htm 9954506 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Available-For-Sale Securities (Details) Sheet http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails FINANCIAL INSTRUMENTS - Schedule of Available-For-Sale Securities (Details) Details 60 false false R61.htm 9954507 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails STOCKHOLDERS' EQUITY (Details) Details http://www.pacira.com/role/STOCKHOLDERSEQUITYTables 61 false false R62.htm 9954508 - Disclosure - STOCK PLANS - Schedule of Stock Based Compensation Expenses (Details) Sheet http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails STOCK PLANS - Schedule of Stock Based Compensation Expenses (Details) Details 62 false false R63.htm 9954509 - Disclosure - STOCK PLANS - Schedule of Stock Based Compensation Activity (Details) Sheet http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails STOCK PLANS - Schedule of Stock Based Compensation Activity (Details) Details 63 false false R64.htm 9954510 - Disclosure - STOCK PLANS - Narrative (Details) Sheet http://www.pacira.com/role/STOCKPLANSNarrativeDetails STOCK PLANS - Narrative (Details) Details 64 false false R65.htm 9954511 - Disclosure - STOCK PLANS - Schedule of Valuation Assumptions (Details) Sheet http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails STOCK PLANS - Schedule of Valuation Assumptions (Details) Details 65 false false R66.htm 9954512 - Disclosure - NET INCOME (LOSS) PER SHARE - Schedule of Computation of EPS (Details) Sheet http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails NET INCOME (LOSS) PER SHARE - Schedule of Computation of EPS (Details) Details http://www.pacira.com/role/NETINCOMELOSSPERSHARETables 66 false false R67.htm 9954513 - Disclosure - NET INCOME (LOSS) PER SHARE- Schedule of Antidilutive Securities (Details) Sheet http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails NET INCOME (LOSS) PER SHARE- Schedule of Antidilutive Securities (Details) Details http://www.pacira.com/role/NETINCOMELOSSPERSHARETables 67 false false R68.htm 9954514 - Disclosure - INCOME TAXES (Details) Sheet http://www.pacira.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.pacira.com/role/INCOMETAXESTables 68 false false R69.htm 9954515 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Acquisition Related Charges (Gains) and Other (Details) Sheet http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Acquisition Related Charges (Gains) and Other (Details) Details http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables 69 false false R70.htm 9954516 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Narrative (Details) Sheet http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Narrative (Details) Details http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables 70 false false R71.htm 9954517 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Schedule of Restructuring Charges (Details) Sheet http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Schedule of Restructuring Charges (Details) Details http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables 71 false false R72.htm 9954518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES 72 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration, pcrx:AccountsReceivablePaymentTerms, pcrx:DebtInstrumentMarketPrice, us-gaap:DebtInstrumentConvertibleConversionRatio1 - pcrx-20240331.htm 4 pcrx-20240331.htm pcrx-20240331.xsd pcrx-20240331_cal.xml pcrx-20240331_def.xml pcrx-20240331_lab.xml pcrx-20240331_pre.xml pcrx-20240331_g1.jpg pcrx-20240331_g2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pcrx-20240331.htm": { "nsprefix": "pcrx", "nsuri": "http://www.pacira.com/20240331", "dts": { "inline": { "local": [ "pcrx-20240331.htm" ] }, "schema": { "local": [ "pcrx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "pcrx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "pcrx-20240331_def.xml" ] }, "labelLink": { "local": [ "pcrx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "pcrx-20240331_pre.xml" ] } }, "keyStandard": 296, "keyCustom": 39, "axisStandard": 28, "axisCustom": 3, "memberStandard": 52, "memberCustom": 39, "hidden": { "total": 13, "http://fasb.org/us-gaap/2023": 1, "http://xbrl.sec.gov/ecd/2023": 5, "http://www.pacira.com/20240331": 2, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 272, "entityCount": 1, "segmentCount": 97, "elementCount": 658, "unitCount": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 744, "http://xbrl.sec.gov/ecd/2023": 31, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.pacira.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R5": { "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R6": { "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R8": { "role": "http://www.pacira.com/role/DESCRIPTIONOFBUSINESS", "longName": "0000008 - Disclosure - DESCRIPTION OF BUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.pacira.com/role/REVENUE", "longName": "0000010 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pacira.com/role/INVENTORIES", "longName": "0000011 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pacira.com/role/FIXEDASSETS", "longName": "0000012 - Disclosure - FIXED ASSETS", "shortName": "FIXED ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pacira.com/role/LEASES", "longName": "0000013 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "0000014 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.pacira.com/role/DEBT", "longName": "0000015 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTS", "longName": "0000016 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITY", "longName": "0000017 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.pacira.com/role/STOCKPLANS", "longName": "0000018 - Disclosure - STOCK PLANS", "shortName": "STOCK PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHARE", "longName": "0000019 - Disclosure - NET INCOME (LOSS) PER SHARE", "shortName": "NET INCOME (LOSS) PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.pacira.com/role/INCOMETAXES", "longName": "0000020 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHER", "longName": "0000021 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER", "shortName": "CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000022 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "pcrx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pcrx:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.pacira.com/role/REVENUETables", "longName": "9954473 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.pacira.com/role/INVENTORIESTables", "longName": "9954474 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.pacira.com/role/FIXEDASSETSTables", "longName": "9954475 - Disclosure - FIXED ASSETS (Tables)", "shortName": "FIXED ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.pacira.com/role/LEASESTables", "longName": "9954476 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954477 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.pacira.com/role/DEBTTables", "longName": "9954478 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables", "longName": "9954479 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954480 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.pacira.com/role/STOCKPLANSTables", "longName": "9954481 - Disclosure - STOCK PLANS (Tables)", "shortName": "STOCK PLANS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHARETables", "longName": "9954482 - Disclosure - NET INCOME (LOSS) PER SHARE (Tables)", "shortName": "NET INCOME (LOSS) PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.pacira.com/role/INCOMETAXESTables", "longName": "9954483 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables", "longName": "9954484 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER (Tables)", "shortName": "CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "longName": "9954485 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "shortName": "DESCRIPTION OF BUSINESS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "longName": "9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-41", "name": "pcrx:ConcentrationRiskNumberOfCustomers", "unitRef": "customer", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "pcrx:ConcentrationRiskNumberOfCustomers", "unitRef": "customer", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.pacira.com/role/REVENUENarrativeDetails", "longName": "9954487 - Disclosure - REVENUE - Narrative (Details)", "shortName": "REVENUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-51", "name": "pcrx:AccountsReceivablePaymentTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-51", "name": "pcrx:AccountsReceivablePaymentTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails", "longName": "9954488 - Disclosure - REVENUE - Schedule of Disaggregated Revenue (Details)", "shortName": "REVENUE - Schedule of Disaggregated Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R43": { "role": "http://www.pacira.com/role/INVENTORIESDetails", "longName": "9954489 - Disclosure - INVENTORIES (Details)", "shortName": "INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails", "longName": "9954490 - Disclosure - FIXED ASSETS - Schedule of Major Categories (Details)", "shortName": "FIXED ASSETS - Schedule of Major Categories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "longName": "9954491 - Disclosure - FIXED ASSETS - Narrative (Details)", "shortName": "FIXED ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetRetirementObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R46": { "role": "http://www.pacira.com/role/LEASESNarrativeDetails", "longName": "9954492 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "pcrx:NumberOfLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "pcrx:NumberOfLeases", "unitRef": "lease", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails", "longName": "9954493 - Disclosure - LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)", "shortName": "LEASES - Schedule of Operating Lease Expense and Other Operating Lease Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails", "longName": "9954494 - Disclosure - LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)", "shortName": "LEASES - Schedule of Maturities of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "longName": "9954495 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R50": { "role": "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "longName": "9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS -Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "longName": "9954497 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)", "shortName": "DEBT - Schedule of Long-Term Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.pacira.com/role/DEBTNarrativeDetails", "longName": "9954498 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "pcrx:DebtInstrumentCovenantLeverageRatioMaximum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R53": { "role": "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "longName": "9954499 - Disclosure - DEBT - Schedule of Debt (Details)", "shortName": "DEBT - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-87", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R54": { "role": "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails", "longName": "9954500 - Disclosure - DEBT - Schedule of Interest Expense (Details)", "shortName": "DEBT - Schedule of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "pcrx:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "pcrx:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "longName": "9954501 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Carrying Amount and Fair Value of the Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "pcrx:DebtInstrumentConvertibleConversionPremiumShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R56": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails", "longName": "9954502 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Investments Without Readily Determinable Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R57": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "longName": "9954503 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)", "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InterestReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R58": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails", "longName": "9954504 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Key Assumptions used in the Valuation of Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-156", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails", "longName": "9954505 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Change in Contingent Consideration Recorded at Fair Value Using Level 3 Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-161", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R60": { "role": "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "longName": "9954506 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Available-For-Sale Securities (Details)", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Available-For-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails", "longName": "9954507 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "shortName": "STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R62": { "role": "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails", "longName": "9954508 - Disclosure - STOCK PLANS - Schedule of Stock Based Compensation Expenses (Details)", "shortName": "STOCK PLANS - Schedule of Stock Based Compensation Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails", "longName": "9954509 - Disclosure - STOCK PLANS - Schedule of Stock Based Compensation Activity (Details)", "shortName": "STOCK PLANS - Schedule of Stock Based Compensation Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.pacira.com/role/STOCKPLANSNarrativeDetails", "longName": "9954510 - Disclosure - STOCK PLANS - Narrative (Details)", "shortName": "STOCK PLANS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails", "longName": "9954511 - Disclosure - STOCK PLANS - Schedule of Valuation Assumptions (Details)", "shortName": "STOCK PLANS - Schedule of Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-235", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-235", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails", "longName": "9954512 - Disclosure - NET INCOME (LOSS) PER SHARE - Schedule of Computation of EPS (Details)", "shortName": "NET INCOME (LOSS) PER SHARE - Schedule of Computation of EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAttributableToParentDiluted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R67": { "role": "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "longName": "9954513 - Disclosure - NET INCOME (LOSS) PER SHARE- Schedule of Antidilutive Securities (Details)", "shortName": "NET INCOME (LOSS) PER SHARE- Schedule of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.pacira.com/role/INCOMETAXESDetails", "longName": "9954514 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "longName": "9954515 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Acquisition Related Charges (Gains) and Other (Details)", "shortName": "CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Acquisition Related Charges (Gains) and Other (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "pcrx:COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R70": { "role": "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "longName": "9954516 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Narrative (Details)", "shortName": "CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-254", "name": "pcrx:AverageSalesPriceMarginPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "unique": true } }, "R71": { "role": "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails", "longName": "9954517 - Disclosure - CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Schedule of Restructuring Charges (Details)", "shortName": "CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER - Schedule of Restructuring Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-263", "name": "pcrx:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-263", "name": "pcrx:LitigationSettlementAmountExpectedToBeAwardedFromOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "pcrx-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate202006Member", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update 2020-06", "label": "Accounting Standards Update 2020-06 [Member]", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": [ "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r792" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r737" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r281", "r282" ] }, "pcrx_AccountsReceivablePaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AccountsReceivablePaymentTerms", "presentation": [ "http://www.pacira.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, payment terms", "label": "Accounts Receivable, Payment Terms", "documentation": "Accounts Receivable, Payment Terms" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r63", "r188", "r630" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Unrealized Gain (Loss) From Available-For-Sale Investments", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r196", "r197", "r198", "r200", "r207", "r208", "r899" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206", "r207", "r544", "r545", "r546", "r547", "r548", "r549" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r34", "r35", "r109", "r192", "r627", "r652", "r656" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r206", "r207", "r544", "r545", "r546", "r547", "r548", "r549" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Income (Loss)", "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r14", "r35", "r511", "r514", "r576", "r647", "r648", "r899", "r900", "r901", "r911", "r912", "r913" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r4", "r14", "r35", "r207", "r208", "r545", "r546", "r547", "r548", "r549", "r899" ] }, "pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AchievementOfDevelopmentAndRegulatoryMilestonesMember", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Development and Regulatory Milestones", "label": "Achievement of Development and Regulatory Milestones [Member]", "documentation": "Achievement of Development and Regulatory Milestones" } } }, "auth_ref": [] }, "pcrx_AchievementOfMilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AchievementOfMilestoneAxis", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Milestone [Axis]", "label": "Achievement of Milestone [Axis]", "documentation": "Information by categories of milestones achieved." } } }, "auth_ref": [] }, "pcrx_AchievementOfMilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AchievementOfMilestoneDomain", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Milestone [Domain]", "label": "Achievement of Milestone [Domain]", "documentation": "Different categories of achievement of milestones." } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Useful Lives", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r132" ] }, "pcrx_AcquisitionRelatedChargesImpairmentAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AcquisitionRelatedChargesImpairmentAndOtherMember", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration (gains) charges, restructuring charges and other", "label": "Acquisition-Related Charges, Impairment And Other [Member]", "documentation": "Acquisition-Related Charges, Impairment And Other" } } }, "auth_ref": [] }, "pcrx_AcquisitionRelatedFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AcquisitionRelatedFeesMember", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related fees", "label": "Acquisition Related Fees [Member]", "documentation": "Acquisition Related Fees" } } }, "auth_ref": [] }, "pcrx_AcquisitionRelatedGainLossChargesImpairmentAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AcquisitionRelatedGainLossChargesImpairmentAndOther", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration (gains) charges, restructuring charges and other", "label": "Acquisition-Related (Gain) Loss, Charges, Impairment And Other", "documentation": "Acquisition-Related (Gain) Loss, Charges, Impairment And Other" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r845" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r101", "r792", "r965" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r471", "r472", "r473", "r664", "r911", "r912", "r913", "r942", "r967" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r851" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r851" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r851" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]", "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r230", "r231", "r232", "r233", "r242", "r284", "r285", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r346", "r471", "r472", "r473", "r484", "r485", "r486", "r487", "r497", "r498", "r499", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r535", "r536", "r540", "r541", "r542", "r543", "r551", "r552", "r556", "r557", "r558", "r559", "r572", "r573", "r574", "r575", "r576", "r612", "r613", "r614", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock withheld for employee withholding tax liabilities on vested restricted stock units", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r74", "r75", "r441" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r819", "r830", "r840", "r865" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r851" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r858" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r823", "r831", "r841", "r858", "r866", "r870", "r878" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r876" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r470", "r474" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r193", "r283", "r329" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 3.0 }, "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r11", "r89", "r119", "r397" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 }, "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r113", "r397", "r554", "r906" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r57", "r61" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive effects of including these potential shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r257" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r47" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r47" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r785", "r918", "r919", "r920" ] }, "us-gaap_AssetRetirementObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligation", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement obligation", "label": "Asset Retirement Obligation", "documentation": "The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r347", "r348" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r159", "r191", "r221", "r262", "r271", "r275", "r318", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r502", "r504", "r539", "r623", "r691", "r792", "r807", "r936", "r937", "r950" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r183", "r195", "r221", "r318", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r502", "r504", "r539", "r792", "r936", "r937", "r950" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r290" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r291" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r287", "r335", "r622" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r288", "r335", "r617", "r917" ] }, "pcrx_AverageSalesPriceMarginPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "AverageSalesPriceMarginPercentage", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EXPAREL at average sales price margin", "label": "Average Sales Price, Margin Percentage", "documentation": "Average Sales Price, Margin Percentage" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r873" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r874" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r869" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r869" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails", "http://www.pacira.com/role/STOCKPLANSNarrativeDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r872" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r871" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r870" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r870" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "pcrx_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Presentation and Principles of Consolidation [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of presentation and principles of consolidation." } } }, "auth_ref": [] }, "pcrx_BupivacaineLiposomeInjectableSuspensionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "BupivacaineLiposomeInjectableSuspensionMember", "presentation": [ "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bupivacaine liposome injectable suspension", "label": "Bupivacaine Liposome Injectable Suspension [Member]", "documentation": "Bupivacaine Liposome Injectable Suspension" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r496", "r788", "r789" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r77", "r78", "r496", "r788", "r789" ] }, "us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHER" ], "lang": { "en-us": { "role": { "terseLabel": "CONTINGENT CONSIDERATION CHARGES (GAINS), RESTRUCTURING CHARGES AND OTHER", "label": "Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block]", "documentation": "The entire description for costs incurred to effect a business combination that have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." } } }, "auth_ref": [ "r152" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r496" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails": { "parentTag": "pcrx_ContingentConsiderationGainLossRestructuringChargesAndOther", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related fees", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r76" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails": { "parentTag": "pcrx_ContingentConsiderationGainLossRestructuringChargesAndOther", "weight": -1.0, "order": 3.0 }, "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in contingent consideration", "negatedTerseLabel": "Flexion contingent consideration", "negatedLabel": "Contingent consideration gain", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r501", "r905" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r80", "r500" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement input, contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r533" ] }, "pcrx_COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "COMMERCIALPARTNERSANDOTHERAGREEMENTSTableTextBlock", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquisition-Related Charges (Gain), Restructuring Charges and Other", "label": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]", "documentation": "COMMERCIAL PARTNERS AND OTHER AGREEMENTS [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets included in accounts payable and accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r43", "r44", "r45" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r84", "r85" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r41", "r185", "r753" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r41", "r124", "r217" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r124" ] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow, Operating Activities, Lessee [Abstract]", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r849" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r850" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r850" ] }, "pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum milestone payment to be received", "label": "Collaborative Arrangement, Milestone Payments to be Received, Maximum", "documentation": "Collaborative Arrangement, Milestone Payments to be Received, Maximum" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r140", "r799", "r800", "r801", "r802" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r32", "r93", "r624", "r678" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r138", "r358", "r359", "r738", "r930" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common\u00a0Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r795", "r796", "r797", "r799", "r800", "r801", "r802", "r911", "r912", "r942", "r964", "r967" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r679" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r100", "r679", "r697", "r967", "r968" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value $0.001; 250,000,000 shares authorized; 46,517,410 and 46,481,174 shares issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r626", "r792" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r855" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r854" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r856" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r853" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "presentation": [ "http://www.pacira.com/role/STOCKPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK PLANS", "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]", "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r147", "r148", "r149" ] }, "pcrx_CompensationExpenseFromEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "CompensationExpenseFromEmployeeStockPurchasePlan", "crdr": "debit", "calculation": { "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails": { "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Compensation Expense From Employee Stock Purchase Plan", "documentation": "Compensation Expense From Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "pcrx_Compensationexpensefromstockoptionsemployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "Compensationexpensefromstockoptionsemployees", "crdr": "debit", "calculation": { "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails": { "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Compensation expense from stock options, employees", "documentation": "Compensation expense from stock options (employee and board of director awards)" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r36", "r203", "r205", "r210", "r618", "r635" ] }, "pcrx_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "label": "Computer Equipment and Software [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r50", "r53", "r86", "r87", "r280", "r737" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r50", "r53", "r86", "r87", "r280", "r657", "r737" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r50", "r53", "r86", "r87", "r280", "r737", "r887" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "verboseLabel": "Concentration of Major Customers", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r737" ] }, "pcrx_ConcentrationRiskNumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ConcentrationRiskNumberOfCustomers", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of customers", "label": "Concentration Risk, Number of Customers", "documentation": "Concentration Risk, Number of Customers" } } }, "auth_ref": [] }, "pcrx_ConcentrationRiskNumberOfProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ConcentrationRiskNumberOfProducts", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of products (in products)", "label": "Concentration Risk, Number Of Products", "documentation": "Concentration Risk, Number Of Products" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Percentage of revenue from customers to total revenue (in percent)", "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r50", "r53", "r86", "r87", "r280" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r49", "r50", "r53", "r54", "r86", "r158", "r737" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r50", "r53", "r86", "r87", "r280", "r737" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "pcrx_ContingentConsiderationGainLossRestructuringChargesAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ContingentConsiderationGainLossRestructuringChargesAndOther", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total contingent consideration (gains) charges, restructuring charges and other", "label": "Contingent Consideration Gain (Loss), Restructuring Charges and Other", "documentation": "Contingent Consideration Gain (Loss), Restructuring Charges and Other" } } }, "auth_ref": [] }, "pcrx_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration [Member]" } } }, "auth_ref": [] }, "pcrx_ContingentConsiderationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ContingentConsiderationNoncurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration, Noncurrent", "documentation": "Contingent Consideration, Noncurrent" } } }, "auth_ref": [] }, "pcrx_ContingentConsiderationPaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ContingentConsiderationPaymentTerm", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment term", "label": "Contingent Consideration, Payment Term", "documentation": "Contingent Consideration, Payment Term" } } }, "auth_ref": [] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractTerminationMember", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Termination Costs", "label": "Contract Termination [Member]", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [ "r768", "r769", "r770", "r771" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of convertible senior notes, net", "label": "Convertible Debt, Current", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible senior notes, net", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r30" ] }, "pcrx_ConvertibleNotesReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ConvertibleNotesReceivableMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Receivable", "label": "Convertible Notes Receivable [Member]", "documentation": "Convertible Notes Receivable" } } }, "auth_ref": [] }, "pcrx_ConvertibleSeniorNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ConvertibleSeniorNotesDue2024Member", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.375% Convertible senior notes due May 2024 (1)", "verboseLabel": "3.375% convertible senior notes due 2024", "label": "Convertible Senior Notes Due 2024 [Member]", "documentation": "Convertible Senior Notes Due 2024" } } }, "auth_ref": [] }, "pcrx_ConvertibleSeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ConvertibleSeniorNotesDue2025Member", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.750% Convertible senior notes due August 2025", "label": "Convertible Senior Notes Due 2025 [Member]", "documentation": "Convertible Senior Notes Due 2025" } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r115", "r221", "r318", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r539", "r936" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r114" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r224", "r225", "r379", "r407", "r577", "r758", "r760" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Concentration Risk By Major Customer", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r51", "r280" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r79" ] }, "pcrx_DarylGauglerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DarylGauglerMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Daryl Gaugler [Member]", "documentation": "Daryl Gaugler" } } }, "auth_ref": [] }, "pcrx_DebtConversionAndRedemptionTermsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtConversionAndRedemptionTermsAxis", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Conversion and Redemption Terms [Axis]", "label": "Debt Conversion and Redemption Terms [Axis]", "documentation": "Information regarding the conversion and redemption terms of the debt instruments." } } }, "auth_ref": [] }, "pcrx_DebtConversionAndRedemptionTermsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtConversionAndRedemptionTermsDomain", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Conversion and Redemption Terms [Domain]", "label": "Debt Conversion and Redemption Terms [Domain]", "documentation": "Identification of the conversion and redemption terms of the debt instruments." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r139", "r219", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r391", "r398", "r399", "r401" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r22", "r97", "r98", "r160", "r162", "r226", "r376", "r377", "r378", "r379", "r380", "r382", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r555", "r772", "r773", "r774", "r775", "r776", "r907" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/DEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r22", "r162", "r402" ] }, "pcrx_DebtInstrumentConversionObligationPremiumOnCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentConversionObligationPremiumOnCommonStock", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt, premium on common stock", "label": "Debt Instrument, Conversion Obligation Premium on Common Stock", "documentation": "Represents the percentage of premium added to the last reported sale price of the common stock of the entity to arrive at the conversion price of the debt instrument." } } }, "auth_ref": [] }, "pcrx_DebtInstrumentConvertibleConversionPremiumShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentConvertibleConversionPremiumShares", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum conversion premium (in shares)", "label": "Debt Instrument, Convertible, Conversion Premium, Shares", "documentation": "Debt Instrument, Convertible, Conversion Premium, Shares" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion price of notes into common stock (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r141", "r378" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion rate of common stock per $1,000 of principal amount of Notes", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r29", "r70", "r144", "r145", "r378" ] }, "pcrx_DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentConvertibleRedemptionTradingDaysFromMaturity", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scheduled trading day", "label": "Debt Instrument, Convertible, Redemption, Trading Days From Maturity", "documentation": "Debt Instrument, Convertible, Redemption, Trading Days From Maturity" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold consecutive trading days", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold percentage stock price trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold trading days", "label": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "pcrx_DebtInstrumentCovenantLeverageRatioMaximum": { "xbrltype": "pureItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leverage ratio, maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum" } } }, "auth_ref": [] }, "pcrx_DebtInstrumentCovenantLeverageRatioMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentCovenantLeverageRatioMinimum", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leverage ratio, minimum", "label": "Debt Instrument, Covenant, Leverage Ratio, Minimum", "documentation": "Debt Instrument, Covenant, Leverage Ratio, Minimum" } } }, "auth_ref": [] }, "pcrx_DebtInstrumentCovenantNetLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentCovenantNetLeverageRatio", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net leverage ratio", "label": "Debt Instrument, Covenant, Net Leverage Ratio", "documentation": "Debt Instrument, Covenant, Net Leverage Ratio" } } }, "auth_ref": [] }, "pcrx_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentCovenantUnrestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance of unrestricted cash and cash equivalents", "label": "Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents", "documentation": "Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents" } } }, "auth_ref": [] }, "pcrx_DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsDaysPriorToMaturityDate": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentCovenantUnrestrictedCashAndCashEquivalentsDaysPriorToMaturityDate", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Days prior maturity date", "label": "Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents, Days Prior To Maturity Date", "documentation": "Debt Instrument, Covenant, Unrestricted Cash and Cash Equivalents, Days Prior To Maturity Date" } } }, "auth_ref": [] }, "pcrx_DebtInstrumentDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentDiscountRate", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Debt Instrument, Discount Rate", "documentation": "Debt Instrument, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r90", "r92", "r376", "r555", "r773", "r774" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible senior notes", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r389", "r538", "r773", "r774" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate on total debt (in percent)", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r28", "r90", "r394" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r28", "r377" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "verboseLabel": "DEBT AND FINANCING OBLIGATIONS", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r226", "r376", "r377", "r378", "r379", "r380", "r382", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r400", "r555", "r772", "r773", "r774", "r775", "r776", "r907" ] }, "pcrx_DebtInstrumentMarketPrice": { "xbrltype": "pureItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentMarketPrice", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market price of principal amount of notes", "label": "Debt Instrument, Market Price", "documentation": "Debt market price, per $1,000 principal amount." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r226", "r376", "r377", "r378", "r379", "r380", "r382", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r555", "r772", "r773", "r774", "r775", "r776", "r907" ] }, "pcrx_DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentPercentageOfPrincipalAmountForComputationOfRedemptionPrice", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, percentage of principal amount for computation of redemption price", "label": "Debt Instrument, Percentage of Principal Amount for Computation of Redemption Price", "documentation": "Represents the percentage of principal amount used in computation of the redemption price to be paid on conversion of convertible notes." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Periodic payment, principal", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r30" ] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balloon payment to be paid", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "pcrx_DebtInstrumentPrepaymentFeePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtInstrumentPrepaymentFeePercent", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee percentage", "label": "Debt Instrument, Prepayment Fee, Percent", "documentation": "Debt Instrument, Prepayment Fee, Percent" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of debt principal", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r661" ] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase amount", "label": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r70", "r71", "r89", "r90", "r92", "r94", "r143", "r145", "r226", "r376", "r377", "r378", "r379", "r380", "r382", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r400", "r555", "r772", "r773", "r774", "r775", "r776", "r907" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, unamortized discount", "negatedLabel": "Discount on debt", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r89", "r92", "r939" ] }, "pcrx_DebtRedemptionTermsOnOrAfterAugust12023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtRedemptionTermsOnOrAfterAugust12023Member", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Redemption Terms on or After August 1, 2023", "label": "Debt Redemption Terms on or after August 1, 2023 [Member]", "documentation": "Debt Redemption Terms on or after August 1, 2023" } } }, "auth_ref": [] }, "pcrx_DebtRedemptionTermsPriorToFebruary32023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "DebtRedemptionTermsPriorToFebruary32023Member", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Redemption Terms Prior to February 3, 2023", "label": "Debt Redemption Terms Prior to February 3, 2023 [Member]", "documentation": "Debt Redemption Terms Prior to February 3, 2023" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/DEBTScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r91", "r939" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r477", "r478" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r11", "r151", "r174", "r490", "r491", "r909" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r62" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of fixed assets and amortization of intangible assets", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r267" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technologies", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r153" ] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2020-06 convertible notes if-converted method adjustment", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.pacira.com/role/REVENUENarrativeDetails", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r429", "r778", "r779", "r780", "r781", "r782", "r783", "r784" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.pacira.com/role/REVENUENarrativeDetails", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r429", "r778", "r779", "r780", "r781", "r782", "r783", "r784" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.pacira.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r940" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r811" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r844" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "pcrx_EXPARELMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "EXPARELMember", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EXPAREL", "label": "EXPAREL [Member]", "documentation": "EXPAREL/bupivacaine liposome injectable suspension [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic net income (loss) per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r234", "r235", "r236", "r237", "r238", "r244", "r246", "r254", "r255", "r256", "r260", "r528", "r529", "r619", "r636", "r762" ] }, "pcrx_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share:", "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]", "documentation": "Earnings Per Share, Basic and Diluted EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r246", "r250", "r254" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net income (loss) per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r234", "r235", "r236", "r237", "r238", "r246", "r254", "r255", "r256", "r260", "r528", "r529", "r619", "r636", "r762" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET INCOME (LOSS) PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r243", "r257", "r258", "r259" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (in percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r480" ] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee termination benefits related to share-based compensation", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits." } } }, "auth_ref": [ "r11" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Termination Benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "http://www.pacira.com/role/STOCKPLANSNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average ESPP purchase options", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "netLabel": "Dilutive effect of stock options", "verboseLabel": "Weighted average number of stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r809" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r809" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r809" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r883" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r809" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r809" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r809" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r809" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r179", "r206", "r207", "r208", "r227", "r228", "r229", "r231", "r239", "r241", "r261", "r322", "r328", "r419", "r471", "r472", "r473", "r486", "r487", "r509", "r511", "r512", "r513", "r514", "r516", "r527", "r544", "r545", "r546", "r547", "r548", "r549", "r576", "r647", "r648", "r649", "r664", "r718" ] }, "pcrx_EquityMethodInvestmentsAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "EquityMethodInvestmentsAndOtherAssets", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments and other assets", "label": "Equity Method Investments and Other Assets", "documentation": "Equity Method Investments and Other Assets" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investments", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r55", "r803", "r804", "r805", "r971" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r317" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r852" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r813", "r824", "r834", "r859" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements Using", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r389", "r538", "r773", "r774" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [ "r970", "r972", "r973", "r974" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r858" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Key Assumptions used in the Valuation of Contingent Consideration", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments Without Readily Determinable Fair Value Roll Forward [Abstract]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r17", "r83" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments without Readily Determinable Fair Value", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": [ "r17", "r83" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r81", "r84", "r85" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r389", "r432", "r433", "r434", "r435", "r436", "r437", "r531", "r582", "r583", "r584", "r773", "r774", "r785", "r786", "r787" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r83", "r156" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r21", "r81", "r389", "r773", "r774" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r389", "r773", "r774" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r389", "r432", "r437", "r531", "r582", "r785", "r786", "r787" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r389", "r432", "r437", "r531", "r583", "r773", "r774", "r785", "r786", "r787" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "verboseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r389", "r432", "r433", "r434", "r435", "r436", "r437", "r531", "r584", "r773", "r774", "r785", "r786", "r787" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount and Fair Value of the Long-Term Debt", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r81", "r157" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r17", "r83" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r17", "r83" ] }, "pcrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetForeignCurrencyGainLoss", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency adjustments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Gain (Loss)", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Foreign Currency Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r82" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustments and accretion", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r534" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofChangeinContingentConsiderationRecordedatFairValueUsingLevel3MeasurementsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r389", "r432", "r433", "r434", "r435", "r436", "r437", "r582", "r583", "r584", "r773", "r774", "r785", "r786", "r787" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r330", "r331", "r332", "r333", "r334", "r336", "r337", "r338", "r400", "r417", "r517", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r634", "r766", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r921", "r922", "r923", "r924" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities:", "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "pcrx_FiniteLivedIntangibleAssetExpectedAmortizationYearEight": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearEight", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, eighth period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Eight", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Eight" } } }, "auth_ref": [] }, "pcrx_FiniteLivedIntangibleAssetExpectedAmortizationYearNine": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearNine", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, ninth period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Nine", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Nine" } } }, "auth_ref": [] }, "pcrx_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSeven", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, seventh period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven" } } }, "auth_ref": [] }, "pcrx_FiniteLivedIntangibleAssetExpectedAmortizationYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSix", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, sixth period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Six", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Six" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }, "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r190", "r343" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, first period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, remainder of fiscal year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, fifth period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, fourth period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, third period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense, second period", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r134" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r611", "r615" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r133", "r615" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r58", "r60" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r133", "r611" ] }, "pcrx_FlexionAndMyoScienceAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FlexionAndMyoScienceAcquisitionMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Flexion And MyoScience Acquisition", "label": "Flexion And MyoScience Acquisition [Member]", "documentation": "Flexion And MyoScience Acquisition" } } }, "auth_ref": [] }, "pcrx_FlexionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FlexionMember", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Flexion", "label": "Flexion [Member]", "documentation": "Flexion" } } }, "auth_ref": [] }, "pcrx_FlexionTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FlexionTherapeuticsIncMember", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Flexion", "label": "Flexion Therapeutics, Inc. [Member]", "documentation": "Flexion Therapeutics, Inc." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r820", "r831", "r841", "r866" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r820", "r831", "r841", "r866" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r820", "r831", "r841", "r866" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r820", "r831", "r841", "r866" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r820", "r831", "r841", "r866" ] }, "pcrx_FortisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "FortisMember", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fortis", "label": "Fortis [Member]", "documentation": "Fortis" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office furniture and equipment", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on early extinguishment of debt", "negatedTerseLabel": "Loss on early extinguishment of debt", "negatedLabel": "Loss on early extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r11", "r68", "r69" ] }, "pcrx_GeneQuineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "GeneQuineMember", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GeneQuine", "label": "GeneQuine [Member]", "documentation": "GeneQuine" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "verboseLabel": "Goodwill recorded in connection with the acquisition", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r189", "r340", "r616", "r767", "r792", "r926", "r927" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r131" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired IPR&D", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.pacira.com/role/INCOMETAXESDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r222", "r492" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.pacira.com/role/INCOMETAXESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r110", "r167", "r262", "r270", "r274", "r276", "r620", "r632", "r764" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.pacira.com/role/INCOMETAXESDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r222", "r492" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "presentation": [ "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) before income taxes:", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r345", "r351", "r702" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r351", "r702" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r223", "r476", "r481", "r482", "r483", "r488", "r493", "r494", "r495", "r663" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax (expense) benefit", "terseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r170", "r175", "r240", "r241", "r268", "r479", "r489", "r637" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash (received) paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r42" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and income taxes payable", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2020-06 convertible notes if-converted method adjustment (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r251", "r252", "r256" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of share based compensation arrangements (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r247", "r248", "r249", "r256", "r443" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "verboseLabel": "Intangible Assets, Net", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r135" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r823", "r831", "r841", "r858", "r866", "r870", "r878" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r876" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r812", "r882" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r812", "r882" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r812", "r882" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Carrying Value", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r189" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Intangible Assets, Net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r56", "r59" ] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized interest", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r88" ] }, "us-gaap_InterestCostsCapitalizedAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalizedAdjustment", "crdr": "credit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized interest (Note 5)", "label": "Interest Costs Capitalized Adjustment", "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "totalLabel": "Total", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r91", "r169", "r209", "r266", "r553", "r703", "r806", "r966" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/DEBTScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual interest expense", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r121", "r396", "r775", "r776" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r213", "r215", "r216" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r896", "r969" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r339" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.pacira.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r130", "r755" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.pacira.com/role/INVENTORIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.pacira.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r194", "r754", "r792" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.pacira.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r130", "r757" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.pacira.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r130", "r756" ] }, "pcrx_InvestmentCategorizationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "InvestmentCategorizationAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Categorization [Axis]", "label": "Investment Categorization [Axis]", "documentation": "Investment Categorization" } } }, "auth_ref": [] }, "pcrx_InvestmentCategorizationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "InvestmentCategorizationDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Categorization [Domain]", "label": "Investment Categorization [Domain]", "documentation": "Investment Categorization [Domain]" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r117", "r265" ] }, "pcrx_IoveraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "IoveraMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "iovera\u00b0", "label": "iovera\u00b0 [Member]", "documentation": "iovera\u00b0 [Member]" } } }, "auth_ref": [] }, "pcrx_JonathanSloninMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "JonathanSloninMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jonathan Slonin [Member]", "documentation": "Jonathan Slonin" } } }, "auth_ref": [] }, "pcrx_KristenWilliamsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "KristenWilliamsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Kristen Williams [Member]", "documentation": "Kristen Williams" } } }, "auth_ref": [] }, "pcrx_LargestCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "LargestCustomerMember", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Largest wholesaler", "label": "Largest Customer [Member]", "documentation": "Represents the largest customer of the entity." } } }, "auth_ref": [] }, "pcrx_LaurenRikerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "LaurenRikerMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Lauren Riker [Member]", "documentation": "Lauren Riker" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r564", "r791" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost [Abstract]", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.pacira.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Expense and Other Operating Lease Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r948" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r137" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.pacira.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r949" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r571" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r571" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r571" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r571" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r571" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remaining nine months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r949" ] }, "pcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r571" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.pacira.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r560" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r221", "r318", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r503", "r504", "r505", "r539", "r677", "r763", "r807", "r936", "r950", "r951" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r105", "r163", "r629", "r792", "r908", "r925", "r945" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r184", "r221", "r318", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r503", "r504", "r505", "r539", "r792", "r936", "r950", "r951" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "LitigationSettlementAmountExpectedToBeAwardedFromOtherParty", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expect to receive partial summary judgment", "label": "Litigation Settlement, Amount Expected To Be Awarded from Other Party", "documentation": "Litigation Settlement, Amount Expected To Be Awarded from Other Party" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.pacira.com/role/DEBTScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "totalLabel": "Total debt, net of deferred financing costs", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r22", "r162", "r388", "r403", "r773", "r774", "r961" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent available-for-sale investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r186" ] }, "pcrx_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "LongTermInvestmentsMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent:", "label": "Long-Term Investments [Member]", "documentation": "Long-Term Investments [Member]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r30" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r67" ] }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtWeightedAverageInterestRate", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate, at point in time", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r360", "r361", "r362", "r365", "r932", "r933" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r360", "r361", "r362", "r365", "r932", "r933" ] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, damages sought", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r931", "r932", "r933" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "pcrx_MajorCustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "MajorCustomerOneMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customer One", "label": "Major Customer One [Member]", "documentation": "Represents the major customer of the entity." } } }, "auth_ref": [] }, "pcrx_MajorCustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "MajorCustomerThreeMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customer Three", "label": "Major Customer Three [Member]", "documentation": "Represents the major customer of the entity." } } }, "auth_ref": [] }, "pcrx_MajorCustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "MajorCustomerTwoMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customer Two", "label": "Major Customer Two [Member]", "documentation": "Represents the major customer of the entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major Customers [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r280", "r780", "r940", "r962", "r963" ] }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MajorCustomersPolicyPolicyTextBlock", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Major Customers", "label": "Major Customers, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity." } } }, "auth_ref": [ "r49", "r50", "r53", "r128" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails", "http://www.pacira.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maximum", "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r438", "r609", "r644", "r669", "r670", "r723", "r725", "r727", "r728", "r730", "r748", "r749", "r765", "r777", "r790", "r794", "r938", "r952", "r953", "r954", "r955", "r956", "r957" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r850" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r850" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rates", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r943" ] }, "pcrx_MeasurementInputExpectedMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "MeasurementInputExpectedMilestonePaymentMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of payment for remaining regulatory milestone", "label": "Measurement Input, Expected Milestone Payment [Member]", "documentation": "Measurement Input, Expected Milestone Payment [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r532" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails", "http://www.pacira.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r438", "r609", "r644", "r669", "r670", "r723", "r725", "r727", "r728", "r730", "r748", "r749", "r765", "r777", "r790", "r794", "r938", "r952", "r953", "r954", "r955", "r956", "r957" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r869" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r877" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Major Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r280", "r780", "r940", "r962", "r963" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r214" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r214" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r124", "r125", "r126" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "netLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "verboseLabel": "Net income (loss)\u2014basic", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r111", "r126", "r168", "r182", "r201", "r204", "r208", "r221", "r230", "r234", "r235", "r236", "r237", "r240", "r241", "r253", "r262", "r270", "r274", "r276", "r318", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r529", "r539", "r633", "r699", "r716", "r717", "r764", "r806", "r936" ] }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToParentDiluted", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted net income (loss)\u2014diluted", "label": "Net Income (Loss) Attributable to Parent, Diluted", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Not Adopted as of March\u00a031, 2024", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r850" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r820", "r831", "r841", "r858", "r866" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r848" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r858" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r877" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r877" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes receivable", "label": "Notes Receivable, Fair Value Disclosure", "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date." } } }, "auth_ref": [ "r944" ] }, "pcrx_NumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "NumberOfLeases", "presentation": [ "http://www.pacira.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of embedded leases", "label": "Number Of Leases", "documentation": "Number Of Leases" } } }, "auth_ref": [] }, "pcrx_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "NumberOfMajorCustomers", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of major customers", "label": "Number of Major Customers", "documentation": "Represents the number of major customers of the reporting entity." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r916" ] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OneTimeTerminationBenefitsMember", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One-time Termination Benefits", "label": "One-time Termination Benefits [Member]", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": [ "r768", "r769", "r770", "r771" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r262", "r270", "r274", "r276", "r764" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r565", "r791" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r562" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r562" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r562" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating lease liabilities, net of lease incentives", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r563", "r568" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r561" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate (in percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r570", "r791" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r569", "r791" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "DESCRIPTION OF BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r96", "r154", "r658", "r659" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r8", "r13", "r155" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive (loss) income", "terseLabel": "Other comprehensive loss (Note 10)", "verboseLabel": "Other comprehensive (loss) income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r8", "r13", "r155", "r202", "r205" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized (loss) gain on investments, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r196", "r199", "r316" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on investments, tax expense", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax", "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r5", "r197" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r120" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r850" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r818", "r829", "r839", "r864" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r821", "r832", "r842", "r867" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r821", "r832", "r842", "r867" ] }, "pcrx_PaulHastingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "PaulHastingsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Paul Hastings [Member]", "documentation": "Paul Hastings" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r846" ] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance and financing costs", "label": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PaymentsForReinsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForReinsurance", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments made / settled", "label": "Payments for Reinsurance", "documentation": "Cash payments made for reinsurance during the current period." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt extinguishment costs", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of employee withholding taxes on restricted stock unit vests", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r212" ] }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of debt investments", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": [ "r902" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of fixed assets", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r123" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of available-for-sale investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r122" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r849" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r849" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r848" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r858" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r851" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r537" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r99", "r405" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r99", "r679" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r99", "r405" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r99", "r679", "r697", "r967", "r968" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r99", "r625", "r792" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r898" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issued in private placement", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r903" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Term loan A facility", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r38", "r907" ] }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfShortTermInvestments", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of available-for-sale investments", "label": "Proceeds from Sale of Short-Term Investments", "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercises of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r20" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r52" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net product sales", "verboseLabel": "Total net product sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r778" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r277", "r610", "r638", "r639", "r640", "r641", "r642", "r643", "r750", "r778", "r793", "r888", "r934", "r935", "r940", "r962" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r277", "r610", "r638", "r639", "r640", "r641", "r642", "r643", "r750", "r778", "r793", "r888", "r934", "r935", "r940", "r962" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/FIXEDASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "FIXED ASSETS", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r136", "r171", "r172", "r173" ] }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisposals", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposals", "label": "Property, Plant and Equipment, Disposals", "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r137", "r187", "r631" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FIXED ASSETS", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed assets, net", "totalLabel": "Fixed assets, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r621", "r631", "r792" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fixed Assets Summarized by Major Category", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r137" ] }, "us-gaap_ProvisionForOtherLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForOtherLosses", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other net losses (gains)", "label": "Provision for Other Losses", "documentation": "Amount of expense related to other loss." } } }, "auth_ref": [ "r10", "r112", "r166" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r846" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r846" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails", "http://www.pacira.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r431", "r438", "r466", "r467", "r468", "r585", "r609", "r644", "r669", "r670", "r723", "r725", "r727", "r728", "r730", "r748", "r749", "r765", "r777", "r790", "r794", "r797", "r928", "r938", "r953", "r954", "r955", "r956", "r957" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails", "http://www.pacira.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r431", "r438", "r466", "r467", "r468", "r585", "r609", "r644", "r669", "r670", "r723", "r725", "r727", "r728", "r730", "r748", "r749", "r765", "r777", "r790", "r794", "r797", "r928", "r938", "r953", "r954", "r955", "r956", "r957" ] }, "us-gaap_ReceivablesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesFairValueDisclosureAbstract", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets:", "label": "Receivables, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r813", "r824", "r834", "r859" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r904" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of Term loan B facility", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r40" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r224", "r225", "r379", "r407", "r577", "r759", "r760" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r95", "r475", "r958" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r814", "r825", "r835", "r860" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r822", "r833", "r843", "r868" ] }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockExpense", "crdr": "debit", "calculation": { "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails": { "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock or Unit Expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "netLabel": "Dilutive effect of RSUs", "verboseLabel": "Weighted average number of RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of restructuring costs, once probable", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r349", "r352", "r355", "r357" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.pacira.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges incurred", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11", "r353", "r355", "r929" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r349", "r350", "r355", "r356" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r349", "r350", "r351", "r352", "r355", "r356", "r357" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCosts", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails": { "parentTag": "pcrx_ContingentConsiderationGainLossRestructuringChargesAndOther", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r350", "r354" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r102", "r146", "r628", "r651", "r656", "r662", "r680", "r792" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r179", "r227", "r228", "r229", "r231", "r239", "r241", "r322", "r328", "r471", "r472", "r473", "r486", "r487", "r509", "r512", "r513", "r516", "r527", "r647", "r649", "r664", "r967" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenues", "terseLabel": "Total net product sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r263", "r264", "r269", "r272", "r273", "r277", "r278", "r280", "r428", "r429", "r610" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.pacira.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r176", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r430" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty revenue", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r941" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r877" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r877" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.pacira.com/role/DESCRIPTIONOFBUSINESSDetails", "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r280", "r886" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r439", "r914" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario, Unspecified [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r242", "r439", "r884", "r914" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r35", "r946", "r947" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofFiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Dilutive Effect of the Securities Excluded from the Calculation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term and Noncurrent Available-for-Sale Investments", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r77", "r78", "r496" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.pacira.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r30", "r70", "r71", "r89", "r90", "r92", "r94", "r143", "r145", "r773", "r775", "r910" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.pacira.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Composition of the Company's Debt and Financing Obligations", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r915" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share." } } }, "auth_ref": [ "r46", "r48", "r246", "r250", "r254" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.pacira.com/role/STOCKPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": [ "http://www.pacira.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.pacira.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income (Loss) Before Income Taxes and Income Tax Expense (Benefit)", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r909" ] }, "pcrx_ScheduleOfInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ScheduleOfInterestExpenseTableTextBlock", "presentation": [ "http://www.pacira.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Interest Expense Recognized Related to the Notes", "label": "Schedule of Interest Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of interest rate expenses related to convertible notes." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.pacira.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r23", "r106", "r107", "r108" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails", "http://www.pacira.com/role/FIXEDASSETSScheduleofMajorCategoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r349", "r350", "r351", "r352", "r355", "r356", "r357" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Charges", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r64", "r65", "r66" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r440", "r442", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.pacira.com/role/STOCKPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Company's Stock Option Activity and Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r72" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.pacira.com/role/STOCKPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r150" ] }, "pcrx_ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ScheduleOfShortTermAndNoncurrentAvailableForSaleInvestmentsTable", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities [Table]", "label": "Schedule of Short-Term and Noncurrent Available-For-Sale Investments [Table]", "documentation": "Schedule of Short-Term and Noncurrent Available-For-Sale Investments" } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Percentage of Revenue Comprised of the Three Largest Customers", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r49", "r50", "r53", "r54", "r86", "r158" ] }, "pcrx_SecondLargestCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "SecondLargestCustomerMember", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second largest wholesaler", "label": "Second Largest Customer [Member]", "documentation": "Represents the second largest customer of the entity." } } }, "auth_ref": [] }, "pcrx_SecuredAndUnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "SecuredAndUnsecuredDebtMember", "presentation": [ "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured and Unsecured Debt", "label": "Secured and Unsecured Debt [Member]", "documentation": "Secured and Unsecured Debt" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net", "label": "Secured Long-Term Debt, Noncurrent", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [ "r30" ] }, "pcrx_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r808" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r810" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r278", "r279", "r666", "r667", "r668", "r724", "r726", "r729", "r731", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r751", "r779", "r797", "r940", "r962" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r116" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible senior notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "pcrx_SettlementPeriodConvertibleDebtConversionRequest": { "xbrltype": "durationItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "SettlementPeriodConvertibleDebtConversionRequest", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement period - convertible debt conversion request", "label": "Settlement Period - Convertible Debt Conversion Request", "documentation": "The number of trading days in a settlement period for convertible debt conversion requests." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "totalLabel": "Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAbstract", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation from:", "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at beginning of period (in shares)", "periodEndLabel": "Unvested at end of period in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at beginning of period (in dollars per share)", "periodEndLabel": "Unvested at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value (Per Share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r466" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r468" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Incentive Plans", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r440", "r442", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": { "xbrltype": "integerItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of offering periods for ESPP", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r451" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding beginning of period (in shares)", "periodEndLabel": "Outstanding end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding beginning of period (in dollars per share)", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price (Per Share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "pcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP purchasing period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails", "http://www.pacira.com/role/STOCKPLANSNarrativeDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails", "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r453" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofStockBasedCompensationActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r451" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Closing sale price (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.pacira.com/role/STOCKPLANSScheduleofValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term of options (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r465" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of common stock, ESPP (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term available-for-sale investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r164", "r165", "r897" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r732", "r733", "r734", "r752" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r127", "r218" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r33", "r179", "r206", "r207", "r208", "r227", "r228", "r229", "r231", "r239", "r241", "r261", "r322", "r328", "r419", "r471", "r472", "r473", "r486", "r487", "r509", "r511", "r512", "r513", "r514", "r516", "r527", "r544", "r545", "r546", "r547", "r548", "r549", "r576", "r647", "r648", "r649", "r664", "r718" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.pacira.com/role/FIXEDASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r278", "r279", "r666", "r667", "r668", "r724", "r726", "r729", "r731", "r736", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r751", "r779", "r797", "r940", "r962" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r227", "r228", "r229", "r261", "r610", "r660", "r665", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r698", "r700", "r701", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r718", "r798" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r242", "r439", "r884", "r885", "r914" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r227", "r228", "r229", "r261", "r610", "r660", "r665", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r698", "r700", "r701", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r718", "r798" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r817", "r828", "r838", "r863" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.pacira.com/role/STOCKPLANSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued under employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r15", "r99", "r100", "r146" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Vested restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r99", "r100", "r146" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r99", "r100", "r146", "r452" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Vested restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r15", "r146" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r33", "r146" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at ending of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r100", "r103", "r104", "r129", "r681", "r697", "r719", "r720", "r792", "r807", "r908", "r925", "r945", "r967" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r142", "r220", "r404", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r518", "r721", "r722", "r735" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r567", "r791" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r550", "r578" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r550", "r578" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.pacira.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r550", "r578" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r857" ] }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.pacira.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Taxes Payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes." } } }, "auth_ref": [ "r98", "r161", "r960" ] }, "pcrx_TermLoanAFacilityDueMarch2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "TermLoanAFacilityDueMarch2028Member", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan A facility maturing March 2028", "label": "Term Loan A Facility Due March 2028 [Member]", "documentation": "Term Loan A Facility Due March 2028" } } }, "auth_ref": [] }, "pcrx_TermLoanAFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "TermLoanAFacilityMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan A Facility", "label": "Term Loan A Facility [Member]", "documentation": "Term Loan A Facility" } } }, "auth_ref": [] }, "pcrx_TermLoanBFacilityDueDecember2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "TermLoanBFacilityDueDecember2026Member", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan B Facility Due December 2026", "label": "Term Loan B Facility Due December 2026 [Member]", "documentation": "Term Loan B Facility Due December 2026" } } }, "auth_ref": [] }, "pcrx_TermLoanBFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "TermLoanBFacilityMember", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan B Facility", "label": "Term Loan B Facility [Member]", "documentation": "Term Loan B Facility" } } }, "auth_ref": [] }, "pcrx_ThirdLargestCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ThirdLargestCustomerMember", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third largest wholesaler", "label": "Third Largest Customer [Member]", "documentation": "Represents the third largest customer of the entity." } } }, "auth_ref": [] }, "pcrx_ThreeLargestCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ThreeLargestCustomersMember", "presentation": [ "http://www.pacira.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Three Largest Customers [Member]", "documentation": "Three Largest Customers" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r849" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r856" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r876" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r878" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.pacira.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofInvestmentsWithoutReadilyDeterminableFairValueDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofKeyAssumptionsusedintheValuationofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r400", "r417", "r517", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r634", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r921", "r922", "r923", "r924" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r879" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r880" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r878" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r878" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r881" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r879" ] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesDetails", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Adoption [Domain]", "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r230", "r231", "r232", "r233", "r242", "r284", "r285", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r346", "r471", "r472", "r473", "r484", "r485", "r486", "r487", "r497", "r498", "r499", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r535", "r536", "r540", "r541", "r542", "r543", "r551", "r552", "r556", "r557", "r558", "r559", "r572", "r573", "r574", "r575", "r576", "r612", "r613", "r614", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERAcquisitionRelatedChargesGainsandOtherDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERNarrativeDetails", "http://www.pacira.com/role/CONTINGENTCONSIDERATIONCHARGESGAINSRESTRUCTURINGCHARGESANDOTHERScheduleofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r349", "r350", "r355", "r356" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal agency bonds", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r761", "r785", "r959" ] }, "us-gaap_USTreasuryBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBondSecuritiesMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government bonds", "label": "US Treasury Bond Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r959" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r875" ] }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebtMember", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails", "http://www.pacira.com/role/DEBTScheduleofDebtDetails", "http://www.pacira.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails", "http://www.pacira.com/role/FINANCIALINSTRUMENTSScheduleofCarryingAmountandFairValueoftheLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debt", "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pacira.com/role/LEASESScheduleofOperatingLeaseExpenseandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r566", "r791" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.pacira.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.pacira.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r748", "r749", "r952", "r954", "r957" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computation of diluted securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average number of shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r245", "r256" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding:", "verboseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pacira.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.pacira.com/role/NETINCOMELOSSPERSHAREScheduleofComputationofEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r244", "r256" ] }, "pcrx_ZILRETTAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pacira.com/20240331", "localname": "ZILRETTAMember", "presentation": [ "http://www.pacira.com/role/REVENUEScheduleofDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ZILRETTA", "label": "ZILRETTA [Member]", "documentation": "ZILRETTA" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481999/410-20-25-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r884": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r885": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 93 0001396814-24-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001396814-24-000045-xbrl.zip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

^1[[@ L25XB2ES&]VV'%NGV,D /?0GT_MQ,[VAMCX<$??'JC?3(Q;UGN@KM2?T@>[: M)'/( + #Q,:-.6O79D2*Y[OWQL$\U_8Y,E$)OYP]XZ.-CHOMI<'4-S\P_#+* M ]_!F=LT0"0TM2:>#[ZWFWDXZ>%$-[-_]NT>_.DHVY M)^X+]?S95T?47!RJSHL!>]B3Y#W4PV? KWO@G+O4C\ Y;S@_DT/)76[L0V3V M* S?$/C,L!Y^AT_NBF<$/OG$YYGT)[=)W[.AY4,!Z0]-]X3RP0\\SZ0^N4U] M"WAR!<\S:4_N%@!VH,.E]!TZ=JV"\R\0J<#GF=0G=^L@ I]\XO,\^E/C;CD( M\?E$[)>0+0RNIFV.)J-,*@B-NP6,30P@;]EE )G$DNN,S'?,"+F\G8?"4Z;DNX-\>.!Z%?Q_X7U7T\-*4W\<;! M<[(I.%PF)[AGUGDDJ\)=I+Y4$@D3\:>/%K']IFW@5I0Q/F-3>N4;T8? /G>Z M?.%1]YXDV/6EPEVPGA(>)-@?M,)=O+X7#^XI\>C0L8S.:.R"/X#7I:83586[ M,#TE/$A2#KB+SF/Q@-ESW(8X\:D[OP*N[CD#_R=Q4],)K,)=7)XB/B0I#]Q% MY'OII+N):YO^Q*5PX9WYAK^EQRQP%XBG@P5)2@%W\?=>+&@Y;(<>.U&S8\.M M+\"#],@!=W%U6IB0H"141;R.92,4/PO'SG3T'G>!.V9\ MYTUL?J5 >S(>FCJQ%M4G[0ER,ZDB,,XS! FZ(57N,@2"V0FZ._/MIA:.>_/& M:O;5[/[HNTVKW.8T[DP8-+TW7ZG1L8%8+^:S19N>1WWO9AJ4M5K$>]?]ZI:^ M4@N 8/2I/K0=RWF9/IDOPQ1),K>Y#=[YP8.7Q&U69"_FS>JCGZC%2J.]H3E. MCR!QFQ[AF1<\"!&W*96]&,?"#!VBC"?J4>+J0_!-0JV8IO7P&K0>=P\YM-H5GVW0D0>(N3Y(&7O @1-SE/%+K)R0I3MSF M$Z)W [V=T&_( :!,+:GTU+UCO_CP(AS%>CZJ1_6)2PW\,C4.(;>)"L'H9"6: MVZ3&5D:W'/N5NCZJW1ZU3<=]<'SJ ;>!,EIJ!(S;!,;'$/]N>Y%!+E@=L)K; ME(=@=<+:M,YM'B4MK"ZG1:KKW*9H!*N3EFIN$SJ;63WK/XEBJ24M0-7&;+1,@ M/+DC5$O0$>(V-7<47'$3W?V M;H>;$N3^%0P.=F]Z N:OHO:&>.S3]"@G;O-]*6?Q7D)RK);%QP(/=XG+R],\ MR\G8[BMU;2PVO3-M8NNF_8+7];IW3^F!E,C+)J,E!*3FD!(98*[][_,4WT4-,'9'4P-RDFH@O>G6 M2T'&>=J.R*7T)DPO"!EG6#R6Y?1F=#.,C./4C\@R=^G5M!4_'K>DN50H51/C M-;?9T!/RFO$3'Q3P%#]LVL83->AHC!LQ494LG[^(E[[[]A%H[O:=._KL3H@[ M55$DLP;!%4/$0!C-17F'USW7D'R7&*;]\L^M:TE+%^RQIB1SE]D52N\\B'L/ M#&[SLP(8Y^QU(\OIR[(>PJ536-&NW76; \!T<_(R\7PY@A4]V&VN+4'G,%E5@8=- 78M>NIE^=+#E FWZ=H36AF#FM?W](58;4:")6S<6?0-03&D+AG3 MB6_J7L?6SVK5RL=43#)X.EJAI"2CF-*7\#TQX3>DY2M1-(#"/(]*,AJ V^1K M6OS,HTIDR.MJ(A*I<)M.O2.F^U=B3>C-]%L0/.,#;HAGOF]615QWBL41=.RX M/C6:(V=B^_/;;TU/MQR\/S55$PJW:<_(3&E[OCD"#=0=S&^)SY%]AC7_]3>8 M*)9M3.^Q_]6[$WMF%W7L\<3WV!5R>N#!;:8TP_!0T@,/;O.'2? AL5SV:;'* M$3RXS2*>W.(?[@1FO5CP6!A,7\+R))S.L/WNW%5KE="#P#KS/L)R266L^Z/'"[ M\BGD@M;E@=M5V$OWVCD5SJS+ W?KL,?O0,9+XIJ';70JORN/00,X8KUG MU5P/_#&!\;(%+M,WZ7'/3582; ZE\KN^M8WF[\6#"<83U:GYBKW\TD-Z;A=U M.( [#UWRRMRN,O C&USPZ>C9[[00@M^TY_DURG'.4I/+W";Y^%$2QR(]M_DD M#N#.@T-?YC?!P8UL<,$G[@)OC@3I2,F.S/Q3)MZ7E,' M6'LF=C]9;WW1M(UO4Z>GF]36Z=*5Z:$_MX$OO_1/TF_2N(UK(]'_J'26"[*\ M=*+F873FMBKK_'16L&-24G3F-NP]$YW?-[&)ZE.^ _]!/J7&;5S, U/.Y.AK MW$;,/##E3+WV-7ZC9)[* )86XMGCUTL!WE^!"_!8-'FD$^O^1O%L*&HT(1XB M+\E5X.P*OWP3AF%C+T4/F.R2"+XG[V)XI$!#XRZO!OO^Z_3:F.GA]WTR+>KYCTTI(]KS";?9Z9YE*T_.H?T/T']2(7*NR\^V,J1W[%?Q0 M?&,+8/WBN.:_R<)OF[?>&CJNCYW)%I>GIU2FDND$>6*[AP4(CPI"[G+)Y^4[ M5QN&+P:$_*9?=X&PY8Q&U,4K'@G,67 \(L>Y2P^>B^-Z_OLEJSJ8@8]V)]>G/CQV*],(KGP&%Z,_9IP*$PA5%QR&_J_J+. M*JKQF\.^J#-R:NG-*%]BPS($QO OF" MJL<2Y7AZ$[0\:IXH"-*.=LZ^RLENAG'^\<0W!&R[\6^S2M?=.W$SD7:,.'U@VIF[UV[.'D@<]#A6REQFWY,!SS[/QT!SR/"D]NT M:$K@.72IT)_'!"BW.=QT /12S/MY3KI12MQF>-,!STLQ[^>")W?YWY3!\V+, M^YD *G.7*O\0'!VL5B='3;DDV*)"D;G-0O=\@ S>T_YC@B=+.:.Q8V-Z=TWV M)Z.)!=<:#]3_;KN46.:_J;'(!_]*3/O>\=*3%I:Y30O'YTG?);9G!4E[XU^3 M@"/IX02WB>$42 J76U'B@FW"1T\K,K=9GC1(1Z*.$$OYF$R;-'_Y@@*U[AQWJ^^=T%QW:3M4*IF@S)N8W].[;NC.ANI;C^=U!CU@[-U6D-,A7N WR.>//N0PZMP%_)/X\48]BF6P3:(!EL,Z8 MF9NW,3QMUX)=6B6*V\0 ]QP[EXQQFS:(Q+$>M2S3?OF5VM0E%O"M:8Q,V_38 MHO0K#5F75?O%;:(A1;P[D]RIW.88/N0=JS!HZA R>2:K^J L-&H-B?M"OSDUP+G09MTF*')?$>N,QC A?9+.OK%>%5X 3:!L#&^SXV@/S EU*IDA&0O.>8W7W(*/O>H;8*KY/A97;8I\YMQR19_SR6__"9X3L'?B\J>EOE-&667U^>2 M:WYS12?WOS(JS?SFD;+&X7/),+\Y)KY\K^CC%AG.R.C3N,VCW4P\TZ:>MU0= MLE0S::?DS"[LVK0/M^/Q"*;-/-<;:M.!>8PC M$KA0=MRF@R*S;!X$4FPC!\Y[:NI,-6[S,Y&)WW*PG:+N+PE,>LC/;?*$)^QS MH:6X38+P)2@\\*K";/[=J6"G(IHB)BER:EB(X>Q\=U74HU^%\R0.,R[OT :+AG]O>) M>?BY"6&*8VB";L:A=0??3 MTBV.OYD"6+EC:&<^4S@MVQW' MW],78K49,\Z0Y%S@3*ZRB#XAG'$7T0NE(X2V%LY<5?7-/SJ?TWT[),,LIH/J_" M74YC*S_^QP'O?DCLGN789E:#8>X2%UO9\4@FUF_$PP*'C,I&E;O,Q)F8<:3H MM\I=\F$K?6^).[5^)9,7*ZN&N- 5.QMZV\T1;IM]KSN6XU[_J<3^[\L "%,8D)%I3:__C*NEGO1 M?TI/SHC8?\Y[Q/8*'I!R$%SHF?^FUW(-YL7^_!E,M K/L2!,FTU<5G"VWQ\Z M_?:MU.LW^^T>]Z/MM5O?GSK]3KLG-1]NI?;?6[\U'WYM2ZWNMV^=7J_3?=@Z MA1%Q7X#KSX[O.Z-K%5YW_$DID2;U-^(-P>I N)J7;HNMHJ24M'(]%B]\/$YN M=L&SXX*D%&#X%AE[]'KVRQ?#],86F8(4LD&PF[ZLTD6#$;]2%X)98H4O8>\+ MO@[E1"T7Z^4*BHH/ ND;LQ>'4E2$25VM?UZO%>NES5^5BC+[_(H]SYU]&5() M>)5C]\!$D":_Y-3D1 2 M?H)//PU@HDG!7??IVW__2:Z4OGP%Q6@[]L-D!$_2I5!_/M$!&B0Y)]D$C0WF M,&X=?8(*'/=!YYCJ', %#;E4^)VIU\53MNNL:"(DL)@ %L]/6#"&Q5)@$&-1 MMJB4ZQ\2-NJ3:K6BIFV^Y1V/MC%D1G-E_(947T?K>RJ,3,.P:-)27=\EU(S* MG[X1]X?4M>GGN?SYQJZ9K:(I04H B*.3H>F:Q)*^VZ;N&%3ZUMNFW>1WA"AO M)$1\G?;[!!Q\ZEK3)SIV7#\G#1QW1'SP#M_\ZX'Y1HV"[T[F:@_<]/_^4[U: MKGS9JOEV4WX#)2TZ6)>K.'1,RJM@9/S]>_.IWWZZ_X?TU'[L/O6EQ^]/O>_- MA[[4[TK@1_7!60J,B*Q*W2=)UCX9GX,/NG=2_[>VM.1LS1VM9JLO=>_"^^IJ M>85BFU5:PM.O[ (1,Y%2;%?V[/YZ*9KM=US)'U)ICGDIZ&LEM6V#&E)\X0EN M;P>![ZKHX%:;P@@>,<3;"@:9%J:4N 5JST1)S36^83/L !"JG)9N0"QO;N_*H;TK M9]K>]9^:#[T.6K5S&[R,*+>9I?'G>)."=)TT<)U10)'UGY+OS&9VI$&S)UZ; M/I!(CS"-^,8G>5F MK#3,@>APA'?Y14Q)YJS!R]2)ZK!Z4^!7052ZHJ__-%+OYK M_)*3B.6CP=%-ESR;CJ>;U-:I1TI:\/4J!>J5\=L^C%+*<".;=4(3/4=B.5J> M,*XT/M$7=K*&[6.)UTPB*[G&8[/5>6I*-YUNK]5I/[3:O7R@[3L/K>(VIR+9 M&95IA-CH56)4N,BW5^O%LJK%I7:Y5BQ7*['"P^V?5\KQ MGO3AH&H92##O=MIBAIJ!.1(JKF&K?4(C^)2P\(/^<2Q 3HUNH'1K@IHE(+?NVZ M?>?GW"[(I5RC3T9C\IX&^=A9A/ =3"%TW4;9]C@!K/ M!K0>AX[]+DLGET'#:6JA4JGQI,,BHGD1=?_WGVJ*7/WB27UJT3'.,TQEYB7P M':P)6G4)ZIQ(V)CSTHM5*L5LLGC94#_IXI1.N;OL4L'"7Z4-(MXGEG#!?.2PJ7 M,#7H34?/CG6I5)AE;!D>Z)L^)/8+?&!+/X#?#G5(L-3V/E1%#?,N2JVB$O(,\H?TJ^4\0\C5 Y]5 M]R6L&Z;^[KS?J?(V46X[JX?+@@#<%J=C O%Y*NE#JO^01EA__7-(6381O5EW ML3CW20XKA8;$DP:F!K MCD*G>OA M3AQ/^##6Q)V-A V7>+Y4+P5/,,C4*ZZN$YZZO#Q7#W4YH#F#\Z:7LJNTD*9!7$=F;X/ M4LZ,A>O8:#&MJ81]]J92!_4VT5G>[I;X)*CF>J?.%L]83@ \32P:$+5-"H*B?*\6*HB24 MNRW+\9[$Y?2V#@H>54]DE\_^:487M5E*TPB+^GFW!6KHQ7&G&[((["*FH/3P MHD5"02GE&O>;U5VR^X222=-UU&PV?S!KKC,\DPPN[\7@"]0[#YO\ M+ &*;#&YM\TGS1ZCX]I11IK9V7D[-]0J"8S;]O;J_*0 Y2+X,/4AQYR=RK_D.@]W&Y:;62D6J\1BA\=[W8G/ MU#?H\54$V)-1P7#\0OA ,/'@",&S2G,\E'.-].EL/RL*\H"QL5@PVKPZ;EX7EI9_4I9*S&.EZ5GS&L.7VOV,GL'#7+I[> M:[[2M8; BVPX2VR7%K>09\^Q)O[V6^+4R;SO,1RMQ7%UWN)XZ"[\JQ=:>'8I M^5$@ WCI-;%^DJF'GM;F/LAEI5C5MK9"W@#SP>!H, \<;,!3N'7O>@)RY^)5 M,";"S5BDH8O2]*=('.JS117 .)ZVAF4R7Z_(1NZ?="-*M [%._H_Q"P0._7H MUSHA=A\D;*$K!AS,O=^\ MN6]+W3NIU7WHMQ_Z\1J4GW@'2KU8T]2XJYBU8EE.9H=&32[6$WI4I:CN6"_< M?Z_'IJ9Q1\H*1:KK7_7%SYD#NN1916N1_ @^C?2GW1LL*HL*'$=,-F% M<(R#.O[_1]7EV]L:[JUCRG[0C?"H&MNP_B@F,N$F?%QZ94,#=^=)+X*&]A_^9V M3;+V4;^F=6RP_UMOU'3N^W=M)$M(SRU#60 V"<"JN4;'IV&[5+F8C.H27#T_ M5^_FZQNL[TBP\^73=YM,#-.GQN>SHK(>A6<*\;R# T[AK/&/D8IPUH2SQLM88D!7BZC> M6+G9T+'@%5Y8_26U_YB8_E0X;]F'2%4X;\)YXV4L,:!;B^J\$6\HW5G.3Y%8 MNP!(U(2O)GPU7L82';JJC-O!?1B3[TA;U-JFM4_AH&4?%W4>'#0AZ,DPM%Y= M+DU1#BY-$2SE@J7?B$U>F$J>;Y^Z-3U]$IS6BUW'FC:QII[)7-*%)D=5'VSS MQ6N>J#>QDEY $5XK__!1N'!;A4)(:$D,6Y4LE+QZGOI#P=/$>?H[]DXP?;99 ME2EL^,":_8WZWG*\"6ZJ;3X[DUF/>.G)]'X(/_T"X%%6A:>>)9:6E[5X6;CJ M&>$I;@5W@6-,@S^ZCDX-5-K"S[X WB>HHKG)#T?MPGB6!''FILKA,4@;YAM_ MA^YAUDGLT#WN#EVENK)%MU.4NOW?VD])[L\5]HMW^P48*!]W'^ZJ]HN_C_9( M]Y\H?A([-A/?K5=*=B.N8"LW;+VG+\0*PB=V=)2(GRZ!Z[OLCTAJGW\L<5BZ MVBBA*58J,L)47'.0[HCN.ZZH$;H$AB>HF$6>F@.65D294!9Y^MT.&BU3/""U M1ZR@ 7.PV6;Y3&I]C MQP:];9N.NZ2^A<=] 1@0'G>F6%I61+5/%GGZ#>X!3WM P<%>*M$4WO0%\%YX MT]EBJ;:LHC7A36>$IUUV#E['#HZW@D<)__D"N%[FHFN<$.2$6*JM['FJ"/\Y M(SQMOPW-9U-T);X(9B>HDX5SQ0%+R[E&#^A*_"1"7FYV 9Q_$X#05><'=OG# MQG6S,^U/O!]CRTGVD?X:O4BK6Q.,(WQEB. M=H3OL>5]VT&]\XTY$FO_HGS9=H3>1KV0V'C52,/=IIZ.9J"C#B.JU*JYL[-\ M>5/#?")'&@A[XK7I@[K6(PQM@;Q>O]EO?\,3?%>/R#H1]V..^SAD5 \=#;=D MBBTVE=P&IR,\[#;?NAU[[%([1[W?O.+0CB MK733O ?);$N]W]KMQ:G:B0ZPO*_J/9]?N'F(GSJVY ^="3S$ )>0OND4CXL= M$C?HO#.F[NRO$<1NOK>NU_B;T[H2/OUIZ14M[FGIU7*Q5OKX9/*HCY)+Q4JI M'NM1VS\O5Y7$!B5__/*()Z_OV/#*25>!:,=^?R.N/I14.<^"5@S#8AQLGB5" MW%*=CIY!W2S10EVA1>SDJ*Y3>D R_,0FC5&AV>LMV:Q8Z;1PMEM/_L:![[UE M_!TI][T_WN!.O1_]Q$DLQO#6Q'5!%B7B>=3WKH]T3H*+;^1JWLD="W'H,>1I M)5>VU.%'T][VDQTY@5ZJCK_0/R;F*[&"U-4JK.*0I"2E@3#_>= 4^<;Z5_/M MVG;L.Y?HK&7SQ#;])TQD3CPC!U"W#>H;HZ(Y?V2P[]L,J)X9>&% MD/$U(J1I&_A/>P&/IM\BKCL%S(J& [+J.)C09Z M+)1)%B8 !@7T[KHD%;_NJW,OP37:HW!DEIR ?<06CDFO4*_EJ[>"$B7!J.03.#@U["'"J MJ%'+>543SBPO&O71I6-B&A)]&^/AJ4$/+8=M+=57UK*$=[NOJ@U)W XHW+0- MMG.WR:BZIVM2PYQUOE;*4,I:X"FJ!CX"GNJYAB+GM5*9$SP)3_?CGWW')U82 M"CJD6Z1"CHQ*VZ[J MY^OU@[7Y*4!W"2[X@V//=77RJW67X13M4-/WCOWRX5++P'RC1N'?U'4VB(R" MYIAM0>/$ 1(.]0FU[4[L[-:Y*CC0^;)K!RO0SO8H=R[8) $!_F?T^)1QE]NX/O'F4Q7ER9J$!L M5\M7%%Z6I(6?>D+EFBB2JKE&1:7,R\JS\$I/J#CW14V=-]1<@@?:L7UBOYC8X4'XGXE4>LWH&:PJ0"36 M?M.M"9)D3\'0\$S;2BU?5X4?FD5$[2P!2QY1V$:W!JI6$WO,3H>)6SJ@+IZI MZ).W!*H(,BX5._3LC)@=6W=&M$_>YL(15Q;"76,EC9?$EW!63ZA=D\,1[ATK ME_/EFL8)CB[#?9TO(B[5THH:VOV4ZUAWWZZ#@WZ_47_H&$OD7:U\C"L2ULBBAS2*Y(V/TUBJQYY\= MA1*I2CBNTJB @Y;7(.Q5%3D-M9H)Q %"MH1L[54,'5>VJDRVJN6\6CLX2E:W@;7._UOM.\Z9SW^EWVCVI^7 K]?K=UE]^Z][?MI]Z MK$"X^D5J__Z]T_]'0CU=54"*X4QPL6,+D/@6\P/Z?B;?@S:#Q+P$-W[6,]-\7 MOOA^0E(IY1J52KXFB\ZW6431;CV;#(ID0%%9%.!RI&K9WI/E6%T4-22S,VPF M+-,]147)->KY4NE@2>''31=(VF]GV*%(4C'@JY4.7I(4[FU2)R.%&=*QXS*D M. .$!QL_.PB3VJ;C2K;CB[:XAYXPM"#K+7W>LW-TIY$,I"H;&0V]5.[V#(U0%RU;QZ^)E71X?<)<2F+1%JGB#47/2( MC2DMU5*NH=;K>>7P[I,BE.,01O'"IOUA)".,:GDML;;18JUE-Q"P]6QPC*L! MS!.=3@X[L94"]*DQ:^>+XA!7"'#KO:SDR]6#M]Z+910. ;3KP-;# 81[[F4M MKW!S-,\E>*C)K$E?ACNQWYKT_FY%.=?00*&6D]J$)9Q3GM"TW[KT_FC2\$"= M?*W$"YI$,IH#P$((A!C#;#*@TS,-!CK'%I[T7NU6%N1L+5-S?Z&MY!I**5^K M\^(2"9_Z5*U6$H=2%:!43D_I?0KU?PK=?]:V1[C_B;C_2,JE!9S])14[;BL@ MJ2(IG448[?+[$X,1[K52\UI5; !(4W''L8LZ+F"1/7I=1TR1JN'.K+JM5QT7/JV$4=%P"YZ'4=<2$GYQK54CFO:$GUB^?K2-H#?6;#?#U7XF0T,I=Z MU>JS<$T''DN?'AR?2K+V>Y3$U8-OGGEMF]8O.=^=T/7U[_DBE1>&A-7>B76A$K_ M^9$*>Z1N;TA<^J$KVWFX6S\T-'P?D^!'XG;=GD]\:OP5W[EX:NA6E.;Z;<<^ MJVWC*1]K/%JN42J6-FR<7/O@B[1UX!X^W#MLS&R 7G/B#QT7&&]$\]<6$_EH M9\_F\<7C\:'CJ^8:6AZ$ /_;36PI&+)$YN\["?F[$]_SP:T"D=YY%/UB:K63 MD+[C>9/W9/]P6/78P]J'9'&'52^=A%I[<;(.00]FX7?C,P*"34:8X$")Q6 D MXDO?B*L/ SNFRGE)*2EE=MDMU>GHF;HK7ZD[7'F1V-R1=EE%![,'.Q$Q#X/K M"GH:,_O'2@ ]T/NO).\<)#@X+)+3227WCV+/;Y.7MGEGRCO':P+;Z>;M'5\<3 M4?.:7,V7-^S#6B<[NFC'AOC^TP'UEKB_GPP,Y)+,*%VNR7FYNKY5:2O D_*@ M\Q(\;4SAX:_4FA[@3U]&==C.39!S4(0.T7O'1RZ!UUP6VW&R"(Z=6QMW@T-% M;< )."ZAUFY''UZ8"#* 6. -FT;!M"6=C$V?6*(D;^^.O'.:/@)).W8K(&C, M)7BY!)% O5;/5VNB(B^+*-K5D3C!^^.V]Q#Q1G\";C#9Q;:"'MT3FVX#*L86GPOK:U.1U;_:S M<&13#:HU[7LZ4.%!AZ5*OEI?=X-/CBKA 2\KX^#H=]T9C5TZI+9GOE+)M.'O MM1.:A!\3XWR*&7W9)H/6,G4[C+CWCN<]4+\[Z).W30*#.U.T@_80_#L M/I;B4/#4<0/BP=DHX?N><#.*M[4N5.Q-.4X?IB6"MQFAXSHUCMZN!T./1D@%ZUE)?5@_-D6=RKDDX3L+0?D2WM13<)N^@8,C>@ MSZ83J \35NYX$?V@R>0)E!TM%GUS9],V$M!IV-8PK]74O*HSQ( ML"=>XR*9J7\,$H7M/J14(CHF^X@]Q&\QU;+TK2_TG2[W)0 MIW4'TB+)I<+O[--'\D*E\KN:K*6?.$T4'+-DU'6Y1O5JK2R7Y>=*32,P"*(_ MEP>Z9BC:/V7<[Q+<-'079<UIOI>A@Q_=3L=^ " M[N?SJ6-+_M"9P#,,T#/T3:=@N\;4#S7[[,NLN9-GLSN^G+B+@OH/-"6X/Z[IUQ9^\+O@Y58;U> MK&DJ:L,P=1&^.%2419C)U?KG5:58J2L;ORH5Y?_:'A>+GFKJ36-$'5?_P43O24!&;"AS.@?K:*S>$7@'H3Q-BU'=)+7,*^F#UJ/0- MKAMZ4AN,H?'UV;UJL,IT297S<3H4\)'9BS3MR-TJN!#@30F'&)$0WPA$;SI* MVY H$][5.B1+1%/CB&8F%F2?Z"NU)]2+TE2'6[E-8JWF7$FKE#0"RC(I$UIU M"_+"*N<"_T A$G(=8Z(#%XGU04M/S@3_X&(H[E@1.T>?T2R[]G&6/311=ZXS MPLP0/O%OIC]L33R8'G7;;[HU0;(T/8_"_PQ6ZQ4S\5[.->2*EJ\IO!R7=X(E M,2$P/,TMCL!4SB\P&I;=UO-E-:D5:$ZJ)]-AQ)^<*;'\J>0&G$Z+"<_X'I,X M(EP]OPA7<+%9J2=U+'?*RBXSCJ_:$?"U#J%JKE$__*#J2SF]A]>K1-5IE*K3 MT-:F)EZ.LY%H:W8GZVI2/K\9Q@ULE6I>WK"/^*"*KQW,3,'VMHM%9?W\J,23 MFBJEO%I.N,+X"*B\A&6:^=&[$GT;8_GAA2W8I'V)@9?5FK33\:*6:EJ.YV,] MY(OC&!XRT4B=S(M-[#L\3.1Q=Q!:]+A66BEA,\5\6>;E '71_^"$;N!AT,'& MJ_5\2>&E?]QEY>^I1UDU(&Y?-8"#EC/&+2.9TN^7D6C=F4$(.-VTC=L%G]N! M$Q];:''G9RVOJ+P482WS*>55)JN^:B!=XPM(.VY P MEJJ<8>FB H;YB? ^:SMB&C3HM2!]>B&F[7V6]"%Q7["IADO!^$]T?^+B:F'X M<7!0$C9)S93)N P7<(O)&.ONVW43?8.@& =V&"(;8WJ99P_Y *9D5+0U_>$\!P%/QL)&-5]64]&+ M_!)*\X.C&J1/%C@6GZ6!ZXQF]@4BG4S9E5VEL!<@WCOLRKS.=7%^1VP)QT5R M-:_(21T*PX5E.79)?4JA%^M8KS73LN58KR1 J.8::KY47Z^>CWZ*URG@=PGA M#@M,PZ.ZI$]AP/+YLNKG,U#ZS4L)?09(>5&I\P[VF:.>O^NP/E[%7N0H=_B, M'?L5V(M9R,!>SQ@>VV:7T6:+1'UVZO M,+T[N 66KXKOP'RC1N'?U'4V26X-0^":(BM?.'')A%]_EJQN3%!%L FL1TJ^ MOF'G1>PDKW#SXR9T\Y)-LZ7Z+\116]/]VU9AD,L/CNVLKL;,';@U>2RSFA(. M/#3AV9]GV2XV8+ 69'W_:UH]>JYU=@(UAQN7\;)G!C*Z4I]@>!!+QI5G(P]4!;[4 M==B._'W7#\ME5KU82:PO"Q)5^NKI^J%#O(XLOHI7E- MI3,W=(LP"HR@30=F)B.IK"N&2,8-Y#ST7&\"3L>6Y0H$4OE*)8&*YI0%2BG$ MS_'LRN$XJN8:E7S]\!:&?*V<<*WQ\)&E8/%'/:VH"E9BG" UG M@YB150,92M83Y.MCRJEU4G",A&E-?&I@/<0&V8:_1V#WF8BG1<(/ M3LQPQZU+/<#^D;H]1-Z'L9SRWL%L$]>&R7NSNQG6Y[YD:>Y+:J53O/TVD*]- M[Y=SC5)17@\:.4EQ)>!O"5%,DRA^&.YMDX;Z.VG8$O5%%DIE/Z'<* MTKFAE?WY%S+$B>6G.K$\A3':W]@?X- 1&!5YH2LNG"_#Z:3%H3M' M$)/8_:)*FZGZU&'MPE9X _40<]%DIFN:@:IYF(R>J=L=,,OJ=1>:)C3V\5*] M6CG7*%?RY?K!JRK\^,,"73'VWA\771J@2\O7R[R@ZQ)\DX_M1.B+9\I2I'>O MW4DL1?H%(NP3\]C9<,JRQF'R9YX;?KP-CW"P'N42D2'R!E&,\7S M*FS'A_?Y#J+2P#)&E$^;E0S@ 2?2P+2)K9O$@K'#!]@=PBMNG7CXKK)2K&HP MPK$3G)9R[>)Q*>8K_?+3-/SA3%"6;@P <%U:W$*>81" \:VW')W(]:(6"0R/ M1#==(MV83D\WJ:WCJ5,=6R]*TO])TN^RI)24LG0'8BG)I<+O[--'S%]HJV1< M_HG31 DU2T9=EVM4K];*FFT^VU.NV'5KN7#]1?YZ&U71/P,OI6]^&V_=!KWTKP6Z][W[EM]N&/7A_^ M^=9^Z/>D[AU\]>WQJ?T;7-?Y:UN">76_M:5/]]U>[S/W$_S4L25_Z$S@&8:7 M@N%^M\G$,,&TQ!LK\P@6UH)5,,&8+3+VZ/7LER^S:,:TV9O935]&Q'T!51>: M&%1S[[P/]K[@ZU #UNO%FJ:B$@P#U_#%H7XLPDRNUC^O*L5*7=GX5:DH_]?Y M [HHU04?3U&6BQ6UNFN*$3_7U)W$BCZH^H>/VI&$.%DA8GWME1MBF@#TIPEJ MZKNDEOD"?3!V5/H&UPT]J0TVT/CZ[%XUOA%7'TJJG(]3;\1'7B?2M".7GG$A MP)OB\CV;]O.'0'2BH]0 1IGPKB6P+!%-/:P4,(6Y6+&Y*VL%1QG;?,++YBY- M;.X2\I5!^>)O6LLU=F:[I"8X_PQ2X2X?4]LQ7NNHO9*M\;(\>:6G;X'*^ M_7.9(^5%]Y^\I4XY9'.5 M_7@MMEO+EB&P^=_G(/G-L9!2V#L?'8&NW:/ZQ#5]DWI-U_3@JUOXTWYYA%DY M!@"L.^B3MPTN006;Y49RSKN)0]J'>. M"W_:$C#.I;8^E7P7GF:Q%62)&/^:A&8E4Z8D@\6]>QS7OD6^0T2T0D#T$0_! MVYJVT5^@HSD'QTRR'QV7?>'[KOD\80N:?>>1P&/\34+/SGKGI/!7E)6?)5-Q M=@RJN<8A?@U?9>>AQ0G*HW@V.LN'0JPF-\*X)H/'/8LVR(?'-NAE[BGHY5RC MKG&>T3QQ>),U*)X@]CD @-A.>\-&=@Z7KRXAL=[:GE)/B]6)F/H-2PDW=$_; M"J),+R F3)WLJ,0=X>(&;;C(Z,1;8JQ4<#&_5EL_6>"@DYT.Y26G[7F$' LY M/DKPG:1$5UG1@+)AZ^>^)V2=0YK%ACZQH>]"-O15$MG0IXD-?6)#G]C0=]"& MOEZ_V_K+;]W[V_93[[__5%/DZA>I_?OW3O\?W,_OKOLD]7]KPW]/[;;TK?O0 M_ZTGM6'.M]*WYE/K-]QN$VB@YL.MM%+AS^N4+F2+8G I[HM:N^W4^Q=!X1=+ M@=*/LX%1K14U^>.-=%$?52EJI7B[^S[:)[CY'5D84ZT(5D:,:>>89'A47>-L M4$ H[>,G;3XM0RE_<%H&'RG?)/9'[:HI= MY^?[-:14T:0)8T5_F5C,P#T2TRAT;/9[BXPQ6A5$:C1U?3*:6!AF,\K&G7+@4O*19B0=.W*CB8,0=,V ML9D]K@X9.1,["67*PV6IH#@K*BE>T,[:U/5;MR0Z! M8Z(V="P@C-?^8V+ZTTV25$=)$E(DI.A2I6A'"=K>0K:BHJ M686<"3D[RCX&)6*)50(2)^/>ZTJ^6N>]'XL0-B%LQS!J:@*N857!W1=58;.$ M&%VH&)6/[AKB5MIJ*2^KI32(F3B^,V-7"89F["K!T(Q=E6A?':6H\-[EX*_4 MPTT,+OSCFCK^ZJ&5969Z^Y)J-KN'Q%V B>*N=#QO0HWE%E/!8LS3G.#LLN9/ MX@;-I^X<=T!-?\)>N.[ E'.-#4U/13^:E"%J4PRY'YS^2JP)W1=-6JYQ\(J> M -.)P,3V72A?!'L$>P1[!'NRQ9X$FT K]AX^C7Q&">]O7?W4X.B-;)@ MCV!/W 5X[6,[M>@+ZCU1MI6C[_3)V]\6R@R,$LL6W!"/&KBQ@]H>VV6_R43A MP>.B^SG_&!(B+M@CV'.>5JY'5< U+A2P6)'*V%67MB+% O/",PD:;2U$[L(6 MHT2^2K!'L.J9/>]1]-74: M)"*?J.Z\V.PI+"<9NX@-#[]4\_+A9Q$). IM(=@CV,,Y>XX3\G&ARVLESG2Y M"!\S=I5@:,:NNK3UWTW'B^,9*-*G!\>GDES:?AA*-E.@(D,MV"/8(]@CV"/8 MP_?R6^5L1RG6Y&2.4A2(X@M1YP.4P@>@+FTU$+BUZZ#=;":]1$Y2L$>P1[ G MD^R)9?.K'Z?TP4(LC'OL_#LV!,G7JW5.TN\".D*R4\V>!-?J#A/L,E^"?6&- MOK\15Q_.3U9+H,OW'B>MEBZC#7CM=&W :QIK Z[)"3>I2X"Y?'>Q.Q9ZN0O7 M]VUSEP2!4BK6FPSC#IF.U$ZR5@%A%8(J!%4(ZO$$=>T8^Z0[5M:JN4:]5L]7 M:PEWK!2B+$0YZZ(<:VU)63O>XVC]TFLU/*$@7]O@1^_;+EV(LQ#GK(MS+&G> MXYB1=3G%G3::(@ROD%0AJ<>25/78+G2]E&O4ZDI>KF1#DEDJ^8H5K)R&"Z<-X+#+VZ/7LER^S6G;39D]E-WT9$??%M&?4Q(*4 M=U-GI F^_C([O+Y4+ 5("W/JX9L_/EY>K14UN9[(2?65HE928CUI^^>:^O&9 M]VD>4ZU8*\=]]R6.289'U37.!@6$TCY^TN:SM)5RA+.T-RZ*UMP M;[#($A@39K#$$?6-Q>Y*=@H];K$L=.S@C/I@HZ4@4J.IZY/1A/4>8I2YI0-3 M-Y,XE#MKE&$EO0%ZENMZV2=8('#$<\PW*SE9V5?)+85?F3E,/EA;CL"$2%.^ M&+(U1Q!>)"'N/%R6"HKWG?>6Y\)*! M+4LP.]J#;#D--EB.85]V S+/Z&]L\E:J$%P?7#TJFE"('B&"/3$CD2A;H;<< M]AQ9NFL0ZJOK9[<)_/")'R'>@CV"/:?0OE&VMQ^J?.L\*=]+.USAK]3SJ2&! M*^R[IHZ_!J$'@F*_P".]G8A/&7@\S0G.+FO^)*[!&A/?.>Z FOZ$O?"]L"BE M$@A+4@E3#M8>,HXHTL$>P1[!'L$>PYZ+8(Q9C,G:58&C&KKJTU3469A78 MJ:Z2OG2LZX4MKHGSAG M3X+K8-SI&;M9-BF8!Y*ZGPG%'ITX/C4TDNK>WT M$AECD= 7[!'L$>P1[!'L.5]F;4P1[!'LRR9Y878+4J,>\'7+\N%+2<@VYGM?4]3:3 MT1L("0 )^1;LB2G?:_[\4<2[PH]X7UC[\F_$U8>SWN5J KW+CW5<'7]R%'.# MF[KC",4$FYLKI6K0W+PJ3CD.[S\S>KD+W,5ABXDH>!QW$-+GU7*.N5O)EN2Y$68BR$.7CI9S44W6!5^02!*:56EZI51/K M7"WD63[D5(=UD<6--ZH05R&N0ER/XDFO'0N1N-%5?WH ME31ZTBRC?,7J6.!?PWQM?(4?LT&/B/MBVNS5]4V'?1X/$NR)U[B9QM0_!HG" MMGQ3*A$=2[R)/05Z2+;CP_M\!P%B4#O8"FXSVN$QP]+ M(FMF\2"L<,';#]/ M<AD['MNP<^U2B_CF*_TR.]B= 7;IQI"KI<4MY!D&,?&W MWW)T(M>+VB[!8S1])+KI$NG&='JZ26V=>GFI8^M%2?H_2?I=QIQ\6;H#Z9'D M4N%W]NDC>:%2=96,RS]QFBA(9LFHZW*-ZM5:62[+SY6:1F 01'\N#W3-4+1_ M*K7<[*;A_#3F,3R^\.Q2\J- !D"9:V+])%,/<;P,6D#LC&$XT_>$WDK.P> X M:@RH&8@.J!7'97O!KD$/4!>O@C$1;L8B#5U4I'_:S9]JKM%'I8$=S%NH@VWL M(4@:FW@?0Z$$GY@HLOZU6F&G;I]X$2K ?K/5>6I*-YUNK]5I/[3:O7R@W3L/ MK>UJXH3Z\6JY3\'RS]U;,D?.A-XAN%]YHA@6X;[W283PP1+ M/!\K\T$6=I/Y/# CW[YRF[Z$6B4TMJCSW_D[;-K!UPMS M4"P%)B%<3P_?''Y=A*^NUC^O5HH5I;[QJU)1WOCYMD?5BY6J%NM)VS_7Y%IB M8_KX23LJ$#ZL6*FO7;8A,COE*?+U:*?(@U&DTC>X;NA);3!-QM=G]ZHQ+TZ( M<\#\!Q/G+_+:',]LBOQC1"A\\QI]VJ0FO%$&,DHT-8X09*),J3NFZ#Y#J(G1 M_RL$=]2[C@*=),ZTXT5O;"9-=+VQUSZF2Z=E0MMX.)&N[5MW9EOT<0O/0966 M6[HVKIH%I>6 J"'[JP84@I$D0^"MOE\NBO/V4 M"%CJ'X;+$RX%GNNF127[OPZKR:$GM+S5'*2=CTY]8@.C4J/ MY5VFG5Q)[@.O2]*HJN0:U;Q:7C^]-ZVN3$IT[!C<&),M M)N-Z\,!\ X5+/(^"CT-L^'6$75/^/;_ M'UBOYBXWA-<=6'=]Q+5RPO:P^\6 M9=UI;*.Y1/+88H0G8-?R926I?3\MD'A7 MS\UWVM>@SQ!I>MZ$;;/6'6]/_9M>7R9!_;M,W.[@+J@JM%]:2-5-@E#/-2JU M@TM'A=?+(5)V-8Z/AQ2EA%OVUK<*<-G4/5/N[$9]:9B>#O/SA:>:C*:\!:+> MAC1]=.G(G(PV"8&,_1,Y\1F$%WHV;1D1+0H8UZK&"5PNR<7$A2<)&$Z):TTE M&"A,8&)Z0USFF*E0X6/NJSE_):;M(8FIU[7;*\0-1&,U'&/IE\*_J>MLDA%U MW@*-$]=".*%'5:M;,J\Q,;4[Q%=P';F2KQ^>-#J-RYJM8UAX-Q")'LEZ&0[2 MKNY-V(;MYOT98[&E%GN7JGE92VHWJW"R><+0#B<[(0Q5DCJ!3GC>L='0&A+[ M!1YGVHSU,'QTN7&KLVE0]Q*/O8ZU4+VF9+>X2S<3#U[D>2 GSZ;-R-J:D[NU M3.VFZR)'6(%7P)R.#<'L!/VJ+;?_"0.\=EU T" M^DV26<\UJKR<0R1\_+,4VT5'BUK*-91UM,3N4L:)(\^U5EQRX)?J^A>UN\=]-$_[P?T"-?Q3_\@+(=4F.15-G"X,>;J:AYBNV!,FCGR$7ENJ@R M/3U&.O8KM7W'-;%-X+[*]S*2._LKWR4BQY8-%??&:-6#94/D"SF$U/Y:]Q!( ME=&0EVHI6?'/E,_[Z-(Q,0V)!AOF@EC181DVL:7J:/HWI/ILVV*X6[%I&RR? MTF2$WR0H6JY1JPM_-RU@.BS]E@R(8JIB7(/?6'R5UJ1=*K3P//,P)E,,6"[, MZ3W*4OOVP/ Q(')LV:CF&I5\O2H6R5, J:-JWD.!5,LUE'Q%24&BWR^6H&*+3)WU>:F*\M*T .HH2\_' M@%89%ZFUO*RLEYT*G_?H93Q+R]+"Z3V&T\O(/&\RO2(GZZ(@YQK5#3I6^+?< MH>>H_FTLS"BY1EGAI1/%115JRBKG*OXA:M?10YSMK3W:LR[6NQMXFTE XG'YD=?,O2^0M1LTO(B_+Y>(_J'R>N/B286'W7 MP/7"\JF'1??O-ER0*=MWUW>:^A\3TZ5@1\%R^M-'B]A^TS;P".HQ7A+;>FJX M$E$[Z,P&D5'E$5(['+(C0JJ"JZ1:9;U]ELBFGDKODE=B6KB(50#>%3S@D&0R MQVP4'*\L\JQ):>+>T'']/G5'G05]8TM,-=?0*OF2=HC(B,0KCW"*JX43@5.- M96?*&^H$Q>D%QVQ-!7PXEO9-K].2["YU((/AW;G."(G='20B+G40%S6O5D1I M018QM4L#'P536BG7D)5*'N(K3D"5O1Q)5GSUX!2%B_7.C^FN:7]>*>HP M-ZS[B:*.8U;Z;5E2GR_ [K^DKJG@O6IY34V@(%94=O (R.-7=B0!PW*N4:GD MY5I2[>9$9<H[."CLB-3Z>-9)DH:N,Y(HF_4U#AH0>2 M,T;=)_+'R>2/D:3=@*+MD-9&G.2 EEAR0*2-.812G+3Q9BBM0Z:2:Z@J+[US MTQY=BP&*E/JR]0R2=6@MZ6AL.5-*I9^F/QPZ%LXEW-H-0N]"6.*:ND^-T*RB M%I P6+FTS/LQZF*>J$6 M'VG3][^MB#_G>-N.R)F74U6R=>J'&R\N*0P8(MZO=@H()YPU$XC'"K;&2IS<'J7B $2M<\[@H $['.9 MMR@R[/<)=@?##NB>D-1\%!V)>W0'"$]8'N (G;7J%M"TD;1[TD MM_0NW'\>/9R(JP01L13!U:G@:5_5#;DJ$06<9LDVV /E>1-BZY1UY![,JPWW MU[R7X<]%T[S=P;Q^LVD;K&2E$]([MOZM\N;>B0#A#/HW'J(B:.$:GCPC5S@( M."_*&T_/SJ-PX]&2;3APKU&L^NDL2OJ!>XT6"F#O31Z5>I!F2J!7R?FW&B7D MWU\N'J,> W$\/%9QY5I3\_52 FL"'&TXVFP9N=?[9MB:7OIDA,WI/Z,%8.8 MPP3V"_UC8KX"'P]LKI,IL4LP@D!)P__:"S(_S8MH\0MP_U8_6+KR$8;O&.LG M#.C6!$G:?M.'Q'ZA3\2G[<& ZK'7*:IX"'P)HO?UFE'>=@F*':N*F! MIZ?4>3F&42PC)(DU94<=VFG!AJ=4E,IY6:US K9+B" ^T-L43[G?IK'WMJ:1 MG"ONR/2?QYM_=M2)RI,VT4";U,KYDJ8<.^CA).X1$BDD9I8@=E&XO+-D3D*6HFM=O""LD^MM.<0Q0 S/\!,12!W2^?3 M8\1A38Q@BPG1=9@B?#@F4SS)D^EV^-"=P/>629ZQ3.&X3UZ7&S<1_A"$"]+5\-&77GE\&J7T\0WW-MP,ODE_ 07,^NKRDRGF*(^GG"S)UZCW)GZQ^*NL!5R2IEW,X+13#%. MM1T?WN<[*.H&M7&/+?S&ZDVP"?T^9\%UE#88W=CR3 M+;F[V,_;?*5??IJ&/YSIG:6[0D*6%K>09QC!Q-]^R]$I7"]JN_2G$K2QT$V7 M2#>FT]--:NO4RTN@]8J2]'^2]+LL*26E+-V!OI/D4N%W]NDC>:%2;96&RS]Q MFJCZS))1U^4:U:NULER6GRLUC< @B/Y<'NB:H6C_5,%W"&\:NK.IC^'QA6>7 MDA\%,@#*7!/K)YEZ".ME# -<9]Q2BE6<['M:;Z7H8' <@P0$#40';('C!O4: MH+ZIBU?!F @W8Y&&+IK$/^UF4377Z+,0PAE(+;2F;)LB:6QB_RGQO3O/%<"[ MV>H\-:6;3K?7ZK0?6NU>/C"ZG8?6=C7 R^@?NOUV3^IWI5;WX;;]T&O?XF^] M[GWGMMF'/^XZ#\V'5J=Y+_7Z\,&W]D._Q_VD/GVWR03\*VI\YFBLF[7C.P%V.:_F>YHS6TJ_-&TC4=P MCK%,#?^4*/IAY_A "@X MSV/DOSL!A7G;[K6>.H_]3O=!ZMY)-]][G8=VKS=SH\-IO%-%\%WX;#:XQ3L+ MU(7'/A7D_[<*B2;G#83G2#_6E'0_)]):#:X%*'. M1;\"4U&F[TG>Y-DS#9.X)KSY$XS-HKCD0*UI7O*'5$+(*J4OK<#58W_)7R3' MG7T1O"7\_+-D>NPN^,\%!$T@\I$(^!"210D8/4R* 6(*SMAT3 .7Z6T)Y@F> M!NOAA4)AU],X1+? M1'G #\ ]],Q9.@ZB2@K.*3O="0;N.H&-#9[LL2("D#%],IO35')L:UJ4^G#Q M$E'DZA=/LAS[I8 QI?V2AS\@Z(-7$.N%>J:>E]I_?VP^M>]G.$H4$I5(;N8& M7QI16U#9W>\#5>+1P&$"U%3+7Z2C##PBEC\]3\;F*]&!T52R3)@'EG68]K\ MK,PM\B8>'N0#<_N$I>L2RII)%)K8^#)*RR.7O-MH]B:E)<+2! MQ]^+O6(>OVZ.7=,"=UM6@FSM&!$7W GT@-=)[8GKC"G0@"5WF=S@E4O/_0L MP'!&X8/_$CSX 1XS>@89 %=>+L[0((&(6$"(0&S> PK>#<.A/G>FAB(<< M2A.+N',BL)>,O_WU/B\9[N1%,H!IP,FIY%-]: -[7N#7(?$ET !D[$WP3"2/ M7>HQ>7,FOD0L,.VA!)BN- (9"%[B@0'0,0,3BHJ%F]/94$<23,<%835@1"!# MX1XX%!T?&%^$X&5UQOGE"4+L^,>$W79GT3<4[?Y"8821#YO8[.M/2ZIH]ED3 MGQ'@>:9^\@'/#,R__V_G_JG=[S?3*F_G%#>@MVN2D6XB@&P,]:GOV*9!L:$M M!=MF%$(P;)%!5+UH70# !B (5*[K#\!Q<8ISOLQ,Q[YU('G#5U@ M3B#^W69>^F%3RDP) ^]<#]3?(9>!RT3T$V14Y3B,RKI"#_&QT-+ F$&@A)@7 M@"0G"P%'MGV;SAR9)06Q^'!%1RQ]O$%-!-9[F8>2-P50C!"31!H"&(?4 @_$ MG3HS XZ:[M6$Y['^<3#\4-'"]6.7XFFM>>9,N^A!,;MA(0C#L0-9X28Z BU) MF#Z%!X!6?Z&(4AL<3/I!-HQS!]-D3B0*'\[*-;T? 5]AYBP?B'*#1A(MJ G# M(.@&&A-O83K!X7M!.VS.VI[DI6&!'OUE(07?Q MBCR:*)-U?V5G=+Y2B&R"2[>N3X0::JW'1&EYD:+S<#>+RL:Z^W8-81C&PT$^ MYPEF##$0&+KNX#%XVNK&/Z"OCNL3/QW7@&AMOC116D1B$*&".J)T;6EBID'? MS8W,"6.S-R/&?@[!;GOP9#?"Q<#\R8"@;4>1 _% ZMF B[G;@)H#.&([KVR6 M\+5!<46&AD_]0:=H]#W'MJFU^D)_:+I&80PJ=@I.D\O$)G#\[$ MU=%LH*RP4<-%?JC$ U]_[OTLO)D !^'+F*YX04&VF79WZ0MZ.,S[9RX+0Z,; MG 3)X#@% GAX(('I3],G,P'HRW<(*$3"& K8"B9]G4>S T9GB M<@*;";J,6LX8:99?P@+%/]P?-(A@#!-E%"01^<&X1H+@Z(/0*_ 37ZB-@P'] M* TI>)=#B>7AD2TKD=/R')ZGBV$O/="G9!2X=;B> ".:!XIH/YREW A;6PC] MU=!F#TTZD-IOP&XVENY@ %!TPRP,R,O,!WGO=^OLQH"B*!^H"5@$.B(_YO<' M@PQP!E&&HS//&H)%!FOX'*BQN@AB(=7!]6>-G'! _P.41W0K>9;@?^=IC,?H MV2!'F61NF4T1\\$KA-D<24"<"Z/RP&9^/+O506#FPV.DGD,)\+55FWKT!;GV M8=G#DC*==V(,U><314<1G\*#8BE3+-C[OS)2Q,/1XMZ@;X2:X*Y M!N:U4I>]E;D:,]8N.)N'&_W98QCN E,>0 'NI#H!EQ:?-)@P:[]8_8*'0!SW MWMA?OJPGX)K;?#*JH@&&/($G@U7D;4IF5 M#:G,RGHJL_?]V[?FTS\PC=GK_/K0N>NTF@]]J=EJ=;\_]#L/OTJ/W?M.J]/> MG=W%206P[M_]P)PWS0VO-[@?\U<_]G30[1Z,Q2OO%AR&X3O@C ,UF"?D4K07^7#,^P#"&SH3""Z?T4"1<&SV MOR9V8)D7P72PUC<;[^[G(CW"J@X<)@;L2_/?Y&/LR">(Y?YPN7_H^V/O^NKJ MY\^?1?!HBA"_7#5=\,I>J7=%C1?B7@%?R)6LUBLUN7P%XPU_5+5TA::E M "ZC*L/_BD-_E< \8&+A3Z^5@M$N!?+A7^,L^%32D$X"S%)MV"1\@"0E5F M#JBZ7%%PIKSC0NQQ0-+*K.;YFS3J^UA"#;'#-P*0"/@7LJ>AMEW+^3KAEO9G4C1/*['@<,>ZH,@TQ)*-OJZ$C'^-?'\8!B?PI@K[$S* M$K2!.@1E@R69;(O2XH;/TL^AJ0_S,PT!0:(=!O.+D"X8@DGLG! M"LE4# Y!&_9]%),?MGLB8%M M7+B-Z=0C80@9K%*',:@WTPI+3L1,)S!I<_RYQ)G,E6%+))A&@,?,GLC6"4=D MBLX$?1M3?;:&@K1VT U8>SA\.=-'@PEH#P3'SN#V?6BUH?(SK"44Q9\?%7_6 MMQ=_BCK.]-=Q;@_PE5S$%,0LG?*-_,MQ6V"F';C<"Y(,6U,-M0WI@]IZ+B4% MR825=1JVAHATD.:$6%=46]02K_9@*T:07RNK!1ZU+&]>=0*^HS-YP6(KPW7& M!6]HCG&YY<4E(XG!.G#D)-9<+3 A\#7:#UQ&"6]>6G"2/LW7[H+409 JO:'N M"YC@WX(U@%98T 7CS$LMXL+58-R#+T.%AW;\F_X7S%/;TBW6LX3C_QPXJCC0 MP#\)$PNS @,<(7,A#1/\'M]B;B5:N5?30 ]KYBGDP1V!>8'C-'0\ML\(/B*C M9\P-..",0LC_@M4S@4'PPJS'_#'CX=0SP2>Q,8/[WJY),5.<6)$TF:4 %SCM M#G!%\6:*/^_ GW'<#3):WR"C]749100$6>]G&K0P9*Y7L.H!-AS?BI:$.0%L MN92MW8Z!@<&2S,8X?UOV7P_E:FTQ=5O^_^/%U+F8QEP$J)>VKJ:R%6//7X$N M>(64Z+,8:N%07TO[5;C6/ZAP59FF",ME9HX+:V"(E9=D[-'KV2]?9IN)3)O) M/;OIR^J>H0U5'DPU!5\O+'BQ%%CQ<*]4^.;PZR)\=;7^>;57_ M.L^&JLA719JB7"IJ=6W7%"-^KJF;7[+MC@\'5?OP43OVO45L?W$X!^IKK]RP M#3?0I*?9K%J/U'2EC[I!^H:)$["(F#'Y^NQ>-5C6!%-A<9IIG(S6Q[DJ3G]H MOIF*,5*4GC%1)KRK;TR6B*;&07N&.N;M'@FTZ*OU_E2@"PZ<:LE*6C77J*X? '-6AU!P?SOWZ\ER MOQ:!^QM:X*T7!,5:-P7:+6T)<1T;?M6#\K"/"QOJ]0@E#"%NZFO=^+@I:GBB MR!1I00-IE0C2@P/?&LXXW S(RA[6"D)WE;Z%=&"CY+7ZX5V/"378NC;O@K1, MHIY/;./_9^]-F]O&DG3AOX+@[7K#CH!8!+B[.A@ARW*-Y[HLM:7JFKE?)B#P M4$07";"P2%;'_/@W,P\V$@ !D" )D.=#N2@2RUER/YE/:O;4D3Y:\#\.+G'] M\%$.DB!3K_U]A:F(=/'UP^\\+?2J,Y0/73I?DB+\8CD_C12G\.[16@$GJ:/. M>UGZLB0,DS"O,ZJRDX([(YBHJ#3M) G@F+ 2RT!QYM3&IK!1^_$2_B"PKVH M3 -^)421)6_,O;)!R%&F8Y"LPLPY)OU.UTH[M">$/W&B6K/PR9C^:"+6"56& MA&F/5.O)%/7OL2P!WQFM?D]-K!:H29%^&J M\)0<%A:2XG-G!HIHRL!TI"<&'$LH&93T%Z7Z*WT_NYEGMJQG/Q8F5@"-U8&%%Q6[P7 M&N^0%GO[(64-+S[Q\\HUWS AN;"*205:O4.)B?&N8B*1 ;9'I7:O6^]*[>Y. ME=K?>=[@9]M:8D(S>@%_@.H(DO<29GBWTTGD+L)WR=S%[[?_O/WV^^TN27C^ M\U+>THPBZ.]QZ)I@57V#(2-YN0')RFF0B29SPQQ>#+X[ 8\),(&^10FX M&MF.H4Q'$)'% E2'CZ@")(1/0W'[;#..DA+6IP40+16,*RYXIQ850KM\=S _ M? U=*8 \X35"[AQI*UBA8 -Q[<)]@&D](UI6N'5#A"S7$L$/+X+3%0DN0R1MF6"K)8;>0&]D+U(:BD M!YQ:DV7$H4L6$ ^/[!#_CHV*@M5"TWD./-A!5\ 1"%"%J@],C^*U QS^2/=' M0PA8B'0'+.Q$&*!4:$IH=/M,,,$DPA#I05H'>%/ZWF&AB0.F&O(9X2O,FD M@D^T@\E*PVQZ\ OC3XZ**&1)!Q(P=/[8H'!UR:8TB6 =03:%"[X^?OC"XJA[ MI!_#I2,^3UEZ)_)Z\26\)#4H",%H,I 42**Y1N(U#B[%82)_O;^#$00<%@@8 MPR%S^QFN11DSYW@/B 086_PE550\6T%%)OD%,X9=;:("6Z[9J7P:6$];8D2* M5V7ZQ;U.4#!+0CCP&Z(%X56;CB]?*=*PX"_ *H< 9X,J-H/W<_O9 MOLLLP)Q[ 6XBLV*-.N7PW5,?&RYD%,*I _+P0L _HJ:HBAO%$RQ)G,S\BW \ MLN0Y@>^WM!R$BOP39;//-4L&1#V5D>C9RO5QO&E'9%]1&#$50((VJ'@N@LTE MRI7+ERLK'5&O7(^Q'+->^81>]U8JQN@1\\7$1I0I5B0)\BXFP'S)YWN)25$5 MF&P_"(S1<%'&@,Q_HA4D/:ZMG3:@5K4= C\&[;CTN- (E6U,6*+\(D,E_E** MN*-79NFZ9Y.%0M8'C@&/ \F< BMMTP/"W]/%-=?O((A>V+1Y:OHFTH<\2LE\ M11DJ6MRAOSP0HC.#K+%0S:8:BS8+@&EH5T,ZL)Y "ONX&QP[ Q41V0:!,]0SQ<-8JE5<$@VZL>-@3S%$@ M8 RU\FEV>YV/T?&2YG*JQ+X4KX%;CA-98'C%_XF;$&2B<><],-)\2YL>2878 MG_PU1/.7G"["RL9(":PSTL\BOIZ!9^8;KW0HY&P,G_H5Q,!G;8=C ='R2^#J M^$T[_&X%B-()ZTZ=.WQ46=JO-3/=1XKEKE1\*]PC":OP1K9G0 M:3(U$)2<$(^?F/O*?-X*743?C@LB3AA%]K@K"'OM(^U%8B':;QK86UOZ'K?6 M@+Z (0TGUJ?" 7"78.) M&?Y!"_?@_$&BA(.9PV;]&9J[P8.CL*/EAKA(P4B#5\5LS-@.S0@X-Y(OL3!E M,)1PAU*\,1HU/01S=+9<2S+]"<&Q%]-U(9$FHN1-/X _.%Q(CH/D6_4<0F%F M!9&2^.O!Y25-\L;DP7HB &)UDZ@-&'G]$#"$ M8*+3NC]-Z]4,Q %'$_;AMJ;P4$U_B^9$1.&0$"21@-#-P4$;7&H#MP+[\%.U M4EO*?0X$>3-F;[6)=5X'V%_?0]'52$)=(B0-: ,ZN0SF%(EC$+J&PP+HMGC4 MFKO3@842B+]I$)-?:P=0*& I9\3\Y-2 WQ9H%'#WWGSP=AO8+)+=-@\_P?#\ MCG[Q14=@CROCQ]7CE@$(B O'']8C# M2H**3#T[!!4)?!?P7&:6AV?YB!:P>189G;O@645*",-O2$0(A9CFPYNJ\:,* MTUKS!?S#:-#;",!BF9@ = 9L>A]AJ4MWD=W<.%:]CJ/"QSP ;@;[ 5YN<@4Z M@ P+/PR*QQ8$I E?8YP5?;4@YK<1'N6,Y?A>G.'&! ,U*$M+5+RQIJ$]XZ$+K)^FX&DZ(B%TC T1PZ@AC+6 MSH%/#MHWS3,SKMUHJV&=V(JO_EH/!SJ&\?&6>/ _/ LPPHR4^/%^9+H1&> L MT?PC(DM?1,HI) CGPCC9)>@+4Y]9&;@L9._Q6WI#PP<^*][X]Y#)-I37^RL M3S6((Q EI7(==*E:4CJZS]1.CJ,-'UJH'"8S&!ON:\06).(-KY""D'*KC M6 N6],5+'U7&#M,0X<$KO\=2O+,:MP7BC,0;CU#O$%H_ YL$^A:_/QTG/*#R M0--$/0.W'-<3J:['!I(['SP5KB?'(WX(M/XF,&\USV'KNXM.R (H QZ YU8! M\2(3P1)O.=RD*^AV@GR-O59.OF$M $?]@;@@>R5)BJBJKV"OT/GRVN,W7=*Y MQB4_M[]L% P4OPB" O[)';5#;%HBP2?#T9Z?D4N1"_WCKQU:8 1)8K'G<80[ M_D0*+:=DB'6+8TW61QT\KJ6E\!2;F$"8KBUI,@G%%W5!*G:$ZZPY_F,)91'/ M:CT8YM1Y_R'8D&;@R:GM83Y$6BTJ"W?&DU/: V5<-SPY&)2Z_>5UP3@3>'(" M3ZXNFRKPY 2>7+$BW&^;JOS#6175EP$;VQ?=XJ!(:.'#+Q/ZP7?LFD*;93:C M(S5A2_ZVN?2EIAB?&OF:M9I;)A"!YTPW40CZ:\B,5]V2!46W/WR@^6L>6YL^ M:C_68OD(#GXUM2CU"5\20A=T(P>SUYHH757N=9,P/_[)Q!Y[A2*HU)[MCGH6 M%YB"8\Z68[JGYY@^&82S MDUH\",DV18V'5ZGE=B950#6G+G7-RD 2!100V/#V!C5N3GMSI*#4AL,OT)SX6 MQH@X*S5R(?;@Z.1=E4'(WVFL?8*%^B,!.+I%:[:FBB#OCQ*:?2RFV%=*:!Z M'0_&!*L+5B_/ZJ++21.DE48*57A*+ M^,NW?]Y^>[S[_N7V(1>/N/@0'_0YFWH+=C<+!WO#X:TS"F.4?J(P)@-TB2;1 MF+*9L.*90\#ZBV'X6"2$.Y)?!9-?6W5&=3*B'B4W6[A1F?/IQ2*7,_^P9\!A MZF4:M18%2T_.=.J75T#R77L-H= 3\=-*2A_.,391>O[G$WK(20<.C4D@K-\" MNOK&7"R[YFAFI2,-@]:DK\B#_9-_R^[:B<[X!-<)KDMTSSPZUX'KWN_)G7%5 MV;J'C]Z=^;GH'Y;])SC-5WYCB4PC3228%551N*)?S'N^GOMQRZ@U44;R<%#5 MN5<-3JX$0966OA42U+@U 6]45?;.71(9BH5)XK-A<@1D A#;21NI540$; M+.BON)Y[\8.*J7P#N:?LG1(N^$ MZ2%GYBV+_)G]%1B(F-*"16U-Q@-Y.%+/(B]&I, )%JXE"Q>VRZ;+MO]PO-=*_-Z>U?GK%" M<-UM*3UJ2DJ/FI+2\_G+?]U^DJX?'FX?\W-ZTE)L5)YB4\V,4N:1S/5I0#;/ M9^,'0=8ZS.7).[+D>$ML,OMO#M5-[2XD!)I_!LD@Q_OHK/=U%ED^(LOGW-(; M1):/R/(163ZGS_+9EEM^4.OZ-TV?PY?V&W438('V#UL.5SJF07X) 0PJI4X" M=>E5MYVB_[ 7&L^%?Z>\W\@@%PE+(G4BJU:JL]U3S#2+?[4MIWQ<>8"^XT > M#*LZJ:A%>$>D*PF>*\-SRE%Y;@@\IRKR<+AWO$8D*U5#+%\9*.LYMI$UEM@; ME/:0.:D), MEY"KA(W@/!?[%H9^''IUCC5S7S6;B>2E;.;(.3FJECFZ';!-AK*J5F6:U,#B M%\04$5,.Z$[%Q*00,2FCO26M2%HJ3 YWLQEV*9YY-M"!A]7@\>B9,&FS>2,' MI:9BWE )[+%7U9&]L&AK14LYF,$5TU*W7K1T&0:MZ;BVQTG!P-[PUK.]:YW3 MA1@?.1"[%3-%CT>VQZ-A3:P/8+H54Q/V=.KTY7&G+NC,EV#+%L'6 MS4W)+V.6['?XTVR&.FH0KHO=E<:JK/:KZI%6BW/'BJSC2R;#XX:[AJU)MS.6 MU6[%J=,U.8IK:N[/5["D/TB:KGM+;Z&Y; HTL;)A&WE6\1FE )VY1?>N0@UT M'9'#IQ@UP.<%PP\@#:Z7%LS]W_1]IJ0H+200+4'MR+U^$B[AO7 B&DUR.=KF M9"0WQA:R?;G;28;.CTYRPM-(_INHW1"%P***L+X^V@Y5A3TZ"5;D4437[_:_[Z^^W7^%FTYO!N_A*^Z"#DN;20C[.F;VT MI,\(QF-+U/S#-6:&+MW/-9B=],#L%P-ND. )!CSW35I8.KW0,*6'5\.<6J8L MW9K/L$[3-CXNW)N@?-J17$O"U83;:(1JIU-FB YL3/CZ]D:L(*76O>ZUS99= M@MQIP['235Z/\[ ?V%"52:^:4X[PE>UT'_?E2E-XMS7IM9-=A*2 MG$NI08[ M/N!@>ZU)OYV,;0:#E26;.2NF8QQK\=:6=MXVN,G>89^&.1OU!/>6([K MW&@KPP45\&\V+;T._=:DT\Y2>COOW% ]TO"Q2JN=98?'A*H>O0-$%W^Y9)FT MIWH\8P&N71='#H@J9X,<"N((U$?J7+N99!J44Z_]A(1+K3EG22@&P\2N8S"V M=+&]GL>\2*T?B6N16P]UK63PO="68$NYY?5Y=T=]7MA6C-$<'HWTMLB.'=BE M=\3ACV#X@W;6Z6*&_&L>Q5,7H-)$'S-@YII/^+ 4KF$3Y4K6$UC:I'& M)EK";X'JT8'+-8,^XMCH@9+V##8'R:"P")\,]FS)\.7" !XU#6W=#05I9<&+ M'"E3U-%4MLKJ+]\^!X2VTNT?'X 00'?Q;?N M_WWY^OWV\?&Z+5U+*SS:XY>0U1:)1'*-%F\2GO!+,P8CP\5_8LQ$8O'-/BX: M??$6Z]OW1/(3E9,4)!' J&$B+]K"8_BSL2D#F\E*#P;2\W]ZL%!@>*BTOI_9 MD^UI]ENJ*>(O(?B[UK-I_)L<$PPGX@+"LRR,D< .+K0G;/-IP5-("P4J"7;\ M#^L)U)0,)I'C:/HM@R]-FU-I^PJ8AGMK4,*-B= M P._,FJ\Z(#P1'M*6FEV"-3V><%^X'NO=3!H>?9(6_IBKBV%'_+S52&61@;S M1MV);.MK_H""$VN0-?E"VM0G#-$6N$Q;8#6[+;#H\-O\#K_9)D^Z<5,[\8L& M@A48B:$:0N,^$"*1-1.X%C$)!&K[:E-W(42E/D^9%\2:+33AG"T_JT6[O%[4/ 32)7F/1O/L+1--""4VSPP_HA]07*[@NI%\\1W@$=?"$R2&--Q!+H)JL'!(Y L^DB M1VKGTP46_*?T[VQJL3^]=UASJ;T=+JRN4GBWH%V1>LUL1^ZL0PU5+DV]15J% MFF[GX,.@@\&'T6#O?E,5;EL3\00$LPIF+6I^[,ZL2FO2DSL]M>',6A@HH%;Y M>P_>:K6@DABLJM&:KZ1D^;DY:$5JG1K3 Z9TAZ/ MZY@Z5<]\+O6(W:93+VMH M!1DK#.<>$.F3FU;[9-XU)M]LI/VCLYJ7'+=7F9 M23=H*ZPT@U<+;2:KQZJ#><*Z-9/"Z#46WKVP(J>/(L]!Y#D<+YGH7GNCVO#2 M'HR*X095R<()J%6N@V TP6BG3BC:F=&ZR&C#P3GTM*Y%*+_ 52EAC:WEO>O^ M^*#&E>./&V7A;,%T/\Z!%HN/H10";P>5UK3M5];L"O$!.*H-5@_23RQ6\!^5 M6@?&T)NTLL'\,5;: BNIDS@J1HBBE8:C0I6)'/2)8+C\6$WA,OXF[<42%LZS ML6 >9YMM7"*N!8R6.2Z(#.KA8#@ZX5X12"(6S<\-'?$<82V]Q50"EK>M5PZ, M0($E\"5\,#/"1) 05ZH)Z)RI_;Q17!)!)=$<.E8GL(BQX\+MNF:[]+W8)/HQT?8(B6)Z#7U[#>FV9%/1_#!(V43M$+"JRJ/$8H] M3NYQ G_R )O<;TT&8!(5V.1+J,5)B+%#XDHE4G8@EOA"'NE2/^3 MOTO?89/NF:U3TRT_2(6N7D#L@]9DV.XD$[!/4!MQFBWY29#P04FX?W@:'A(- M5]6QM/$TO!X%3893 F2M_?!UOP:!PM\T!!IUWS* Q+#+_3ID6!-2S?Q)$6#T M+ [*2?C$PU]R GV$?7DIJ69U#&JIO?98W3ZH@O&0D]IHQ=SN_P;#M( 6*QGA M:43$X?KYV6;/&#[_#0S]I;?\^Y/]\R0XLY,^>:R2>,2N[E7MK'G";GT712C@ MGZ"O3:*T2AR]BZ/W(S?LW&IH!%S-O?HI0K%_-M <_&]RWTL>SX];D[$\'#8" M6.<2X@P@F?K"%:LUXX$V_09/?'QEBQ?&D[[+LMT0N^BJP'?].GAK%X+& *PU M.%AP^CR+W4_ 6JC%'E^MTARE$$>-E+WA;^I5,5]WCAH*9=4(CL(*I=(\I1)/ M]4<",^BH/#426JH)//79\DK[6\,NL%1''JM[&WY"314'=,$NQ-1E1RBK8S,6 MM8S;RE6/UD=VKQG3:]R@G?FJ!WPUD'MHX0M5=23RX"L;_Y>WP9EYKF<'F?0K M7VB>4J?M%V(]2[XLJ_!*,V2_-1GVY6ZG*G],1!8KYU;<^P_8FMQS8XWAA8X\ M'![@/LSXNQFDG+'I[0_L-G]-[>)+<^8 L2;E43]I@A:'%11:3(A86%I\F/#3JTY^6M2 M7I[7FO- .T-/_&" WC'T GL5+'C!'+WZ)"P^IJ0H/ON3P5[=W@+;W&*7;JH5 MCSIO8WZCW_&9-Y?7F4<<''1]?I>6_7@#ZPGBS#2TF#IWO"?'F!J:_?:>O^KA MSS?F=ZS_#VN!XB-XIFF]2O]DV*)>DWX%8;62OAI+ PP\6=)BSZ'!S4%\KJ3? M+-LV'+@=C'632$Y;\*>]QUITM=,9\I;AO[T%?:OC#<;Y-D[;@?7==OZAZ)E&%)9?"747F';'QP9^8SC +>NVGKO2J.=+?RFB8 MWIJ&212]!%1:3*4,(KDPWD?153:,$28!#+KM)(IFAJ8#?EE@DWC1N?U G=N[ M&RLK.K=?0N?V)FAEI0]$$]D^$C=^$J9(<9/J09^SJ;=@F#P(H@_L\Q>6,*Y( M*=A@OCCWFNW>S3YZ#@S*<4 -/AE<^R2MKE'"OFJ"X1!;6P*(X1AX,L&Y&(X; MUC_ V%>VA=$7-"<800R@RINR%[:P5A@NE27+EK[$JF'Z MW(1)/;]%=DB:$LZ\"W_0/0>D,[,YT"]<[LR-5&LFYHCT;HJE%#8B MZ'B8-;Y>KB&=6;U&M]?N#[=#:YP [Z/75CKE'B4&5:-!]=OJ:'OESOF4VX3P M*E)!>)!S++P!I\U!-]"VW]#U^Z>V\(H4@Y_C4ESKNK?T..[\=0R$[4*7(V&L MR?#@(H=KY[@8047SE5_2+/WNL)FWD+XF0(4K+TUKU%G1IZ3!=[KCH$L_[;FH MPYQA?_MISA8OD71@V6.=$;C<_7%'AA5H0H*(X#K!=8=("-F#[6+V5MS<*LV( MF)'<[\OCE%JTTFTF!0_6BA0OE@>/Q()@T)=FMUYKTNOVY$YE%0!UY[E*K/@< M0_Z8'D\5 '[#P2:5!:'V+=2V 0O%7:BOQHRE@OF]PE(ZS(P(KX^5)QR]3Y;Z M/MI%9G+#I>#ZW:1&TD4.[.'$[7!?1R,I4P>MR;BJQK$U: ![YM12SD#>G5PR M#>0D 0U!*=<@'5K03DTD#1EV23(9I9))\^7,?CJ]<<;7Z.#&UQJ2\FB,EM.D8@8;Z [FC)JFRNGBI(,BSEXD[! _'JA\\'%Z61-SE_DL( M7@5V:Y1M*@)7AW,G<_JE?C&G;);-[K<_](6'ZU.N7"3&_-A)M2>/!G6!.!'D ME>_L4+&CV)YZ;D^CN+]WQMR_R_TB6,*#)<>)CQS0_J_=JE>7-7&N*1,Y3D]J M]&=_"8@-Z=2>/.[O+0*;X/P(CCMWCFM8W&MP*7$OP7GGSGD'U'7?F+N_IL-T MA,%('G8+;@RVF1>25U)@5;QG^0:65-')7NR+ROITM7#=BA6\!0@X M07UL]T(+_T1]K*B/%?6QHCY6U,?6=U%%E5 !-V#4.7+RTTC4QPJN.T>N*Q7V MVH/MJHI[8?9N3Y$'>^&E"QX4/%BCB1^)!;R1W]R^T: C/56+% MYQCR32O1&"7P*@]=']OK**(^5M3'UD#7PO6Q MO4X7\\Y%?6S]:>=(I)-:']OK(+9)77H%B_K8G8VO!"4&FO,_3CI>/1F><)7BQ!'H<>=PD>COS@ MX3C94^F<):*HCQ7UL2?G]%$.JQ^X0J[7&9]QA=QYDI>HCZWU]C2)^Y7.&7._ MJ(\]D_K8]*;3HJ)H[Z4Y'T&:*T/J\>/J ^KF">N">@ND7HZZL]I-,?'':>?^@Y\_4:CAL#;Z1X-> M7M5QA2"Q'RMF.DS"?N:;KH[TJCG2W\I0M[)&W?U$(D#LS7>S35HO1M>#B*Y[ MY5AO?-3!859"KYW,>LI@0=CG!4X WB(!P<^I#[<[MQGS4TDE!J0SE:AM+K\E MZ)U+?;FQ2+A=L,=VC4C1<;PE5O::EJ3/8<&9WS><2<]4^JL'I;^\J[C?1MUA M:7XYWC7S7,]F$G-R;29;;*2W?*#? MV5+#;;+O9I\-)+'_IL27DI0XP.R[=M8A?YSP<%%L>B?M"6Q70'RP[DAJ\@D7 M ^?^^&J5GOYP'\"."L;\&:XM/>C1"0?]#9[[^,H6+^PWVOS2@Q]7,OB5;O_8 M,G(M7)JPK:\TL)(Q;ZMPR)JL8HOUB4< MT_0YI05*,]M:HCSK2ZX%_^]VJI%KNU(L>V$%/?/80B*<[[#=RYDS*%.8GW+2 M^=VBPB\]/S#NANUQH>FI9 &=<(;?0%.6GB 8B&H[*]%D?8*;EAW>@_,Q3$_C ME(^V'C[8Z$S'NC)B^G $]K'R-!CU-3"]-/VI-]/[4[7_/P,4&SD&XL&MP02, M!5F#W^X>;_GT1_[1[M9$XT21UR?VY'X".VEA.6 $/L*5'Q>6_F>TY -.!K!L ML(>N_QT^A\'VK.!)KNVQUN33[@ ]+>86:DS.=F,J#/F=3 M;\'N9CBI+Z8#(UN"N>ZDS&JX.?XF6/Z/8&J&QOT+XOKXMKUT8RUA/&]$ <-? MP/3T7 >X$#UQX-DG5S(<";P&F!B\#@Q\!QAOL;!>'>D=N0Z6!^.:.N\_%/2& M$.@+/?H-_"I8B(6VTXOSG M7UZ-J3O'H%&[PP-'_@&K_V;_YS;\]'/R^Z':'G;3?^JTE=3OLQZE*.V!,B[U MJ.SO^Q4.2MW^\H( 7^<$[4/^/L* 72BT41P)K4PUQSFN!7K@%TH&"0R\2\A/ M>63V4EI8\.)K::;IQL)PWR0P,3T;=2&7#+ PH\/!4)SUD=1EP7#DM*G_:IG/ M2&]H;I8]8%)'K8FBJ')ON'?U9D- -P2'"0Y+<-C@@!R&*%)*7P9IWP0..W9Q M"#EXM:(/V%(P6A,DLM92^LNWSVD1C,C9_X)6&'/<[YK+'EP\SKIG-MIFVC,+ MB>1*#:FDVVE-.NUA/WG4\Q-XU2:M'CFZS#0L6S(M%U9B"I[WM??L.2Y%1#<" M39M6ILA4'XT.Q^9=I37ICL>RJ@BXE;.DG9PN8'O1CHJT,Y+[XZPS@6/3SK%= MM*9H@7'GL%H 3X;:W6$2 "]'"_RFO4GQ$$.E2SG 6'/N6OZRLAP#Q_J!XX6] ML%_00KGJME,BJT^:P_ !K8GT3GF_A^)*H;LS%#[C'"#&O81/KS49R8.>4I%U M6@,73U!.1#G* 2FG7R_*N82Z]@)U;V5M!9$ ?]BE.2-AD@,;MYSV8MDALJPJPX>&LVQ*<4CU'NDHWXVB]!IP MB"1,L:F9:SK*=DWU(JXI/_W$K!]S*KW"NR6;K33809@:7N-71*2DRQ6JT3D< M+](3/QA@61EZ@>W#4UV)CG^_\N/?S_[Q;^,J/.Y,*4QAH2(5.9[D)5&B :^^ ML"1-TN&SX4K:L\T8$ICT#B_&5# 5#-.OU](-O^ ZN(!^4GYY+[T:[ESZS_O? M+/L9)GDSUQPF?=3,/V7I6_NZ+6.:F#9=&J8!M$N!!7@)W"\3)>E >)IA2@NL ML4'\=AB,C7@CFJDS&B\NY1/0M\F<]8PT#^](S5N#[\PK]@->B-<]?OV8&+ST M#D9%N"8^14\-1_<-@-TP ,Q_'@Q^B=:4N26+.0CJ+%@O?Z MS])@M4M+B;4BQNY:\NRZ@,!L3*S;00&1*A#&>&+133NPF/JWTL*L;.O%F#*' MJE0TR8$57; K;?K"-R@M3\(O(UK9AJD;*VT1JR JE2F\/MEDWOSZA(%/V36] MJ&P^<*^##9([>74ZLO0Z-X"=, F2Z20+G]XDQWM"BG0-;;%XD^"?K&1*7$SD M.[S!F!J:_28]>YH-MUIV=!%E_;>E!^_I7TQWD1L"#H&UF5* SEGGXZ7V)A,M MP6<7Y(>,$MDRF03[M;1 3ENZKCDT?E"S:[^8(&CT!;Z3RHQH,_U=-!B-^&>X M%';19LC469N*WR,-T$-(M 2L1P_'5;+97Q[CW\4'0(_&S8/G;;R=,Z#)7*1 MG;&I$[QJC;&X*M)6<-$/JCN#32A'9/WM1';OO_VS;2V_@KAP[F:<[4M3&;:I MZ(W;63@=0=ZY-H.5@"%-/9W6"^9H@?T#$G'!)4?$GX=EJ-]-OX*/30-A4GK. M*@J9G$J)0AGVON[,5*Z3OS_9/T\R=;2O&'MJ>XA67#+6'>8'_[2>Q.W;LIWH M%NT)+%?/S;XED=Y>04OT'IC)UJ2/AO6@&PS$-4B.+Z;>EJ3_E:1_*-RL M^PP;*BF=JW_0M_?8PE+I;>Q([-]YV+!Y!9=>/8%D^/.*2/:#MGC5WARTQ^/& M$5A&&XN_N6Z9JS.;'#+ M/5(J/LF7];K)DM""K'_ M*6HH7$(IH[H('72Q+Q_2M93AE*F6$&41HBRBMOG@HBQ"E$6(L@A1%B'*(D32 M]B'+(M:=T1N_8+5,A"R8C])+@DR5AK:N@:TM:&57&[,@K6!_J.$^7:Q%AGJEG5E0 M8%(S%CSLH .0M921:4%#?NQ%:_0/46076!V^AW*H/;J'P+FYCK M+IA8,/'1$3WZ2F6('K5@XO-HC?"8R)G@"><.3S"/Y3&/R,C(S,'%5$,#[_O+ MTVR7V8LWRE1_(PQ/-%BB%$8_4777]-1!F6RZ>U@6:VKH]WPD]\$@RJ;4]54$ MK\TJL@J2"'FFJFXMEYCW14GZ_^F93$*\99X*[F=UHG'F6B4G/CS)Q*FX/F_B M_I2CXTB?:/HRSU/78BC[3]IB8<$]/G%0]NH>B:2C/58%J=[YR,<3?&5]9/>: M,2V]3E@0WD_!^5Y?**SMT%S_\-9]:TN?/$QIDEZL!3 #9B='?+**,=!2F[+U M!&3#P7*1@.^F^)"E]B7K!7M #Q\:H$ ;5[#C<=<@16?NFO)*)#OC/= MS ^\7.?!ST?_!B[95P:: M,XOV-VWUJA@R_OTD;Q7H:K, 6;5T2$R=8+S0%M MIKWAWX3B/J-N&(%PE?%[TY+@,9I+PX2%+5O3,,ZH?$JI:KBQ7ACXE&XP29KC M;QIPK+<,>:$3\4(?948G>>B+=*3 #Z1*WAFTEI^-'S#UFSG0#^Y#WBI6O((+ M+&\YS?*!-,Q8O@%82NV4,_-@^7B2?AFJC@A8PYEA"1M8*-@N1M><.2\)P@]X M]PL,!Z4%R&DJ-D'Y[,)"X8*6ZXW4R2JNV[)&O\<&=P-#NC;I?[?1P$I+9BRX M[.36F7!2P.5:K1LNN)+4.N$;5>?%:9(7+<7+0'BGA9@FKTP M0 [!:J& Y/P'B^5NW)-R9_Z'[2PY*P(^KP8MC7P*MP%Y@+0T5"?$Z M3M3(1O96ZN% M0>S)[:O%(FUX.85SS=3FL0HLB2W\1,I"F&3))L^ MT56HTK$6BM,=.CY/8+O.8[S]\)Z/?:@MG2+^B>J MV0M_0L5#Z/[PY=;AP@ U&S>>5Q_S&D:Z9 6SU4P0@BBZL9S+"CGP.GSB1WPB M5B26,$M6"\\)5+0#)*Y-:6#3H)789IU=ODED8V,1F,MV"9FN;96.4EY*PAC6 M-&Y:/69_C'Y=BJGR$RYEZ5&JAQGEH(.C3*LB+T)3N)[4MWT7R!4@0(H MHD /),J#5X4_?:)W/FRP%5EI1A&#KVZTV3W0KBL99O1NM-D[T"@1AC&#-C_Q M#.7BG1TW:VRGH(WW,CJ3 8'OH7''ZZ3*FI.#;I%(T'9_?FUEJ$$77Y%XD4,* M=H"_'HY?YS5-^OBEHVE*)Z<0]S!1I4&OR"*"4'AE8-F4;LJ:-ZF]:0 =W$YN M33%L1DY<9ZO=%[-%UNVX*%@+\W8,DJGP-/#[%F]A17FJ31.)<+AL+X^WEW8V MX/IG W^0S<:FUUQVQ%%34D4(.+RC=@HB'HB0/!/5C_Z/P'RL+[3)(+9E'YL+ M;?+%C"04S$K9BFP2F20Y&"=)F)!],4["DPKL:X<.$8=&?>_D!F\@QGCHNQFRT[ M!/]-R5^"!3:GIY[">+3/UEX=)FK%=W!A%*7$J=1^^[3-C/M1CFMDU[&6&$7T%GWZ"$3MC2UH! M''W,9'Q:9 N[O@&+JU<2PZDH"PI(IPHAG3:["PE(IPN!=$I!68)O>]M:5=*'SOEA+>8J)5MF-4#-?\$\O 4AZG;6-3P=I#+75RW&"YUN+,#GW"V: MJBC'\6V'_=:DUX$ES;$ T!)]!IWZ3/-*<=T-URFO0+/.XJK!3!X.LINZ;<5, MYOF&EAW+!.!HM^N1*5/B) F>/E>J2 N@AFQGKME(&?;*HA#IH^TY+@\U2>]P M?RBK]0^V6#C29Z!T*Q:+>A^]^$OP=#_W$>:^\D^IT](4XLD0NFY[;./ ;4;Y M43O&; ^^5\/LO<)#0CS;D/%P@@.KL:6!QX844D'2!)L.3QAA'I_9D^UAZ$0Y M53,F=>=F3(Y[D#$7E&U$X7X_0[%X911H@@)(\41 BDUI7KK>_KAZ M"WJTH[>3V\):8-$)++JRO;RKQ*(;CBE&(?=3PN(UQ*(3Z(^"XT[0 ;U*CAMU M&L5QEX#K(] ?=P"SRE52&=A^);D%T^ME=9SD%0$.V7 "RI6YU1 05C[(XTXR M#:-NV)%!H W&R++I[9!770*XY0X8;GLBMJUK:0'V=(0%JK>8K%+-[@/V-$+4 MF/%85I6*+=&:([;M[QP*)A9,7*&ILQ<3]Y")1W)_G-5*LEE,G('8MG?&Y+&/ M:__#6F#39@) \$/$"5B-&"+)&H:'OK <2B1Y\AR#)_+RC/;P;\3,,99+-C5X MXTO,<]5Q$#:3ELPET+.%1X^ :Z=1 MD0$\^L6P/$="RC.GFAVA\X00/C9;63;F9SEP#0&21.FRFZ4XB$)FX798^I]4 MS[,//I*B9!7S9X1NHF#]X]QFSAQV*0K]W\T><%3W./Q'H--G?&'R-&"$_3M2 MNT/[4^;[[?A%";Q7MXFE0@L@>>0D*N@*X'HRI^S:&N['_Z3@T50Q[T?^> 2A M24&<&0WP^"F).&-Y45_C4XX>OL-",$QAB4U$29L)5MNES$2/GB#Y@^5X.O[T M?#)?*P/WO^/%-ER\9A;(1TVI:;]C1$&58X@+!XS7R'(,)%^J%4M*&PY?MU6* MP:K#TL0JY&.KGR'5UE-[9&F>+ET-.T.^-F^5?U\18F- ,]&47XW%0L*%(;K- M;CN^L19^AW7V0\>=B!'CB[;PF(S27?<65.ZQ!M.!"8(\YQ*KY)?,'S7FXOK@ M'%S$(8E3DI;//=N[XBK=M7J.!^:Z"Q9A%\08'B7!33C:[[Q7^IJ1!"NL?P"% M18(FX/D1!MDWL5ZS63ZF[ZPGV+$7GB2VHM$0\ GU9)]YF!0Y98YN&T\1^LEZ M1NG[-E892S#?W!]-P-\@UKCGP[@S;VAAR?)+L_;&'3 ?TI+X?XJ;ZR@]T/@]./G1;41@*?0U M5EJ3?J^M)!'XR]%7(/R_:94XQA.''8$7!HC6OCHGVD;Q#K*,5\%*9-'B MG63=K#:&2:"X\'Q']GV$P"),42>!HJ,!KCS;\30S+-W!RMMU2-C0,MM8)I)3 M,="0N+EL!^H55.(&N">MXA-; _6.ZJ]+EJ+UBD. ?'%PGCK;K1Q]K!8N1HNH MBTS3T'=84_1CQ4CF$PX["93%/JV0$IA2@<6CC?@\''@NZ M('$&^,5I1DDW[HN%9->\*BAW?E*MF!\O>6(S]%(3,-#O-Q$*WX@"V9('IHA; MD?)LD*AVFL U8@&_M5BO+^A3$&LW?.)"5N<<'O/$,%2:&QO-<@FR4+H.& X> M]W8*!\,Z,3""P:">61P,.0B?[!D9WG\)MD>&Q_WTR/!:0.7=ZYR1/<#3X>.1 ME_=!M 5I\513+!X^'@]*AH\9%]IH>:$.#,]5.!,6X%W?B8H8%CSGJ>.;3CQ$ M!TOJNYDQ5;(&T[[[>QP/R)"_@#OZL5=P^B7[RP<51EN-._-(PI7Q:QK,2XPQ M0S IGH/[V;)Y?3B9('>S2$VM>\IQKAT"UV[#@LE'L(>UQ!7FHA3-Q!CD<7;P M)'[2AF>E^%;JMQ3^/$/.D*G-"49IV(\U HKM!FX@V;3!/(9=EMBFC*185NRP+(BR1%? 3@1$RI6301C:H<&>!,[O M'Q!P0"1GSA@!(*3$/K#^>&&9SU>$4\DSZO 5OM,95DUQ!Q+IA2.S^1 TELW!/4F/KG4X0RA!DH4N]V8(S5];O/V;84?6 M%:/]DCQT4./!F6(Q]_6S\N!H8 FD#1,E#Y8?(SAI[B?^&?CG20$SU_PS'HJ\ M&;S'4X%L@J)#2@2HN'-+]LD3X\#%4\8QO7RZD:PP@LHQPR(BTKCN*(-W)8"J MR@!5#01053W&JMP8P'^T@_$)T'6.-R(B9M1&A3W(+2_",C M( J9Z&+MT78D:80G?QN-UI "PL-"2@OS3!_?G$S2'."AK]3N=;-8*>Q&MXXQ=A4!C%A>1 AMK%V"QB'_$\NT%+18>4::J M\?6H$*8N:[X]P]U7'?/BR0.=:8;M'Y[YPM#W(/-;I=3.O+EVZ, *??/ 0TU= M'1[K3,1=-.ES+)!T0X&D,.#XC8K"&+\R)MWSG_7$= WSI\!"=Q?\V#>(;*4LR%40JHW%K3B9 MK(()4B6$TY;N8AU;!H$"U HM>[#J!2<9#_92!DYX>AV,:?U *'D4F5P7V5=) MT3-XD!AIP>]6RYO/E596:Z5OZK$BP_V.LF-D.)5F>(0X6)L@2+PE/HR/LAF% M>A+QW__43,JVYCE78#K&4OVBW YH7[ 4)DB -#OX8A '9 MCY5AQP*H?@8>KE"PR^OB 7::K0+P_Y).:4YGA41W$'\ .[FF_0ZVQABKN7T6 MMD,LIU ;<0;9Y*#)C2FU1#!Y-/0==1\&A@E^02J>VMJK^9Y.%E*>1@_*/:'X MYA^[7:?&U(,#(.P3OMZB("ZB7\MVXAOG-&,L7YX8VYTN=HW+V9MX=R>_/PW% MXE$*A2Y3X"'PI2AL2-4F.A:X4]+MCQ6>J23@:;.K)=9K)?PTD+M9\$3_@11G M?(3;/BXHE3G8@5Y+8K O*PR!@])I#MIM3(+Y'J/K1)K,!\,-Y3KCJT!V^+.) MG:/";FC\^$7R<]"1?Z>(;FO[_.](Z?BX^91U1@BZM00DN7!D7Y^B$!4@7FGM M)SVGEV$701^J.)3 '_@*2Y:L5Z*\5& @FK!R@(#56"@)MSV[1@U&\X& M^H*W06#JFO=JI?!"2?R:?@>[M,M=)=E7O(9@J )^6+#> 5@O!Q[J8*PW:$W& M$ 7&^@YY@J MWD%VZAB$/BO!GK(Y9\BNI00[6FV?_+WVH6?2>';S.0C/8@3;'41:191)KW.^0I+;VZ_"PG*]VO5@%E<98C..SD9SFE M.:R'1S;]T;@)'.9;$,$@@B7E2:556JHU4[QEYA7;@)1.*T4SBO9 M5V45[2663[,1/Q5)K11QY5T)=WPHPAVT)OUV5Q!N/+TUV9LLUF$D ^T*US,? M*V@P;)VPG"DKTY?*<;[=/=Y*8ZK-5'\I5JP4D)]_3JTM(AIT\&AC82$86;)> M":L'_15DTVO7_PZ?NU[%]/G+M^MO-U^NOTI?OCT\?O_]M]MOCP_)_=@HLDH! M6/*?GO).M1&P2Y\1;."?!#;P6X3PYC2NB/5S!)I@1 "3?CUO )R+)9D1 #N5 M]E()NT.UOR96%F-O"CN$A\?*:!M&A<6N6APTT-RHY89[EA8"K$Q?-*HEQYYW M/AH@P9Q+9 QC&2@^CTO"MO1H14"6A)?GN,S4W_PB[.5*LV-OC.%"Q,#X?,C[ MS]VD.8&L[$ZY+%M8%BH)7U/0Z!" 2)],K970R*B4,BD&H^^H@ M;72^EQ'OY* M5*-\D X\U*VK]0_/PGI+'TWSG6<&;8;>N)X-<( M$,U7)$"[FB"MXY-6][2D]7N*7@V)RT/:(BT+$LQ%J%#$'8Q3#.$5OVC& N\O M). 6UFNZ?.N6E6^U,0^IXYUFVV]HA?"9H[D1>!_#Y#J8EWJ<'$-A%)W5GX4,-H(CA/I(_$X<\MV.?:U MJ1% #8==(6P=MDRJJ4RDZ0B34N J'PA7>2APE>LQEF/B*G,'/\WM[Y[&[=]* MVVMXM 3Z!@+J\>NUA, \TE<+75\$&(JZ^'HN6,3_1AGH:Q(T6#2_'S7B+Z-' M^X*G.W-V11(/X:#\KB'^+7XC!(?Y+W[G&VKOBXHO+1T0#]'XT90/ .;]?7&B MYD+K((IH9*&8]FR;]P< -SL83-KVBU(P+GY]U3L651O'\J,PA6%AO4PGH8 M-N]C9TO>ZE6SI_AI:KV:]#GJT.I$9F;,6H@%&YQ-T*-R<3@8!T6)OD;.DA\O MFMZ9WX/%_8AKFXS*J9TFH@AM@]%:MR4X8<2WUZ?H"(0H,C5\QQ/OB'F>'.)+ M<_Q;L!-,*JQ0(T"#>OUV9SRJ(:).+6%^Q*"*#DKM%P%$VDP94;>DC.R%NE(P M3\(&=MX\;MP?]*<1&"\W@9@DW5$<(J=R-"3L6)E?2I*^@$MC.EVPTRQ@QO&, M]#OV#$]#SRE#_%6 2Q7:L*RZSZ,-X.AO2$^"JS>S^C'L W%IR:2TBUISM3EK M7HZ5F[LE9PE-5CPBSI5/Z+-<1SY+]&7,%0R4$[G>,9U%KG?H'4KD'GXX6#I7 M@?LKX1,QN&8/[A+0@#9Y=S>NJR@37-Q?L_LKTF>4A#FL.2?<)L*X52N@O7.( M:[=FI8NUSK0>2U$[VRNR.'$]H(5#AM ?//[_G8?_/\6B_V$$O4RCBJAV2\6^ M,GUY--P;DJD^^"Z";\Z7;W)JA2OBFYGQ@TVO_LUL*XUE5)YIA$GG@F<$S]2> M9]0:\$Q7\(S@F0;Q3+Y19OW,3)FE3/"=A MDN/L42^^[R%EA1(C*D@L+37Z(#54N=/=&T5]"_<>&0).,,CY,DB.5U>60;:; MHH/*3%'!'((Y3NZ^5=(NHBS1K@N".PJ'G7VV[>K4/EAT=8 MI4VX;FNB**K5KJR, M%,$6@BWJSQ;#@RN*ZE)&ZU6%4?]^]\F4AY)MJ$:C.'5\^?:Y>">J!Q?S*>Z9 MC6!"VC-+ZT;5';8FG?:PG\P&^VD-T74-*A==17 2^X?I@C'(1Z;N(#!] GX; M84ZNNNT4!$_$@.6XS.^4J.,6I/N>"RK2EU2,P5; M"+;8PA8Y79DKL%O&XJ!;<$1S.**;DW98D:+H=4!1C+IR=W\'5["%8(O#LT5. M;N'^BJ)7NXRH8U>U--?!'7<.ZN#V5!"6[>ZPOX.#VVNB@ZONX^"*".0E1B"[ M.>FL5=DMW=9D) ]Z(BPOF*(!3)&3M5J!U2+.;P5'-(DCCI/HT^L+-2&8HC%, M=[!<6-@3BGK!?&VTO3]M,OO)NEC:U.@]9BV((T]H#U1J5+YO*&J4OMA['TENNO M8DL#OJ+>Y+KE+:;\9KIQRKO!X-OH1)T 7[!I:^8.T%2=I!Q:3Z[J!XN_TNT? MQ5:>1OG@/[V(RAY$NS-N3?KM089X O9>X!3XR(OPH"R]S@U]CCU!/10*IH7= MQVVF8:=OPA3ML#L]+@=]VR5Q9]RUYP[PKU93^EK%*YK*I7Y*S?V3%R M]IOVQ@7-DIJT3ZD_$O5Q!;FJ&215\1J?/3=VY^>U!KPG:1J=67B4Z(RE]+/Z M0>W8!:H(I9YF[NFDZW<1P1G'T691C$E?4EJ+;)]6?9H=&@#[7S&>NEPPD/-H[N-PQ@*XT>VV4B>[3&\)J MLY.XOR9^*_9IM"Y93-#C!FH;+/FX[QX785/J.]+T,Q/PY+LFC M!<;32=NDGBP9X*.V $N8 @^?@ S0:5ESQ=73'$T7;L)[IK'7XO,_I\!L3EE- M: K'&LAC&Y2$[>NL&[_KEC+9T3L=<_35BCNCE&DU7<=#$,&EE\BE.;45)^?2 M;FO2E[M*,@@FF%0PZ64P:5[=]LEYM->:J(JL[ _N=@PF/1-PKI))P?>>K<\U MA^W69+H(Z)-:;@E3Y5.S^53IYE1D5 M_@HHBT%K,I"'_60B@2#!/Y,FE,=?.KP[T"IZB"UU%8WP-F_8)K-*=X].4JC"G#D>Q(IY5-IYU^@'6;DE$B$]X MNE4:)!GBO7XAOL$YHI*<.2F^*T>+"<@"!V8 GVH0?L'>#9VD4?Q>T%RS::Z^ M%#>H"<5=8K O!:SA-.C\OC/B5TUV8?NFEH20[.&3ULXD+(U*6\G2U%N4 ME=.>-<^&'0P/$P[=BP!J"BHMV%ZP?5&VKWDYV6!$$>5.MZKF(8+M!=M?/-O7 M_1AIW)JH0WG<:;JN3T$4_'D#/J4):$C7^E^>P5';K[XC:CNUFL<%^X->Q=0J MC[0ED*.;"SZ8U,NC=-R[@$4_>@[,Q'%@Y$^&2:.*=F1M0P+$KK>RZ'?##G!A MISW.@;]#Y**2\ _<:V-FT"(NE\PFQ#R\P6;/^';+?I. GN#1 M%A!U_!U L@PFZQ*1V8CIZ .!(?!7]-)@:0@0TH%EY(('2%K'YW.0SQ7L%RYY MN!6QUW@(5RBMM+< 6RT!3)BID'Q)V5/;0\3<2O;N"*&V?EK'_O)5;2>Z17L" M@O+<[%L2Z#>5X]P4Q*V\UW3#UJ2/AO4 [&#JN&M?3+TM2?\K2?]0N #XC(AV M2N?J'_3M/4+B*:.-E8W].[5I,.IK\"A-?^K-]/Y4[?_/$ P $B+ ,JAD^(&Q-DG;R0S@.V6,%O0F M3"!\V\N$PQN(+%LQ\AIO-0*:&D,0P"3' \D?W&W9Z4-,D::; JX! M-N@74_IFO9 Q@=)%D>-0PH2FN6"NKW%3C,T 5QCVZL68\K4H9+S&KN&*@_P9 MA^M;@K8U',?CUP;O);ACQ YE-M=1 3QQ@.WYJME3*;B #XS#0VO/ST 7J+&\ M%0?I=A%3K+QQW.^QNP,G#3XJWLHBFG7[1N:])3^^TLU)E@T58V(B_[SM6F[?S 5F[(*2I- MB>"RX7(:#:X,F4Q<'H/Y8\-C4&2 /6ZMT 9"BO/).7PL\,[4TX%78&^,*:RY M+-W??/^OJVY'2;?A(U,=7[W4_F31/H;&%AJM"S :0V?1V$T29 M_F'JV5/M+=H_T&B#SB8ZK 27A/#G# ;K?YP92 #27YX&%D]K2)\\. ME A,GL&RP #G#CX!UB,5[SXN%"//2'I&[BHO1+J;_+!Q>%^>,:YM&S4J[?P- M*=4TLS41QSSK&+K&"N!TB/D88](")1;E!L'JSC#I@_!1L1< MLS15OX2%QK_2/!OIZ2V->(DF?JP,7_<@8Y7?^F[FUH,)8S_G]W9(;GZO*F%X MW#W'K XEKR-!8 Z@M@AV/6;4<;'*>Q!,U[W+R,'6B!L"2]%8HFE!DPP"6YOB MD*PSO !8_LFR;0Z%30\%U]1;$(W-;&M)=S]^O99NP-XS7.D:=!Q_,CE]\'K# M=+$Q B<$VO_ ?8]E=0;(^SXI^!(QT^AYAT+">>\3C$-!&M<&@<])T?^:9*U% MZB+JQP#FH<-#)!09)MO)P48#?!Q >];*?XV3W:L#'Q9&.[07N.%YP[6G_2K9 M*T'IKR6])2+Y.RCU6,R?8OQI/12&X#:-4LCPITW;>Q\4]VMS&NLVD(+I#A=\ MLTQ[[= ![_?!W/6Y:?SE,8?\NR2V^W"TB>+>% #_"&G>]>-?%,WBS6#^9&^< MMU<\BDCA(I^87X+%R6Y6DLX^'XKW;V@$QOMPU!ZJO:J0R[OI+RF-7#YJ=WO; M0= +(I>?] BW&)KT=4BB1X'3SDL9/%X,LM#J?.>!F4RNJ\DP?W=!..-!&9V3 MU'BT)#J+967N6C]3!ERQUKD5G]:.&PY6/'.J)3TF7>Z;N9%E\PU.8O.-T>9+ MIF']A!Y%Z2D,3S&%4:$['ZJ0@[LF;=^"L*[7W?W_: 518^W._L'0SMM MEC(_%'^/3L(<2FN2PMWE6>/@U:W)A*IXKZK=7,[MGN9NW<-&:E,]3'XRF!7J MV7*R%&6KQ!)#>.+'5XR_2]T@?20,CVN.[]"FM"'CI'=[E)G\^6>Q*_T# M\,ZZX@_-J)V2V4<<849)Z6E><1N'NM3JTGN'-6>OS['>J[%3)3ILUW6;%0Q- M"D3S74OG!PE(UHSS]VJJ44(F#HKFO_!3D^D7\U:ST=,M#7@^ZK4F7;FG[E-E M?QRL\\LQ//:!U*P(].)BH=Z4P8&Z%%2KC_M8^B$/QGOW*6B*/JZU'D[!\A*: M^<2:.8&,VSC-/$#-/.HD,U3JIIG/"0JP#D9!M= [^XL8N_5 MJ;?8+2=U#U247ZWQ-,2:8'E4=4_*?0FAPN+\^%E2 TKS7S1C@5.X@HV\>H#M MDKZ8+VP3^G1[VEY]#I\>L$CLRF7V4C*B:?!C)H?J-C3,#;U">L(T7"1M7IE& MYT!PH\8SDI[>))WG%^M8CF2#KV@0BSAR[,G2LZU-6;P49Z6MF.W7Y]@KK"QD MLC1C&/Q?2-HSQY:%7Y\MH"N3GO%DF5.'$I EX*1@/,\VP^%@*96YEN4N2T^> M*\% '/X;YLZ_,@O[V/==!K@1>E8T,X3 M6GF:-M;&V6S.8(E>*!/66C+I';[K?58N]M;:?6VQR$J.C8T+GV"F[Q8.4U_ M1O&:<"PP7V-11Z.,W=@-?GG/E.&C@2.F?J4//S!5X6+,5%_R.D@B,UY4H;-5 MD,O[>_NAG2#)H R EY3Y-?MI)[.."V- 0@$) .X6)GI84[;P:3I1:,_+H=8+ M_WFJ_ 87&3&L@'AA0?KK>-&AY_AYS$1M5\0R?'J/-CWK30+UM> )\[BX9F* M6>/+8IXU9O>YV<"",* F8T7U9.$TJ*[2MJTGNI@XS241,M5" M.&$H?+8X)%HYF"4R@V;ST_)P?FG+D4HO:P +"_\=FX,EI@K+=C%IR&\7R5DG MA];GVA1W#%E*[?QR3?]7?L$I/#$7Y0\>L<+;8%D??"KQ(P/:\M^^%BMN0^19"65-FDJ[>&X=B4\2GN@ MC,6@CCRH[J@<(31NI=23E(4=+?I1+"$O3?YEQCH.6DU6QV1%QSU*(5W]IOZK M#O#Q>#$X/8>W"7E#U^G1Y.K3DS:.QFI=@M7&KO_ M; _\W :E)MV8@XQ\U&5M_!(J#GV4Z\'(/E-.,\=$1@W&M- MQCU92;'6=LON%^WJSXF^BKK02;K"DEM!4TVAJ9)NY8&(*M>M'+0F?64/MU+0 M4RUEU.CX?MBP,C],T%0M:2H')^I@CLN(VU/*WB_2##KG>+0D:"I&4PF,KJ.X-(-.ETRMX=[1/'$4 M4YI J&I_ XMD=]]&Q Z*,5H.+-.!?9M!!\]DY-YP7),0@B"O.I%7];Y-7\1" MFT9P)7V; U%4WMZ*D<.97,*JW"N1'G-6=.4P?)Q2Q@:XW( MUAK4Q=:ZI..:5$@R<6AS0"8KF1W!L5'$H4WC"*ZD M8W,@BLMS;!2E-4DF>(A#F]J14SEJ*IG66)4-JJBD%O>W0059U9*LCI[>.%"Z M==-\)^R)(JZJM(?,Z0T:W2@+759XV,L9Z_'[WC&JA!+<(;JDX"T/MM";)/@B"0VI# M18)##LPA&TD-A2LC5:5NE9&"?P3_;.&?@X"^;F>1:#(?RN+>WQR.@'\^0OG9W MHON(3ML51"6(Z@A^YT V)XWP1T$P'8[30E0Y#.GJ9+PAI5Y-B.PN$9RI[&1U1"_JJ MC+XJ1['N"A3KQA%<.13K0U%<7N%W5P%)EI1B L:Z=O14CIR.CS?42\IQ"7C??K0;ZW:],ES#9Y-*Y+-RQ! M7W6BK^I=&]%YM'$$5\ZU.13%Y;HV [ ;1.?1!M!3.7(JF4U%<4--@#6:SI_+8?U.7^CLX8Y+G: ME]7]H6Q+[64#(EF"*(^=A]C#8KY.53UQ!2'6D1!+>DT'HL0\KZFGM"8IQ]JE M#X0$#=:1!LN18,G\V:H\K9Y:E:S1 M;TV&@J0$21V^^+)77?&E(+A:$ES)#.H*SN]ZU15?"IJJ)4T=)(VZ@+DU(G,K MI2%;+3->3U]Q**X2+=8;=Y78JL9<567*_WGGQ524;7;!)QTERVPJ#_6,*PKU ME-K)!B1 "I(\=GBHWZD@/"3(4)#A84)*_>IPI 61G@F1JIV#M(;=3H?555X+ M.CP;.CQ1F4R_6U'HZN"D6-&1?:U=.;[FN_W[>(C:B(+943OTHR[$U+7;H-(( M[A4NT/E(NQ.C4_>Q9EX=RH-N50UYJMOE$YTB"3X7?%XW/M\]#H$HX8K@;<'; M@KS> E M*Y4K8_ 16N6J/%(J+LT[$8=3//)G%U<*_C\U7B;!M+YY2]A'??)W^#*8Q%*S MGPV3AC(.^,PPIU@8IZKM/C#]T4E'I>(@5_I-L_4YWX&N(DN@ 7JRY,Z9S:17 M_,>T),-\88Z+B)*.I 7T@?LO.;#+<+'F\FN!'F _":Q!=-A*5Q+LIEN/9OP&,F +PS@-!M6 M"K]FQ@NMDL-6F@W+(LUL:TE7A2MX!2MX12L86^"VE+XGDF9.I4_PW.43L]=^ MZM)VI;Z\X#NC:4SA:VEEPYB!5=B/%3,=6$)\M84D(?G5G)*&166.]*HYTM_* MB)]UX=/?%#Y?_#E\#Z=03,P,(C$S;DTZ[2SG'^AB@4/$"94:=^_0XQYT<-Q9 MHM$?MPP;Y:R ]HP7MG@KRD.'8QAZX@?#!=FH%V"A&YM-#5?Z;CA_-H[]/QNF M9E+W2L-T7-OC?$.2;V6Y\ >7>H[W]"_8'V+(0%J F !BTN$:D .PBXYDS22= MKX4-:X&_.@8P[LH&XK!A['2!YLR)3ND#^\L#NEK@2V7)F8,HO0**6](%"\M\ M]O_:SN5XL:;KH$HYR_NDVI;BLFVI@2"!_QR2&YFCD%X-=R[-886N_*G\Y0$9 MN&_2;&VE#->C.;>E!T^?HQ:@MR\UD*(_= 8"Q^_&LGB#?78\>):T,);P[N:I M",ZKU[2_J5HU4^*\SBW0E["R=B*-)BYXOGS['$B>E6[_^ "6!BB#N]EOVK\L M^\9SP#1A]KIE!G/14?R\@BWD,#.4/)U(\BBMB3NW&4O('BD:EB,Q#;>/4P_N M&BA_Q)F6E,Y/.-\8P5-RP_ 7)XW69 D8)G,93)I/TF1=D[[JIO"]B3,7"I=[ M9N,7VC-3POE>J=&$U=:DFW0S?]JR/UD#ZU<[,$2O2!D8,6#IL0VJ'1L>F@V2 M8R-S)>T>@^'[M*7Y8[>8-@.*3J9F[4/RHVH$-JZ3X<;5C&V51/'C& M$GJ/^#>I.4Y].$:;/6LV^I6IY!&C+M#BC$G?P'20U$#1U<-*DT%3+T'%DA7R M $ZO,0,'&&S^:T[<.+E[<*7U&(C$*;1M6[K]K_OK[[=?B5C^WY>OWV\?'Z]A M!UZ8Z:'3 OYH9%&!C0%&\Y1[1$N4'FN\CH] RQK,%C!AIF"-V<:3YUJV;^,] M,Y,;*=)<>P&G+K8L9!F!76YY0$[.NC&U8C;2!E@$YK.%"^?;2@RL*"\R!LG2 M"H09^%;@5]FV1E('!Q:]?&K!Q$P+?3PPQ6""L-AXB@*_@B!>+*Q7,+W@$I15 M_JL6EH,NG&46%5BT<($5""-XTASX%^Z?PZI8-@9#I)7V1OTE5IH++S>!FD/' M$,8+!J>!D0!8;<\%BTX"[]*TEH:.',O9!N[0GG%!8/:I8X#'X*J\VH;+KJS9 MS'_[&TPSV[Z*12U*>7>JTMGNWX5+"ZS_R?*>W)FW\-G!B7R^&[X&I5V_0BXK M+E3.!I.CG[:8CF,!9>.&D-5NH!K3X/'#P2_!>FZ++ 34/#6V".4\ISFFR2M8 MU90,VTB_#\&7-JW$>KHP&H8NT]O.*VG"1\!*R](74V]+TO]*TC\4'M*"?5^".77U M#_KV'C2QA"T UE8V]B_.$[?8Z$S'NC)B^G#4 WOQ:3#J:S *37_JS?3^5.W_ M#U* ?]/<#N:^@N=?/=E,^_-*F\'2?- 6K]J;@\'[QUN@Y""O?^T@(.G1KXO!!]?2_P1; M!-;0N06U[KZA6?C)<'002* ^'^'>CPNX)A)P"A>U(&[8]-KUO\,G,Q"&*Y0# MM@>$\?!X=_-__^/NZZ?;[P^^RI=N__'[E\?_3IQ5K*WZAC2+7@NOV+X;M8DU MQC),I#L*7:,6L]F)Q=BG*>'.> LM(&YSV5F[R9Y32IN04 MSR8=K)3\M"$>OJE[YZ8UH21;L(]@GSC[Y*1\%V,?*JJ\"!0BP3Z"?6(1H9Q\ MZF+Q?KD(Q:6*)M6DM,!4 OBT*3:V MA9"!%.]FC]J/>\RHM\QKERV;ITLD:U$:=.4WY MQT@"E+R>V],R*16[#/&;!/.164.(/82P/U6Y/N*-E7KT8:Z&(.1W.SN9_1 MPSRG;&Y)I',?0^'FM#BN/M]D-&A-U'Y5O:UJ<"1RYN0D,KEKO3UUY_9AG;A= M)'&+)&Z1Q'T9VU/.<5([)RMQ&8U:DWT*7 1%"8K:H*AQ+2CJ8ISSK9G+^P ( MB40LD8AU#%&52,7:)VPX[H#)/TSF9%7;X+8&<7G!G8([#^^SJU5@&XTI?[G? M\#Q)P9B",>NC-KN)4LV]M"9F,J=T.&J,UMRIF^SA8-='!;L\9"+%(W(Y0@I) MW_@AFE:J<8BRO1M+EL\794#^!] +; &=&?8NO;<.!GS[!G^;S/:&# M@XM8HKO(N(O=19:&J2V2_<-<[8?TQ$PV,]SR34;')YYV?JN:<0];U615# 2M M:G 1_-ZQ(0X[]5N3EC#?N2,Q<\JFF4UN>>.9C4ZGFPU6I.*X[;_4M!WJPQP[ M+7UG*P_608.UNK>M9UM;-J[OY9T)>_DF#6-MF,*>09II@IC58;NICQ8VUOEH M:?:4>@X9-NPP]MB"Z4O::F5;V*)+DTP8ET.K8T>KL^*K(TML-N.$(1G+)9MB M8Z/%FRR]S@WLU^>Y<\N&P3N;/5C#!WDK_!.627M^QGYM+O4@*=>X2/GAJ.;C-:.;_7F 42 M *ZT_T05@,\#A?L\QYYL+[1EL,W/ELO[4M&A"I^)WT(M:_^#H3@>R >2(_!L M?+GE-\_ \=&6 XE+3V\;U#CEM&:B@#)X^QIIZI- D/XL^>)H4*C+4\&.1-U6 M+D>?L'<-IQY%V:F!#:XN"'M:DVMS>KM<+:PWQCYR/7B_@+&1[GJ<:R8)O8_8 M4BY^5[(?RGB0[(]BIIPU_9LJ;U-1>*[73(4GQ! M*^EH$VSD [-?#)VE;QTV<=/IT]WL>]A&GEL8-Y;C.BE[.RS0U:9V6B[>U]$. M)\KEYQ5ODJC'UB6T@/SV-LE&-)KCM\AQRO:DB:BP$:6,0[4][*;_%"NK2PE. MG!X_IO!5Q8H"E?9 J:JFLY^_I(4'I6Y_>365BL?:IW$S*]0>R4/ZC7M(MVC9 M_/W)_GE"7A):)&6JTVJV(X>Y*C,:DQ*0J??6KT$T;3GB+#+AG"T_JT7KGK1B M\Q0Q5K2HT%5YMM"6@-V;%J";NC)PMAHM7PQQ[L<(I>=?[[."H.YI;O5&.S7-P2 [$YFIK,I3'H[W97)0$U9*H]?@-K0JZ#0Q3CR,!\7A(@TX!KAN_$3U'<)T..\E'7;XF3F4(^;: MGNY24EOP-:D:"_,-+E##7(@AV4V4!QY%&/1:$U56*ZL$$-Y)O8@J!U-[%Z)* MR22.T5,_K(.O"45=@FN2A'C8_N^CY6*F]SFI$A'J%Z'^[347Q]*HV).X*RO[ M8]R(0S;!>36:^.YE/\?B/&P-K,CC<58E0:TXS[=+@D$$2\V3@:LT@VNFJ'?/ MC@NP5Q]R,HOG]G6\L-YV:65Q4M/='DWE&1VFUB:>R",[6[,CR>E6[_6"MI\PMY4-Y2L8]/YLRO MCG)*FUZCUF0@#]5Q38(^1P &$4Q2I[E5X)P) MF#G'>JJ%ZF_P56)Y#[^\VX&]TV%%UU.=>FI[B!!]R6ZP(3+?3^LPBCZW=J); MM"=@3,_-OB4!]U0YL%-!6/%[33=L3?IH6 ^ZP4P=:WV^F'I;DOY7DOZA<*CH MSR 4):5S]0_Z]EY[9I*J; "VQOZ=A]EC*[CTZLEFVI]7V@QF^4%;O&IO#NY6 M'&K1,*\V%G]SW3)79S8[& XE%YP@_"U>%/6!P'IYT]^_:[49BS2W4>/]GP+ MN*W)(X%86C,)*[]X+T5MDK:3V1BNS4!KY?T+I.M7S9XZZQ/<$:(UW6*@$,D= M/X&]1JAL>"LM<@*+=:@,FHK%RK%3L?"/I*M#BX9]O V3VTO4H//)\MQ4*&PG MEK)$)8-VVBFGC.C2WQ]^ER7-7\>2B/9GA^7:::N]?MT@3-5V;SRHXZ"V@[WF M!08Y#: O&+>KD[FRR1]K$3HLAN/(U@UTI/KW8!VCA1+Z_G2#I OVUK)F_6 M\?$MNN1>>\.OR!;UQ4B,"KBP*19YZD3&Y! A6#K#L3SL"=A,4=%W*15]H&&( ML;8RK'I =@UTH*\" PU("C"-3T>M26_<[C6I]N\BTZKXO[\"1<#F%K&-13K* MKLI5.;!RI4UTOIB\,\ZOMN44S(F/L>VX-1EW.O)X+!!H&D^%6]2&LI_:<$I1 M8DG5H79:DZ[2K@T%GLGQE4@1^VS9,V;LJN8N-RT_N^OR:?2O#H0,67U MG(J O?V^W!WOT]%9%(9DX%%VG0'E75@D!X0?LJB%MLV"J\H(:K MA]NP[>[NZ@&3^WM]N3-*UH845P_" [I<]9!"A&750Z\UZ7?::ET:51S;?ZC7 M>55*WD5M#JL.E2'>($9/US3=NI]FJ7T\S>J/.K*Z/PQ%+5*IA2]S"&75K>DI MCSH %V;8WA^NO$H79CT5.B?5<",7^;@)]3O[I(?U^E6EHJF5I6*UE>J MRX^K<%!#D1^7E^440]_A25^_%T3?$8ERF"@7+5\L;Z[H$I[O(B6RYNA42/JD MN4SZK!FV]$]MX8GDN>W6PN_F"U 7+*+(F3N]A9;N9:A=]5!^!J_F^&)B#R** M.MQATZ''N6;ZIMLWRZ>/'?T/A.B6NX.>/%!$-IW(IKOT;+H-5J[.TRK.R!L> M&.E,5)FH,4EAIK'QB-RPP=YH-"+93B3;-8Z?L[3RP:)_N3M5/J?R3K >1V7;0U(53*A6^ MP;LJE:X"##N0NRE9M2+?K79TV2QULDZ9.ZD3M37I=]LIR9@B%:Z)N=*7:P@V M2:.$>[RS4NF"I])19;63C#R(-+G:T6:SM$HLP7HGE=*CF-AP;[C1AGHHM3BQ M$EESM>;[+)5T,!2(0Y]G=1&75.ZIJCS^_]E[]^:VE:-/^*M,^7G.EET+\? N MR=YU%8\LGRBQ+4?22?+N/UL0,!1Q# (,+I*9V@__]F4&&)#@32(ED,)NGL0B M06#0T]W3UU^?UCC#M:^T^%3;$6[";O,\'2RWZS7:V\KS[*#<;A9Y=$^0_AYT MK8JM:E6&6*!R3P4JX5"82'ZQN./\C7#3B+ !UT;J$P]V+/[[!;H5GM*NO1YG M8B%!I]&?CRZ)B8P$'30-\70(2G/Q)@0EKHM?.H[3,7^V (ZR<\+$]8(4WC%1 MG^'CBR"5! "9<4&\F T>9"3AMPGL#OZ9QIHI?O-!\([@-4+$CE0XD/=ZI< M MKO3%@Y>,Z.H<;'*.&>W\I=[/8_N:]E0Y?"F_WR'6PIXT&\W69L6BSU!V>MQH M]I;7PM9EI[#31?F8*Q?,1;FN1"VAW@T=.5_YR#G/CQPQYVE5KIKR))F)5TMAK[O.5%_\X&J+B M\9 'P>H1$1!S9TF"IY'OX 2ENU,QP'+I8_-$XG6^-_V4K M1\X^R4-VJMR'."S#!^?_)4^46A:V?63\(]O7A=( GE6WV3B=+]9[HCCLX?&0 MB0.PVA@]YG!]S/7Z?#!DHCQ$0A)0PO2WJYG^=A.FOX'=:Q4,)'@=Y[V;1E-I M1SGG8]5&HWTR&Y(0>%4\S_SSD<*%,XFJ.EU%SZ#F'C\](E9\-V=0K]-V7)6X MY^S(DL&8@Y#H<2XZ83 M57(PR^+]!9X!#>Y]M([G?-+E,)OJ2T^/YYD8GBXDL%-%N[7G'WSDY0=5[(7@S8@K6HO1:(DJ# +\9 M1N%8_-4&(8VF(AM^M55^[:\ULZMD,!F*U%&G41)?1'7'$ZO$3I:\IH@EH?AK M&DC1:9)$_37U@88"/M6MG*+3:H@_<*85Q8!9AJ02M5B,[:F0/NAD_ TR5>3= MIHD4-%3L*+%_"M@KW*88+YAHF>2\+B;@-S2QUH+F>LQIDW$N DE<#N'78S5# M"G@9C^%2RZKWYN/)?$;A%S0LD%J.'U*LG:+TH&5_R"1/V90-9'+HL3J,'PCI M87:.+LTDP<7V9#5_*2,H?FB)AY'GC"1PFO!BX;PR &*HO?Z;CT&)UE-\1@D032L^.SQ:#E(D3.]& M&6\W9JH_RDP EM2/U$J_\$RM9Q9N,K.PO7AF(;XG[O(:4_2 ">I!AR^PEMT, M.IPW4)5HH(WZ7.;WH@0'L?NWRYMS5IVM-JGP]H?-$LCGZFS42?7Y7'#W>#X7 MW#V>SP5_.[\1%]_.+K^>B[=?+J^OWXGOYU?B^B^#J_-'Y6/I&2OVH#)^ IBA M0&O4ZJZ'BM(5 1RT7@"GJ11OX0R.WY'=J$]7)#6>D'"*.*E/'L3ME-,N^J2< MOX&=L&U#[$O&3GZS&'^?E%5I!!J'9>;ZT #O,ZHTV,J%,WL?WV/BIS'O )QO M8A*B='NVO]&;K_)1J\A^WQ>\*=#=3UU)KZ=??E@T\= *H8U()_ 97BCUX#:, M31FD*E1V6'0IEFGA5W#EU?4?,0E P2C$@A!^+OE(VL81;_,*D 1.QC@%QXGO M/Y;)*'3?6<(;"GLR\<%A@=4UQ*)7M.,X=#SB/"H3<;!X#/P*0NA8_YH9:PW3_3.*&B-/K9V':)0_$'&PBVE@;49G:,;V)8VF)D MNR)_-!GIQII=>9L(M1-#+XH3,*RG2$=I.R/%HV(";XYF%LCIP%BR6FF :M9. MP$ WW\%V039MH#"]OH27 MN0"Q6('*J2X2?(G":J;B\DF[ :,!=J4 MV$WM +PS/ O_.14/8>J[2%\;GJZ58T/,'<*/J3J;-1_H'!P$KCH]%I27=4_6 MF':\R18N#&P_9YQP9A*RB"5(!/B/F33ENP3,?#MG,;QD$&:.R\H6\^)4GF?] MN2G0+QK)6EK7BEN-6&3BK8?:/4SA42Z#H^M6QKIX7$VG/=0C$H ]UX0 M\WY9>ZAO)P])G+[Y>&*='I]6! IA"P6 M2#LDR L!L4ID83364F(8?WPKZV* M1*^)&)M6KU,!X)HM&8?TW..*<_G@^@\,%#6/FOV2;$9)WL)(6^S+(?V*\1;F MJSF/EY]KGU3(_EHZ:>0EGHS/AT/I))S?V.8@9$RKV7SR5)V--JZB MWG@M[D[O:3-N-F?;R"ZSJ537A:L+5A-N+JUY#P<"G MO)+ZT$L&9E"#JU0PL')IKS,JDJ$1ZA:=A6TV^UA'L%;\^ '':S18#T?(YC! MP]5($MQ??9DS H63-_95>F\^=OM6]_2 DO,U=RWUAI^3NP@PW#KM5H6[#LNN M*>>/LV(SC&Z!B;/\TT%:.R]MTNS*;JG+*JK&C/6ILDYEQ47@1 3)8_L*;8?N M4PRSGA%;Q/"\R^$G>9OD.?*-3YKC-Q][5G]K^8[:C*DUM&25KGJ=[MK&*Q.9^0D7JWJO5QZ4[ M52WF7%YJTT!AO_/F8Z]MM4X[VYW/_(*5T=N=2_XJ>?)Q2=*M\61W6VG2G?/D M8;F*"Y!D2F$AB7$.*W4Z7V->,EY^6_./'OO[#5?W.FVKQV!D[PLK/SE^6;G] M6[^'I^P5]_3@??1T^=D.Z:PK9VY.2+_W',]7E5#S3^^_^=ALM.;/\(I$>;=@ M3M:BN$^BN+1I;I$LG,[(PH+>N;6%XOAQ(OG(92S1#2VJ'F8\3F'!-SF)B)YB^\P)B.$.?S(8I@XSFD> T6 M7H.%;P$L?!$Y:LSO[6-^OSBM=Q3Q.21$ZQH&O(8!7\/IF^W*Y_8J9.-S\BJ[2JR:NO-Q[[5V0-6 M?>X1QY:HAZ_+;K?-1[7K(=JW.<478[K#*/-<\54H3EP=U MN+PBVW$%/,F6I'Q>D/O87E 1V[!V2;;.5BM 2';&5@AO4Y5&T]?@WTU+-S>4G-JE$(J@H 5;/3MMGE9'6&AZI W[;>":P$75BO.5\D M";M)59()55^-N?I*8O65R"JO$"*R8V$])=SXSS1@9GSPDI&PQ7]O;(H5V;3W M@FS:S]CT!.>Z-A8%CV"O?'RUY8"8(@F)E($>:,_ELX%K%/-UVXQ@9;#Y#F)6J_E*L>U;2U\Q_8M^"K*7)XI_,55QMO;9J32'Y M;CM>9(O?O/#:\63@R-@2%X'3$.+_"?'W%C)[5WP&[A&MYM'?Z=/O&&4P:K*8 MTL9_XWLB)WE-]]1IG4CG^*3;ZK9N^R<]&U9A.[?=H=-SV[W_B_I0_6@4Y>6* M=_+H-I+VCR-["*1Y;_L/]C1&M6/J&% P,SLV2^R%)!T.=U9\SCH41"N,B,/> M@\Z6$6>/_Y==F;4(4'"@@/YKC2UZ\_&&2L'#H3A#W14D\?_ZU?Y8MOWE1\#I M,_0!S)4.$G-_N[PY%ZV.SK!NU$7!,[5N[)^?O-CQPS@MZX#?YU?SRLEDY S"BI_$-STT7T@_"Z_23@%9/Y>\#\Q MG.Z#P 7Y!K(%M,\E+]E>UO11W.@/E>D!N2@T6=S2N^O."S@N)/=RY!]D1]#; M6QG(H9>\$]B,8<>JDR06;UWL>HB$36=J+,K[)E9+0MU947=6U)T5=6?%RU]U M4$T"=6=%W5FQ1A1II5UP6. XJ\J8-V'\9YBCML;B7D-2OP3F5UGK^\*<3\ZR M5FY/-AY9O4<8&UN0H1#SCA\I8\_:FT?23#D73^[TG MUQM5IU*AEIM]DIN=#'1_3@GJ@A5X;!T?SP/*;#SCO:['>,RYKD)O^W*L'W@5 M[D;R/'<0;D^>%5>422R6V,Z?=\^.]E17=&_3IEH]V.71'+3A@="GQH&GS]&M M*[C79A0JP)L!A2J)2^S+$;%J:]:.GQVH>;O^^Q^.?MN^SWC^,XELH*07V-'T M(I'C^%L8X$.CT(>UWEVHRI*-%> Q^Y3=)[=.;;K=%74X:W$]#'&MBJNZ,\$] M 5>V;W6/YPN(-W9E=RJSRJ29J3IK<:7$;B+OE; +'ID1V":6__;S%3O!\M]# M&_9B21W-H1BNK^"PVZ/S;.OF)YQ.Y\RZOS'C;GP"G;[YV+7Z_2[)PG#81E^VT,P\X4R<:=L *YX05CBTM>"2#+;XW:U28P8 VG.FB M=SD3TBO8Z3(W+)/(HW8NDJTW'SO;:K=\DE"^S%;\LD[!8)W0>"SKSLX^V2KK MMM'9KUEWK;+-:JGU*EU5$ZXF7$VXO;BJ)EQ-N)IP>W%53;B:<#7A]N*JFG U MX6K"[<55:TP)W0-4!L1C0L B.Y@2*L?QAW@Y!D,DU:1*'MN)70YC@@>R@R"U M?344TPQT"WLR\3VX0@$03:6-N?HC%[]S5:.$"#F^%-R)?(1\"4':K7:O?;I# M@L2I#Z_&L$DX+S2,A".CQ/8" 1S@1#+A-_.P4J:Q)LA$M?>[9,M6X6YQ8$^! M;W75^%-$AHJ!>(3/Q/L-TG $/TH=A1:%H]*.<'P+BM@8>8M151#Z8^9:^5,Z M# )F7FF)B1WA8%5_*L+A,):)N)W2NF%K7"]A%!%;#&TO$O>VGTH3 @M?Z[,O M?^(C&=7E#C^&?\:>J^*;#;$+&G4TC6)%)/SUHF4"X5:M4KTF_E3]C9@H=N!( M(+^#]3#P]1UP;9P08?]H7#?@&^+N]6BX<*^4*MA#YA_0K-XR!L87_B0=2?,? M=S8HT.L^\O&XYQMT*T#L"L?-B+5Z(("1"V+=(^)Y]Z_D$ MST?8=6K@,KRDBV>:2P*%E82DK/0FQB,IYWB['*9N/4BUD_:;E2+R@G!<3,U6 M]U&87+^E,=PTC@?.OU./H?:P7/2.==05G.P1J/,T @T&O'&)VW+%A\,9*L%Y M:*O3WCQ^UVEO'K_K[/+;S<6WW\^_W0CXY_7%I_.KPOJ&2=[74AP29. M]//]V>77K^=79Q>#+]\'5S??SJ^N85FTJL'O5^?G7^'MKA= @)WV]Q$"[&S1 M8?:63JIWPAG!RA'Q,#)91W],6IIE>T/[!'](AW V=!X$7L*!N6C8^EI'&N<= M\=3VAM,:1^PYKEKK%6L!#YL[+FN M+U^H\F:5H[PO99:K]N0)DP,JMV?KUWQO]O(K:\1>]*TWJ@9O]YIKUH-K'^PL M'-]Z ?%\;F>?F:(PB"(;/L404WPVPG]>!(Q'?SE<\),ORH>>MC:N+S]^\[%C MG33GBP(WAL;8]M0$Q06+CX--:DQKN3UTN=U,;%>T-E556D_>?&RUK'[KR?.' M=RZSS]2]^:(L=U46_M@72R:[ZI7-]MN\S[&PS101W5AN3W%L>*]3E1E^CY3) M>C3D8U"H5K'/T/LIW:/_R"BJ2M1ZA*>2A'N(.(C1FKN M2!=F#.6!61-/ZN';(^>BO;%S86R_F7DM.Q!:"&3YLNVG6_7,:\XQ.*>S2\YI MO_G8/7E9A,JU_<-J*;4J7543KB9<3;B]N&I+,3#2K<<5-V 9C7=A'>RFI4/[ M8O>NVLJ=S1FO''3.8Q%"GT::PXDBK8+%YUK$\HS"[R!N;R'660MY+>0["A6_M)!C-7_;:C6W-0KJI:3\ MZ6U^LV7"):RTC:XVNN-[#XPESUFC%EO731ENOC#JL\]*:ZBVU.BS\R:^3VS\ M887XDE["G=>[SU>GOV1GXXN2HJ0JWQ+)2Y+#:.W"CKF[@+H"[)UQ5 M:8[SA%J-15!]*XG._G3C1?78->SRMS!Y6=U^^I(DL):]^DL8$\#A@>/9OK@( MT(8D7GY9 F&'F!>P<"#C1O+.QB$7K"K&,AF%+D6%?LBIL.,X'4\(W5*D,3>1 MXF5&>_98VG$:L91BI^_2QNPQSXI:]'2'I!Q[5HTGK-M.71D+LEBD=C93I+8O MIN)%(#[+VRBUHZFV2HSCP8,CP&-XBYG XL2'M28AG#/(%L*C)N0'Z?MB$K(Y MK= C_#"X.TID-!;@USPD(\87*+F9!@AX+]YZB+,1C^R)YI@Y.((,'"&1]MB" M7]!/$ 3 810-.82'JU9^N%>81@X0;1B%XP4W9(@ O%SC74@[\J? %?:=A*/N M7OKAA. ))E%X%]GC&%\?T0*<< R>$(G_!)XY!."Y=^)]<[P'.HW9/F\9N/\\>WF/ = MJ?T]329 %/PKE@ER0RQN)3PU8&*+O]J!YO<>[P(]LQT&[!2[B+3B4JNFBL#.D,@B1G1B0JLI>OCV'4!T!T68)@ K^2*):!(RUD1@N?8PN0 M4%@O:,($6-)2C>;\>&32K'IJ'6@(13#U5MUVXQA[NO7)\)YN!:*5MW+_4NS@ M5V&N9OX3^S8._319_).YUL2M-R'B*;W&[GVW'2^RQ6]>>.V $G(P*7<1. TA M_I\0?V]Q1_YGD#K1:A[]G3[]CGK8Z/5DRAK_/+/TFTA=8;#G;$VFSTN^IS$+.]3$+\(KX(UV959BP - M 2KUOU:#F\!91 @5*&[HJ[+=;W\LV\G%8!KM9? 5+V07FNJ&$)LL5#-DX-DQ MG3RH^L7<90VQ&83*M3.2;NK+R^$L7,I2I)23YND< @E\-H^44@9FM2!%3G[- M(D"4\MU3CRQ92/N%,$9* XUL6FMC.K>%T!*!$Q#_J=&"IAH)*+9>] A$\W5M MM)*Y,VB9Q.G=629Q>P%ETCMN]-J][:!SM!OM9K=JD"&57=3Q,^"8;%AD#[S[ MW/;06J ,Y]I^O3%."C6S*]Z-']!KG,Q::F5K*S%'40$<=1JM$JE%,YH-E;>M M=S/'^^)2JJ?O=?5@-L[TV6_N*)W2:]26'2)!J$+O)8!'7K0ZXS<%&&@G\\B1 M.^J3KT$"#J0;H[]!8R?\(:-[N4%K9VM[K9TU D>UV*P6KM7"=;Q;X6K5PE4+ MURL5KNYN1:N]/Z+U3"@T+VKAJA091L\0TMM=Z-[L#*EC;P2CW3O9!*MCD]RC M(1^=-Q_;5J^_K9+JYSI>7A3L98]8:".X%\U"\US2??/QN+.MYIJ:1ZK$(QOA M23U2R6!1KM5IS@]B>!D&>@VAI#,['N$T$:Z &MNN%+]2Z8[_R$-W?U$M-@1) M77'J?EJ8N8I#U?9;C;?LL M-0=52L>L.'+7US G%=$PK\%S-7(SV?@'439-X$E=I^LWGK[&'NP-J',X;=CM M_AQL^Z8ALC5,]%., [1.6L_16KW^-NXCAD(MPK4(SXGP)EYV)L)S4MIN;C,. M4\MH+:.UC):/)MW)(=MNX2%[VGHR(.K+"W"IQ0_^R",K+3,N6=9$\3A6.5G/ M?VN]V[CMG_LZ(RD>['C3MK*3Y6UENL)3%W4. O<:.X]^P\:C,Z/OZ%L8.'8\ MVK3EK-T&3FRT5[><+6V5,GNJ%C5&"?E3#='-^D2Y$-R^#>^E:K.B/D":*8TO MHYKY9B9.(T.IEL")[;E'7B <>X*=Q;.#=;-JP7F(G85=517MAS:1ME7OAO@L M][ E>D$SIEV"),ZSS#<=?%V"7/)X..(-A:GSYF-SI3 A4^\<#F1;;]3%-UK5 MD>K6B$C51T3*YA2_+'1&)..)=+ AP)]:V!B/34C^U#Q![FW'#KBCG]H&T\3S M24EH6#%?PND2\W3V!SQW"6+#/%E* ,BV.76]MP]3UWN/FKH..F3L,5P"V!H9 M1)#CR?B3%SM^B(@4\QV#[?G9ZO!9V6SUKU\O;FCZ.,U)SV:MGUV<7S]F7KIZ M2LFSE[:A%0_$+G7QOE!3X6=B6K@C\C[^;Q$E9&0CP()4V"_VE.T@^ B,*\2! MN0_]>P:5\>4=VD11Z$CI$C #B%:L8!GPEB&BQ" V@Q,B.@(>K6B\W:KCH]C* M&,;2%$J\<&)3#RZMQ ,N\GV0Y)2?.0$[G@0Z=,$Y,CH>\>([L/"B8,P0$@C' MX=W1'L8-!VP$NZP"F1=ZO[$6>P4F*P"A$=!!RN( %]8<-JX(G470_? MS[\[:0QAYSJCP.*"Q[\+NH6V;/16,5Z $4%8.AT [Q"$I[@#2D3%6 MX$U3'SN#AQG^$3 YF[ZX-C*0AT"H^&G@/MO@[PV-V:]3W;TOOGH^L$,82/$E M(_"V;=J=2_ %'#3I70HL >=KL\BXQ&6PQ7%Z&WNN!])G"05BF.Q<"]]^(PBL67+V?9X_F[_*EQZ,-1C0\C.!Y[ LM# ML8X):(?$D?K[,O@1M#!E)&+I@%F83$>A#VD0AZ\9*3M")1J?1OT3&/]\K"$.[BI?0>?::81C8L11X4\"I#;K$5RM%W1,8'CE2U+7'-C7G M&PIM=B_,5T-D#+@_O-'0 RV/S RV?^(QB@]HIT"R-T,[A'>;I!&B-IR#) M8TEA*4@AO9 5EY>P6<81<;[,_'6)U)=.$F+''4NS$A8E?7@.QP]X'Z)FBOV2 MP*/>N/18*-T>Q=M 4'2 [Q$:Z=I,::6G0 [!W(: M*Q *FD'6$'MWC@Q$0D;" X. H"'%EMTUF$CYZCA+]-"&;DC@&KE*,82?\)YJF>V=JR'_( M #CD^\@&[G-D2K%F\<6^#>E40=65&QY;CZ8]A^5A**O6'/RL].[)9/@6)HA M]T4F":HN//?9RH?-74TB-E LM#KY8@MYY'L$[H),4 KQ;?Z*=NT40;-NP8$T M#L//GP:H-@>WH+7O&>\0K_\4I7=B,)G /BK@++@]N(0#5LLVZ,T(=+4]&8F+ M?Y"&I-.66%*K4#L%/R7R_L.?ZA,>J)H.;8U DT/$D5$/-CZ?C. *HRFNPML: MNN]MN]\7X[M?VTTQ_O*N #1(J(+ZI4#>O!P,C+[_3MX1D+HA6BVKV>E8W=-> M;E>T^A_P;_:AWJTK2)5BM6]P6(W+>4W;IOQZ"$^*Q.G_R8E"'3J(,7+V[V<= ]YSO8.-:1\[]4>OTI'WZ#@-"R##D^AHK M40;#W':@@D0-%WEW<*ZJ8SY-0@18=42G>41Z%"AN3]GZ(3S"";B;<,;JNZHW M8Q8F=Y"81!+:Y%]3L!)5)*XA+G.8Q#Y]UK;TSS,S8\!F!@F#:6?$F@61]/ ! MV43@B=_I$.S%+/" \8Z8A>27(9@KL: MT1;@1_J-M;.?>^X([$GOD<%!$3E()\3Q?!1N/_@^@V!8JF/!X8$S>QU5NTA% M@DD5N,2H*N"R4!V>/93T M6DH&@YC/=$#0;Q]%(OJ^!GO<$=ACKP9[K,9:GA/LD6/^99F SN80D#L_5HK6 M8NOXU.IT^@5K$?_6UF)F'8 E1$$,// Y[(*_*)XYI#9![D<+S %46J7/H>*+ M99;"7I[>)@)[N]QJ54?2"QJO;31>F\WCUHEIO-).XN_,,X:M FU[/7B^GZUX M=L-QH7.['"L&4++)H@X4H"UXO1V5 $4#[3;,Y@AIN_9]PL50PN9&'.HZD\_#?[UA-_7 \L MS%)93U*R'52R[4[_>+6.I6*919HQGE&-)>&?;KMO=;HGQ0,=_LX.] NEOA;( MK6UZ_\S"^'IE^;#MR.M2"L&<+$1)GV\8G5/>U^P']W MFEWKM*G^C50[Z?._>\?6V^J^?:&X>X<><4/[&\7['^;$0GYHQ/QFS9#YCJ?Q: M)07*2\82\:IN\/ES46\_4"(?M$'$X:@) M&&=P$989A \"0U>^/'*].]#=43BU_62JCT9$ZE;Y7AI)<@\J3$\!T@E-K3!Y M9!8\"@<6$<:]OD";I#&.%\PC8GIY>?HS?V$^DP7IN 8M=J34$?4JT"U4D;J< M^2FM G.=3HKOFY7EJ(3R[=1\N%66U:9R'3OX$:63Q)D*&@068PE6H/["FBI0 M11'\R%??YW]-)B%6+J(F]^))FDA>MU;7.GB644.I*'JO8AHO4[GS_AUN*>A! M<('92 [@;.N1EA;[C!#8H=$MOQO9A:,9GN_R:N4P4HVZX>;.' M]:G5.^E9)YV3AOA-.G8:9^%MV*+\892G)_)@1 R4:E((=]IY@8*W-&"L[:32 MRI:9RI[UC9Q[V[5U"@2\W&[K'=-7WQ#CH;'Q5(J&ZF)9AVZ<45ZO-'R06!VG M=L+C"CIDF5E+ :FJPZ/:5R,.F]^8_3M7+[/:KA-SQ&?)UE@E>V*)NPATMG)[ M9J5F'&9A:;)J0!'Q5 :#);Q@UBB;O0L[)J39"ONKH^>PA:AU81=H1_/M-$>6 M$2Y0+F3=WA&8!O!',51.]96QGN8QO[MB$/,LN]1/BFS/CE"LBEXP9;)I!4JG MO *%!J'E*?QK C9"RO&4TW/E@-V$O\G!@XV-1%AO2V/'OV,!Z<:%*<=O/K:Z M*ULB2+CHL,VJY'1^SI"G69'#?B8M9;P90'$X)!;*T_P>9E*]? LQ!^E(+EA% MDQ!GU(6W;#/J5<49+<$91V*RVW,KLZS7C"F!WW*[%@6 LE]3P3)JC:P(*R]S M]0*R2-\B@P2Q? <>BTQR=QDU '>2Y8$:C" E64)7W8J*B6=RU)O)JN'7VV(, M1K,A1B[L"T9"F;5Q>>8+%@8%8_DP&P/#F0B"4L8E1-,Q:VV Y2P"QW/H<-%$ M=J:UFTVUM?G.ETEI&2.!B*H !UCZA+Q)KE.L!@7Q5,E"N5'W550/E7=3D)H0 M1DL$>:2%IHCJOM("-X(8&Y.;-\0&QLOMW=E\P]E>&IYEF]7Q>;I6AYU6 6Q^/PXPVBXV##3$ MM0>TQO&J9(N>I]B<,5,UC-:JH5'X&MA &FZ*K0AB0(6?P42(QE$SCP7 M9AN'^(XC9HE"H!'H;6+03UPOPKE[2K1CZ[1*LP\*B7FC#$R\_3H89>\\8? MH%S!_O&4*_='XV^-S/+!];N1_8#9 WWLX2^LW"0W:QH\S V"(1B@(>.XDVR^U'#S8] M()N0FW$BBMNL8)"31+83.)\!0B0H6:%# UT$B:.,DS@%VCI4M7S'+=TV_->= MC#U[';'R<% L'J /843U'AE'DUH QB79S;D:__J+A+-U1"-\K^1=ZK,/QOP. MW/>7*V _'!2,Z2G8#B6AV86PDA'6";":H )Y?<#GRW5RK;I6WV%=Y?&(*H]^ M7>51C;4\=Y5'I[3*H_LR51X;VE^9\9@8O6\:Z''OSJ KM&506WX#[T*<+IMJ M^0*T%I^SULF+ %%["D1^"7I9VKBDF ,=GG#*A2@'JL%3,T=)*]!,D]GJ'O?J M2\/WLZM_';6;K;UC?+UP\#W YKJ7/MK:X"\<81S/ 5LAHB)2W*C(GDRSN*@# M%@A%,51HG6TA-6(<-A]SM;X]'BM; YUV[+S$\]F7*=@X1RTR]B8)93(2^RX, MO#@1;R^^'+6N;+!<5KR4^LF9*)UK&5749&"'DRI1FNW_^.)@+E M+^P)=:G$XO?Q[5\H'^:0P4I/O?/#6S0H*66"7YI;M7Q/*'YIOK01U4\G6>(- M/KQ3G;4;QC"[2V*89SCXEGINP- ;@(.H$O;9*:$/"0QE7BE[_ZO]TQNGXXV# MF"=O/O;ZJ[KK\ 4SY9;/1NJ06< MNO.U#XQ-_YC==94F!9?WZNO@YATV\8 OF'52:*V9.?QTL&@AUX>+TI-XN#3F MR;RX [=V=#=Q=(\7.[KK@Q:='K^IO>/#\8ZWCX^Y)L+412+'K*W;C5UCG&V8 MKODZ^#;X_1S!I:KEARKKNEK$NA:?+J[/_KB^OKC\1E!<0+PO_]_UQ;6X_"P^ M7WP;?#N[&'Q!@*Y/%S?ZFJOSZS^^W- EE]_/KP;XQ?64>O\9QG[Z:0179@WV4(,.0J(1Q:2DVM9* ,P.*:QAY51N1QA[,L*8777#&F M$YV@6=H:H]@,ETHF=9A&B_+>.1)4E@&'(X3;(J@2IZ\]_.B/T?C@W212F/-3U^=GB M $>%>8=:9/X.IAHZ\5-@ G2R,?"#9[T"Z\,#?QZK!M,(:9!E_*C XW8J4NI! MH.O .L.JEB,_#"D!DC.&+KB@AE=I!ZJY]5H5,[9;YQE.5$[^C/0#KHQHG7:Z MG%Y5W1@F3))Y<8Z+I+O+OD?>/7K)QMWS,AT@ CH.^6-.>X8K:-':PQ1AY,9> MHJI7C5?+(V'O25[NHO A8;C@88JMZ_,X:KRN""L8+?I-C-E=>8>8=3YL-WQX M^R<#4\*_N5Q)D?UM+G?8"H\[\^#%4G,_!>]"O(-Z=GZY^6RUQBS89[J^N!Y: M16D5/LKS-"MW2:FB5-["^S-D'(:-0&J)(#JDD85QK((C!5^#>S"&'ZF:3H+, M*EZ#3G]6M:N(Y#E84N^A@"]!_^,\.58.$O,:^T6Q+D9V3@1( \**H)N+-2MQ M ^6 BT0(+BHF=+"I4>7#J4H%U5>L_IFYF8A'*DY!FM-S53?:0C%IB'^BN07$ M$%CYB>1^ %46:Q[/B6LI%M??J)+5V8\=.YC[")*'^C)KKN,( Q01X-28I 68=27\" MW@CR]W"Z1#41T8%0M)\Q HJ*:9CR-B-_:]H@7!^:$B M2/A%P?P@VP)K!$'MPU+#,8/DLMD&VC_?/8K-9\9LX$4BL6!V N)XR M6%7\7'=*E")[6@:NIS*>,I,QKW3\P/69O"^:1Q"9)59H%B8EY!"8."&3#@D2 MYN%M-"]DA O0A3AYY=1.G)5^'BG9R(8J"1!AO.ZH0_>;'2$!MC0' <"V.NZ^ MF-NU("?Y]C:=> AQC<$XWX,W8QQ?5-'D_,=IC*6P\+; 3/_GXLO5^ MPN_3MX?S.#\=:Y32KE$%RPO[.AC,L0J"NJ+;H'TV7C;VALK"9)S9W'8L>(Q"YF[",B-/ M)IA &H.%@7ZO*ES0AQ*M8?+U'[!U+A+.!>UPC_C2B71&J"_OIDR1622\4KM" M/93[Y[,(QY]@H\380\!FS2SW%6T6,AEAGY4IF0LI+E*-'%*/^*#B:+,+*8)] M(9HU"2H(R8M7]2AR>NL^!*S3@+1N&1]IN97CJC M^B%3(6:X89AF4/FFM4[6*(Z!PM!%&CF4[E:QA_D(WEK1X@J']RYF'3Y5*Z%Z M29&IBFXH[.A"+S0L>*%8*P9\Y[%#NM@7M72+ OEE#^8F:7]-XR0(]#Y42,H( M^RCG+U_SO2MQ\L?#9EOA+[!T9[\O 8A'4BYHA.TNY5#8ATJM8$?=U M^5E?^W*7O]#.EQ/*S@Y2>BF#WBJ(YZJ*(7H"PR7I3JG5H>'#$YH;BK$C__/&8>"7\%+ MQR96(CLR,HN;5@NN"H?-"2X'E\SXEWI]M52.#V WIAS'8LP" S_%5GTOR#0O M/!2[*K O'1-/TE7<# N25-$!UV)/*_/-Q5&>J6T-&CJ6=X7!G\_\8!W24\^G M&R"=5AC^3TVC;^;!/'>2?UNK4VG_49),XO>__OKP\-"(I=.X"^]_'<"1B/;6 MK]*]LZ-?0378O[8ZI_V35O=7> /USW877Z?3_!7+ X^P9Z<%_VF,DO&;CX,@ M0$XNZ@LL&_E;5J\SE1B@I:1-UC:L9H%US**":NB#0F*)^I,*KZC32SKAR*(> MT7>D?!E6(4L^EJ8*#S M_4?@4Z&ZS&R3 M,K.3;929 6'J.K/#JC-;B)7U0C,.+\'A1:N[$G;O.J+HL89.\M8%3(;;.,<2 MH1E 2R)*7SCQ0L_ENMIQ5FZD(27)>L1Z(!RHA+Z$JHQ1^?I[CQSQ)?<)E>N? M4&O'F.%&N*F6>CU"N!V-8R:;T@5G/L@12YA7^,X<$X03QDGS7HHP\*<-<0G& M(V+-'*$]C74HVV\;.-S/:X6=[Y8WV M>$O$&)4#03%[YE41UR2<(.H+027'LH+[#[&=>8ZWB"KC_"-XIR\=2:C^:YGEEA3!<9CFR MPLI@%Q$SG:81LK6X=P $_]25DI2C"PW\0*X%4*64-@6 UZ\J\8*9*@(P/F!; MXP^P?G 76P8@*BIFR?7=+%^$9@%7V ]9NC16HWDB/'"PW(=2LYD;184]!$;'I*K#UP<3Y?3K#9 FN6FW*Z4FF8AZZ4\8K&VRC$9(S0 M'27$1QGN7:&TSZ&X!]P.2][Q+731.14FJK=FT#J%M@H?.U&8,8H,[CTP7 U@ M^UBXT\#&[UCLJ2V)@)/A^&)=I()UTQS GJLTX$F#7'OK-R^P 0]8C+Q858:@ MC15) ],5MD[&4O*: SL+[)!KP-ZZR5I4-N)*1+U%KU757IB5)?K\-T[O+'?/ M?CIW@MQ*C2=;-HMI:?+N9;0;@K 1?Z"[T1H,]O(.%*>"H]@L&)\.4S>=_HS M:O"HU7E!/4A^RHY,\/4R( 7JX$^6H6%DH2X2>ISAPT#IJS"4$:A9"M6/I-VU M,\KKB3-[/"&,2W$-+__)DW>@OL_ Y(=;!YY-X9[<-@,3*4K(\B5;(2^1U?:+ M,7'7S3*F^?IX)>C.JB8Y#&)9!;5%?5=NA*)N<[AJ:-^'D1KO$S,LS_R#8[3= M40!5[5Y&BKL(](M@OHS5Y(-UX)MK%MX%"V\*Z,)S7KX.;JR%F"YOX38_O""R M"0_+"_YCP[; /COON#>6$,W$Q8 X"\Q\UN\$Q4,7>A'P_]N_?!JX[]:".7-" M5QG=&R"9K0T\0R<5OG#!.7V@H!7$OJ2VONXV3HG07A+#0OY5' ;?0ZP6T6O#3^E.2+D/M-; MJD@[+QR<^!CCC%X\DN;(EG9K_R(V;&/U6(.-R7:XXDN M.I.E"JS5)1S+P6/(U=C9\XALF$77XP*4@,)?8SVQ7 5,"/&B_2'O8D21QW3- M[!59FS>W*RN4011?S**XWG!JD7$>Q=Q;H(UGR9VSZ#-X0WF$$H'MZ21)8*BB M"(:1V2-)C?[P$1^"IE!G#002@]&4W%&I/F/137!),@!X(5YQ2>MKN6714LIMT6I)139H@-S,W5HG M5J_?*]P-_YZ[&VC3$9>!8/B'R@,VK'N8>7 '9X2>%AZ,?Z]X\((! ^&\;6;%DL"D+)T(:PQW;/,8X<^GHPXZEL7TH M(%D[U+O5EMFLZJZETLAK!#U()"-5W9 MFAHB:Y=$,)F"7XHO%'"9!_FH1YF/JHM@\["6,9AJB5HOZ[D3]$@VCJ3BVE*Q3 VP0IA05R[R^WT LZ>SG5!ZJ 3H?LF)( MZB1=U+>L7-R,3X0WYAF!H,?5=RK-H7KZL>,^5@EYOM,""/E6K]EH"@-SG5+< M:0(BRM$D#-V&2&8PBAK80:-NF(_8]>+,^]= 3 @52 V0<[B5V#X823U\@DIC M)S+0,!IKK*=+,H0# MV( [9D8O9R5@Y:?W;$-;?T8!8%\Z2^*BM:4Q3R0#VMYZ05;.DG79$PH3RCM6 ML)C @CD\TZ8-9NOVSW3>O'AF:Z9,O[I=Q\L;\Q=4E^=C+P^@#-Q:JP[\NB36 M378L)UY!_*41NUE(;3Z8P$)B1%5+X1'^KTIA=H0>[NGI MJJZL#\7T#(<$'X3C+:G0AXK"(O7&1O_9(YOK7U0];(B/OS<*(QO*FUND+Y*R M_"=7DOF9_LK3YQ,PP\>V@R OE#C,0BC9F.8X"V%P*IP.[^Q$+DYC+J"]%8PR M]H?RPQF171"[Z&)HB >I(^TKC&B$+*Q&#UI2L$:9V* IESU+74DU;[H>ER1? M=^*B7.MWHG*!'$D?A]"3BL"1QHI65(RGX%P>,;XV"^4NG&/+Y9#9EQKSW*Q4 M%H4Z ]J(,OV9#PF6-,V9WN&Q8X<)"VZOQ@YO0:5563<>ANETC:#T&"*XLT&3 M((_0[K^L-82ST:F4P5/ZZ<&>JB)$PEWDS'TFC:5Z1TC=1IZO0:QIK#QH$M<+,69E.RB,9*9,2;QQJG8>?(7G<@,X#[=. M&'WU;V R74Y @< -OS"P&D6U_W;YA9"O31$#'W-$,D:%S>6OH:K T;K2D)'\ MZO 35:ML@TZ@5T3],I32O;71QU3J6?VX8.$M)EH.BJDW@)0[S@_ #X?/GD- M"-9^,#UFO,L2^A(9OE\./C?HO[E<1\7RN&B*D-"IDTGKM&5;8C'8.:.;TW4< M4.PV?Z$"3_R1[1@F(SVES=]F-S,+Z1M( T MH!]I]&YK#\#5^1T*5I)M3'>@(*=N#=(5_HBM.IKZ>%,'9Z_$9, _SF2NZXDV MJ"?J-.MZHFJLY7F'WG7H_[U(W.Q,)U!_4P"XVV@".:E2YYMQCNJ71G4<28*F M,%'+38 :U44,BA,CWZ"LP!JAV6%BDHXGL9Y%,D05;8S&)9-H'+K*-@=?0(7F MMP?:AW8W>[X3%4LNU.,1Z8,N3N6$WCJRF_0\IS0#@6 M8/W! ]FFC&W\+=6YVP[CN5TAZGJ4Y>;)0%/=.K!M6$Z0@6?=PW=C66_:#C<- MS[5;68R(K949U@T)"Q*_1KZRX"KM&@J,.J!KAMD=PPS!4?$]KKXN)*%MF@21#9JV ([8,KG8&>[A=<2N0#A=,F5%U>*#>?%U33=MWJB\'1"U5UB0%60@Y MBO$F#:..@(Y-HXZ#S6CK4>",\=DZ7"-.D;1N?KV.,QL"F-\BDDD4ZM)1YU/O/5I$J^S6BK2TSR*R[:;R9QON MVE)FS;!7%/;CIBAG66?8D.ISL,,UPW<;EAOJ)H\+1VGG83P6PX^'3GA MT9T_!;)GP&@8D_SR.SQHC"'+GRHS@FW/X8ZO>GX]G&20V+>A3]4UB%)D1[=8Q.>%/_%Q%-&EMG801"_)D4.I/4^==+,; M ]SD\$\QG!Z;Q4I9(1+]/H>$"HS2'H:Z4LGT;"N-30-1]\,'?ZHBM%2I&*8Q MR3B_[2+8/9K4H_/Z)ED-56%2EGBKI5IJU>81HNM$PNG.&*49S&9TGB>SG4JP%XAH95RTI9!694R7[,58 M"\.-ERA:,:=.<^UNS?/, GU/_]X]"("\4Z\^S!1*D4*P Q:(2(V.YJC:,7;0ZDK:)4ZR#96 MJW2T)(OV0IG'@OG*.TI.'2F2#^G_?7BN#<#33]-9)YPY@6DV%65D+3-VW<)[ M;O$P>\E<_3\7,=8H]-W%>+0\?L4TQB@A.PJQ\?8.FXIX9DE)$;8Z<_()G33% MG@VH9$WS=>[9@1H7A0T=5+9]+2=)#M;,K<,#BL8#C0=J%J"*P5]&R2B<2G@;CUU$W2ZZ-641I M?+ONKQ^=7**,6+H*18=ED=FCD.E#5I"7_!AF8$SY2> M,11B#E$G,V*P:([U,SZ+*DX+%70XDI0Q\.2/'#6].,TV>S35PN&7&H5PAZ;3 MSIWD,BCB/64Z/ @*^*_Q%.1IS/Z> 9Z['G)P5F)7@AO,8$'K(08#[Y'N0]>% M1^^";I%V5'16+&X0$V?GI.KT5U1?J1Q$_2OD_!P&%BX\@W=P[4PB*%BJ1C+R ML5TL#U]$HU(P8GB?K+0R< T\"?"#8517@#&>T". M4+%/*N$AR'A\*WJQDST=3Y)P/#]<-N^&-BK?Z4YG='&:Z(:[5 ')".H5C%_& $WXRCZR/ M"]#[=*RQ^;T47/$Z;\(P9F2@9Y+56]H"ZSP(7CWB16>^- (C<]6P]HWGGW"! MC>A2-U>PA?HG=QVIZS:X7>YJ%@/9ZJQI]?BP476@^I@TAO:86[$):D-E^/&[ M@6*2X5D6FKS(@\_"3BK+9HD,X._1!5*OL&UAXR8%QF_!FI!Q&$U&6! B-? 2 M(J4&<3J>Z,XF;KVA*O@DA%6CA@%&1@M\&H,,$FQ*(3K#_81@41ZW!3A542S> M3OZ'GWQH-IJ]=Y9081;S0S+>=.S&_&*;F"4U&\QV[6F5]C *@?313-5)X4"@ MKX%[/Z12X?8/F0UEQ*XW!<]JEK@K'/>4HC]FE!-^3![/@I\G%!PD MC4KV>X@SE!(&%[[YV\#2W*EO9^E8%WY)O^+;510$@ MH/5[..2ZV9^6T)S:JCGU63A5IV1-UN1=*IPN/*L4<538.C#SG]G)PVV;Z+ Z M.&\@)Y( M&TL,L /<"#.8D](*IADY*G0F4# NY$%_ZH2@@%:DT>VE,7/@T>6N]:YN MOJN1G( CA($(2PLSN(QDE5!#?Q$D+]LC!7F$O\50<+UE._8>BL&"O.C #67, M P"\^ <<'&,,!RI/'[0K)9S)W24LX'J;GE&RL-@D +GQ&-M )5-4^D3W5S/\ M11H;L"]'6)&*QI.X'N,8F1MO\J2:[GKO-MP[U1&0=[.IW!8.L:(438H] #$U M&F.VFVV;B("*P.C"$5]@TOBP99A_VDN3=*!2P)/4P(>CH<]L+7)&UQ7M_G%N M"[YM]4_)M67( PIM@'L7R!2,00Y=S,4],8U&Z3K,"9T8=N4HG)MM4AXP?5>H M7YG,N=@+ WV$-])K_:+")S/Q&:H2(A2"/%(3"Y)$.K2T8"TB"0SPE0J5K=1 M*2=!2^GJJODU9O@MQ1C24.*BY^."^0,("]>)O E'$6F.G/PAV@JF ?[9GPE# M5#\7OJA.9G!Y_?BJ%P9.9C[!'4(+]UX-9.+\[]QTE:*$AHENAP40N_[4&UQ,P^J_952^5LHO7BY?J;+K#=AC /: M%"P(-F>29ZQ?M9"%1R\?*RG,*6!<+ZJGY%")&(-?T&V'"*FDH4X9-@.;$BTQ M\B9<&8]LH,><7_)8=ZS33SR?6E@8NLY6C[F5-! ."]\P5 G'9TI1"S65R*R[?PBC6 ;&X#GD6SR)];Q0#W1C MG'C#8< 3>D"!/?" /5*@5'GH8"^!A55TBGAI3!A37+R8JTWX,9!/#?54TF:6 M+MJDF?5 4#TETPW5(9'8\0\:781@.0TQ<$#!LY7-AC?/#&0 \4]JF\Y43(2Z ME!1B#RSE[=FGLW<6OJNM!\LB!3J@%#-X:(5(:I3![+48$*:A-Y3D1I+; MRO M.(*2I(;N(KW'Y;@@TQ-?,ZP!3@(CN!(:KP%EO.6W3IP(NY!X9EH MV(#K2@>QM+&S#19JY1AM=A"D%*YRU*0I#$VI&W%>D9!P8I2;Y$$R=*SH]6C; M^UT-4>>[M+J(.:W5S;8:4W=PU*3V#(@6M'/J-"9GP326,@ MF\VIY&YO^^G=QQ\O"PR"SLO%8G&G\Z'D#Z@''C@@JDY]SPY4A:XO?WKY7.!\ MZQ"NJ% HG2?WF<4\*G'/BL0HX8\-3$=#S*(4D)#FC-9;74>ORV>Q>#A4H,3 M[;!09$Q+3$9@2N!JL2*,^M"LK/*+D)W8&/3&MW!T<#D )B*!K_4\Z M%WL7ANW8KIK/J4 6*9MF3@A%OW48@O& 69H)!A_5T?X9SSHX= ;.OU./]:4Q M8%95CM_CI-R%TX.!.^YI! M6:^&D(R[+7G(O9D-(%**B?XNT_+[\.SMX9/0U9D('K4 KH/;99 M<3&SD+=_0]&XX*X*O-/,\RYUH]LUWO>=^-OEY746E,#N5QK"QI!V2/9>^XC" MJE0.0M'B?(3=8R;/B;@\C;P[-UX-G]EJ=GE=&1<0U5CV&%QE MK<%I/NT[H;&C6UR5P.2&=L+DZS^^''%S%3'9$_U33=XRB M=^,+TR:P9ZS-&BQ#RBKQ=O%P6M\/F"F M3_^*\+T0RDV]5H8'](# 'YZ:C6;KR7_Z8)F;-56^C0KG"'RSJ%K2,5L%@I@*8S(&(CD,Z)'EA> [G]1UW&:>: M2.O(IQ@5R,#3?8*#I&0"U>!B$Z]K3[.9% LFXZG1$2"#/$F5;$#,#1[Y"&'/ M/\)GFZ]NS KD 3*>CP*&J!K>A(L\J?=0,Q#%SHHMX;'":P$+& QXB9T;&(I7 M=6-II+&TE/6M1A*6+3;3%#0;D<(C#&$?S!MR>Q?*__\<'U8GCN]+T7$'O2CS[, MUP8 9U!UK8I D03QUWG@I='DX$L2P?^Y^LGJZP9\]>O\Y^UNH]GMEW[5;+1* M/U]TJU:KT6EOYU;=;N.DN:55]1K==GOIK7XE@C'18%]P(__WF\Z;Q=@=TL;_ M_T'M*9>2H!L&OK,K4&OIK[!/;^8;58#ROCWY*5JZZ,,,*\YN]=AS75]N/=BX M2N,3*ZG9G!ES)VY-I#DBF5&O:U0D-;F6DRLK(Z%QU=H2O,FLP]W2+^*U'"1M MOV=0-3=&,&N &T+$ -OM) 4SUIPL)8.'& &[\A ^+GW MHC06;P>#?[Q3]2BHPS)P(QF ZRJEJNI6P3\.16>IOBN=ZAO,I_IR="B5R@-7 MGY3EV_C=3-J[5H:U,EQ?&?X=2V9,PS@6OX]O_U*K0T80T?'.6B.NTHA_@7\? M.?;$=B@'HBH<4"?^Y6S@;J 4/WT;+--VJNB BC2C1-YBY!/[,6I%N*$BY))O MLX@>R9C5T+_]].G3NTQ#2C OL,*$AWI,$X2DH[W;KX2RN)%1*E*>U M4/N*FHZNY[=CQ@I]=W2Z$ZRN*[ MJ@K8\T(2K%@U9H'3&T\*;YS5E>BO'?B4(9YT982E"AVXZC$ =>U-*.(""Y9Q M$@893 Y50OPD$"Q$N#Q1Z#K6;.&"JLGD2H0%50PK:;G.'LRH/F]\)^+( 87A M1#^/4.<2@)_=]#,\_L?(&&%_7UH8358_^$ KUTGDI&5UQ MDS6KX=2RBQM+##-BJ$Y=[#2&^]W8XPFX'I_A34"*U*@,^N8O(58D!I:XD3_M M6#"^#*Z>*;YHV=A=28R2(7."^YZ$^C%Z&7<3*:$1\D#C) MN_^IKM'[=\J-!1ED$N))<%< 5S52T9(N^X>[42U6)%0!NT(,*)N%R"^0$R+# M83-:$ND]N#03L9P0CT]B33O<$6>I"1G<>U$8<%F4JDF4] +WTN(>\2/J0&7* MJ/?$]1".,)>G4X>Y4?1&/0N6.0+5-0>?\HP(VQG)6.'Q S7T.!C+G).HFAFS MQD09@,8ROQDC&(>N%\-5M3M'(X8]MJ?FRS7$.;;PJB)4X""3;D/)\P=,/P@<&P.>,;(SH MD#NB'^T#GW@T5"%..)R#U5\"MS,4#WQ]7J?FT^[ RR6I(N^='][2(9+75\=< M+'@721DPE>TP8?5E'JFIWP!W"6>S8 C_" MR95<684X&LU'7?#P* M)\7;DSASWS[L*PV.H"XE[+6>P O+GQ*$"'\?8MUYUJ? 62T:W^G^.[41_Z0> M*[ EEZ"[V"78I*WW]$WM2!R4(S(7AB--GL#'*C:<,V$JJSC+PXS(#M;PA2^2N9]>*<)LY]Q=X>->ZX9>6=.M@_(*K[QN5* MZ0HQ4-!B6G/AU0%'^R9S%R^VP3%CX(0XX8F!/L\\>NN]RZ=FFQ.,<%@18W;\ MT?A;XP-<"%?FTXOS2^DK^*X(+&C>2HTTPGN=IQ$8U_3/M][]NWP=>(K>IA/O MWG:PRQ5L #C!$.N&2Y.X1#V-)UC/KZ8DWLL$ 3ZP50$.X@;0; H.&X)1J2U# M*TWWM**%+*B8_394$3VC.P!M$AYKD4T?LGVYG77M'>.@M3/,VH_X%94ECVD_ MC$&SO0GVM,T -TBEC.PY^ARV2WHAP:BK*4VFY:IQ/NJLZ!DGB]7G< 7N1!7+46N4X:IR?'&_59 M+/Z\URE_QJ8=&Q5=T^E:320SGD:KQ:*S9A&[&@J[(#U4_'8F"Z2^U(F@)J:! M*LZAV56G;T04/O"_VZO)LW&RBQ7+RY3DSQMR%+PC8TZ '?>H9H&Q%6E] Y-9?RX(7[>[)BS[_51L*B&+F MO1(0]!R?HG;6HL0*)GD=9%ZKVF=365[_1HXCY7+M75;]LQN:K7:2FJ7>]?LU M2%A57;);O:1V=S?2.,,ZC_W] 2UN8^DKMYT$_N]QQ:501:Y>H^AMLIU-L0\J M];]GMW&C5S1?C8H2*_5NK4[;ZG::'!5_RGMJR5S[?;=@F]?OJFW;-. M.J<;JILEK+P+=;..+7Z@N].U.IWN_N_.TR((%3P,^D\\#/;8<3.+!>H#X8FV M=?543L]J[K&S<^";T[6:S=;^;\[A^09//0_VV#GX;>T2J_JT.#P#U>JU>_MO MGQ[FYO1/-HTC57!K#LYUP/\6_W,7[D.ECXF;$)N1@MG<:WTF;*E684]T4JO? MLT[:FX8T'E&X477OX^ VMG=J=3N/=$[V9F,/SG/I[L1QJ?1)---L4I] !V?X MMJSV:6?_3=_#W)S3UJ;AQ0INS<%Y)=W-TMO5TF+U5:NO>DTI*O8U=5?C:SS@ MUS2X5;=D!_;5#5.,UFX GB@Q6);(4VUC^!6_]AJM8Z?Y*L]B3X5+86LI>)U M2T73ZG2?%L'81ZEX7<&-.:!7O:BJ8CIHB ]ESB * W6;NJ+]2X:^2!W C- H MY$(H%QQ4G<8\#58@( P8# $#V^!=])T5T /-GNW\8GZ,Z,5Q+.YQ_-=]Z*=C MJ<=MXYSN<#B,98(SAFP1C[PAS*#_-4.LEGPZD)]"W.)$SO"V67^U%@L YGHN]F( MGF'3<%.:QAT1^ _/2 W3"4YF=49VS,AZ=W;@_8<1-1#NC/#'@KO&_B'.9.@P M\US6?P*7X4X@4"C0VTTE[]1Q<7,Q([1Z@_4O8K41.#N]_$<$$&C?AQ$7'RS8 M6ZN4$VS1^D6X,E_<#[@A\_G^8<',@PCA5-PBTD^F2;:\R4&^Q?#03I?N?CU& ME,@;;Y*ICO(]:!?W8'Z?\QNIY^4OPB\*'S%NY1*)X%T+(A'-F(IU$SPA? M?"C1.&PG2N'<-#6D/EKQ^TR;(T4WX( ,ZNWMHP"DUKK*G5:O1;IUM:5.=D)=K8NHMJ=C:[U3-0JMDX[BU_^(K0=25RS^OA M=6203&)-@)0U_?6*N.7K$>%*)FD4Q(11-<@.ME=*C.\1N.$)T>*[/44@2_KW M)R]V"$KQE9+E6D;W8.X3+3[+5\L=_R!'B:AP)6\1)1]M-/K[;(0C_3!0]UJ) M\SOZLD$F,HI KY08E/+<2BG78]&Q*I?C^,WV::R&G8A/TI'C6QGIH_=QH%E+ M"D.V1M1#2Q]M_/X5SQ%9)_U'-E54HL:U9N&:A:W.QO@R-0O7+%RA%^]8_=-- MJU=J%JY9N$(OWK-.CA]9!UVS<*5V\M6R<,MJ'3^R][MFX4KMY.MEX8YUVJJB M,?P:.L*_8U)\35R0&@0HI]MQ?_\1@ YS9SI6L_?(JOIZ^+6"OGAS7&U.]C>E9S7ZWWICJ;4R[;W7:S7IG MJK0WQ4Z.^;>.Z\N>#36@N:W\_]'3)]@E4;7%O M6E:G]\CP?RTEM92\$BEI6=W:XJJEI):25=60[>.]=-^7(_NIE^RV&\<((C,) M8P\AV]X3>HYW+W/L&,2-,7ZHWJ:9_\2^A86GR>*?E$'@;+<=&+&-EF]FFQ/7 MCA?9XC]A_L:8Q[8<(#><'1#/%GZ;:0.L/A;C@=B,., MY4HGC B[[SVPLXSP*EB379FUB%$DA__[S7]Y3??4:9U(Y_BDV^JV;OLG/1MN M93NWW:'3<]N]_WO\YN,-P2R%0W$&#^02!?MCV4[.HSEUK@GAG#K;PYC:VJ*:O6U1JG/2 MVQJ<4W^YZ!THG-,ZF!*'B#Q2PSD5>UIJ.*<:SJF&#0UFM,:5FJ-YK0-3(?V20VU4;UM 7NUW:HWIGH;T[5:_7:],=7; M&+!3^R?/#TY3[\SJ(^:T7V]+!;>E:75?8&=>0P!U$9K3XT85UOV@=3_H-H8= MMNNNZ5I*:BE9@>94X]344E)+R8H:O\VGCM924DO)ZY*2GM5Y;'*FEI):2EZ) ME)PT:QFI9:26D17%D-W>7KHER[&G=SMKV!61=%,' M87QBA.(!XL:QF$0A?BABVX?'#:-PS/\\(O@IZ0H[ TW ;G!A.TZ4VGXL'F0D MQ7]WNHV.@ 7[<%?Z_K\[S49??V*),!*MXT;K%_JNU6^T?UGP:$L,X=ID).'_ M(BG%&-YI% L)Q'-G .3I7AA[M."-XHET$"7+GS;$#?P:V[1AR:+9./U%>($3 M23N6\(\UW\J&_XB)C+#G&O&F%M#IP<9//-ANV"NA;YJ$,S>"Y:5^@C<9P6;( M2#A9'WW92HCZ\B?P![ZT Q2(;'BYX$[((5 GB1M%R*2%C/?L0$@G7<+/6@R$ M-'M&J)\Q[-8"!!?^0D77];>*K3O\L/(SJZ @BBI@_MS:1*!W)[UTQ_<>2*GG MK"'/9V%,;/5[&+JQN Y]=TW.J(Y*TJ]P1Z\ .^3.252,$H4JP8%KZ0^60FF) M"8@0RB<*KRM]4 "1"--(BRE=[*0Q,(",8M(,H 5 M&00PVU!+_BI*X5O Z^ M%K$?Q!B>%WD@N1;\,TB'('AIA**'"F4D;9<>%3I."K1RIKPD"YX]B:3C$3@: MO@W\SO.]Q$.%%H53VT^FL%8NZ['$OT$U>,F413OTZ98R@.V1$I^UKGA79Q-1 MXPY#U&!(*M8Y$ZRU=XG*H+3&3)I(WMF12_2$77+F]QY)P9J6WU6X3'[NBK(]G+3R9VP.O%?) M-9TNAVXK/Y5;[67'\@J#'MTW\[0N?CMCS:]3A%LQ#LVN.GT#1\/#HPJ%JX\, M1,;[5S;>S]&.);BDS(#?6?]5QR#J^CRWG*OV@N*_(&XN>SF_BK>?)/^[6 2S M0%I;CY'6%Q"Y]=>RX$6[VU=+>ZEYMD;XQ\)V54]\GCJ1;BU*K&"2UT'F[9:* MO89^$(Z/SCO*:Q"RJAKEJ?;]JX5)V*1V=VU:'&\: '^AEL!CJ]OJURB*-4=M MC:-.K6:[N;/.NAT"GS[GT;YVW?V[7YX&!KO:[ZJ<./'9_+L1L7R-I_):.J1D M=_>DH^3X)5K17^95?]E99.8P6>.Q@Z1KUMB&X[=W!1CF09&5);BJUB&O-SB: MA%Z6M%JG% +X)$YCJH8PTJ=N*C$!ZHAAASA9HVZYM M83J7\LFN>)!<%Q,@\8,[3$K?@@#KZI")/57T]O+D]A70C385]^23O >23S!? M+#ZC.'#Z%&MC]#Z.;5<*FL-%/^_VCGP/3,*9M#7LMB/CN(%#U("#(FFF8RT1 M U]]"Q,I6CU+Z VK2FW#>.PQ] 61!$>&P1O)P/'R@0LOP286[ABGKY%I8Z[1 M(2[1 JD_5T4J>Z=%"V_D M&F^4E=WD!Q3*C<=A3:[M,4KH'+@ULJI(J!Z';J>_#M,D]D#]Q3RQ)[:R4\U\ M(%7J)'@Z18O6I,IW\C(2];!D9">HQ>U(DIBG7'\'RP(%)"-8A B 7"#PMJF4 M+?%_+KYC(DX# +I6W.4A*_P",!S?0IOZD7N$9WL2,%4\L MQY[8CL>6"+"A09W\?>>VD-[=+/RRQ,/(@PW7OS#(D3&#_'?JT3UF7U&77(:1 M<7=UDLZM/K.GX \Z :@<;'9]!F/'H'F](6P(?!G#MLBC=$*5N+C^!;3 !ZF: MLNG,&V>O \+N ==R;L4GH6F6+X9;%=,33 M7'R%U<- -ND28YDE7OI12.@[M)*F^=--&1T@4(SD2803NO@N MLJFZSGZP(Y>^!M*0D2:5Y,%+>7@%4.[J^@^\% D$-)3CB1].I52735*@)S(V M'*EC>?I&.]>C>0Q_=6SD396FYJBV([<#$T#IYH?60 MZ;6Z2+4N4JV+5/>L2'5IV5M=BRKW;1CETTM.'U-96A>0+I>D%Q"'K92#UE6? M^U":L-WBSFW4CZ^[LWRJ!M]4\?UR.[)7ML3ZG6Z3Q.A>Z :M57 MH:W^ZS-4%Y6_U%KT $VJEG72W/JTE-= M>/*F._5UZ*[,D2%8II*JU,-89/65(-([=83J*0A+/#7<6)'R5$Z47#Y M4>C[]$BXN9WWW<:C,/4)% '[.7FJ1Y"#7TC7L[$GD+^V5%>NOG'>"8DW#8H- MO$#S&.0=:P7HQWJ<@'Y5-0NE#"0#E_^ '4'!'>B:!QH18(OO9U?_.FHW6^([ M-1NV!';<3JFQ\T< A+H<( H'-RKA\NZ]V%-]C^GMGQ([,NF)&#/V)78YPJJ_ MP9+'M_#^#&"![\A!1_Z'NQ\X-D\-N?S)^ YW?>+F_<-/M"=QNUF4V&, ME"\@3N%+?,!G>1NE=C0EJN"-O3@CJX!_EXE(&-R%"K!D;O_F6J@SR5'B79!3 M;$H&^MU&=@!:_!HV(1$WWF3_6'E9)[>A8%NKCZ%RH""E6_,[&4J5" NG.C(G M,J.7%-O#@1KA+<(OV.J*K-F;E1AWWV,7_0_<;^#>((G_QW^=M%O'H$FGXPF8 M2MP/CB\4,:<^>,D(+H:7,1 %C(>"0D3E!2^*^G'_-G1AG_MV=,X\\A/>QQN# M6DCXQ"D()K?'IP92T%UDC]7.\<@J/E)LQY$^@5XL0;#@L5UAK!](J%%XWPA; MCUV^$P(K$(9/PM ?KN2F9/'V#G8]?J<&8Q%V@+DV]7$N!C5^3HV?PR(E??CP MSA*_$RX+&WP#=PRF*3 0H2_L+Y3.-0V98^LE^B%Y!-P*%!U#)/&'MT"6H6? MA:@!?V'D\-2L#(:#,6\0W26,DOQ2*W]VCO=!5C.:%PD"F0A[.+2]",R3B9)G M^%6V3A/2!ZR;-"#X$-4M/Y*V#SH_3!/X3N:K589.CN:"^')QHK&T=+<^-NB! MF:"62(HJ9H*I(P>>[HUOTRCFLT2_'9T[<&=]>"G=EU/)F!EF,I9=9*SL'=?> M 5_>H=?!$&'26@W#L@8("UF1'M_/!&))I#,*R,BWQ"@%9D2E"B]'2!VW:0SL M5H2SP4V33DJO5@KIH\BGD PT>LL%7.+'H8:6H1F)0[@UDQ:A?\Q7M\'=@" M5K@.Q4_FS,UZ7&$]KK B#0/[T-!=CRNL%IGK<86/*_HKB5V^QJ*_ND#Z]19( M=TZM;N=Q74MUR7W-467S"EM6[_BTQL393I-<[_7.*UP8WGR-9_1C]WIONF?; M7:O??!PVVVMN.FXWK9/CRO1J5U^AMDY>'_J-;-VJ/WBJ MG5B=TQ=%<]PO7;HKXW2/$!PV2,:_1CV[M2CL(<#K=&M?9WW?<#NNSL(*_8VRN?L@;344Q*90$/,1U\/HV>]V-NS9WY@0 M!]VSOXX[]"K9JENSU8[9ZC&_WV:#?7T%9L9$NDK=JG[VT_ ME0+I;+3A$E5\NM36\ *QG-@TN/XK-?%%BS &]DYL5G<5FAW^)UOJ"D<!M@9KQN#=O,4Z% MAF3P@?/OB(]H!W6S7QI%9KH#>QBY$<^.X]#QJ(.1.OIIW1'";'!?8DC<'@ A MST:>'(KSK.OP%?#NIS!"NQ@J@!C;/?>BY$24>A+0E^QJ(L3 M"!['A-Z04*-E,O(B]PAQ,*9&"V0#&^Q@ZX?F0$F6G#G(3L,X(A(5J)4['W[K2WB M=#Q&':# ?.P9VMB:-EY.&YMH4_?V[JU5N9SM?>B M3VH+';2/:93=@W[8]>BWHV[8%Q"'K?2VUBVL^]!FL=U.U6TTI!X2T=:IQ7B5 M[:6SGM1B;^$U5A9LD.T\R!JN[;U_M9.\K:[5:;>?G/%>J2M;"UZG&T#2_ML2#7!;:5!BR!$4XU+"LF,W,8%Q+?D00JJJ@@/.?B D[ M\B:QQ;E7K%084]XDC>4P]87OW4O,T27[K_V_O:KL31X[U7]'QF3W'SL48\6:82>8> MQL8;LEY[8CQW<^\W&35&.T(B>K%-?OVMJNZ66B P8# 25DZ2W1FD5K]45U=7 M/?64=I>([U\H\?U;C.^O&!-L9]AD62\*.U=DA_]E.ERBQ"T9?H2;8V8&9V*V.-\K\?\2A;.MP5'A\30.:H1S8^(?(V+-^^N.=N$Q MTPJTSB/, K5TC/UC0Y@RY,*TW><3C?0Q3T!%%E\^/Q]UXZ:K1%SM1KD1;=Q2IRLZL=H?2A$G;@F6$^+B4T!QZ2O\X]EC]) M>R4ONIVUO.BK*+NXYZ"(CWG^Y$Z[N)QS&>T,SE1=S]ID;3UG9SQ'>7$OM6'O=4LSY7[LDD6[69J*9>:9VL3?U II"OEW;YI)C:-]V0^ M)6:K:;IK;_.#AMMRAVJ/O,A^("Y)!9*F2'\\O/3'V@9HF#QD/Q:2>_B2J]>W M3:R,#.&!_8A61O348>:&'M=*-7T-7HP, M9H4>Z,*T2XU6.]<+ [IP7KN^CZ@I9GCV%)$IT/W0\D<$@.!]67_6KZO%996IG#2_J$?[SUG,CMG8&0 M*X34*$Z#PS-*]4:^3=)#799*KE?EX"X*^/_:?VWEIK!:M#E_2>1+('X?\>!8 M40R*%-@=34VV%7R]^C82T,SFO[X]2%;LB ^Y(XZKM5*M5=N4T#F/&^)P+\RI M-(@Y30=7[1J>L( YJI\JY7J4SKA69G=94]L5=I+2<+6V8)\ M-AN_Q(G3ZGP*45/S;3:<5"7;WK.>F(/)\+;[#!,,OS@#:X+B'09^ !.,GS)\ MWQU8E#1')71E=O4]\\;:M0OSE))6'8P,OB,2^=6NS*^60B_RQCT&!O@ \\!# M#]MW3M4.W%]_6^%C(P,SUX6HQ",1XD#2DA2@HIKL=JK)MHMJLMGHRWM5DR5[ MK)(ES=FC^CE_ALZ ,A<1]<4GO5EN1R>XO4*8 M-4&=@85$.1N%K"/JL<#BO!5$I%!MG9<%-;O\B/'XB+F6 5,5\)!TX:NJ;ST3 MX[5ZYJVLI:)?*F'L?0A6D46>DG589)%O)LPB?_S>>-%$"KEV_(WSE9SDCV9H MDSSR,'(Q!S )TJ0]?I"34"23)S=3D4Q>)),?9C)Y+O,RBXSP(B.\R A?XZG] M9(3G4K<4.=\'DO.=QVDNTKXWS-FJ5UK;:\">4;$=P,L:Z9-F**8\RLF2'QGJ+_LS--TF*)1;1:B\9XI+QO%(+,5MF-S9P96 M*?"85JO_0D"I:O,7;>AZZZ#,Z#4J)N(Q?\*;MZ=E+>6*[+$)/$.A<@)I^($U MIFBZX3BA8:=T3S,F$]OB91_PE2DST&XYQ2"\9D+[T,1 $74'/U/J9="JSSS+7M@@I%XE*VM,#% DAFUCT9ZASP*$'6*_!P3(X7!. M0QL:EJ<]&7;(U I P3R]UJ&2&!:^ M*V8,(^:$2$38D(<],*@R54 3^:/<+TOQ+2V9J84K(@N@I,FT9?[MZ'5PF*Y7 MC_8(JECDJR2QO[;^'5HF5G["2;@P)@B^P#(4;N@-E!KG>=G&?0LE0> BV"00 MJ/%JI=(D8-K( "DVV9.+^W(,$BF!80/#1]BL&#>*(O0E'!JB%@=I84:2C1,% M+3#;G9#4DO0PVZ:G0&(10,VEU!Q;CN4''F%<-0.WD!58+*$8 MHJ"L_T0E=KK_^MZYZU[C :#AR_O.PB:0^4@ 7-R M3RF%['%.;K <%-;K@FVJM\@T.RP0U0J87J5_F6*"''#>"O8L"=0]!B7KH.EPAE+!!U,34 MC"]6Q[:-!U>LJFW![=TG6#?\%A=$\V!-G9"5M0X-<%&M* )9.UA/*1R'7"@0 MD#BP.+BQ?1Y7=2MQ&:4NX+\P6 50@W3LD[@]&9:-QM,IZ-A3&G:,XN=%IVK5 MAH+%Q)>>7>\GE:82.Q^?JM?;Y7/Y5/Y0_W]0S3F&=:$0QAYM[HTGSH%5PJF" M"8'3 #8?-(!G(.S> >X8^H0_J@*/(CB^/W&4QX:)O4# HB M5L,2FX D4*H?6 :!A(2U@:;Q'11F;!!VF.6S-4"0[PW62S]I^N$8>D85!B]P M%:[@V,[?^9(&TO-I9-"('PO;$$?'E5!D19>$6$EE$:^P:W<@BO0MO!9ZR&]%G5*KY2;[7;V.G5>6?[Q5URQ*U[+ MES[6GGLL%X'WM2!7*T[C7AW7JPW[(H+27ZA0^GX,H$_H7.W2"(S/*WA^5G7P MY"#JL5U\S#9@,(&#W+:!SIA@7<%! 8?A.]#L>A3ZF;)ZOLO_W& M*=^:FO\^G?LX<61G<5DEL[\2K%JU@@@-8D7RNU]/-<4\X>Z,+H#:R9UGCWI?D(%@@Z+"+F ML6/)F46,* OC9]NV359T#J33&U:6,1S..I$.[4:Q_0G*MBJH54KGC75!O%N? MI&SGU!3;Y,-OD^-FJ]1HU[?+([OS+9) N\CS+\J?C4S5$BQ=[@S;_7G!5QQ MN2X5)^>)G8NRN"FN)]TY:>U24%K'"@KS2?^&R&N M*N5*U"IVP0@"SWH( PG_D:^8$C%6$MRA$;?FQ+!,@7K]I->4YB;&E""#8\., M>&$G'@+;$,XMD+:(2((;(8'UAHQQZ"&-S85?%?2:Y.\K6#RWPN)9KQ0LGMGH MRWNR>&;I2(A]R1_T2!"Q=A5U-W,8B(5)PSCF,EA>]$6&IH#'17@"RKL' ^G1B>^R<"8P4L5@*Z+TC# M:A?&>!(2UU\?FKFTV*-;@K^T+6C8L8S\(8%7$)XH3V6!*;%8=IK- MGV=U(;==G\!&= ($C4\\)JU=D(0D67[$\5S6^@7O\@YYE[G^"#V>*V/Y@] G M-2 R>Q*K\F$.B]?E6F_4XJ0;>5+$J4N4WD@YM7@NP#9HJWSI,W+_+4WN58L" M&F@H^TC9-V!1&'8P79 W2KDE04KZ5'*OH1K6X1+=S($B3D]#43=B]OJ<+IH@ M1A4!9AM,% 8@>X1KNZA, '?W\&PO M7!++]T/XD;>ZJ#+"W#BB)8T&@ I#M 5&E:%5RK7*+_1UY.'F)I.D!.=G)#IO MP(PTS"<^Z*A+'6THI$3Q#4F%0;3>?#CZNKG7WQID%**I,&O-;.E:UJ4[SDV MP,"T*7G/U1Y=/P31 F_@4/$:S\ #& MZ @VPL^9)TP#U:YOC2=@=?=OK^X2JVTY"]?O1&FHK'4-Z'L\W=%/\>QA7N>R M_D(/#<^/'7VTXO3(A'G$W3!&FQC6"^8"1X\=ZT0M?L,6[_#?5NT_Z'X;+'*: M(I <.!P,4^,I[WB,HPG/$V/[8MTQ)'S-,"GXD3YEP?XRG$?L.QT0U3(6@H7> MH5?JEY7F9.':I"_-&R=+TE703J,&:<+@4]%/E_3-_HPX,(/W=R_36I/36N/3 MNH'=_5]^7+,M.1G-5\*)=LP%/2XX' #AJYX>,(O^(QXAO!EUR>V@^?,5W-=Y>F M62O;/ZF@XR,U-L*@:S ,HZ6J)%8^N"Q5KFN_Y)3RI/4/(ZT'B!]&C1C!-1%F$O<0R@>.OX3SQVQ/:_(07(Q@C6!#KBO=7'! MAG]+-VVT1:B/>KD1]9%;%"LL1SSST$+HH#+T+/(Y+PHY\: ME=F3GW<-#W-UDXO1P5YJT.7:3RN;A!L"W@M /KD.:^LX%;X(2 FB"SK[T2(A MGB'09;2SB;/(\&P++;)AI+R1#<$/9MZ9[TRTML2D0<\XXKQ!@66HQ1TW8?RE M&4+)5J4-]!QS"5"FO@NGA.6/EBR68?LNL=<@!8T&1F/@4MJ[,1Q:5,#EB9?. M<[! %2?U>8*;F8/L-/$E7/G+B-Q)D%X0%8'AH8%E84M$(25B(4P,-O91NO6+I%IZ8O7AB7KV,BT!L"SJ:W:MN M V-O$56+.%AH5^;NA.TYVC]"L"5@5!7:9K2]&%&SH19Z(OL5*W5&MEB]4HUC M4K@CTXK9Q6H+!:D"5B+8BPL);K#H*\YK">U>5<>1OS]Q]W8T/FUPB//]+[CG MI */W^8J4-7#@X$7LAD#G8L HO0"$)6-OAP^("H]]',5DKZ.22[I6CU.Y+&L:S@G;+C;8A@Z"0)'Z)3@+_9+:< GZ?:(>Z&X+'EL1UJ:%!513E(>UE']>X), M69ZMJN?!@074]*KPJ9:UVQ / >I!Z)/DQQU69I'W-]%'F@1.>(F]&*-#!*84 M+NOFJ>VZQ+.(("[7\Y7:JR7M(0S(>6I;8XNS@JY:854"[4\Q(P/$@E2X*I&G M>FMO\DA!K>:7_5D%R=G1Z_PBR$E(A=@$,.7HVN02-7%1PZ&1$/-X1FXP%&$X MU< TD'RJQ! Z3A;Z_U+L5-WNE.M\00T M)FZ=1]M]P!,"ULT=6P-:2;*=?8HR5[_$U:R3+\)JV;16XCEQ0(@##",9<(Y8 M@K.9F'TY57D)3K/)!!$Z(]B;F);A/,+NMYEAGJ*?FQPHT+KQP*/L(&$\7HY! MP/@<%(U 1^2'D(<\]1SDGEOXZ2'T+8(L$'DT>YP68K9;,8O/ ?*)O03"@HGB M")K0\]+GIA@3$5Q!..#P<2OI:$M^0O'C.:::YR,#+HLL&*49>E,1<9Y$Y$L_ MW9,!@O9@*T:2)R(C\RTK84V+F*A=SXP# (' N41QH#1_?R&>N[=78NV@*AQ. MH3X,;8XD!'7"(_<$TC9G&-?GV>1+"FG\# %\L:;O;H/R18NXY$6]*W2I4.&VYP_+A6KFA@S\')6"S/GI8'+2GFX4UL9E,-H"4,)FD!6=MS>4[J M7L3FE%1[T: -@&2O[KD)V7W]PZ'VT?7$&D?&1-$7?!2&N*4+21D M/Q(B$88KU=>)$#/DUAS@08R^@6)[[]':C<]7X9&-[D@Q?I^-)[8[94P6ZD(\ MA9/8X_/^U;A.!U[J>=46K!?E$"(+&X@*L2&DV!I:O"X/\[S9\F#X\!=\NA"3 M=Q:3V5MZ7 H+<2[%H"-A@Y,(A',*+SEZ\FDB7$ :4>8I0\ M"U,@\FGCS#0$CS+&(T-B0RE4*0O"&G$9+L^&$ R41_R1!EBE>0_K\R(KTB*C#A'XV9VQ14E19G,'WC61![M M SDH(Q[4Q+710>OS6*E!%2YY(2_KT0&%#P9 H/T9FH]Q_)%%\R"3/GE6%0.! MC,T('F18'EI 5.^0>?(D>D6[%H@%@5@8!<'$_WQV]OS\7/;9H/SH/IUUO,$( M=KA_QLQ'PSN#.3?.]%J[V=+K9]!?\:_5.G:^5CF;#+R74TP\U.&_Y5$PY@5, MM ZOE'O')JX7J!"'?0@Q(I01(_B+1TEQ>]AJW*];"(R,QLXS+"T.8BME)D M%_5U)O#.+1ZAM7VX9GS'HJB]7DGK@3+7SN7G"QU>Z/"$#B]0HUM!C587HT;7 M.!JJ>G0T%%C3 FNZ[;,=CP)AXI3W!L5*[]H_?W1N[GOWG?O>_W2USLVE!G]Q M+?]\V>M?7-_V?]QU^UKGV^V/>^WWSMUOW7OMKM?_+7<>D?N1K#P^A1,=FXI 8K@'-B@9_D_R0,3^[-@ETU>9^>.0 (D5U\&%.QOC%?"T^7%1EO MR2$)B8'_.:=*9_EO J61?,.F1':L\^V7U"3DD6@J.92D5$D<,H;!L/Z\-II. M<-WX%1%.+>2F@-F*S-E'\RFG;4;-FQ,+ 9JRN)\HB(*YZ>60C.:T@92X4#\*A#Q&MJD*5E:*<:#7M9G6.RBY3N75>X""^G:<.4E28%@PF"=ITM#]!Z?JF-1 6!RHO\JRJ M80FX$CB^,1!^5$_>QG!SPFRX5(A[-*"WK M$%^TB=?J&2XK#.UPGK P&1G>V!BPD.]/"8B@8#J9AD\BK1(!+P)3QW>+Q_^* MHVY*@E );U4/B6 0'%'P*;8P*!1%W4M1?"C.JXQB]8)1%RGV4]9P54]??4D0 M*"M>HGK6O$07MS?W=[?7??(0?;^[O>A>HE,H;T2Y7;S51*'X2["<;=>GG&\, M]K@VUW7?D>381!+2_&F*)"+U#LPY3:\9IWKC^.%$.>.[4B-V,,--9 ^ J<*W M<0R-PU\N1A8;PAM@V9##[!93UY@7I9OPW^.43O%[B79U2%=9F B6F'K2*H2I M@!8Y^>Y00#'QP.!MR^TO[S5FO%X#=;TFT7HI9'N49"W2=F$N79/(R2*DKN4+ M=Q391XH)B%/FRSEC)_0!O6&*/RV:P56Z-OM;!"B53\2>,CX+W!('.P>;Y=:U M$J94J31!VXH>\/'QL@K833Y(Y/_&R@ZDL>$H'8-QFSX4C28&4[R86>*=0UIC M/(#'>++\1Q >2U]>B1'R_'LVR*$HRAI/F M\O4)%)?@4N04);RF$8A27>DO[7R>(T">XOSD][%X!GFH'<0K=Y*4 FJ9 MP;)8PJT$F,74C-@*XCIEHZ4!"_+N9IYJ]2+Z0M;4\%&!%U+[J!*+!B M^"YRJ4Q!)_[$'1ZX\R^4UNOVRH3%F1',GH.+!C>5Z^A@H&3I[JRA(:V]W$GE M[<+S@NB2-STO3)=P@$$BC+1(S8EDJ=7%G\)-$T]<(CWB1AX06EMCGB<=#$0D MZQFAB>XBV:8_]>%.5!*0,MPJ(SC%J)9)=+#'IB+NB$'L)H6E)\>PV!NL1$.4 MD!@*@H:>J 0APF;RNP4V9RO8G%K!Z):-OAP:RB9=3KFVB.X8$<0CIA\C6J3[ M^)I)%962RD8;(U.G*-0G8J]*9-UCXL3E:2WD'@\\S,07B2WD3.:99G361'J3 MVGW@;X!V\JBB+]<:@I7#$L0R9>V*Q_9*\#R')T1X!''"V=T;/SDE&T.K@HQHT_%"L([I)!,]]GAL\4'J*R&"&") PQAQ!:,[B?R M'E^HTTQT[[CJE@=703P"XUQAL"@L6 /R9 ^XM/@NOT'#D87Y:.C&M>U0!G># M9U>3B.4)0:AG!$T[(CH%LD349;P M#A@#L%B>"+>#&0,!79L?7N;OG%Z1>3Q-L M7=KM_=^[=UKOYNKV[O?.?>_V9C?CKU7V/_XX0*!G+4!PW?VU<\TC ]W+WLVO M\Z&!Y:N0M:26*TH15GV$$=<'Y77 EP3Y\=W7A&1%[V)LO8(^Z0WL@9^NHB3 M54@UXU$%/0>;7BDWNT]4U *I>>_NO &;M2/U6ZME2OUTLJ9_$)"N774N[F_O M\JYZ_M<--7]$P)1=8\&7WC]]"R%J-OQ$-XP-"=M.[O5-DK9"K17)5KV9)KC*'_ON]=],%'7;5!=6EI(3F7IX"A,G %&# M8UW)*@*"&P0$ZUM)UJ_'#%E%&/$@PHC[UKB-K&G6=W)H7@%U MA'=JO*Y*OXXR>)EK3V6?>2 P\O7@;56\@KD:J[X69]P(+P$GRE9 M%>;:]EDLFF"S&?R%OYXEOO@50Z(6;MQ4V>, M(SU7'[0ZXGMO[ 2K#AA=P)M.[5H?JA]]Y>7KC93)?9_)WG4@H+G21IP'@GW] MJ]B.THKSX' \Q2B],?'99_DO7TS+G]C&]+/E4*OTDN3U%:9?2EU;TD#\Y]@N M*5>X;1)X\#]3?EG\7(:?SN;_OGI>KC:KJ3]5RGKJWR]J2H<7&N=%4RLU52]7 M&^D_;=*KYO*FSD@BN%2 X*&D_NVH=A1;Q$2,_+FBZ7"2G>WRL>;<8]7)"S[X M9>[.,E?*F:1]ZS>9UPQ VE+29NC$VCS:\(&Y[0E;<;ER,7,W2&Y$N7+B]KK& MO.5B@)W!(8[J$@[T%<8D3C5$<\*0- J :]BY+[D:K6+J_N7CC/I&&/ETUQ&C M7V7XN1KDO8ND[F""/B [^Y#&VA\9'N<\?F!:W[7-0QMT]V5B<9\,C7=N,[]R MP"#=VZ/GAHYY*CJ,0,OA\,M&@H_E%F8G9VR9ILW>V6GY^IV:F\_+;D[59E.] M.W%O2,\Q\9B+KT6-HZ_71N@Q1[NS?C)O_F*TS*^0URFXMP);F8/FT=?O$0^- M4@- Y!(MGY-ERG>KPIF^=R/QS/KDK^$3(:=U;UA- M@;OMF+F;<$;S]?A@!2LRS05!D/YS2)+^BAH_7\&.:Q]]_@6Y'# E MO&."TK"H+NULWGB?#3P6&-YTBY;=ZT*9P1VYSH1O:K_5]6W:;P<_S4NL- 1T MUQG$.SG=)G8<9VJDO;Z7=F$FGJSAQ@^=IZZ\SMQF92 M8P=NKL.=YF5F4G/+9M)[36867%9O=4P=T+GRXVB=N$^6EMJ4^VB M1@7M(KU:^(\RYC_*KLA=>;RPB18Z%A%XY(A*ZL6'[?SOJW5S- MRV0_*H[7>7SL8/&\SCA(;G\G')^:+N5I84NQY.IPKI?.SQM2:F6_LBVVF0R> M'9Z=OEP]GNNO&S:-*J)(O:FM_6J$C_;!H: 6S$'2L&G4I/?GEM>HV"4 *E][ M;YW9W=3.:=0+_\_:0IQNYS2V;><4#J ,3=)^[9SJ3NVX;\XHWW!WV9.M%8DBTO(G]]*1OU"I$LHV#5S-AR/;'W(29@/.;2+Y M?$*JW2&O*CG4E-R1X\')SM-15Q['7Y!:E(HO;'TPKV3')Y-7F]M/CE]U#H[U M$R)[,QX?L7Q1P#1'YH%HOIH#XF-%]DGH^:'!"[CS?/;Y%&[-YA5.C0<7)HYR MW2>,> !D>="X@&Y@O!#[,I9[3]1-"B?B6:RS3B1R0V1@"^ HQ;9YH6Y4FIP6 M6Q1+Q/*9)2K[[9C"?#[( M!5Y7 2+1E813Y/=NGY(A'[-P233&DSD> K'4,Y91C=3)IIGMV^$(6>,[[^2, MAZYL[(G?U5%?R;HMLKR#2SC1K9?_-MW!WU;E1J_A(/28&[T:0F+WXVI5B>.K0I6%PN>D88=;ZUW M[)$R@)R \GYF,+YEO'3_989'(ET1Z8UEFFC7,>.MO5\HJ)PK*-(JM9J.]^$7 M]E+3A6H!%5.HEO54RP5V9(AERT75M$659E5G&SH=1;68FG&JUX^-$_Y'5"]Z MP^1_Q8N5C\F;64Y5+[L'*^QO8OF$9!1KDRT93)FJ0D4?FHJN1BJZ6JCH;:CH MN6+?A8HN5'2AH@L5O:F*KDHKNEI8T;NRHJDRYPKJ6V]I/\K]\D4963JP4:G+ M&Q6NLSFF+O%.XLEVI2G+1/<-[\%PF']Z^V*SJ=89D+>_6JE4R^FW_D+G%SK_ MW71^U@1$K^@9!0XN/1WWE!R:J&8ABQOZVM!SQZ1[_LFK =A369P1U&,,8 U MM!#R,'2]U>H)E 2H,. %+*Q_?;N[UHY[%&+4V+\"YO@6!B>_B=**HB?8X6O# M>0R-1W;R63NV3NAS%U%YX NU// WPZ;B[/T18X'_!1Y?_GP_+B+L1E!R>(#> M7.=5+%7IL1$. HX1F!FL/7]\[?K^";;UM$93?80I(;:)\6JQ^OD7K?OOT JF MT-(Z#5U@(= K+ 3*2Y .V,XHW,]Y5Z+UW"G1 MO=B-+G2%8[@0Q$HX9]CFET9@P&8!I75\%>DVL/J$4B,-AQL/8=F&K-PC(^MP M@"DXT-=PP_E&=-3*Y]7ZEA =M=9Z+2WJ4[M6KK>7UV?9'-&1)K[OA&1(E^!U MZ."Z42''TH M"<7[L#=!#S?BG*>:QX:@'O&B#E=/?B,=0[>FXKKK+_='E"1 VE&P5-55;.D9 MJ2Y2639/96ENI8XTYI$7=:0/,9U%7"X1B-Q*N/8/(D"?E'NO=9]&8S0'I-1 M/[U=JY=$HQ$H>&1@!5\X$P=&B,Y;)1%(IMO"2O.#$?.*'MC(L(=XWF)#M/?Y M R+Q-73@+6K0"(.1Z\'0S?F,HE6%[=TW=+M=;C5JZ[JBZN6:OIU*L_5V6=>W MDUU4*S=:C:VT5"W7]=IV^M0H5YK-G%2_W7T>TGLXG].5Y_?.1>^NHWWKW?8O M>MV;BVZ_Q%5*[^:B3&[AX[ONK[W^_5WGYOYDG3CPDDGPL /9<< C9<[G7123 MW"M["-Y>SGET]&UCRU:TY-OTC4N5K>&L#$7)E_"=^6?:%:B,W[3+LG;=[6ZB M.+*HV1=F0%8J>2M!=@5FWT]:'K96F=DL+T_F5H!:3",@6! *7H(8C)F6B[7* MPEH=QW5RYQ8LU5!:!\B2AX7;@A.], 0+0_!]#,&\*:-7K:N+OW?NKKM]K5/6 M[KJ]&_C3?4GK]7J'"TR,#(T,#,S,2YX5E>\Y9.B&73G?.I//&(T, M[,XM>]5L?N9D;6N]L>EBZ:*ST[.+L%GXU+[^,/MPI9_-KIH?R=5Y\^("7S3Q M_&+6Q%>:=G:%/YQ]NL!_6UR?GU^=MBXO+YNSLRO2O#AOZM MDV_W_0EOV@C:&M3\GFC]-+.-L/WY"7L\PPX)FZ\U^RG1?(TU:N/WFK4Z89T] M/3]OA6T9)UK FYJ.BTUMRUMW[::[61.GE4T$ST_8^ \;"+NN36>>2[J 0/Y/M"W M-.QRUV8MG;!/J?8GQ' =]JW)OKU_F(=F:Y#I=+Q]DWULML[ #R3$YGEO>=GPK1G2'4.':'3*Z1#2':A# MYH#,\P41)?_N'*K&=G1+JQ%02JF1/5N4Q"(D8"!Z(26&7^[ MS=D'F1&78$(T749FV)Q]R)")3=-R.3W[)?AMO:;FW/)_@)^8KUZ'#CLF\W#> M3BU<&;,"_^<:VYIM&8(IY&1M6VMBNY0X\46/,UC:9'[38$M?,YR@_UC;Y#UH M$C9)"4B..O88)! 'E@C>WW[4H9 %<[R;A@,X&,0W497[KY.Y;/^!A)KT_Z+W M!I[)]AY(B/$_WW$-&[(=!Q+-,_;Q>D8^A>>(ZC>-M@4Q^P@O0#WV^\.XEQ=$ M<:E1\Y!GR#5RP\^G_+\6:D9!?A-Q2L1(?SG9)=AAY3E$'YJ?^>?=T1T0!TT* M"'?L4YHN.9PRR8(?0SL667):3\7'=4)U/X_[TZF$Z&W>%('2O3'CP] -$U/YP<"]0\[D*$+_=!."$-^>+0.R;P;>C&0)E, MA^U?OPS['74\4?_YT)O^?B2T,Q@+@?ZP#]!Q07]%OJ@WA&/#3IE\Z?:'7X\V MC+?\A'A>[35P@3_B FJ$8D>=M,>]$5N1AMW;ATEOH):==[-)A=A\9*D%=33# M[N^5\>\P=_7N!KUNKZT,IDJ[/7P83'N#NQ'X:[NG MED2E)"\A3)]V80H8\YDO8HTBWBAD7B/DQNIOZN!!+0=-V%AD^];IKNT#RAH9 MMC> 'D^'X])^'R<0&KBU:^ 8=8V,W.U]4SO*9%*ZE!$G$!KY;-?(G!KYY#6R MM<8>/=',$6737ZB]D); MI_)03HPX=8U,/%"G44ET!&[V11F7S&>R286&3V66P"=9)T7 #'%N-0+"M\!4 M^58^XXD(1$8_2Z64@<$Y>8VLW![R6@6L8:P2V.L$NS%M<+8[=7*GP!HW5MDR MUYZ"_0=WP0.(ZH;3+^JX="GS("%"-%/Y:R01)42B@#5ZQZ7^_#>4$+Q]S*)6 M+KM6KG!_WYOR< :ZO[5@^5);$0,AA*GL.,:-PY'@5R-8RA4P1Y9!-4J<8Q9% MMSP+P/OTZ?+BXBHU_LH71]&[4$R=M@/+ 3#%,^.XD 8:* M%\OK:'J_H"UC]02%T."I.I=/7D=3%U3"9>PO9B,$)57_*BZKUQ$L5OZ60276 M7FC^C*,9M],Z&CFK="ZW .32"T%(E<B>GMA5$YCD+@4N6'"+A0 M K+F*"$#!4)J"6BL.B\%6P:=$)Q462*Q-5!#X\>*_)'_W^-_6W8;''-AV90X M4JC(,!3!]2E5LTCL)R0'%)>!(B%UAW._]:J(@1"N5(5C!ZYZ+US^ULQ^L.30 M"A%)53F"_:$W+)@9H@EJN";,&N:B3[!#U*PY\W2+J1]BF?4 MX(\.?W@C]:;W[P$GY0<%9@OV5> MAJ$0X5293G ,H>XQ08'QHV'89?)@R#T2O0<]-1=T9A#%<8CK*-J?'K6)CIT1 MMEUK?NLYU"2.T[96,VK*!PPOJ(_0EU(U0Y$OQ2<17\= MN$UZ2*@(\C7A=3^F"^+*L!;LS^'LK)-O7K2+9\]\A&'&(X>OU%U:GCLF6*?& M!BP%9H,X$<+*+<9'=*3]! M]*>.E5V)?BNF" F50H V*JQ-WL#=7\DVY[V9= M"4Y"L%,[!7E@USLN*QZ(OY(-9(W>:LVD.4P&92\[9U[.]88YWS)9Z10, )\< MJO-2JF1)Z)EU$+I*JFA<9EX M5!,+\040]3D*\M6-[X8;;5#"?7>W"T=0"PQ M&(J:.8".B6;9.M&QNYW['QR^7_!(C/-[@AE\\AGZ"^LD=,>,ZZ8E0AZN)G/ M7'\+5478C2]67%W$]47G**[QFX>FO$%Y!'OPZ,.R)]@@$Z(%.TE'=#FQ$*$/ ME7M3W(X/;>4V07"324:1Z%HZ0_I>FMP1YUQR(8"EWC977TSX];)HQ$Q<2_M^ MBX%CVUJQH@#7,:@/R W-_=D+,2UZJ]W.4.02$1>)XC+#FD>-AV,I;!0-(GKJ M;IX)^EWV0NC3;VR7ASX46G/H]TLJ"^A%X*5?^9X$K]X)9-:@V>8_L03IX)%8 MQ%0(8>$MY>3XBY*W>'I71V@S;R+',B.8G#PWR,'5D=PUASUY"X&6N@"]DT)% M,ME7D/J&>AH9!;)+G1H>F_#VS'X.DB#T@%3AK\ #=O*?F."Z9SZQ&^^2UY=2 M=$+$,MYL%K\J7T/K'WB!G1_Q<:A?GS+85;SV$ML+XMQA"M%D4=H;](OAC"Q4Z6:J&=DPGJW?2 M<""64:PP)NQPF\:.\YN+8)"^I%>5TT3H:JEJWS%=+1[B)+2,9K5:NF#N"\(E M'4C(1PA_JC!8^+[Q_W>X?CEYDW-N<5^\;^;IN7KSG^"7XCA_P51!N9: MLY_^8*=XVI;Y2&R'50E,?4QTXN?O[)2/T[%6L'@W$)[!&,":>]. H4 :R,0K MBJ.NQ;W>VY:UO&GYS MZI)5 [E^<]=NLD].ZUKG,GKPD'%JG.1V=;JT">GSP>NV/<>U5J#V/5G-B)W7 MOT*22G0J>2::C0=V>&L,\5>\3W-L. G0\DC$?8)(SL6F*]\E8**!O!)]FL , M2]+E8UC[S05O>KN)FHSPAOVD_,"V/O)L;0D_CKB^N08X&O^C>X#_2TA4PE3; M_?/8%C0[:371:UDW]7U:6"6N$O9$>=OX4 MZ+(+(]%L. *34&_%/2G?BO*,GLGI',Z^1-?_89G876)S8E@F-8OGS^RVSS=Q MEI\W_=>0!%/ZT"3%_< MXU;A?)J5;2E!%2FW\P?QK.S\'1U0#M\2Y+NS\D2=O$F@F.8(4X'N7NL4^#O! MVK\S0;O,Q&7B7(B\^Q8V;[N8+;KNIL..>VM\RCH[/?L@"'E+4E=BZF,C<8E=&BCN30%! M)<#)BNG8F![.#+K@PH.0;FA" @*S%C^](A4BEF%7B5QNX#%@AO-$!)4?#N@A+6,%Z*LOH@$7T62.K.V*2 M?WI4%#NGFE5BC*;WUKJ$".:=8II*=*L#T!EWV%L8Q!:L>ADMJ[ :9*S&0W-H M*W.7V(JW@"FAM=>27L2D$M#UP;'\Z7Q"7-=_ZE_%#/.NJ75+>!T*' ^F#!YC MLY=1;'(GFX-X5C2A"W=FAKOWI?G;WZ?DR;TUBI;3TO3/Z15N**9$AWF=;#@? MQ;8B(,."$-74Z-H@\(AE9I9!=3\8@$_:1FR'0]E6Q3RIA$4ROZG2Y#=AE5)] M9\.AN#^%))68V%18-9F9W:6EQT+VL$K@OV$GUTU+4E=TLKKUUO01:V HTJ=K MRP%P>N:_8>9ENDX\9^UG^\402S*I!.BY9Y=ZJS6F-E^( @AE@RXAHTJ,Y'WW MF,(,*+G7E#\^CB^H KG6=A=D0DQJV0/+)4['(Q"S711[2RG22@R0/O9L8H[I M=]$ R&A8!0<'2[,20'"AESK?0W\2)_EE2%_="?E19J+#W/( L2'_S+(*X6)< M1%0)Q\O>S1B0Y(:&Y&9(FKP2U:>Y[\:J&OWI5'&*M@^KJJ1E MBC\;L OQ;#M%(_<0M5$S<#%XDMOK$I3/N "6]T^I-*W*"9JB+2E,WNS'X?R> M@ME=R'"*3_X5TU2B6UUV2D%0TDVVJ8;:TN(62M YC&9,$.C5OV9CNE"O>D]F)6"4,4)>N7^^?Y MEY7J9.KH!2@) 8VV!$T_2I[:R"*M1"=WC!Q@H^Q:T(/) M-E7!-5FM'CM+Z![[AVWD/$*'S(+-GOT95C>R"??=_?IZ;.%*7IX:DS\]Z&5^ MG5^:T>O?3HGIR-?G,=$(Y1=#2J_N.7256/7VR*SHTS'S-,:MHEF:BB$4-Q<. M.&NX_40U&+@=]JH0HJNCB1*8(<\)9#@\UYV8?2?"K?O&#B'96 =F';QQV$&; MX*^IY1_=.83E\P0$Y?=.$J8A+I_RES"/( M>6T?R-E%"7:@6=@C>^4D0?KZBUOLVB._YAC.TMN(-M!7X/R27"HQ*+H&>1)N MH^TTJH3BBL;O.L<"BIA3Y8>E(K+7=\;XV0_B'V>=+)M_RWV\3.[ZS.Q$X[,2N[X@P2^"GPIN+ MAS&M:&@Y75);[HQD$44EYJ5?;>JXQ/P*NE"\$I1\\04[; 0)YM2L MEE684).Y,7L;D4PN'6]?"4#\K1EBLP0VW*:<6'/W![:%)4$Q926Z6.9E$8*H M38;%J^[]!"D>0'&_L28:)3!OQ\XEE,H/1<25 %6^-JNR6_\*#X:)Z)ZV:[Q%P$ZVI*L\.>?_@M02P,$ M% @ 4X"G6%(((HI.(P !4\! !4 !P8W)X+3(P,C0P,S,Q7V-A;"YX M;6S=?5ES&SFVYGO_"D_-ZZ",?:GHZANR)+L4(TL*2]75\\3 <#V?#P<'?_^OKQ>C59VBFP\GX]U_8K_27 M5S".DS0__?U_$?*O-Q\.7^U-XN4%C&>O=AOP,TBO MO@QG'U_-/L*KOR;-?X:?_:N3D9_E27-!R#_:/]N=?/K6#,\_SEYQRN75QZY^ MV_RF@S:)!T,L&$&D])+X+ /Q)D9NO.9.^O]S_IL0AC*E% G< )&")6(5%X3) ME!4$([E6[4-'P_%_?BO_!#^%5SB\\;3]]O=?/LYFGWY[_?K+ER^_?@W-Z-=) M<_Z:4RI>7WWZE\7'O][[_!?1?IHYYUZWO[W^Z'2X[(/X6/;Z7^\/3^-'N/!D M.)[._#B6%TR'OTW;'QY.HI^UL_Y#7*\>_$3YCEQ]C)0?$<:)8+]^G:9?_O&W M5Z_FT]%,1O !\JOR_S\_'-QZY2Z$?QJR7UY]@:)W%FIMCLDW\1Z-;B^IQ2=>3R\O+MIG MDN$,+J[^/C>3BZK2GTWJ3OI-IKN:T'=2&I:Q^]&)'Z:#\:[_-)SYT<#2 MJ"#38EH0D81BGP6CA".*$%50@H?*LG\ RBH4$"^3 C4FOQH3/L#,#\>0]GTS M1F=PNA/1\2M3#6D/\C .9P.@+*&!EX0B/")#%L33B ..*4NGJ4^N-BE^C&H5 M?LB7R8_*(JFG-+[C.,9(H$%5]JF!CS">#C_# 483%W XF4Z/8':2 M^909B0V4I%0MP596YD\#>(J)%(ODT1="JL:HPZ'/@Q'J QA MNGN)SM!X-LB>RBRH)!DU'I&):V*]!B(T3D2,5LIL*I/F/HH**V5R.9Y-3_PW M'T9P-3:I,=BU(A#N#<,Y+OZ=A4B"P9^;Y"RP5']!+$'2)[]Z0PXLX?VF4U]3 M83:7D):,D NM)8V2\(0&7F8PQ#EJ2,!OJ3<4$%!])BP'TR=GNSX9*@B@&A^. M/T&#LS ^/P0_A2M4WZXP,<<]U0EPD (YFK,FSBM+O*0N\A ;.V8^W%$??+! M*S.CHB@J1N+CS]#,AJBV]B#,KK"D#$H#CC!F5Q*G2I. B A-0>C@&08-M:W& M4,=N',[@_3Y+V709O.-==*;&CR3@N MX/CL*,88E@11$ET:_PF*9N*T\A%-L9#2=ZO'OH/IJ<^S$0/JS'PU(IP"OAY] MK\GX_ R:BP)I ""!:\L)F& (VE*&7KAF)$"*WHE E:P=W"V!T5.W9B/A;SK; M7?NX-]BH0.>80R8A!TUDE(K8G!@1F67.2U2F:_LS/P354]=F(TK4E<3&!"E[ MQ45'%43X^92EUF721%"Y A[HW"$^ !1^#$ZJ^ _1@/->;N&=S)CP2##UIRJL6 M50QGI8"NC.Y:,<=V/7,FT0\'@FLZE*0".N("-(DIZXSKT#DC.JBO> !.3R.A M^IRH)9)Z =+]\2F5@[&6$1"E^%&"(4$;1ESB3/<<&Q6RXGZTUX5)\1&PJ@ MWC;1= JSZ2"(D 7-G(CHBJ)B@GAF$]%2)JF9"U'6%O[\S77P7V>=+/4QHG^B MDT6_(G/ *52*>!FXH$E:U,"=#*.'R;TU)'MO"VOMR:WGM"V2"@?CSS"=:]"! M#3FF0 .QVDKT'LNZHQI#QT!5Y"[94%U3+8'1)^-50=:;3G0UB9\TDT_0S+Z= MC/QXAHJW:,=/!<\1S ::Z\@<(2]3%!&4T#;2RJ*_ M>G>?N702\"JX^)>TJ$*&Z**J19&]Q7&5>.GKFOUX#'*"249)! M)E1(CZ15$01K,*(S,/DM_#[.,DW?!1 MT4MI\\R+X>+K54:WA'B@Z+$F!\0:]%1RXABI9TK9W?S6 SLX*[UN%7G;_LN[ MH_FMG*.XKHOB/AGJ$W%"8AA*4R1!>(,!J4M*0)9*ZNW%^&ND9_WT8TD"XO_* MG'_VHW:>9[N^:;ZAJIV?S,*9]-YK7%L6R@(+$N4H DDZAVBKRZ1>IO;CI)G=#46RN,)TYK5,56:.(XEP10 MU7/I4DRJ@Q-.#^+I7RJD!A>J2:!BP/09WSUIOA4WS$:IM;&4.%42=-)B#-X> M)TA" P\>T"97#XR^O[]_^8X:,E][ABNF0.&3'Z;]KY]@/(7;+MC5"+6(5,H, MY7P>CLM(1P)SFJ2<%.HBC,58[03("K#ZEQNIP8C:\KA#E+^_OCM;A_A]QWT6S08N6!QW?4:V65P51JNK([F;81T$+P MTT&TBB6K(\'PEI6J5DJ\1B%'Z;41+C@G:Q^)N(MA\^J0Z>PX?P#4<<6E-99Q M#!6)2:#*%K8D+J*'JZ0QPG!GN*H>9MP$T*=P8B-IWZ_X6'>:*W97F (^I@0V M>XAC-&FWL'H!8;%P_]IY^0XW]TL&*A A8XB$I8Q2I8V M:N(S-3@+FL?('*CJG9L>1]2GX*0J22H*HDYJ?B?^]^5PVK85^@!MUX]W?C@N M'3YV/_KF'*8'%^@^-T7M7?G. RLLBQPHR;$4$YGB.'-5-I.RHBZ9Z(7_D3.Z M[LO[%*148<96I%!-D6!8_;T'S$#;H(0'=(U 90RP$Q OP!(3@"F/8U90^QC& M+0";YV.NGO06A3LO[;U$';XHGIB,IV\@3QJXWD2#Z?Y7U.?(L^'8-]\.D![M MT0C\2V1.4?^XI*&!Z:QLYK@XSH M;5CEJ[A!,C63Z?(=G_MCKE:=U\#I Q@C=HA6.%L%VWJ68I>=@NDBL M+\/2*[59A17+$NX;2Z%F15K[]JN124M%4MFCQ- ]DAP4<31G MI2]$9UBJ;V ML;D[$/JE[SJBP/J37J^X%/WE:5'C,#T>HY'&$:)'_;$0\SBW70U2(D1C. 6'7GF#"72\H!A M-ZHXY1(74F>O>.T#3$M@;+Z_T&YN7(4]C8^SOX:SC[N7TQF^H;FN'2YY*?PO ME4ZO%B6+BU$2D9W$L"8$XGDH)><44.4'JUSM_:8U8/;)Y=J4/_>W([J56L5C M['WWQ]9D^L-C,VFO#*Z8=N M\BF&)Z.Y322:THZAM#0)&DV!IB8&]" U81Q=;JL*?R!% MXI1)!%WNZ)6.G%5OD?A#R_2\^KM#KI(76/+Z/\<-^-'P?R#],1FUARH7 M^[/'X[:#YKS33#.,IQIUE M0L>I_6XA_/3OR_E&P"KSKH,"GA/&HAKMD90N$;1#GG#EH\TYY&!JNQ=;'6"? M7)8^KI'G9U7-EGUW1W>]DH$RYP/+A*+_3J13 IUZ_,HXGY@1)M'J-UD] J=R M\4]6W$3)">7H7$J1-/&42:(@AJ0]MUK7+G!YI/CGN_]HQW;A=6 MU1Z&^Z2EQT"66@QJ>%0(FN+P.15<*AO1I/79AWSN:O9NB+5-J3YK4+ES^L?; MP^._.@HCKY^^C- M<4%;KKV-A%KT4:7-*'LPOIR/23'*J$2L;=161U?7QD7%74#_AEA-4>,:H4A( MR9'(-/(_!0.J=E?IWMJXCACRN,E[B@"Z:UETIZ@O6VZDII$P[TJ+K6*'(^/$ MJR"SX"QG6WLC] >0^F2RML23FD*JR!PTJ''83A-^/8)%1'/SV,<@,,VH<1C> MLX!1BN,.1\T5@>QTDCIDGVI7$*R"JU>U2-OB4&5Q=71@Z^UP[,<1Q]UN\PZ\ MDXHYA6%N"6YET)HXXX#('!S3(@05:Z=E'\/3J]JD[1"GFG@Z(DPIK-L;3MO^ M)R<-7 PO+P;(5B9# I*#1QX'Y+$-(A"=M D*P*N[I[8JLV8)J#Z=YGH6ZFPJ MJ"W6SP:6I)5.$I5"0%@T8+@I*/&"FV 41*]K!_)5ZF?U%D^3;(- =255L=>9 M;^"-QR&7M )Z8G/K:7+,R0I+G$08DJ=(K"W%2)HIHURV4+T"?SF2/O7WW!)3 M*HBD&CW>7$Z'8YA.$4E /QIV[IM]V/Y\F",2O.RT/N!/[F^ MHXX-4E+*F-*.P90M )$3L3XI(H(2V>!LFEQ[GW5+0^M3P](M$;B/I*EY5\+G MX12!O)TT\^O66IT^8,E:7G+[!A0&KK1U)"$2] B$C")X[VMOC3X 917&N9^+ M<36$4K.)5\7=I5<>!RTMI926A[+;-;@3/P[/J0MV"!3SQWUIMR@5SB94&"ZRDV)A(Q($197%XX9GC M@=7V]W\(:B5:_62I]+J2ZI9 S26DFS>]75(9-:[?C]GJT; ,& S!@[$C3*R'>I,9XLQZ*CL3I ML "F=MG $^"MQ*N?+.O>E?1J-E9;-@_76TLWYB%SEH33GF13;OBRG!/OT3,L MF0IE70HI;ZG^9@FZ"EF1")#:TU7M/;O'G]I35?M?H8E#?.M ::%E,D!XU(4& M H?/LR,BR6R=MIF+VG6G/P3U NIT-F72DDQ)14'5S*I=PSHLR2$@V$*45>">\RKEV_Y<'P;R >ITN^;*^8"HVV/[DO[7I MXN/)36N3 MI(94ZJF2:R@%P^V=UGFE1Q9(5,4XR2DZ(L%F$JAVA*F@%=.4INK]3W\(ZHG5 M.#\%;>I*JC:!;A0([8Q3:RL/IM-+_ G,P<5(I0-&B:.2E5)%2D+@I"&0&V>HYC7:POH:BG*PW6J5R[#E;GO4!O3XI/5$@0 M@&M#E[/,BA*?,')GUDJ#WP:3.SA!L2*Z6JOQ;-(V<&\ W_D)FMFWDY%O.[67 M"RG;*T,&0E(P%-D@13F[1W,HE>BEN1-/ 2U39*SV-NWJZ)X8OC[+BMN47 ^M MN,JRJZ[IK_$MO=I2 KB@?2:TC9U2.0/(HB8NE.M.\3<0:I?7K02L5\W6GHM1 M&TNLDZS(J1\!1E=+L95[\)0UQ#J'899CAO@@!,$P7,;@O4FARQ3)P\A>P-F4 MZFRJ+[+N=-/A9'P^NX,,P$LN.9"$ 1:1J#9):=.*C@H/@"Y2]++V>8-5<+V$ M^+ASS;2IO.HUS\#1W[FY^P,B:H81O>#%S=ZW?W#CD_.V.?>W=A9=4/>_QK82 M] -ZU/LY0YP-O'#*4!.)4F")!(J6W(,B7CIO%%61A]K>Z'9'V)%GOVP[CCL+ MW@8@H$TN=U5YX@U3)&/@HY!++/+:E]BN>PS\F9N#])?C2PY?=R'^YP@\F>4R M:XHS4%KJHHHLM[F@TU[2?B([H-GV)?!\YA8C+YZ>FXK_.3;QO#^='T"KUO;FJL?Z&PAL(*1DKQ451E9.WD9;KBE(BZ&%G M'_'+&.L7+G]_?XT;L=IG??!?WB.EFZ$?S;LYE7N,F\^%=]1I'P*&B[ZTEO20 MB7="$1.I92DEBA:]JQ$^B*I/SMK:?%AV,59%852L8US@^FO2_*?4?D\B3.\ MXSPFI:,F*DGT[6*6Q'(1B'"2,R:BKE\JLP*L/CE-]6E221SU>?*V7&+]$=*[ MR23= 1:5]BP'1Z*F[<:G).7:RW+Q5U16.BMM9SQY&%:?O)?Z/*DDC@Z=BK<' M_]K?VSD]W3\[/8V(]'($D_S>_WO2[*(>/&_/,VW@;3SE\9N[(6L/II)_\N"N M5"$4HRX%7"'$R!11G_R6:CQ9L@]12RCUFAW%>'EQV59* MK-+"Z^&=71VTSBH'8B1'#PQ-*;&4H0(U4FN0$7BJWDFK$O9>[;!VQKYGD72' MMO%P?^=T_X8E^7X I20F%B+DY>U?'HSSI+E8#']MZUD7P.;VM<,)J62! MVW>5DK^!I3QFK3E1)D8B%4,B.PS:N)2"JD@SJU[+=/WR:A>&?1^.P+!!Q00D M0KF;7!A#0E:6J.R5LX8Q4[TD\#Z*/MG0]23]X.5>Z\UT-2/Y3]\,R\';[S " MDUH$2(0+AS"2Y\1&'TEP*4DI?5)0V]K= ]&G(+Z.O#>;YWK]URX1PSRY/;D MI%R,4I?JTR@P%M1"$(LVCJ2@I1)"&E6],.PV@EX=7ZDCZ0VF>(LNQ7L_6]PQ M=->:WCCD6M&#>-+[ZCL,ZP^WFG\PG0(L?_6WJ\J;O4L8@+4B.N:)84Z4] ]Z MQ$$*(H )KB17GM8NB%H5VZ;*Y]'W_#E.BPZGI;=(26_..[,-)$X(+^% UN6Z M<&5116KOB3/&.>O13*K:-=%K >V7C](!V^XJNN[%6?^*]ML@!\ ]+04 Z&B% MTK"-YOFE5=;+$#/$F*K;OP>@],OCV0)[:HBDI_9RP+9M,0?LF6WFW2%OVVI* M"CHK&8A@H3!1*Q(@H_^F'3@M'$NJ=IEA+ZSF]Q-A%WZ($]Z4 XE3),#_ ]\, M8E0R,UQ&20.ZL=IX8BFZL4PS7&(J2%G]#I[UT;Y(^_D4WCW)?M83;#4CNNJD M'.'B/_L"H\_P?C*>?6R;PAEJ@YYO9F)D&U";EUO!)!>>)FXXK9U"6A?KBS3# MG9-P4Z%NG8)ED9Q]F0P2!NU6,TZ"BD"D5)'X@/Y*4I91[AASIG;IP1,A]JD, MH5>$6T>$S\,S) X,>,Q,41>(2@PU![-,5//WC MVI/%^"QL>SNY; :@5$#^TW)A!\<8VCOB[(0-Z9:"30,G?IAV\@R::Y B*R^]TJAN*6I?%P)QU%@2(;O$E9,0 M[C#M?F"[YKN?V.#CY3)H&[+I,%/R[OAX[Z^#P\.=H[V#H[.=HW<';THFX78M M7*E'G.& /I>C#C,_/A^&$QP3[$%M%MGH%YKJFL M=DKB-IPCF.U_71RB*86H7X:CTYN)7I,PH=5F$VC68CR/J4[:E.F_N MVN:*PJE8.9\@/XSK_@2$"+Z4;A.T+*CNA0\DE"UE8SRD* R34'_A/ UCG[(G MG9.J4P%6I-EM6&T][GUL2O%HC4I$A1+W.%KN0<9X6WCE DC)J:Y_/] JR#K4 MR_/29$!_VXAR^C>7AA:4>A)L=NA*I4R9U%+EVB/_$:8^Z^8*_'F"=GZZB)Y/ M/R?-T"&'2"*WI8!9"1)<3N5F36%CUI'&^DOHY]'/'1"K4Q%6(]H/G)/2B4"A M>T(4*Q>!Q:"(YZ5,T 0 ;VCP2CRCY]B!1O8Y 64Q$^]5*/=AEY, RA$O7 (M M3$Z^=E'&2]+(%?GR9$W\%-%L8X'<./AQ\X#'(&>6!9.\+.1RWLAH8@5')>( M;,!U;:#V[0]/1]FKLSG/PZH:\OLI4EOKE0QM%=]+2F]U5(ZT4DPI?/0&-2') M,HE2FU%N(*,H$2Q9H5K5USS827*OZ:X)R'"E'QPF@W)1"#E+D M;+RH77*T3B#9KZ!J8Q[=]WRK"^LYS;GVX- %!\*T=41ZZ4B(RA.N;(PA9J>J M7Q7ZPLUYYPSK6(H=&O6]_3=GW\U-N0ID@^VEAQ^VN;E<$6BM4MO)^+RT#6YO MTI&4 N?2HJA02C)$C+IM%L1*">B,*1JJWYYV\_V;JICRC(/Q=-9[^*;Y M5AJKS0\@ %6^;(^2%%*Y830KXA@(DL%S)[4O?FWEL3V&IT]V:6T.W-4.U010 MS>I<75L\;[,WOYRE!#:!FJ02Y80YI= $.H-@#"J M'): ZM<9V6Y4Q*:RV)J_@,X.-#"=+7I.5',='GAN;2]B%?CU@N6;KQHP28TL MMUD8T);(%"*N>-3]0L7$%'JBL8-V@;<@;-Q0Z(8W>^/BKZN[XWBP5 5"F0SH M3'L@EN-:,%:4DGANDJY=X?$8GCZY%9LPX5ZKGUHRJ+G#WHZNA;#K/PUG?E3T MV$[Z]^7\UH1!XM1G(0()B:&>Y%H0YW5$!XC)TM)/)EU[#^?'J'KE;]2D2&6! MU.M'=HNZ;3RW,'4G#5P,+R\&T8&R.N(P72RM'S,C-I9[I(S523J//ZB=//LA MJ#X=4.E.D6PJC>K:Y-I A^^)FUO9% [1L"0-H1;=9BD16 C@4>LQX25U(=+: M;:96Q=:GK1SM'NP<[AP='IV8<_W^\?W=QHV?F,KE]I252N MC?0C:&]2WK3MRZ:OK-&*M>*@*[G"=]]:F//]S3M7D4\Q6&_\=%AN69*>1E0] MB<9<[A=(Q+-@B/ ^:5P'F6E7VQ \$>/&UO#Q]WW/(;=[%W^.&YA;\7=^.'X# M>=+ F?\Z\#88SXT@.D1)I'*4N!P8T9%QSYPOGM]V)VHUX+VZ2[-3>MZSNUN7 M>ST';DWHA_C==^B*)BNY,H1Q:M#WC)0$;11A&*Y DO@K5SL8J *\3\6#+X*Q MZXN],\;>-'5;> M51%>A^[FZ=GQ[O\].=PYNN%OGCF2C8XLWWP0S">SK,IIF>W) MI_+3*2!=)M\ VKM)064GB=4!%YM+BI0*!Q(]R]3Z9(45/^+5D]_:IT1K!2K< M.I3Q7,W#?[W1K%^!UE&^4UC8ZDH,I6\PR$Q^")$G;%*GSWN?:/M9R)'UR MFBJRH^+TUVEML$3IEBNQ]Q?L;-&=7#;Q(PZ_M/T?).>3-!%(EC*A.\8]6D^$ M*)1**MO >51/UA6KO+E/[DR7^J*Z%#KT7([VSPZ.=H_?[Q\>GYZ>['\X_6/G MP_YWVUZ&=3EKWS')^R>;7(*XYILV]UEJ#+&2P_)72VU(.Y^A\>=P='D12GN[ MO>'HLBB2PLGI\>5L.O/CDED=I)@USRF1:$5['XA".MI$;#9),Y^<5+7;QST1 MXJ96[('7W7M/B2GB0,LD+=64Z*P\D88#"9 \ 48].O]92%>[..]) /OD$77) MM;O&L#LI5MQ=B@V4'5 _PA5_,1G/P>W,T(H'7/\8;)Y-OEN%16>;G:8I]]^V M36X&$" S004!82C:]BB(*P>#K$&CCMI<1%6_#<&FJ/ODAFV3DEN6=Z=W$!?C M=;;SKPWO(+[WE!IW$#\.K5H]5;E/HB05BT^U.QG/AN-+),BB9Q3&8O-DX_QS M9_XK3/>_SAJ/]!Z.??/M %DY/9K@;\+NJOA5-"23X6VAU],9ZC6P6LI@]9$!(\>K0^:X#K!Q>N- MCM+)Z%W]\T]KP^V3J>X+OY?HT*VPH::1?RK@M_CM\'P\ ,F=IRF0X)PC4J*> M]U!LC2CY:\>=-/7/+JZ+MD]&_23Z;O_H#+\Z/=C;_[!S M=G!\M(OQZ[O]TW<[!T>G&,B>??AS]PP?=?1N\8N=H[WCLS_PP^7,\'18,'R M=I=N%]V=3IU96!&[@46\6WN;/R?-.YH1NT2# 5 I^7,T5(W6%:D+B\ MO'"\34=>QG)MQ?A\ 6QG@6D0'+/&<4L 7&E8SDJ7-P6$ZJ"5THX;XW\D[$U! M;*K:EYQX7R*1MA9:">&Y#8%H"!95AY>E7U(@5@F-;KN+FM>N1U\=72_*7[;* MJ+N*N2-)UMU8N1YXBT-2%SV$3%($- C:X7"-CX31FVYI:+TXV-OOP$.L@92.B0!4D.NJG+)DLRS$7L?( ((1/SK__YV__?S[YW?$_OR__^U?_N5?_Q]"_O/5Z?N?W@SC] (&DY]> MC\!/(/WT1W]R]M/D#'[Z^W#TC_Y7_]/'OAY??1_TO9Y.? M..5R^6O+GX[^JH,VB0=#+!A!I/22^"P#\29&;KSF3OK_]\M?A3"4*:5(X :( M%"P1J[@@3*:L(!C)M9I]Z'E_\(^_EC^"'\-/.+S!>/;7O_U\-IE<_O677_[X MXX^_? NC\[\,1U]^X92*7Y:__?/BU[_=^?T_Q.RWF7/NE]E/KWYUW%_UB_BQ M[)?__.W]IW@&%Y[T!^.)'\0?#\#'I\G5/[R.1OTR_R'^ZKC_U_'LW[\?1C^9 M$?3@$'Y:^QOE;V3Y:Z1\BS!.!/O+MW'Z^=_^Y:>?YI;SHS@:GL,IY)\67_Y^ M>GP7:7\P^27U+WY9_,XO_OP<$<\^8?+]$O[V\[A_<7D.R^^=C2"O1;\<<@&E M"IS_53[MEYTQG2&049P&(/A=&!2)5\2XZM-WQWSU621!]M/S247$=S^[*M[A MA>_7-/"=CZZ =O9!Y (N HQJ0KWQN==P+D'>1E@^\M+'_LC_)0XO?IF!>WWR MXOL$O/IV\/WYS]/GMFT^?\<_?WG[X_.GDW]3Q-MQ*-%J3#,$-\?S0RM'H^7(%J_> M1BM('@TOJO(Y&58SXYPI!/WS3\-1@A$Z3?BCV7SPUW@^'$/ZV\^3T11^?',X MF*"JWY[/'HAO*WPI7VRKA/%HTOLX&J9IG)R,/L'H:S_"T;?^N,>BH4$FCKY1 MP#^80/R:!9),S$E%@09B7;2 #[BF _S;#PVL>W9%%=RS9M^CBBUH'%8TYRI- M[$[O^&B0%HC&;V8+3"=0O5N.P^Y'_LI050B M$^$-(])R2CR7DF@MN'7SV +8;S/GL<>8D\ T MAL-*)2)YCL0)9T@2)OD0@]:N$\D;+.DW -0D>96WO9+A74D9UK+H77KIKO2> M#K_[\\GW!1CT6JAST1*P#KT6&0,)W ?B%<]:"*FXY97IO0'@.="[O44;O+VG M\!4&4Q@?A?%DY..D9QCD)-#WB-:B%Z*E(E9Z("(D+9BE3N=.?M@F#-_"L#^2 M&_GG.QFUQ3L\Q_,.Q_T:W?D"Z>_]R=GKZ7@RO(#1VV_Q?%JV3(_&8\#_IL_^ M6\]*R)SB9".HKA=*,F 83Q@D& M.'Z"F-Y^NT0?Z)HA&$M9>)S)E%622"HPDK&Y$C'# M6E9MXA., 3_P#-V>-XCH?'A9=+T8;\_Q;((W!AT>;A%RJEJ.+X6C2_Y_9H>]) M/AY,_.!+/YQ#<6,FXUY4-/@L*6&1&R)=0E4'=* 4(LLY!F,9K:R2^Q$]%W54 MM/M=5 MJOID0H#$TIE0FZR2#!+<T(M5P3&2AZ10(2D<;X$+1CJOJ.TVT,3UT+56Q[EVM= M+90\'D0,=XLN>Q+9T,8FG)020H+LB>-&$.:335H915WM[:<5,)Y/^+BE:1NX MD!^&@^%-5 L=7FD[ \<(GJV&8O)*J&OV M!L[B\> KC"=EP'-XZ+; "+_3RSF ==D1P32&/$862-D2B%)0BXZMN+W\[RR' M=5CVKX+*M T;V+S!SL,2QS*.$3%923%P 2,R+E BD8"!#/HFTK-H.*.V=J1P M"\+S8WY["S=8%(H_.BZK$XQ/!F^_E3&CQWI6E'F2WT"8]*S0U(7BZ^B,H:Q) MG%AO-+'X)?/1TT]8'F7690\]8C!KK"+.I$""-Q0C M)AN,J)U@^F(T4#)L[R].1ML>;[UHP%.,N./,/ITYD<_5F*)SG767),HRDHLC".!*H\P@[;& M&RM%[5/U=5B>/.-5C'R7?%.;_%=^W(\]%US0*69BA<"1&NV)D!\CZ#X1Q0%J^'9UXY4-P*X?_FTY7M+<6U.5H/E:0W8Q>1Y M!W./A8CA;Y1$9"N(A(#K:F#E):1:>8E>=/5MM0TAODQU52%L[?+WK[_<,B9. MP_]H5"OBT^>3U__GWT_>OWE[^NGM__?[\>?_N@FO4LV(%8]I7SOBH;&UJR$1 M&+@@0))@BPR4T,2G2(GRPNIRRU"*VKE4S6M(>%:R&5-"'U$&?(UR(EZR1++/ M,22*8XRULP0>30V)3?A\H(;$)F8\= V).T-X^\]I?_+]]?#BB15)G8B.AUFMG9X"UB[)N8EA=U M.X#:I.3$)I'V*D#[+3W1@+C; 7P$]!PG4LWB32ZP3'!^D MY8[P I5)/(I2344J!43F+,H=*/RK3THG 5J9^N4M5B%Y#@*H8.,&F^U',4XO MIK/K3K.\M3+B$9R5!?+K(A-D 33S7&8F1R#K4I )U>F"9X39HD^G??"I]J30 M%=QST$<;)IK<08@C\&-X _/_/YXO;&?#<_S\\=PPI\/S\W?#T1]^E'H^EXNWIH3@%%?('+2HGC5X'Y[]:Z,IF>L=T]V8:."4W!UU3TD#E)8\ ML^QG]>-QE.5^'J7&N:@#]Z[V&G07Q?-6Q(Y6;U%.HR Z'H^GD-Y,1RC,CS#J M#Q<'-[,?GES.TE???H-1[(\A]8(%[RGZ4T:6D^[,%")V!3%+F=L8F:Z_=[\I MRA>@HW:L-?!KUB#^#W\^A=6 LZ/"<*Z(Y8#V06L1+]'QR]$YAXNV1[/M1V;K M0;Y(E57BK$&F^KVOQ2F,)Z-^+*?2Y=>.BGD^P.0DHZDR]"=3_)V>\4(Q2R6A MH$5Y2S!@9* )RQ:_X7*I?KW/N:T+Z!^7 M'7>OMX;[O'6X+QX;7$"X!OWS<,WN_0QYN(W\%.:5I&!1!WO^[IU"''Z9$4DEY0X;07A D-MEP6%6+VR6^,QO1@Q'UX1#7*FUVT[E[M@ MLP4"W]R/I6@>$CK!)21,)R5+YO/P(XYY,.G1J++)Y3Z[!D>D51&MC*.)V9@< MF13!-JDLL#WDYZW7??)Y5XZN[M5.)<"76M[$9(Y@>(&EM"-">*&#E+3^ELZ! MKW;N4RK;VWK%QF_;\P$3I)7@/"F7F] M@!(KH7NJA>;*&R6"J!UK=#\?J+++ M+;07"$$36RYA25>*60?)B.$11QB=3*SVL?NZ7>Y]IK&_/OKT[^_>G_R]3/FE]S4C:Y:IKIC35D1.(WA*II"4V2T\"#TX8I:SF3RY7/5B1J/"4V(CS MC^0.9S)\NPD'[54RG#-7^]CXT>2J;\+G [GJFYCQL>2JERI:QX,Q/FI6;;MY%\4CR4K?B-)A5=,V..:]B>B# MOX!%,DT77(VRT==A.DQ"^JZO^K\)I2PO-17 M-SY%(G/*) A#,1:-+M LN;K=*G%->?LU#]A_>%?'_,/*MJN8[74#T]$M3(8Q MYZC+A*;2J%&E1%P,G'"K1#RXJJ)^%"?]KVAL&*^J,7>MG**-WG-&TNR:-)$ Y 8(,DTIM;5CQ+%WTRI!0R*4U\2D\." 22<-0SRZ6K M?9ARX.W!0[!X[Z[A)A0TF)9NG,Z4HY4!3IIP ^+G84>+75E'^T@5*WO>B:%_ ME32&6BQKDCT%[Z-W(&J'G2W&\2+5>7!!-,B%?0,91J,""'P TOZE=WC>[P1:]4AK$F]?CB#V9V\>?GT.,WH& MZ7J#M)X*3IL@*%&L'$W[I(E3-I/2_PI)51$=\^K">AC7G^JJ3U^+6X8W>NV] MZP\\6FWP9=9CJ^#_GK+K$M"P".F8M2:% F]/M8)L(%G$6IUPZJYWD\DASD1Z>A"A0U2(-_-1WW M!S#&&/DBX"I<(,W#Y2]H.?QJC*:9A\Q'HY''[\XL^OJL?'D\P!EW6EZ!-?_D M?=^'V;8R0\MEH7RFQ-+DT7*!D2 2SKR. 42O$\3:*?-[&MJ?TGZ4(FJ0KS\S M9SE'?3<]U4DF&5SMZN!KH/RIQ2HD M-V6 15[_U>BI%% JD:5P2)YJDLI^[H_E18 M*RH;Y+??17H49_'0&.T(_:^S7*^@S9\'5X?5 ^.Y+2I/'O;8RE1?$ _Q&^1#UP,1KF'#JJUJ++&A$<,T#2 MK#P^%3;&!EWWU@-Z05+9EH8&.ZYWP7T;>P(E^')N)>% MHSRA#R>4D^6\+1/K4.A,!Y%]]BKS!@WSMD#Z@E15G;B]U(1;3IL?_??9G,F8 M],:*0*A*:)-L)7$0@% #6D6$2%GM=)\'0;T@$>U"1YN&G7NM+MQ;(0(K6Q^OY8%UPO2S6[D-*F7_%M4Y19\,H>UZ%R M;3W34A.M2YZDE9F$$!)!\T@>F-!&MU_,UL)[03*J0U&#_=7N64J]1+,"G@)) MO%3"*WW O3*!J!R$E((SGVO7^NJ.[D7F=S4BKX%WM 9I"1?&&QB+>7 \\$ B MC>7F,Y7$VQ3+W0^G6(P^Z=I[ 760/]>,Z98$-M@W0-]O6;PD_G/:'P&.!T%. MOG\\]X,)!A3EYO=E^95>UM'81#U1WAN";X@A^%>,+APS00%^E]5.]^J.[M', M=DWYO[USWH:\?;VFOVP9U+RIFR-^&!<.2U*Q'&T!:71!.%] MHJSV9;Y.P/X45Q7*&FQIH8$B0!J_0PM^\N=0^D6N0)G1;1 >$N'H298"GQ91 M8H#"$:$WA@5&:T>-W9"]3&75)ZV!@W9'_^^'@R^36Q@UMSH)GHE5$J=5KDO. M8Q8D.N?1@= >US=S=3+%(15-!/G9+FARS6:(E(,@Z5. M46M*JU=.ZX[N10JL$7D-=L36(+W*VNYH+.^8-QK7=2\Q*)*>.6+!4H)ALDH. M8G"I=@I8'>3/-;AL26!K[VQU>?^8K%)<$,9P99?<"0Q+C"&<60\RLJ"J%XE^ M$-2CF=N:LGV?3[8S50TCR(U+!H=DL@T^$*486D6A&^E5X"1(G2U/3/)F0>7C MK_O\&)2W#V(;3VYETA^?Y-8EI<>^29:>="@1,Z2VI7;DE[C31@67. MGU&[*^R"H%ZF@NE0UB @7 *_=W#T:I*N.(/@=F,/T8*TR"B-5RM$(FF42 MF,,8!FS6 AT]KVJ'?!VAO61=5:5M?SD3*RS54S&9Q&@F@D+&B95GXB %C(J% M=2GRM0/9LSE+U"9GRVZ"(&HTN!#!IPM"Z0Z#'B8,H( M7[W0TWY'^.2WR1ZQ(!I$#SN-M@<8+QMN _'XGA)I2S\YYRQ1Z,E**@4SHG8U MO)T OVQQ;D17@]AC-_ F,!XA9\)E+&U'(JX30GF2LLN4890=1.TLVXI:V]Q: MGZ:7E_-Z]_Z\?/2[\^$?QX,\'%W,[U!?+=-,2A4T0VLD0#?-2.(#NFE12:CL_':$]^;>M!04-/.7CP01&*,/2( P=KUXYCI;HHA&O&)1^ZAR7E*Q* MSH-!CSZB->K?Y;P!X0#,MZ#J3L+Y]G9N6EE!$C,@(B M8M(0XS+7-%$<88-+X[=0/%?R=[)V@\."#\-!Q,'^2!48I*OX:C;W78T[>R<9 M0V6RC$.6HC2U*AN/CED?09N@=>W*=YW!/?E%H@T-32+=V=V;V;W.-&^_BZ*> MEKN>KZ:3#\/)?\%L:NMQ0XU4H(EDY;)$LJ:4"%4$$G!6FKQ!]1XX7;$=8#.E M#;UW_/H&W*Q=_7[I^,/;S]]>@,3WS\?W\31 MK;_:O9^WU[F@K]5![C>K!F6:^M7;:'__CQYP#I3F#.N3YQVD)#7.>(X3J?"X0F8,UZQ)AI2#">[017*^ M^O[ 2B3[ZK%6B>\[T\/NYGTL/=?N#.75]U:LAEEQF*9(@C<&U M6!L2G"V7-HM?Q;RJG_[\$*9#]6.K0?M#2MK%_ V"FKOXENB6S<,ZX&O4K>TA M;(?IVE:7T0?E4H&.0\@F2I$YMY3DTJI8\AQ(**7PT6.R27$J=?USEX/(Y8'> M;H=5RR8L-%!)N1@T/H6O,)B6TG'+MF72A6A5(#DFAR.F%(,_+PG/3"AC.56L M]G;92B#[CVWJ\G5[\W1G8S=HYK1"_I_QG\Z4#RZGD%V1.K.EX@B.4WM-DJ0) MI!!.J]J78^Z!\[Q]CJV,WF /[>YH\1\NQ-\%VKX\C1^P'HV3L1V%#P8VN]E_ M'Z[%-8@NX2PF="8ZEA0I@X%=9Q#WVHX("6_6$9T/4)90.H9.LFJK.35OK;K2/7 MM*)]\%&/@/#=]KT:6+1%9] %GE.X'(XFQ4WZ--\C&_<4CLIS#228V4FC$"18 M[]&/3H):YE00U4LHK47SY.50V>#[.!?Y]/MOOQV=_M?)NT_'OWXX?G?\^NC# MYZ/7KT]^__#Y^,.O'T_>'[\^?KO+0C7A_1^EZ$R]L.4J8KDW9),F7BG4N^#:^*RBH;6[C3W: MHY1-^.YZE+*!>1_Q48#-C$Z/O.5+M NW/S8P-*=P@9-W&_GN6B 5:2A4EDKW":%T83YQ%/\H) MR3 F4]:FY@>OCW@SHY4R-C%["T5,QY/A!8S6Q=0LZ624R40Y4:YG '[-G0<(E4C*9JM%4+9NPL+=4#:N5BUG'4IX)1YRU M(('J1$1,0NL(,:3:1_1/)55C([XZI6IL8NR*WL=X-.G]YO][.%IZ1^.9V),, MAG-N"3@W$WLFSH= =(A 0_#1J4[7'/'CK]&.?_M!^>HG/P./HH))*UX]+V@^ M^ LXR3'N=KEOF]4;Z)52M2/3O#?>]'7V \62):K"Q2X;#*P;^G M):[-I1M/,HE :9-CLX',;I486W,2OO+C][2EI-73J3)0*SD@J@H)2VG\!1,)S+O>B+X=AJWA=?TSGCRME)F [:R2 M'C66,T:.4H52 X:B1YIHRI92EKWK2.O:ASP#7NL8L*+7?']*U!7('F52&- X MARAJ, Y$C,%K3P*3"2/!Y$3NMK8^_*Q'$ 6_WRDGH(5-][$/_Q&CR%+LX@NP MGDPI>\,D83RAOR@QY/?!8*@>' O"^!1=[>*:]^%Y\IJH;O1]9)N=OOV/MQ]^ M?_O!CPK>K[!#7MFZC]HY@ZP3QDJY8F_Z8__ERPB^S-@K"8.SO:T?RD@V:\88 M)9:S1&14#A=FQH@'_)*G)(VJOLJ@YNSQ#5#'[H?++B1)V6LI2S#8BHJ1+26T)= M\6\"I\3QZ(G(O/1*SDFQ3J_& YLP5P\\U/YJ/?J&NYJQ\@;;#,0RN.P H^)V MZK5'[W\#=4OCWZ9O!\LU))*#L#$#!B^B7)M)$GT9#YYP"4Z#8)2'3C6\#DW@ M/;NA=?G;Q&"5>?L-+74QO5@ \4JEB),&T=+F4KE$^RX)YSTCJE $K*LRH5A'A?K]\3N>R)]$[O6#BW>_N?'H].W[Q=!CO926QD-X0IP;. C ML28P#%,ANU*%)''6*9*X\;'[#?TJV7E8Q4BU5\S5@BS4Y'CE. B)Z6BXR).),<,4JQTG4C@=>=R-SHL4^> M[79&KIB8=*LVU]7552NRM&7'EO$"!K5I'",QLY2"YME4[]9U \!3YGYWB]ZE M=^?F;8OPK;0_+UU#2\>+O_@E8Y\U!;!%O ?(2;M;MLIK0F:A^;N.^.__/MFZ-/G]Y^_O1C MZW.>X>DG\&4XZN,+MOT>[B8?O_,6[M9CJ;2#B[/()8PFWS^>^\$$)ZC2HO#R M9OLCE:C*G!IBC$XH-X5.GW&.>%9&S--H2I;,BDD5;"E("\9:A[*/FPM9N>-\5V[YV=RMKY,[]TA94''JO]T'; M7:L=PST+' PZ )8#D>6^IO5!$AV,YX9S=-UKI]]U@'6HG>$VI@O$1C4T.L [3!F-ZM1VE^(E<(@,7R 5+.%9 M)F4R\TS4OB%P,.D\4%+C,2AG$SH:*.8W'\]P41]]OPYOF?)8JN\F#R3B&(F4 M/!+':"!66@Q_#V? \'5]W=GC6WC9\Z%G/ MA_<6QFU0W^W==#28M:*=M;S]-FM*NYRL0I"S;E#,EW,]RA.QP@+)/&6IFC3/1QB5+=]@D__U<##&H#H6^QX/T Y?$-H2FZ::&YEQ"0/+B RX M>@6)LU:)U:C$#V.R=IOQ^_ \/UU4LWZ#\X&U8_]U-!R/>P6"S5H3JC@.6V2* M2Q@N9CH[31$BA6[75VH$(3-$CT@==3;9*A+0P+\\BG%Z,3TO6ZB?(!)3P:E5<8)&_%E-% I_@#6E^)+P0G&#+Y%^YJY$,^S M$U$UXS=P@:^KN@>9.4ZMPH=36MSQ0#Q.J<0(EKA"S]SHVLW^KC__V1&_M7'; M)*^L'NJ;_OAR./;GXYYW7-!2C)T;G)YPJ+B ,AU(9#'I'"4WU=LC/(SJV8FB M,A%K'=TVR0HU"K#<]W$UDQ'V4HBE@UIB$PE3=@R(!JDRB40E+'VC<7GD'RPD1RV2#[8A)8#G1QW@?AG M\L&.U&YQA+P-+P>2$%"KDU",9 NE/5) 9\TR1,X=.'0&M:E^4O"4DP]:*V<3 M.AHHYMX-;.JH=#IGHGCII(6&*)4D-!%.A40-LZIZ]L'3.S[8B,!-C@\VL?Z> M\P^BR@ Q1Y(IE/*K4965&$T0E(3$@J&F]L;+D\L_V$47M6Q?^7;UIXF?S+#\ M"JA4?WG6C_Y\WOC(9N&!9>*52#A88,0&)PGP(+D-,F;HM"7[P.WJM0">I>]: MS^05-V)GH.:ATG5(RXYF'4!5K+&P%LC^:RQ4(FK8RLJUIX*UX!0#ZBT5Q&>' M\YXR@3B@B5 !/FBNJ',UBNOMF?I["BWLD_E-C%N9\;?3,L,M%J&DF93>:9*L M\D0&G"U=R9X 'XWR,B;K:M2^O/[,_=X?K43!L(+]&OAV-PYZK!&)HH<26TT3*PI&LG@CSZ4[1=MC>W-FX#HH\'$QB5EAG#\63\VE_V)_Z\ M_S^0>I"CP^D'",M!H@ ]Q4D*RB5UJ2.ZF#S8VKOU2A.;K2/&)AV8%3+=;AKU\I(J=A%%->,W2*HH%\\GIS#ICV9^S$DX M[\\OPO*#^ MZ\G)F[\?OW]_].'-\8?/1Q]^/7[U_NWM&_3ORF/@??\K))P!_>!+'P/?V1C' M1Q$M-X+DQQ_]:#+,KZ9CM.!X_'IX$?J#18K:UN?S>T2W\W'_H2Q9*7M@^?A[ M$/YX-S35&@P##'JB*@FN&/XPJ0E7C&EJ0G*Y=A[!)OCJ910\_-17W^?U)<[] M>#S?$.))66IS)@%"N=DH.$8 QA F!;J+B7F(M;=0=P*\K]R#9@I;GX70FK[' MDIIPCTFO#W#>]%9)([/D) 6)*U"I"1L<=829X T8C?%+I\:_F]PGZ@[O\-N] MS35S^P)2(^X:A!GW0/T!M+2(7#; [@"W44[#AE /D]_0C/KN$JO&VR.06Z:! M F(G7)M9ZTA'/,> "_UUI21'?Y[5WOEX%#)[(!?BL:IL$[H:J.L-?(5SC +3 M9XAG@^'Y\,OWT_Z7LZO36!\-%2 =4=26S&IN2#G918Q<1BHX6-^I&\U&FZ?W M0MI_F-R4TCN;J_7X:+#?NJSI=PKGLUAL?-:_7$)SN.!K+1!:,JITL!,DL/+J M) #) \V6U?;X[X'SO&52BX<&,\HLSR=BR'X*8\!//CL:I(6JKQ4?T3E%JC&> M,<8B2!O*5K&/)./<&GA(7IO:_G+N5=4:L@D1RN) MU(X1)WGIYV&-38%'R6JG[3V$:?^RV=L^0E4Z&BQ)]VXF7MT6OGXKN.=B"$$8 M2AR4,N91:8*:5@1RE#+JX(6J?;%ND\:T@6$?%&].4=!$>2<2'2R$1PM:M+;(KQ&8NI*5T-;HUOC#C(KYO+2 MVBX82Z"D64JC2R]E](%Q*0K9EZJML;ZK\#"N%R2>G6FY*QU3/9GIS=M7GW_D MVKP?#KZ4OMEO($R.9[?Q9I>M=DA'VNCS=TXHVGXTM?I1WWC4#UW91%,NB?$N MEIQ&&3P)0E+"HC1"< 9=5[1FE N>Y[ V1(7+B M;;E"G@(:A/NH6?U#P=LH#M9E>E=>[]7)QO9M"DDGWI8!,[ MUZ[)7]RM]T,_.'J'GMEY?_+]S11^*V>'2(U=9B48Z:S U3&K@#YV,J944RWE M1)B%8%V2O%M1_@X/.T#SQ"JT#!O:M.*QVJ)5P. KC"8E\/D$@_YP]&$X@3&" M1'QJ><73Q4 MND6BE(N10($X:SC),CO#\:?B=F;0VD8,#S[L.7!>VZ;U>V^L MQR<7^&R6"EU?])-DV4UV+)(@2P("Y<@J_I[)=&?.Y%U+O@JJ1 MB[\:T6$<_-T9>T ".YB[@8._!AVU7@>6&2Y'PA/)2E(/2$:2$M'@7R-4S^C< MIP@><.[WI8%-K%Q[T?\$<3J"=#1(OP_&\Z\+NL72!-3*:!3@@F1QSI-.$F<$ M?D4=Y8S)R(SOM-S?^YC]+_0UB!@VL6*#_+A/=P!E8QC-&%0XYU##P' I2]*1 MF'0*.26GF/-=3=S(G5L>C/6DPZ@Q9T$BSFAC$9LK%T+*N<&U&@9LO)SJISU[Z5) MR%I5@.+)&$F,";AT*UK><)V(=MIZ'_"#:9O=(;DM2-Y-CJN,79) M5)4])P,QYJ1E[1)8C_%,?P..NYSI;V+5QW*FOS*T39I25F2+*)(WQ MJZ/$E9*N$:3CQCLI=.V8\8";0C79>7A#: /3-@@>5^U6)(/13DB14![M/)YU MEF'XPX7%!4^!8:XRVX]YYW<7OGU[3H\[97,7UVY'^S;8_EN;NM %UTM-V=R(LZZI>ML8?*\IFTE'9;@C M.O"28H3SD\TZ$ 8J)).5U5"[>,9C3]ELHH--['R(E$VK($I!*1$&USTI(BYY MTN"*)81$,TBM;Q? ?!XIFYO0LFG*YB8VK9VRN<3WZAJ^-Q!GP!"B7D 4F47N M@!*3:*D>E(&@/R+0\7'1Y\Q2U)O1?O_SGA/S%2V[S]S-96YIEDJ#\)+@R&FI MSFJ)%UR3F(R0TD*RIEN.]A/+U]V6]MHVK>CU=Q:<4*(#%//:*K8]7:-"]P_#X87T+LYSZDA;"[@*K9 M?G =D .V']R>I&$K"U=\'QT+, 10ZE#DB.%]N)*ARU62FX516I MOOGT/;_\J[I?%OT[>#Y2K/N#?@ M&).\;M-[34Q?1B 40& M#XEQ'((MD[G@B7A6)G/M L9W :?S3GFN#S!WXZ'[71>W-ONPALTJ+X"_^6_7 M@ !C"43()+I2I!64)X%33VCD$AR4^GV=VBX^1-[UASY!\K:V68,#I?] AZHL MXB7->=$DQ6CI/!!&-2=2.4<1X4K>NV$D=L8GKIO4\6V#P2#0& MX=9''NKS?!/!_L\0=N5D6,V@M0^$%WF()U]A-"AED]_U!WX0^X,OLXM*)^]. ME]U>0@2=J2##= H)+BZ+D>"$:T\Q@+64'.[BCHSR!T='TRW0\8=>0,LJITL&6CF_HX6!_'$/_R9?CU%_SH>92(7_P(#E<\\*E[D+O:<&WCB.WHG*-8=A3M M@*/#WM[#G%Y_ZG[=P9W-/ZQHN\JOY@T\VC%GE M$Q'+$DW,@W@5-6'*:9L6R MN[=?]V/@<(T#UXS"34Q6VQ][=P[?RL1_!B-_"=-)/XZ/!W$QW:LD03(:"?6: M$5G^"( XHU<:J/$YJ6X[,_<]97\+ZFZ&'[:P6@L/ZL=J\:8_CL/I8%89J >@ M*%79X;)=B@NZ:$HCODBB]$(XKYBGW?=;5C_CT!G8[W>JL5+3@,U+<+WS$8XN M"K:>H(X"H-XB+Z>[NA3^ ^Y)<")Y:4+.J78G\W58GK8 JEJZP6')K'4ZI/$[ MM$(9Z?@DOQY!ZD]PRE'&@! D6UTN$*9,@E88 \@0)3A9_E-9 FO!/ \-U+%U M\XO6OP_\O$DUI.5Z*L /4\1%'7 M]A4O;:P&^!%&_6'JQX_^^^ROH_X@]B_]><_'H!G(3)1A'#T49HGW,I&8N?52 MR@"F;?NL=HTRJL% QE;@3RME&T"M_?CX<#I;?&KZ"C[Z?>AK=V^"5)=QH M-$V*91,H:6)42$PFSJ7N=#.@EGKNP?H"]%2+J8I97"LAE"<*F930#-UJ]*I8MS"S^S.?MC!:&KC%F?!# M,.%26$M<%#@_.B$2C1[ =KL@WOV9+T0'6QBXXG[O/3!_ M'Y3*Q:-^G$!Z[<=G1X/9_[W]Y[3_U9^7SKH]I8&'5/JI"U/N8'%!?)**!)%M MEM)Q?3O/?B-5/(S@V6JDLO'O*L8>1#%O_/?E >=O?C(=E?V^LG_C%7##K"1* MYM(6(5#B<7!$*2Z"E=3G#9(+*@)[P?JJ0=5=V;D&LOL -Z?4GN:!NQ@18O", MR.B 6$9SV%R[D;/3[)L]8+Z#1% M'2+Z3)[SLFIZ8C$Z(X T^J23"*YVY<+;&)XV^U4LNX+JJ@6(_PXEFQ;2T5R+ MUYLJ]*PSPL6$Z)QRI?RN(A9X(E0[D!R=:P^U]TLZ0GL>PFC!PPJ]5-Y[+7+N MIQ_[.=0D!(C>M;:EBE_FZ#4QK0B3EODHF0Z\[3G,+4#/0QOU;+Y"$3MON/Z* M9AF_'X[',#X9O/TVZ0^^3/OCLP)U,; 2=!9 M$*69 Z98-*%[!N/]SWK:E+A/BO8V9K,S2H\M#J,Q I.&>>%FD M&BCU*:NDH'8/Q.[HGK9:&K.Q0CA;;Y&N.FX^'H^G?A!A,8EE=',LU6@!U'9) M)]+$R:Q+:7C@CIIL;>U*^>O1/ ]A5++V"B%LO4>Z>KC7RD%^1F['9\/S:ZH] MR9\FP_@/](8B?![UOWR!48^C'RRE!R(81[-D 230Q GC05*>HM:RMEIVA/P\ M)+5/WE;H;NN=UN[X/X]\0A>K;-GUP"5<94O@SIDJ!?!*BJ/,J W#=?+>L- V M@> !@"]%4]MRLD)!6V^:=D>+WRN=2DIOQ6O 62]B-)^X*#<9BO9#D#@&#.LM M3KHA @O&=2K&4U5-:\"^%&75X&I%]MNN%04FDWDCPGD2Q#7@-^])G<(_I^CJ M]8R-@KM@B6*SDD5"D9 9HO6,!2\,3Z%K__C-GORT9=+>V"ND4;GCR#6XUZ"6 M$P84,1-1JEAV X1#;W\FXM(42TE'M49#.=C7A',;W--63ELN5JBF\I[N2J0S M1PV1P,[L6H9@LN5JAFZWW?E0>9 M2VPGX;S_I:@:4<)%?WIQ,G@]O+@8#F;N?L\+&U7(G%@%0*30@3@M*=&<6N5! M0F:LTV*TW?.?MD3V9?@58MDYT_;3F1_!3+B]P*2, >.Z8+0N%Z@I\3H[$I0! M2ST8PW3E.>3'TY^V G:TY@IB:R:X_N9'_X#)')924E 3<7(2('!RBHSX6;5X MYJ--@EJ(?(L7_=HCGC:3%*(I@_14NF[!QO88GITNFA&P0C@U\UNO;_9=G5;/;Q&^&XYP M<;J<3F8+UDG^,:ZY_(6""!E'P0-E1#*.\A<^DVS1)?8T*'=[B>AV*+@UHF4I:!$ITY, MNZ2@W$#TM+73P.HK1+'SSFM)G_J\2)_JL1QD2L&0K$O=QR@B"9YE0@W%H,DX MRNZMO[%MKMKR^<^#\*TMNN).YV++\U]_N6411/J/V0]FWR\C/H7\4_G_WT^/ MKZSSQQ]__.72Q_[(_R4.+WZ9&>;-VU>?/\4S2--S&,Z.+=_ Q/?/QS=1C/L7 ME^55U!J3OYSTM!T6B?RO#2Y*_Q?#B&]+>?\'@PEJ M_NU\Y"L=C*IZV$;?W)"IO9>,&54%N8UJV+NN JE&_A-6(#M,S87?&'I# #N;> MGQA2E%XKB;,BQV!%4H]A2["!:-!)B@0AFMHG[/L4P0,]%/:E@4VLW(#[167X M FI9B4PQ"R)KXDJS'JD-+7TJ(S%.A.09U:EZG8\[(/8?$-1@Y_:>\TZF;5 , M[/=9=L9-2%X$JC!&((S>!)=R)%E*4*L_9*O@/$L^-[5O W>[INN MS&P*"]DQ]&4$R4:4? JXAB^;#-3R@,Y+TAC^>ER,E,K$,\8X1L;& M5K^?NE\A/.#@[4L'F]BY=J'>LAWY?N@'1^]\[)^70@E3^ T__@RILVZ;- MY_E[[ZTIE[SQSA$.+!(IK2>>NEQJ63MCLJ'4M+WN\S1N$=;;'Z[&1O,*T:_] M:/2]/_BRK%W,75+@!6$^22+1%R;>,$JBCR)#9L*Y^_IE5,A>O8'G.6IC!XLW MF44RC#"$G3<(A-?#\63\ 28]H &5J(" 1O=(>L7*I?A$$@4/02>J6/V+QRNA M/!<-[&[G@]2)IBGE9(4A5I:TA9!PO4LB$!,"2P$,)-4VG_U1UXFN-RWL:OL& M=:)OY#VZ-K*SA431MX= M?SCZ\/KXZ/WQAT^?3W__[>V'SY]^)&;<7+;\(+WS_=%_^/,I_FQR!M='MD.> M274,.Z>GM+5*I:R6JZ>^\N=E>?ET!C#Y=32<7B*V1>]??S[S1.& 8TORQ -X(,16619.R5P5\R[SFX_GO]]%8+Y7K&V(I1F M=J1T]"@!9"0VPW\./I M:/;QK_RX/^_LJATWN"1@(! <^H2VE/S7*1&72GC@;0ZJW VNB\9P.8ASD"JDKS[3)!C3EJ M(*L5 ,MT/7=BELUBC>5"(*B2]:+PM1*2A(R!*J/3HJ*5^ MJI-QX'DH1DYSJFI&]W!_7#68HMZ.)_T+C$-.<@>[6(_S,@^,!,I+6"+P*RU+TQON/'J,/IO: MFYJ;X'N^HFK&4H.]\6N+_M67_]Z'43GZ_UZZ$9S/UGYA>.V)3+,6E,;H- M7$>:QSB^BW?A '0!VRAZVPCHP>.W:HRO M$U4SNEH&' YG8QG%F"+!1FXC\8(3DQF.&E3*4JG2$6BX(8&K7UBS01T%\X!0[GZ M1*Z3S(XL-(CA5D'C"VA!&R[!. *BM%(0 =\2_ 02H@B6.VDS;^8+W87ST@2R M#0M[FD'$ IKS8(51&!4:C!BDBYF$@$-6G"MG@K*2UZYL=@^JX#:!(,1@*2L5BZT'*2K (1+64<:&5=/)Y+2LT#IAT-WB"U:&W&=A=< M+_76TD:<=;VMLHW!]WEKR3">:6GW9TQ$?$)QXL$9DCPUTDJJ@F_; >?QW5IJ MHH--['R(6TO.&2<$ C+*ESQI'7#U" MC3+$,PQ$.,^()G/IX#G7G&KN\^]L]+4IY]7K#G5!]5*+4&W$6+<"1-N8>W]% MJ+( FB4N32+DTK-!4&(%,&*\8\HZE4-Z:46H&FA@$ROOI0@5!18QAN%$98-3 MG=2&6%YRZ<#HY!CW'&KO'#_>(E0;L?-@$:I-3+NG(E0NVPA4,>(3AK%2>$^< MUT K%V MN@\P=^.A^ULJ=S+[L(;-&OA IQ"A_[6L!#\.>W^DNQZ%\63DXZ0GRSEON0"@ MC6%$QAA+6W]R-IQ.3L&G_OGW-U <3304CN)J$(N:,Q"U\DD:DAVW1&K*B3AG$+V[[=&@*"H=92D4JI/NJ@) M@D_$ZB 5)"F8KUU^;$.(+VPE;$E@@^GIU72,PQZ/7P\O B(OAG@]'$S04/,N M@>,^/L?/2\#,Q_.]AW-ND#YA;!"S(3)92CQEGJ00& M<:B-J+X9;P#R [EI2 M/]PO;XP7E14MG.T(:I-)>ZW2M M;38Q,T6$9(E(DSP)$F?D@(1*X5)X7GW##ZJ&+(*MB;2_D^9?C95M:UI.9 M!\X1GM"J-+O4B@2&<8'U$$*RDL?8MO'K/>!>F'S:D%;QX.?^-MO74<)%?WHQ M>QW0)$E$C#)%*6(I,)SEF7B@E"BM5;FIIM/M*Z:;=C=?\^07(I_VK-R5D-YS MI=%C',1X,KL9U6%?K%FQT>U@-*XW6L$VM4N.'HW',!DO[K.ED\%IV=4#DI&^".>6;X/**AMC%8DA9?2BN"5>>2 .F&+ M;+*Y=I!4>0C5[DWN!&>>;Y!Y ENN@,;,,7;Q-J-+ I1 Y-'EG)-FS8JW[0Y_ M[^5-#Z#AM?%=#.7B"T;Z5L6XO> >&&FS$?1[YP3BCVW,T2)]P_/V(%CG)*]".2\K=>/6/ M%IEX7<;2*!6]YC@.5*6GAD"&CXS=QZY8CY%"9IKCF@,>HPACB-/!$)XDL]DH MRJJ7'WO\2GVHYL]C%^HFI+:HI7@K/>&J\(R.&$%F0H6R1!HJB77>(TBCC! R M>55[YWDUDOT'^X=C]X',D2VH:7B3]U9&P@(N=4SI>J5SY9->H"[J,]"R(M!.'NQK?QZGY[,O3X?GY^^&HS_\*/6DR"$F MQ8@("EU:DR.QY794*IJKZ&P M#E4B]R://=4FW7(\'Z>C>.;',.Y1='/0+0C$I%3R&44@(LXH#0OM#_,GB-WX=!_/XK$OU^."[%:%UVVF& C8Y#'P1WF#/.*E1VD,?N/!Q$,"(S,)89PDVI M-*B<(9YKQ*VRB%+;I'SM#A$'$LH#1XR'T!"X17?>)\X"H((E@YSE(X6FLR(TPYZ5#KEBFV"=7[IK25T5=PNH7%VM7M MBAQG*$9)HAD')"0C(2A!&*=:@3$A\DZ)N(^];E=%/V][ U;FL!NE;HJ M\+>)P2KS]G?H?SDKS7*_PLA? 1(F,LNB(D9$5QHR.1(B981*9ZD#E8S-%1A< M^?##5>[:B(9A31NV.+Q?DS+(@@W.HUXM%R6SAI?^Q[%4(<@97'3,Q>K75AY7 M>GJ#_9(:QFYPPE$UV:O+6/[,-%]WQE=#("T3>+=A][%GFEL,9E2BCH#,"L7]/9BDRD]YZ M&5I/=2 M-(U:8IP+A);F:M*5NQP&#/'.1NFR$8[O(WEIS]IZR!MZ;-+: MA*66DEK1HUE$!]8E21@-I4]?U,0;7.-%2-%Z(X#IZO?>GVZG[(V(W*!3]B8L M-'"$KHU]!NZJ)50RZ-Q1)@EGJ53%1P/37''#&9+ (NO8Y^SHLS\C9J6+N MBC6X[L.U$'X79(U\F?6H#N.XU&&O@R1V,'V#1>0>A%%;);R6!#(U1%+'B-<1 M)[.DK941*)C::\B^1?& Q[%O36QB\3UHH91I+FT#2GW;92]8(Z510I/LC"32 MEP,VC@BILIDF)1FO?F#Q,*K]NQ>U.'Q &CL2T,"EN+-LOOK^"@;Q[,*/_K'8 MFE16AB"(MD(1R4TFY=(4R913S:@)0=>.7!["](Q MQM?(X7@(VV'Q*ET\B @XRS*:'EG5"E0D@G5P=+D&&6\ M]E[M8>3R@$-R6+5LPD(#E1S%V6)XMSZ)YR$I8?/BO,&Q2+STB@1-I?/2QAV7_KDA=UH8-3+X?-^3*-_A.GO4MC<\^BN3(V,7L+14S'D^$%C.Y 7*QQ MVE.36?!$B.C1EXH(+T B*2D6I?=,^4X]CC=1Q?V0'H%WL2U]MV51T?85_8MY MZ]__'HZ6^,:S%X"#SX8:0[*E^ )0BMZ.XHR@!10/2ELMZ_1,OOWD9^ ]5##I M78+M+@1_\!=PDF]@6BBZ"ZB*EU[6 MG_%9A=&1JV,F_E&Q;KP7F9&8",*&M5 M6JE:3GPPG&1EO';,<'[[:NE3X/R>6S-[H7P3J]9.$+V!YV1P=15$<>,!+$E& MS#;H.0D\!V*RYTGB3*9LMXNEJS]_OS=F*EE^6-=LM6\&WX#T^8_A E+VPD:$ M0[2P@4C(E(1L->&>H_,@@Y.WK[9U8?+J\Y\7D]N9K>D[^1E)6J$M::H@;U^U>!^^B_ES2&SS"ZZ.E(HPK"$2\X M+?M'0%R0F7 ,('.YF.UI-X_KX6<]>1FTL&G#6DX/J_1H-"JWNF<)N*_/RI?' M@Z.+E1)#L&C75/$&,JSC)YW, 1"TIQAD.UM[8S*"K!?H%+K4-C M@3L>3& $X\F/ _E>I%Q97EQ*72X99%=JPBE$%).T001GF*\LJKLHGHU&=C1P MQ=N),T_@P[18X59$,NXQ!X9CW$=TUJR$?)1@"((#IAE8-D;'Y#MY5*L__\FS M6H2CM *5N@NM$;Y,P>G9\/_R@MX-\-1V^&TS#)T_.[>5?S>OV3G@";&.>!*&K1"PK" MD\!M(E2P@)& -TS4CL8W OAL)-..EK7Y3XTK_?_H _]_X/O1>#R]N"P/&4_' MD-#V9U"N,)4>#M/1;9ZT=[W0NP5_X M,!R,;G2;N!K!9XAG@_X_IS#^\?Y8'DLNAR(> (B,Y;()%9)$7#2YCLIIUZQ? M4J,Q56Y&6 O?/+]"BI1H:3=$:1 XBX2(*Q'%-2G)N,[56+9AJZ#:TS(S#W/AE 3,3J1R1!/?2I% MVZDU47L1]M&-\DD6^=F?M#9A:<]%?D+4,EDC2M\ -$*"0!Q'(S!P4H**,=!F M5:*>7I&?_]O>EW6W=21IOL]_B>G2V1>7%+T@P^U ;%\F1E[]%)DCR$_?;10N53]9O"Y4L(EZSWD MZ!4(13R>!ZM!2NJEMEG8T"EP./:U"Z,S@IZNAH;+&[J0\?*6-_02_I;A_T^1 M7,/E#2(G3CBS>&J2+14#:F2F"FKW14QT9,L8FTG:V0;24=G,M546<,:Z1W[-#L0^+K7 MM+!KIZ[A(J;5GOERU$+PW>L#Z#)5Q!S)HX&[E"VE\&4)ZZU[0I M3OJ(OW;#T]T5C9QFR1QW$$6I/2*E:CN&,A X*T>MS-$\FD@_Y%++1C+?OM.R MC\!:K)+8LH"%1Q*?/5>J/X(.)EBK:.UE-B/;VS5:JZ*&RAKL MF*BZMZ4++Z_;O[8AMP9 6BY5>HIV&Y@U57F2)$492 3O19D5$TKS!D5G,2A+ M8HQ6N-J=#^-'ZA.W?XT&J'V46MNNVKV!*AJ.!E/2D+1$RI0LDPFMA83OBI.! M2V)Y)SOK)6__ZJ6^[MN_^LA^R*47)#&MHJ>E&+AT[O RW,1D"))0EDDBMOJ^ MK[$MO1BMT59%:<.NSNA"V<^^.J.7]KJO27B*Z(==G9&"9I2;!%HZ!R*PTEQ" M'4A%'=>:ART89\N"D9(YHK,.I&D:&!L/6*&ZP-<3T#9+*-351#(2RZY;7>/J.( MOEQ57][4?#9K2ZQ.8>,VQ;82K=VVN/OPK4[;Y^G,+])\U6N[@GAA81KP7UV> MA.N3)QAQQGE0D>+)8XF!C3%"(,H5F])HV:Q=J"(?UNM5>N' ,,(VPVOW\TWYVZQGGC, M5;+4!0)9(EO"*O0)@DME'J/GEB;/3+,>G$T$'3PR>!"H;&\HW%-E+1MR]I?4 M??:N&E4Z,-BZ][ 5):P)S0[PR,![1WZ+IZ6B9;HEKNL MHI'!NM2MZ/KEP[U["^6S0WL?$ R;4K;,,UE*SSR+I7V0"+#:4B R4NJT3HR& MQYS-,::41Z;3[GGF/@II41I83VYOW'FX.%][Z+/S\U]G\W^Y>3SS1FKG?0;% M2D*5F01>,0&9*Y.THY;>'_(WI@MQ,U//&M^C\\HJ *?ER;@54/K/R?+K V86 M=[E9W.7]^BY9?=:9%H;R+,IZL2Q 9,_ 6,7!<>ZAL5:N=>C\AQ0U6#6>IL[04C!F)(9(B4H^L30!%4\ M0,@FIYB9H;IV 4;#%V2P+-W1GVYR7@A%")^Z\W1:2%N=C&9IM\>_LG$>K2?/ ME1)C5]]_LN/[;VS0%')VA"4PQ@9 ]P>?N& ->,N%$,DH*FK'2WH1N)G$D)RB*:DRL*A=D:('7X9,!R-- M<"(3KFN7>8ZD#? 6.C8Y]=')Z/OFNK RVN?WS9;O@9 FK9//4&[8T>L$YRQ M0#5(9S0(GGE9CR,@2DHRIYFP6+O)9OQ(?6*?WVB VD>I#0"Z*M;\Q85_I'AC MRES-!W"NB(@"R<6.L4JCC)B&:'4TV9ED0_5U&-O)>>8-@;WT?']=1B4E-8A' MOYE]^X86#;+\P:%I<[4%V7,NK5(0@_4@F$);F#D-V5I'J7,R!E\9.1L)^8DQ ML[]B&MPV;V;S[[.Y6Z9?9M.'4"8\6N;18K79"A!(#U@:$S"#G.?RAZEVO=A. M@GYJ]-125(,(YN?3W\K:Y^GJ,?^2D/T2.O++AW>C1F)B5$"]32 "L\_@_ M%8EUP29?>^5'5]I^8FPU45^#676?3S_-5Y'E'QL/0>*")VTD*"-$H2[B(7 , M4"Z:JNR45J$ZN'91]%-#JIJJ*HXG6F^HOX[+O,'K],ML/OEO=SV:36HTT+)$ M<@BZ(@*) >]1!#DDHZ2CT25Q%T-; JF[ON7G"5_5%7C%EVLG85<1BPZD;8Y' M]<3$(>)&E3731=][B+5V\>,C)%+/I>:9@4MEJ MZ=*49EQ4_3E"O8@JIV^#" M0VA\2_SE< KO(\T&+L[U=7?K1KL:WB.C(/CD@*)XFPF1/7A6)OC$3)RG$@V< MVN4DVZD9SEJHKK19$XG7GDKP^VSZ93-5V22=$^<0L]!E5D(9S>H-.&:(%LHG MJ6FG\[[U*YZ_C131964MMNQ>>H MUNR-(*-97V,-7,Y^2Y>Z$/NZ1Z^FQO=:=O84=1U\CYX0UE.7(QA3]EO>&@U4=+ ^W1HU=!/!N]L $-KT@EOM24H,%O+"A. M'*7!626:-=H\)&?L>_1Z*;+#'KVG:*%EU\HMTM@E:29%E:018/$_M Z)!(-& M8AA".IJ9YC[TC@\E-J7J0ZBKP87T"/TAG#QK?23 MI/C;?+98?)[.DSLO#)0VCE]2GLW3)_?7&9FR@$30Z!2$H@0EI9!Y%"A*QYVL MW8-3A?!7>-;4;(."BUT=.[?9.0N:9:=B!*Y8F7HO,PK)9$C!*6.(MT[4]A:[ MTO8S@:R*?K:&MRHVQYU^.GGS[W\[^?WM\N)XU[7T'=OF\=*":99)^EA*CQ& GK,KC@&$C.I="4:U]] M)6 ?^H;J6FN*HP=W4"L%C:5/[72)O)4/.O[G11G"@_S-IL577^_7UIS*4G>= M'.,@J Y@DK: 3KES-F2\9FO[HSL).M2LPW8PN)_UK::.!O;\/9HN8S==B&J4 MK]E(T&'R,A45-VLE]<$@80E'RXXG(%Z6L0G9@!-!ERT*2%KVE 7Q?*'P2!IE M:"3T$78+)__F:GR?EC>NWDV>^VIHR-5.#1&DIEE!6=%;]K,Z<#E3,-P&JVR6 M7%2/N$7Z9\7Y5'^$_]WO5D,7]TL@K%@ M;% @%"]#&3T!A38Z<\(33"Z$-;(K]E*U(%\ MFQJJ>QP.>\B]1<7[5@*-*P.(N0>>G4=#"7]R1";@@<6R<\P047MOS," >,S# M&10/?<3='@=7)I#*47IF@8L24U0T@E$\0J92)T%-(M4' VXDY #YGSJ*VJW^ M)TBYA4MR\N;=T7(YG_B+97G_/LT^N%+2C?[42?[D_KH]I%.$(+S6$H@S9;2X M2N!\3&!=3(DQ9KVH/E6D.WG#PV38*'TC137 U.ER%O[Q=7:.G[98&^1GAANB M"+I39=8H_@_-8D\]A^1-5$PPRV+](/M]*@Z D%9*>Q!2WTOB#9Z470?BBOL/ MI=8,Q;]!0&?$!:I"1!]-E*0ZGH^27L_@6=8T4B*)KIT(W)/DEXNN(779POUY M>#AXXH:G3"&(,K% E^I9H@422$-B01(1],#74;TC=A,'_1M^W63ZY2H(>C*] M5;\TGY05EV\ORC3E#VD^F<52KH20B#PG!U%D]'X5ZLNA]@ -6VJ\C$&)VGUO M#=AXX:; H17?P@,II^-C^GXQ#U_=(GV8S[[,W;>CB^77TI*:XM&WLK6@K!4XJMF-7C-A?5:A2QK/PL=27OAF&NAH*UW?>TZM0^_'[V_-<9\ MQ,TIK]2&D]6BB=?D5# MX $A1^>K#\*?3G*9\_]E6H"TOI)*^\$MY#HJI=;<@LZY3!C">\KX($!$%4UF MV8A8>_Y"91;VOB"O2U+K$+8.=H?H63)4@';1H1T4T" ,,@/EG!GB4S"(7']X$8^."+&4M^W?NNN:U)^O^1S%:^UQG+*(@=M$UHS4A&PU*.E MK[3CWCOK2.U!@CO(.50&; 18F;7160-;= MI5[GD#L0U2IGM).PP:;-J:NP& MCSUT,#A0DHEH<)?( BVGPVBTA'4.P+.,/C,99:H=+3\ 0!Y)HQT&'WU$WV16 M\F)YDDL[SU7=F8J.$FV+=TT-"&H9&**056XM3]3R<'_M3H7YR/>(&-Y!K:BD M!T..]Y%P@Y3'Q[1(I=G_:!K?EN;\V?=5=>S:U;HN*0L\**+**%QDF'-=6L1T M*30Q0J$P!*T=N^A UDN"16TMM ATI?/S$IE+TS1WYTCH4?R&$E\LRQ+G/].5 MNU%X$L"3SO-U!Y'>Q3^>3%9 M3-8[+%?QOS=HQG])BW??OKO)?#6=>[J."5Y22QU%P]Q;8%3B[<@X2DA2!EFH M["3+(KAN[2B4MQLX]WB>>S8#/-Q&I(.600"0TP$WR& M8+U2%'TZ1ZL7=72B[ #%PR.*[C307HM*C\TB\N72#,LS834)4GI('DTQX04* M@!D+4:%]EK6WH?IR\MT4_=R8JJBMVG.V;Q.4UM@NLER4#,;L^VKW;[J4Y.+, M&$*Y"1)$8*F,D.5HZ].(=AS5E' FP_V.W2VO69]O/4 58D5US8:0=0-S&2WZ MY7P2RCU8R+NZ]GB4:'Y)"4%H7TA3X+,*D)W((9&!BHK"KFWJ M;GCS?D617-^JA=T.7 M;WX12&@O\P:&[F8YG 7.;1(Z0C8I(%7"@BNE9R)9@W8_IY%4+U_?2,F+0$9% M86_=TW.0LH^C@-[]9/ECD+*/^U\V8-G'3CXKE7ULP=U\[J9?5L[X+S]N_LH' M]V/E-)?RU!O[%J^*H+UF@*!A()SP8 S^Y'699>J<2ZS^IHU]J:Y7W/$H+8MM MQ*Q3LEHF?)5= .(5!U%D: ASH'3RT4FM.*L]DK<:\4,5<0R,TNUU&T,J>RRU M&FORK[KI#+->9^K!\=)E'X(%?'PH&,&T99JX9*H'GVX3?>^^7;?K=>"I57]S WX.4^.Q!TRZ!:"&U_&SP:_U*D83 M09$RK\8["SXY"B(3P5VTSJK!K:'1X/:1TI.QP[:':ML'UCZC0A8?3S]?IJYD MSD*D6*8C"73BM'+HS"L+E"9C& N*R=IYYYT$C<:%'E#GNX-S>RALN#S0XR;U MR3K>?'*Q7"S=M/0LW6E:-"%:E1RD6)(=(5MP(0:PBBOF(E56U@[SMN%DA/AM M[.0<'A#CAOG[B_7,*#RDV4<-GDA7UERBM$UDX**R+CL94AI-N&,;$\\(W!71 MU0[P3X#&(>S91QCZ#?_B: 1G56I,UA-*3#ON#4L M"^O'=I]O8.,5[R. 1XLY 7NRA&+-:;*\F*=KOLY4DLRI)(!Z*T"8+, I&O 0 M.WQ"M4(AIY$A?@,;KX@? 3P&RYQV9^GXK^^3^>K?W+ DT9O6)''(3)0!:<7E M%E0!C2SYK(D.OGJ'?GTV7A$_ GAL312/R8*7(GB?2 +E!#Y:UE) D3(\T8FF MH*,*H[-I'K'@#RK5_TR3+U^7*1[]F>;N2SK^*\W#I,R;F(14<)VO<)VYSIH; MX)27FI-8:ABT@2"RTH13)DWU1.?@7#ZC6VAT88,60!JAF]61XS-*DLHH?C2F M65E2YB-882.@C<'0MD[,B^H3KX9A[1D=DH%0>IA#U0MBHTK ;71)=[+JHK#* MH3J\"/CHHZD.CJ$%7XKR,Y5E"FSMY2\#LO=ZHO8]40>"VB&"(H^QNL'MW7V+ MH#_,%$&7F)9V2N8U&&$99&5188(K8@?W'ROS^'J^6I^OEJ [1!SF,7XW>-H[ M^8U.&!\B*K[P09F,?70];ZD+4$W;A#/SO9S %9 M<\&#M8R5BDR'KF^D0*Q15@F=6/59A0?QM ;4P'I>\KOI8CF_6"%SU6;_Z:N; M7C+P?K;:^);BG=!G"E0K5Z;!"/1'+'HF5J@,5 4?HI QD-'D7I[$X3.ZX@X< M'FH/H#'E([MS>QG#3C0+[4,&1AL^@0Z4,J_0WTC5M_T,Q=PS.B0# MH'3X _4$B(TIS/HHHW==^3.!SH-A+D!8[8>*R*>3GH!W(@@>T3"+U2?J#L3; MZTDZR$G: V#/ZE'Z^TH?UWP&D[)(C$.44H(PZ#*8X @85\JD:7#,C2;!UY.W MUX-TD(.T!\#&5'OS*)^7P:];K'IN,XTA0.ESP<>W#&I.Z'Y3[K3W@:(77GNK MRX#LO1ZG@QRG_6 VI@!/;V/61:ZUS1%D=KI M+XU2"_=B5"L#Z:U;IE_=9/YW=WZ1;A\>Z94,@5C(>*6#0,&"Y0GAZ237TAMN M\FC"<6U$\(SNQV<3)FH&P6=E:707QUE"G3$9(FC&T/]7^) 9JS5D*VQ25&LJ M1E,F69'O9W3VQ@#^$1[D7LA]QI&KQP61N0K"&0_4<@)"I@!.4@W6)Y&42,ZF MP8N>AF+^]1R/\QRWQ/ SCIX]+@BBC'8F9 B"4+S54+&>&0&H8^YM9C&)YQI> M>SW,S_0PM\3PL[*K;Y6O=;C2A"8ZXD46&8]XI7$'1OD(U'!G22#.BN>3O.W# M^>LQ'NYQDS[" #0E!;TH(FL2QQ" 8,*65CR1&JC&))CZ8WI[IOW&3H M[WLW7V_MJ3+5]\&G51S;NYO2\E?#3SB7MP]*V\WE[:/L M<<[EC5%[Y74&+:/%%TD*,"Q*X/@X,>93D-4+ E_87-Y>&-@YE[>/+D;55KEC M$&(7GE[G\O::R]L+)D,,.'V*CI\+?K.CWN)YAJA=0-X$\D:T 2)M5@*/N B# M5WF.!K>]YO*.#K9]5-L KG>V[%SM-G9L)0Y\03(#$90&SZ*&')6-5ACC:>TU M>AO(&&&XI;E^9W65,\*1I'T3*)P[YZS-($U4()Q+8&VQL)UB4MO,O1MHI6,K M%D>(\\:.SX@A5/'$K':;/9G7=7'<2;Y>?+9B=G%FK(B6)@:<4 S :G"E:%QXR96@@8O3OV]HFK[S-=-=7--EAVIFG\61(LY94<^%*)Y9>MU<.BQ*VV5( M^RA[G!E2EU)F.@C0H31F$JWP8? :I$*49:&9J;[8X85E2'MA8&>&M(\NGDN& MJ0M/KQG27AG27C 9(M7T%!T_&_S*4K]I*#BSVFRB#%AK!#@O*54YE340/RUN M>V5(QP?;'JIMG2%=IR N4W$AH1?C8P3I SIK)CHDS!,P))G(N+:*U"ZRVTK, M"#WLYKK>E2U]LJ+&E#.]SF'=\DJ/__J>RE;6MY,_)Q%=T8]NF5!L7CH6,UA3 MP@8^)#!,E<@%17E*QD4839:T*U,C1'1C=V=4,!G[.?@X6?SCUWE*[]#YFJ?% MF7L_!06$RIA;[70?][[-S M_)CSR?+'BD4J%14D&.!*H0)8"5XS8X!Y:KG'/Q'C/@F;V7H]"P>&RI@2OKM8 M_)3FW^@9]5K*8#@H;P*(+/#$1QN!4K3Z>+2.R28A\B;<_)S8/SPPMB9\*Z;9 MWA]_>O?^SCC\?3J9?%A_2_ J^DW #V61LHJ'T!5N1\3I4%GQ9&QJ)-B'KY 3W MM;WZG135RYEM_)Y??JPK(MZ:PFNMZ9K^HC\^<2[^_"TVN^JE>^JA=,A@C\/T7'SP:_/!+%J 'AK"GO M!EJ@5 I(5LJH.3$Y#QZQ'0UN>^6KQ@?;'JH=-%^E#4HC,@E>9H5>CXG@R^(P M)ZV(0GBJ7.TQTB\]7]5+UYWS57T4U2!._S$MEO-)\997I'U&S2P^GGZ^),X: M;76B&;2C' 0U!*S-&:1BA*K >#2U,^T["7I%4D6%-;B/CN)_72R6*['\.IN_ M3_\Z"F%V,5V6HN@YNOL7T[ 6VNHVUYHJX80!*U9Z*U]Z"U*+->-1IC A]F'J,.BI+ 6>W\:2?"AK=V M]M?A_<>EN@(:V,#OT_+=-,R^I=]GB\71GVYR7A[53[-;W8-?9^?X78O5^WOD MT0)S87FFA;;,QY),%:7*/%AP&2UY$03Q6ENA8FWK^(FD#H^DAJ'T(=35&F5G M3$J*?AZ#R,M\:667*'@.$1,8C:=D&EE\P;/$9O)^<7 M91KK:0H7 M"1%KES4\A=0 M'%&5_5@Z B&11NZ]T+IV(K@K;3\'NIIHJL$(@WM3F*ZFW*S[W4\NEHMBZ>$Y MN!8*=4EI-.A &87TTLS 1RE!24,4%\2ZZOF/OC2^* .IJ8(:/(Q=Z5V)Z"S8 MP*VBZ'^@7X#HYQJ,5 2B$5(I0W@VM2VG7@0.#Z6V^GXBN/HK:RAD75ZC#\5S M'2JY%E0TWI%RTP:I$@C+.5AN,S[E:#T:Z:4/@V"M.\DO_R)KI+X&IA>^YO-5 M<,V=7]H-*YKO/NUORDZ+>8GEG>2WR2]O;,LS(8+A.998?MEYK'@&XRT#9AU1 M.D1J0NWXPIXDC^3N:P61V>'TV^!R[$3^P]SFK=3GF,L9$TT"#S=X*G& M7R9BHLI2:%7[?MR?ZE>0-M1R@VMTB\6Q37YGQJ)/Q<"6^JOHGN[&JRYT9@YFL9+8H\_G%Z+)#FMB X$[6=:7'TN MP0J2P;JHLPM)"'JOPFK+!-3NW_DBC+N6\1=16-TUK)9*0!O+8$OHY. M@BOS13WW,=B4S(-[H#H4!@^3'A(,3Y'[5JMDN+Z^H^ER$A_D#]IU]^W^OM8] M?CVXK=3IM_D;C_\*YQ?XX;\B=&_U'3ZLK+MYTY1AE AJ$*'!(F")0&L7?\I% M]%*'X$+UJL1*M-?K'MR3HLL]939ZYVF&+$T9JAO1D!/>0N2)6B%#R8HU:RVL MP<%0?8<'P>[V#L7!E3^:]L7]&/_EQ^8/6)76&>*U58( =TR7RNP2<_I/=+VT8"EA9EDQLIN]7 T(6^1A77C]%VH.KKL8"A M$TCWU.0A$)>SIL2B\Q>=*=:^3> BY>@+,BFX]8&XVEL1#X.TQ^JYGRO0^BAP MT$Y)Y9F0DBG N]Z@;THC.!:+JQH$C2DPZFIO'Q]1IV1=O77N>NPC]!;3"=-T M,IN_GRW3XHH@Q'XB5H U6H*0PH*)CH.B,4:BA>:R=B;K 1$O3/O[";G!';"[ M=5+JF+5%9XE$&1&(+*,MR"-P*JVR+G/\LY?=Z]H4#?6$WR#%N''YJB=$,RY! M4[RG1"(2#$T"3%!"J)R4);GEN_ B4;"OH!LD>/IUR*6<6<_RX1WS9@H=JJ&Y"TVO#;V!%'#B3.3B+Q#HK/-.UG>%GVM!<'19]1'^PAF;&G4PTHOLNO2FI4;2X M@W"0HC0FN:R5JAYK?DX-S7UT^*2&YCX*:.#>[OD$'WTK+)X)FB)E,D"0!.VR MJ"FL=@7CD8H^(A\ZUW:)JQ ^%I-YX/S=\$K?BMR*515O3MY_>O?^M^/WG_"G MTW=OCS\>?7IW\O[-WXX^_G9\^MO1N_>G'X]//WW\_.83?M3[WR[_X.C]VY-/ M?\._'/YY,5FL:/B8SO&8QC?([)>T^ WUNL #O.K1W*,*8U#Z]J[:.)PT*U5Y MK*((%V&YVK/[9K98'DTC_EZ:_WGK%%$6RDRM!)*5^SW'4J>*][ *3.,MK2GW MI$4DYQ&ZZE5GW/FVU3>ME8'?>SD0B@;G=58:GS@3\ &R'*3(GC.J;:C> M.M*#O*'J*JJC97O-1%V5C*4@8H< 5^9USH+FR#B@H&P9#8.&=F8$O$GH&47G M@Z_=V?L(28>/?U1&PJ8P:B6--'-7[Q!Y'35\G+"F,8T-1!TFL%%5A1M]UEKR M'Q0@+ 2D(P:0B2>\AX-& M$034&+K(*5KKJ[,3 P'HEL' 87?<1>$0^K"O*' M]N2OZ3I9*%DFV7H-@4J.MZ1E919=A*PS0;X5\ORH=?[HMQPJ(K&W)F8MQ-@@ M%/'+Q0(MK<7B%HUK, N>.2DA$>5+1P#S8,K(6EM&XNIDLN*U3_L64EZZQ5!# M PT2'YO(*C_.TW6>L0.!C2R&1XD[C.50194=X+&_'AI8#H\3*IQ17N8(+/@, M@E"!%VA0P&S.A'G.+:L=]CX04!ZQ) Z#DS[BKVU)_'J>_D**/GU-<_<]72PG M8?%N&JY2>58YE4,L*T#+=&RKP*SF_D6: DF))28[61*[OF5X2Z*R1F8MQ-G0 MHG@S^^8GTU4T^\ULE9%)TR7^M)C@]SR8TO_F:_GQW70=YC[)6_[)[Q/G5]LR MZ5GR0DHJ(_+E*(@H*3(<39E1RQEW,4A9.X0V$&O#0[5Y(&Z,H&BUK>.V'/%. MC]28TOP:(%@:J::BV[5ZUK?<;R5[ M5V:.WA73.K-W=)G4.T-#B.4R]R64?3)": 2_C1I8])(Y*8ATI),1M0<1+P@Y M@^IC:]7L>!+U[]V\,/]G.EPN_@$)ATZW[Y9)I8SZ!B_B!MEX11&9?2F^9<6! M('A9>8MW%]?"\*0=-;4W8^RBIUX&?<.W+'[Y<>M7EW&W')E.#H\6+W&WE=.C MK &JA-0Z44UM;>.J+XU#Y=*KX61[#KV!4L:22-\6D8E).$J" RL- 6$T 92; M0;O22#@(8);*, MF5FP7CH0(03P0:P6YWHGHT+Z:V]S>%ZQ\+8XZ2/^06/AT:#O:9F ,G@-W0;J M\!XU CSAP7E4J6&ZDQOWW&+AO332.1;>1YP5XX&W";N.RE,78G1EU6OIJ"<> MC,H*T#"31"C))*5]%/MR-?D$@;5J1M]1[1.2H%R: (K%A.0E TXD"IPZ;F@4 M!'_[9RNM',!"K*F69NVBFZJ'NA#V6E_96X6=Z^B>(O]!ZRNI1;?)_$M8GP&FG#><)J/ EP>D)."Y*OC-$Q7)2F7>Z(O +;N$ M?W6#@6W?_:*-BRH"KSCZY!8]):%T2='B$O)=B.IC271#PT-"AK4>ZNCHH<(K M";CBT[";.,J]8Y8HB*'4BR>\\)Q,Z&+EP%-$IRAWFRTQ+JUO,0T&5'H?N=:. M"!W_OP]''X]_OWQU-!&2*THAB#*%C25TG8-7D-")9CY0RE3'Q26W/W:X1[NB MG&=5A/2,BQR-S_B$60;.$ <"X0TF2@/!1^:=DFC=U!YR]F*+')ME2,<(AMK! MS,OE4*?N/"T^S/$\_^'F7R;3#VC)E=UE7])9B%%:'R-HBS:74![=,\\-V.@< MH]EQ:FVG:^O1KWH!T&D@T^8QT'6!TYF3+,;, IK596&,7[7!>;S%T2VWDDD? M4MOI#6LZ7@ (JHFY8?M7AXK)LO'-"Z9!$W2519 9K,T)I,U6!TZ3EK4CX6,N M9AWRF:FADF=0?'BSMVC343E<16(WN@Y=IO@$Z0TY#8@A)*D(#D@N>3Z9:-D] MEL"FE$79LRMB[?UL8YL&1*A(VOH 5-O2M8+W@RV.D?*6:D/+4*_:[0#/=1I0 M'[3L,PVHCTK&4L3X6 )%"JM$FQK,$S*\ P)@(1RG!2 MN_OV>66KV^"BC]A;;NE))70Q#>FJS(X+$Q@^R"H[#\)%AJ^R\.#0>0WX4BLN M:J-A"RECRDWW4M:V10Q[2+I!W+L$*F:8Y('B/!1(\2J#T _Q&21MJ:NH\[4U,)K61B,BD19H\E0JT MIH1R%A)R^B)3!X-I_RF2;I ]^.!^7&T ^9@FT\7%RH0Y"SZCPXPNNN)H#I=$ M/;Y?=%4 H 712DM;N\1U,R4O"P$5I%VQ>&WGK<2U9H$F MP+9-.8\MY%"]I1 M;1C-@A$_^/W_=#_HJEZTE+FLUK>Z18D=??N.3N3*7'L_FP:W^'IFG8ZYO/-" ME&ZVX D8&0U8J;ESS/',:X?>^M+X BVDIFK:^FA6S9O]\<>[3W\: W[XY/]\IZ/?JI%7)6_2BOE'$J8UFN"VG")"UN@$2R4L1H :4X##UGEL%Q M]*&SLH&H+!U3M>L6ME.S[P7TX)/7L6J>K#?"))!)R-6R7G#,2I""4$=' @D?>1>?3C%;+Z<7/6_">ZET%0#=9Z"R*7_C7(& MY?4L>_!(=N8Q8_/!IP[;B-!(ZK,:(JM=H_T;NCG_<8$&T"4MWCE'E2Z3%WP) M A5%H$+0(1F&U-0X7YAYA;UW?O@%Z?!?017\0#&-#G[/7UQY\=HJBQ_K&X; MZXECG@E(I,RN9$&6]%$&RK0*6F42=K;_+E+XWU]F?_X;?O3Z"L8?;F[?#5_X M DRT?<58,1Y:2%E3<071#G1T,, >5^OM;QW6NMI;_+.*LJM\.N_0(V,@!F]X MR+P8 IIHL":52Q]O"*JB]FY7;]88=+C%]FFFPCXB&WSL%HN*@Z:^M!-J"[;L M^34V6R(CLXYV:UX:Q]BM_03?:[I65ZE5;T@+7R?ISY4Y<)+_F)RGQ7(V75OH M3,FRB[DL#->D[$AVX URS!&TP14)\&[[1+9_QPMX)FM*L6+Z: =95WO8.A"V M^0WMI>9#O)U5=?*XGO<0:/U5@SL(1$>;2(>FN+..E#TYI#A5>-E0O&V\#-KN M=: /\,(>1M%]Y-A4P6_QI_/9]_*+5<[OR\5Y^;<_K@F^=JU/TW*YSI>MIR@<__4]A66*GV:_I*-25Y/BKRBSU4:.#R5:=&:% MY)%H#B;;6"RE"(8F"R8)0:3P(OMN3\D>1#Q[F RJA=H/T9O9.?[6;+VYX]9 MCNLK\*J!G,#TTJ&__8H:JJ,U@615X6Z7#DK-,W !%Z'HLPS-9H85"O:65I$Z43;GMQ# ME40/ 8:G"/FAXL5>97UW8KTIQ'];O8BK?J'I^8_'R_:-\76[QK\RFB)F(WWR&-BWGI75.BP+=_: M1*F;ON%%JW*'2!\J4-:][%3>-DS\G\<*=+ZK?^?<_>[];_W%R][S\\4O. MCL[/;WW%HQC?S?_6#]PKP. NYFGZ[NP])ON[WOU>(JCH"%CT"ILB0AO=IT*T_;^/$C5PMB(KVQ(J@#^[B M_&]N47RLZ[B^0"_*FH#N+T-7J"RZMMP28!)/==:,L]1MN/3#SQZI5O84PE83 MX8DZ>>OF/\Y_X2I9$N:$$),A>R$;&%.*/L20E&4)=F:[&O&%MFR98]AD)T9RQAF>TZ_Z_T_ MS_,NU_6^[_\V]\RY.,MWNS_?S^. )M<4-3R_@$P !],OQ[,^8&F/YM _^V3_ZO[7_C MNKWG8X?3!NZ/'!U,'![9!T)GG@*T@2,,#/]>_\=@/,KX;S S,3$>96%F8?DW MCQUG.W[L&.LQ%A96#E96-G9HL!SGY.)@Y_RW_>\D_P[_=Q3T8C_&@ M-P/!(]P,C-P,]'8 !EE_E.$_X[^<8#C"R'24&3*)E0W:H>H$ M9#XCXQ'(V*-,D+,,(=#? 2;NHR?/R%]G/F7\B.6L%X]":-*G8^(WREIX30;Q M$HJ/O<..L_+Q"P@*G3LO*75!6DE91?6*FKKV31U=/7V#6Z;WS,PM[EM:V=D[ M/'%T>;KYQ\0^#S\Y:N(R*CHF.24-ZEIZ6_?9>3DYN5_+OA26%1>45E5 M75-;5]_:UOZCH_-G5_?0\.^1T;'QBILPJAQWAN M)'TJ:SDNKFB"YWWL//;_S;&P_Y9G_].Q_^77),#.R E MCY$;@ -42DZ,%/#?FKGUWR,ZY!2<[2+D1SZ$)?:.\GTBP/7+)23ZO-LJ#9,. MWK,"RTY?93UC.>3I@%Z%F5BY%GB=IGR,T/')GPY26-RV:LL6?!X C?5YTSI-:48'@Q76*ID^^-+>>B ^6\&6:>2 MGL^G1]AB5W+(Y3\Q>&E@^\Q[SSYE\@5?F%]8U@3KK4Z?A,:Y@2BF_@NYQ&YS?&V#K3W2-:]CWK MX1ID"X[2X,"1JC29)TG.^*Q,5*#\G@;J1F/'6+ZKY1[/NDPF5^$#EY2#=,4^ MKS/]?>)I\%+;JI4[^/U07WMV*FT4#Q6YOUZ'%@YYP4+UTI]75P7 B3A^ M^(#)H\+^B='4[%MKZUH"*T2[_7B-)>KG2?BMD2K\='SV8<-]D'>:LOQ7:L&M MP\C5W M=( -99;Z/.[[O<0O7[,2*AE:9O:4TX-^C^4;%4S]X9K1/A5RSXRMG]EY_\,C M^>Q[C^&'(Q:,O;*'YH$-:=U(!4&)")WEGS_T*3K/9?/Q.6JA9,VI@LK8ACV! MKW96))OB"1FEI_E#A^T3\*26G%FS(93"ZJ3\E*)>R(DK[;D<=""$:RUC74.- M4*$[.F%7FU1YD"B0N0G+?48AV"**)HP>R>AI*&B?AOO^+J2Z\JT5%CR"W=61 M[A>J5ZC_]M-!CPRDA=U'93\2*?G'>LCP+'A$/#-WS%+C-?Z_#ZT MK1W_[0+1E@[@S^I]0]^JKD[X=31&8#Y"JH.7^T91XL,+/BP7%F@\U Q!7ON1 MK;*!M^Z1.W94EGG;Z#DZ #C1!,S(HG$R9^E CY[P J4?GNIF?KZ.(->6)>!= MGQZE9*09:>P3PB,!8F]+W3+QTY&J*:O1\:[&B&J<"I%*@ F0S)VY=(RLF"7Q M7#;G$G(]BZRC2QTC<.>7"5=\X5$Y]Q9AT3RXT87?QCH&9_X3_?_S9%(]=&\J M9$GW85+ESIY+8N0:K<6>"CXZY)OZI,+YV4&B$48#W.]:VC[;$"/%N)0M&,PU MUGBU7G^##E1>&LM6F/I[.@B-[#G;2#RP4E/Y)MW]]+JHS'K,4K #OD*;\,>= MN":QTV\8A?&7HN@A.\\6O\TR_0LR4^Z/-@E/1PQO1M=(RKG+];%G1]IM7G:= MT>*G#=;+M8N+EJPK?3?^QG1*M>L"'7A4#_O4=KU&<74%>KPF/PO,*W((42DP*,E!G-'E)9&SR3V)?_PN/NGX[UHA\8F MXU^1I 2]4J=AY])FJ9R8:SS&.L"_B3I.!UJ0\-E"6*7G>BP=.,I+6(K0$"08 M6@UIP!FG_MP?U_SPH5?E"[YP,NR^==S"3E85SDJ5(F)#MFZU"Z>=FE:]FQ2E M6#+<9[T;Q^L5M5':Y&^YQO!J'K@F"Y3S\%A X]TC--#:X.&<= M%;\*XLVP)*D1BH/=0+"78Q:>(O\@D;PZ4ISVFP[,YL#QQGUW5=^I=AP;P2PE MMBW/=>*JKXWM.NN@?,0NM>JY<<#KP*0=F2LYU6UMFW3@!:B DJ8#82FH/S06 M#I]24@]N,R&V1WDS;I2 '@L&S)!,4$! C*L9*5VB5!:XJ.GB7OG M3\SC'R&'RP1Y9^%5_I23T-4]-S(__IDD36D#)1-\=:!1Q^Y#.9;D9S&\.0A^7[PUI"<>Q!P7%$.UI4;_\QD# M)6WVH]:)S'LD+YS^UM?UUUJ?&Q$UO$5P1PO8+@KT?H#/4M+F5K?R[2:AT4A>B!8(#'1,[@K-=VN8KVD>OH MCQU/49;O'J5)7MH721VV6$09/=O(+YWZM&+1]?1MD>T86VZ0'ZJX8!E\],8B M O)2C0ZX]PG36-G(D@'^.)5T$3__]$A^__Y\R8"Q#F\T@S$2J?W9TLC'1\F/ M2%P>ZKD8QRNN(WBQ'0\ R8A;:4U0D,*A<+G1 9)#XCB7"7XSTWPMNWCPJW)#WO;"U4J;;=374IRQ>= M@@O"7="D"VD8PE4:ZR=?\C4G_I,;^*VH1YEM3_5[8ZF93G-G7D6:6>:8*TAM M:615454I9TCYN11/DL4<1C -;]A)1GS;"K$O,-V@WVP)#IIXL7#8^O718M) MS"?HZR#I(!VIL8S?]R!-[[Z^_B&GKR%?&.V_3@4A*_^_G4CF8 M,UJ79>))/PC]-T@RN6SQ)IX*FP[P)^51?UW#=VF\>W;-^QIBXL0W5'0E]N5Q ME:0\ 5^Y4]QA[Z8Y$H)^ZIGO7N_W"8VC!)60TN\1]J/RFGY__>I[Z1:AV=&G M[L\N1%RO0OKJ(^\MB6H_+"_MZAI&R-?SJG%F5UETA:?=\;,"(?W[F=16=K*;QJ!MOXTT=RNF>98[3J,.DIKWY]U%AI=H] MPO#H@<Y61*-< >FJ?D*;8458QR]8 X]AI6.=5MZ^9(I1 MSS?O+!M\,?'FD,;YLFG7DOH?VY09;3]];,P[ZF/5*^:__G;- "L%JIJP M"JA26YNDJ5_V1 V;,88]0X .; MRGU!QE>CD&EL5ZXS+&5I;W>>7'#(K ,_!,L]WMF5DFBC M_;B"Q-<7T2J?F#?$$2GAU6SFW4U#\-'; N_M+P;^""&*R_WT%I K0;M:Y#RG M"9];\Y]<&KK7YG#PS*+JPOUH^57#G14+J:A,WM!)=Z( +FK^YAO^0Z]4SP?/"$[YR)UJWCX0$ M)ZIF=V!RUZY>>4;6W]C )1P[=B4^'384H&JY%92U-W&Q/U:1P \05B9;!2_0JQ ;#4@7YCB;M\ &V.2R1AT+I5^/WJ,7%?+=39Q7Q3Q/62)+/L/V2LN M5A/A@EK"'8,?BL^CYPQB4M?O3][IU"IP:VOBSP^Q@;KN"2A"J"8NVD1&"+%J M[NI5Q"LZ<$+4ZN9OI>*'&:A/YZ_PFQ>_7-A+UD2GI&"$$;-Z&T%DP> ;U B4 M[ .2(DXV\GQ*H2Y[==K&9Z1']"XJ[_A2L2#CX#&;LN!#1),K%Y&7RR->XYAPS#O;#NR2%Y M#&\X\7MX+,89>4,5Z1)XSK/C>QI&K$/WC>LO)<_NS*K]JMTZ@O(;7@/I()NI M@0-&&ML' K8#6X&@G,*TVRJ30!Q;/SLI16=$:9AWHUQW_:1A7O1 24SWO<@% M;F1N-/:7QO7J@ MZ'LZTR0H?P+6@,5[]%-XV.95-P8);;@X#(^&9R#.591+K\+U*J)LRFIJRN#B MMD/JF7AFOT^":K-4F;T8#"\X.^A^)OL!:>N+W6("Q\D_,#]7(OSP&'JRB-0D MGWLKS=TD5>#+#^_E9,,YA'U X)\S[/:?F)+-!YT'CP:K_K.9-D#3HJ9C'@G# M^2AJ!-W<.,U:@'] BKVQ>^* M$+_%W]HZ81A'C;49^GOX!)2C XYH>.3\\2?WQ)4RO T*BD;>3[@@>(T,;&Q@ MKVDPJ+Y"05>0B[L&UYX> X_8NCY\GFK4!%JM:_RS@X,VGB61_7,XV,"N^/9W M$VRK7PI<\XI^\:PZ]0=TJ'XE'9"9W>\(^HY9J_J@(G*X'N9#!RK&UBUI_)>: M'R[&'99(S+NKF4SG?W]'G(@7D14++UW/V?"(]MW5LFJ$$+46;-'6<+ W;\5V MO,X+CU:"^M3E,LKQ2I=YB@[Y.;1(;HA'?_7EL)CW?:^=!I)TQ"98J#MN'RUV M/^F@0#&Y5NVYYF$R!'AG@Q=\BF3<-$"N;7BZJR?I4L&&UZR1V:=,W'[,F?H7 MJMVC#60C* (^X8H$*S&1>4.4D%DT!ZGZE\Y4_*U6M;S8&;5C6.'G"I?% M1S$G,;/E2+PGFJ*0'>Z+B,EFSONMC#CBG-L_6LF6[AK;QRR[SZV/3N_3758T3^H?? :YL71?=37I27 M.$0S: N1M7&2+50VG&^Q;+Y3SKR X1>402X="/47ZTM"=FJB5L"66AC>7--Z M_ID-?*=TS19M=G!3K;#@QS$Q6SU4Y:TN^1+7LSJULWALE@C M^%(Z'GIVU\2.]M0'3?@B1I>TW%]WO!%UT^KQG>J#608_I+Y5WHJ,/C>=4UV6 M_]D@@X>ZH$VM7"/%)3ZPR";!<+85^(8'-MIZ#:Z!5T[JHIP*D)OUN^)[HE'* M^XN!DAW9$S(ZI.046V>4;6R):M_W4U0Q']HDYTLZ$!BX>1W==]"0+=,S/DCB M)=]>I@."#ZW-ISZO)7VVKTBJ31>U$J=H3WTY]+%-169IP?&<&'QX>[%GH?4? MY[$DF,+,L\=\M\7$5$6#O-5$\:Y8N"/7U&/-Q]8A+!VF>I[/O$2;OHS?_ZN9 M9MN-W7BFB0^4E'N(\5F1EF(Y&Y,<]JU)*EA_2(LS6&6,8HECRR\?H"@6]!3L.3RGG,I9AK= Y+4Y8C]L.,8APVN._3QS&E]#X?4>(R:,VK]7*8V?X5\+5DZZSE;,9Y#I$OS0KE22U,)ZZ+QH,"(]3S8$L] M':B6HRBS4$XM&0PH"Z/A[5C613'A!G.WGT27AI+\3H=MT%NQ2^67ZZ[G">^ M$LV+-KP.7%[0@ERG]B/>[?XQ"+OU7N9ZL'IP?0BV<#^?QQB9DBWV7W(1U(#C MGU5_(,J1+JBDR_X)J6A1#Z[;^]&' ]>K#C;P:[1;G.&0(A8&J0)5AV80L-B. ME\!K(D,]@+_@$>O"?9DO2# >Y4)1IP/)X1_IP+@NE@[H7@*UG_:B4P;!:?BM M[FG\W5UX^3\*FX7HNQ$C]9$K#C/;A*FH2MR (L;T@Q0J,;IVOG#6*>6'NEN[ MCP>Q4Q&6:ZVTED@,W4#V.H /,#7K3_O(QX-=K.,_,^//UV'\;X.._Y);#X,?9,0 MBAJQ9P9G;UKLJB%%.]_DLL_<@3OK8*RM=S5LSX0ER%>-G(?B%^P\]PI4RL;; M8BH*JBJYWH)G'5C"%Z62O:^6L,L0 MY&@6]2NF?LL/P@6YH&M?1R_VC, M8]@DS(;DBIMW/5_UL;2A2_G3DYI:@X\)]DX3+R[6OC[BU2;#^7'L"]@B"G=# MD!XCIL@M6A<:Z\ER$7O.=& .1F!X,B505N^@F]2___BUCMK>MAIR!QBUR)*BYH(SA9-[F] [8]I%V\;ZZDT2I,8*.V/ MU#!&(17_:-8>/\7X/E&=2U;/+NQ^K8!@_U=4+[Q:(DYT0%V#57.E)S[/QPGA&YDJ/\$IY3"?V;)&N M>-)8N[S(=RCFWTGRLS8&Z7/]X7*WGW__49DM&;4GEL2-\)C#IX=,3N095-4+M%F?-AR/LK6"^-$FX>Q]!D/8D7+!(O M9$YB;#"S(]CQ#)A0\&V"1:>12Z^AZYS(LIBH;)UQB-*CKY^1N@G30_*_N9]1 M?UMLF67!SG1G?JX,&R8//7==W5]O3#KD13BF/YQ*G$ &P6]C9M.P>"-/-HA+ MJ, =BSVYG F3JUJ71T]>S3ZU%I.ME>O-W 1]+?)'[('K^[JG)EN3ODFOCH<&1>R1&JJ1+"P+$L)D5.C )XF^!\=SS5Y\Y+=*!)MF/(#4- MDY9!*X'/?N/+=H?V>D3Q1&R2S%<1Y 5F6BJE8&P]2[B'&E%$HP/+B=5S_K1^ MY:5#<>(.C4-DF(*)H /"7\MH#29#C_O)238P:A;FD^7U[S*:5K'0@1OH&ID%.$GN4L$4.)N,$1@F5ZLH@%CU^%SPUDZY MFK5"&V:KC0[@9.9)2)V(;TJGP&-7[=, &]Q/73T[S M^F<@B^O^/HU#>YB2. [OM& ".SL3-GE@=ZOYX#A7HIA&:GDT^@K-<=(+2NAC M5/$._.XRE"T)"D5:U-"H9O396NS5G@"/4ME<)\)+/T*9AI[3$QL4[\YW4>ZK?)A@J^9D6_;&^()DFPUY6 MJ/GS? 7XD"MV#&3 N/>_TKI8\>Y3".P''X>\:3QQ2Z%3/42,/PE1(71XBL9Y MN:GF'Y>M"KYY7]"R='WW[=_)YW"B>]T2UMGJX"K1'[_8&0=W@AU948GI]RT* MB&C]Q6O\*6-*(/O?>&(MI[).7'I#X_1.U;9XR%0 ME^U;^LN,B _FR*-H#SP9]HV5\BSY"_/M[(TD=T^;17YI02?0 :?^\35SDE6- M4'7LD@L-]J#BH4=M!9+83.Z&-\%/J&=7?]$8-OEVGX0FVE K-K4$>SP_DG(L MT1KPUNO>WCO.,^$CN6(?[CW[*>RZWB=G5CVF-"YW%?6RWA3GYI=AZ_ORQ'AJ$U2_CLG!ID1?ZIT^UVG+'5RSF9W2? MK@FVDRY7U%B'O^REOD+] EO\Z8!GJ2HQ&,J IXO1W ?;XU7]L4XS8H,.-2E_ M^;8OD.UGG[;97\W]V2:1HO>>.X9"A83+ [B=-L&"F#W6)+=V@S#'& =SG>.??^,,C7 MOUC5%S0WG6F"UD*X+T3FD22'+9*4;,I'%PM;O0B4]$T-5;^2\7@YP1I+PX2- M)=3"J8$'=6C(I_!"\#%4L]HHV0#3^80DY^JV#NZOH>AZN>X:O*Y194E09?5J MU_+1CWOH+G>Y>[6#RE>#>M06JQHK4AW#G-Z6)*F_[N[6.QW&P.3/>\C,5ZJQ M)K6/65QPH^17D+.*%T+.">K!PL8V9."2=( 3=%2RB ;_W8MUO0I.^1/E\;!V MIQG8!H&&GLKVH; M^D!*G8OZ$H*UW<=C*UB*:!(=D(S%3]':L=2F6G0O(A*Y??<9C'QL"@*W'^CE M.WQT($D9AL?T9>IDU=?P_#]8Y(.IB?&) M]N$_#Q"G$Z3$[UI^F/C&>XTI^0X@^)$K!<*R>IA(J=91L$5.Z\(#A$*G/\Z5 M8:Y8H*OM@6% JZ39_HEW[\FZK@?^Z $NDEPDA??.&)%,PMK-P9EF#%0A,0;T MG*YX[V!AT^299M@+]BLCIW\D??BL.]\WB1%$]6=7T(%8N L\SHK_!>54OE%) M0$J[ZI&942:8-"=:(GY07.?H=#]KD<$*LO$IRO)BPZ6E=O)7HRZLH8PS:E*F M:0Q^H^LIFNW5=QOAD0/Q/7\:QT42KZ]<#.TBY78&GZ%PD*$GNV6WWBG]+6+F M*Q9JJ&@9?&_ 8N-5 (9RBDQ4&(0_!"=,VV &>6,*W) M%ZK#^Y<.5.UOG,NC_817R,6CSKE:"_6T6MFGQ[*I8*OZ6Z\#FAF6&5=:]KQL M=:2]"Y7OL&Y4)N\$B1C'OGECUP _"3IS3\PD?,3*('T4HXN9Q2+&QVB"5VG'"1]7K>+12;C$Z#@- M1"'? P.1DU)\3U/&V)C')@,MLJXCHY!X1/;$OA6TXK/!%H-*3=5V;Z,BN>BJ MND8C'+G\&-:E7#BV7)_7SC&]^XN;V*Y*:!5BN M:#1MUW\Y3UP++.!G"!'3"%QY]"& ML0#%!D]N9VO0)_BEJWRXNL$^NOA[_=WU^6#/:AW-=PSH!5-<>EN?]AQ_.Y8[ M &&^#59IR!?^<;;(,MR*ZV%_)9 +GGSOSBG6'WXZ*Z 8^U" =Z@M,'T*H\V@&YZ4=*)+K\UCA%>'SX M6]N=P"=9-K(Q"%\0#3ER)K+/(\L>[W%%E*-B*2.1RP=A%Y/&FCN4 ^F]DW1 M&:SC;@OX=:N?DY@V4TP96X@!\1YTH%V.8YPV_93$U6$DD04CA;L]KJQQG&)S M29OM8MY)VFY\[(17>^*4_DF9*F$U^2$GLCEUD_B\3S2.:$O !& 18"7 MXD9BZ50O:.,2=6J2&-C,*QMMA(:]D>N1]%+85!BB7T0"Q)A\?B[U+O*Q!2^<\B-T3EVONG"O3P3/Q' M*_LCZB5<):S+^0YW+[67DIHOL5"8#L=V19%=_11>89QV,$0RPF*#748G)F^F M_#A\E7ARG'\!K8 M-HC\1O*DK5A0D#E:8Z^@K@)'#E!QT.?MW,[U7,)U.O =]W-LNR*6XKKW'',! MG!V&'RAE1V.)JI*TI#9DL1E>PX8.B#^G%6_K]3LBMZHTP9N\VXD4?CXY:,'J M$3Z J]QL*(NTI4.+D9'M @H?F6:,(.32FB'O5^[Q+MG3@:U=>">,>D&D%K8? M ^*0[RA5%KL7Z !S:;,X9+ W*9K<-=^# ]ED&)#]-J V#._*0LGU?T 'RE;I M !TPN.A*Y(1##<"0#O" IAM78JG]?Q.'8J#@<&@QR4AV9JD/T@0")"T(DE'* M;"&2V@-NBYC?Z3SFS+I#+3P@ MM=C01=N K)L/?]I?IWV=OL]\O[^WES>;25INP%Y#,[IW3:I%F6U--CK0/R0= M^VEY\<#]P;T-WDT(34SGN:80Q)A,8A6U1.MTL%Z&VFD$WYKIS)2V)+:F>KIZ M1F5?WUQ9PM_J<(K&T46-]L0X>TX5&Q%^+$)9;H7AWZ5;UM4Z4/],AC)9-A>0 M<;?[EH\V<;+)HGRHH?#9]Q@(<7.0O&<&-$[E=XFEN$O'V[7SRW\;KKS??RX/ MQ+V.VXA&^6G%"*8?NE&C03L$"ZT%4_$K$;_5XK=>+81R;&Q\PU6Y.N;!DNDK M+VI3'9H04Q1UN0B@*L96K JBN,AP=BJQSJVIU]T]>".'W%_XRXQS4N=LO7<2HV:[AY[5.<;05<>!3OIV M#[[;4XUW!3?T!PH0C BG8HQM=C&J8!"+-P8GSHX1YZCQ&K[XOPXO781^A&;J M9VA76KN<2+I4L4GCW3$SBUJ-F_\.GJ_O2/2=V[!=0S359/PZ['"LJ0TSDY%0 M$.>U?QC(?NQT^$ ,K4M#>/Z2(H[KU7I5J=BV,%7U;IPA$R$[M7.'222,\QA$ M$WDIZV +!(MED11%N8TYGWD.V>&?^/X?/[,?O"S"7=D[>L8S5ZS$)MD[Q*-L MLAJ_I;Q0K-'D:1 TN&>-SAA;<&^[\LNRATNV'FV+B5P(ZJ0(?2+;@:UJ!/X. MD''/]7MUT]DX4LHU/3<&?]8BFYM-I1)GU>0'V"PTU_99,8G8"4]BZ BD"I&3 MDBT8[F<*V$E;[I%'O_DNDW5Z7<;3F.'3:0J$&K*LZ^%?TB,"S(#4AL=>(SP) M]993@I]R'G!).Q6:J'(\UU+_9)/@<1#'$:V4:;X?#@N M1.7PIK-X>7V,O\Z5)ZQS46)+O(>Q=(#%'NS"452@.*E"ZN.KS/96Z_-[S[=B M*J<$WXT*]]1^],X.D+EBFA@L1'LY9PW:#6*V:254<:B=>[\BHTIH$5HPL&4 M7H&(=4=08(M/[/+0_++DN%"KF-& MB7M> 1XD>3K0E,NXASXU@ID=1KQ,N=71B?-O=W4B'Y^O>)OXXS%B\1[4;\,- MM82CM3QCM:[8;S)GNW MT8%1]"^'R#FUJT6I_&D82BRE_]VS;7^T4OK>LNN_ MF@W_BN(F/>YVHK#-R@F3R@_N'GA^J10RRU7U?*M4;C>V_QBC ,Y^A.&MD/%P M_%WKP,H0GWLU>$R8Y3X7QW+0;%6VJ-; PCM9+F#N5[/NC0OH$4\&B/<79U(*1[N3HJ;5VO[D#.H!J2B5!*I[)A9H!=Y1I",)P423Q M&Z/Y;O[G-JO^NNS(@,$A^1^,OP_(7K5XPJ\VUUAO.\QVRS1C D.20]S[ZFXH MFCJ7K2R@9M@ F5_S!]3*_K9/.6DX[[FQ5635,R?'^L>YB?]="W%I(_:]@9QH]?O";;:^9'-?!D\GLM8:Q;UBGT\N;UJKN< .,WGE6\ MXJ9LQQ/#B6 >.I#JNQ<"'ET(/(CP1?+4:0D0D<50!V^Z2VC%"("SJUM3")< MU5FM>/_]:E)V>YC*QDZG(^,)<*VR))+V5C4?U1JL3WJ51SE'"OH:4&#;8,C! MU>9W:O7YJYYG8/QBKH$\CN%FQ <&U?\70\ ME7)V9>#G&H]4.]AS-AQ^9N=3X+OOT M2;6[3[7LMF=(*P0[?4BH R33.;FV6LNJJ4O24[I#I^,UNBZ6#C(97I6"*?W2 MZY9/\[Z_). .'T\G7D"^O(R.;7R00^Z8?*%0U#WC2;R/LOZ[]*POI8YL_P4> M4-.W)!C>:2?]>)&8%=OEA&'LZGR<=;:QJ F-7R&=0+7#OC7"F"^64A"X+X_J M"?8]36P^D8D&IN-^SM_O/_W.WR":2)+F6@_BVN@GGR#--\NP>[OZ\T7>';!W MXY(TJ:$N-@E0!];9;T\G6Z _2GUEUSJ;+S2(-B(/.J/OV>GF%?;=$2[P(;4U M5&8B&M)FA$C30,-;*="7:L.!X MY$E?N^X%QTJL]SS["*G%4%]B7*SIP'@#L08OUUX,4QMK ML\HP"&$"GV]V[?#^%J^VY4^ZKBD0/HD)ZOV&_U4>-#SC99+XIL9P:Y#2/RA_ M;SZA)0CC;/.<#EC!QB[QZK6)G?M&*(BHI-K=JH^@ X8CI;F-%76O:O2\V&-$ M11&^#J?#EUWV0*W*X0JX*BM- W1J&/N-<8*+_M'W.=<9Y7M<(&OAST_$#GI= M'?,:/KG?EAP )Y:1/N7]S)<8HE@732HD#70&2M.!6]2K;>;?2WT787W99JU8 M483.82K\B; .AIJ/$KLN>4$UNG)\:MDCEQGS[3E-'774-78N,7Z&XW>>>]G* MX6)JSZGQ%UIQL6$85I[*0)BD#.8E$/:-_AL,7(['IF033SG A[>V:-DCZUK"=.!>C,Z MP+^<6#4'SO:/[<(#,?\W#GP 44_F=W2@*X]R!T+^.OAN@A#5"AV*VSH0'MM# M)FL%J=.!D,*UP]/H5/AL#78[!HR'$9D3(=\_HHO6%A&D2_N4G.QY/6HH1"V' MOLC\ZJ(#V&4P 7YHHO84N06!1SM&\< %G8^Q0Y!DP$ZY<<7F&BU^DC_.E4V. M8QJKE7\^.S!ORJ;#0Y1;L*T^,%Q&B)VYLV=8K;]/FV@:TWS*P=CF>^.$3R^;ZVMC;N5YI,O48(L< MEP6KSWX0@6OJ^\B4PG;[7PS3.+VH7_A$/^\TEXR3EZX)8W8U4*EMP;<@G W# MN&Q%JY1ZH,YQ,$]OLSI-ZGS(]5F13+.'A<>036EL9.CR^B_'UV!B6EQ.Q6S- MI8'S,*[[;56B>G)?ICIRPYAO_\QE>G*-X20?Q>KK[42NY/GEBW>$7LJ-7/D\ MO$%#%"8@$8Q1GXN&"F#*#KE:DW@$Y630O^?@PL)<^;2D1ROA)U<'7$^<^R-V MEA!1RZ=V^@V+GK92O(QN=TMD6IS\4-,Z]35\]C<=8">9$X?-26/SSHVF%V^+ M[L*X6"K+0*)]O=OM57#\?B+C7_0ER!T?^.Q7$%\:?-V.# _6&Y&?VW@1W)L.W39J/DV7#IZ MS'0D"A:8:-)YL3/9X&_]+2ETW^*%6W=,_-T.H@UJ_*!BU@^+D?IX!,,(SBYO M31G2^- ;ESY21 2:[FRPR'M5,3/&XR_A;N;WHN<5&Y,8C MLHX3'2BW6)^>AT<+;8X.-XKG]P0_EOLVW: /\9!,53& M%_@3Q"I%J+J/2NSM5*,7,$HA,*ZY,8TR7RT!N4[:$4K_%)*DLD-4H@,1+M1P M=\JC0JL#K?.D.@77%+X'!F)9H6D=BJOY0@8MN_6=+N1T7$'K!ZYY>+AL)>R$ M9>EB_,^?FA*A9 -AD"T.C_JX<)+S5V2.)+1U(M?1W;M'C'@J'E MS#1"JJ"FE&;&.\XU?5=SVK2[8<:%4-;#W\X5'LX-[7B:!ZG+,!RJBPBOB:2< M"K+Z':Q^9L2WG^6FALW0#;Z;O,U?O\UT5?3+'2!^RO#,DO_7O.Q%T=UH1ISW_HE=+V^$QT 4&G8,US9[R?R^J>2T?)\ZO9 MO:+@-3C>=6PCB0ZPA1,-1[5X5M-MG]3@F[9ZOW%BE>IMAA4_"BXVUE$6-5-M MN5>0K[%XL^P)%)9XG=J$.AN@:E1C#7)!''7#B%V/5KS.[R)[YGX_X>)CA(Q6 MF= $Y+$Z;0*);Z,#-6-A%+- 7R*2?74;:OQPW$EKM\>M*ZE6>G3@B2"3:=92 M5^=S:D_4Y:=]Y9'2ZM5OYM=GA0 TLY5I%Q2CJH "4 M]_]\;'R"A:8H/%=#C<:00WR0;T'.7]@H(6[X[HD:.C 8B_R,Q?M)D#'NB9%> M=,"_Y1CV W6(R-IZ=_%$P:>GE)/&UA%91(UF5-^B)XT6 64.OZ MR-6#):D+$R%-\4J;+.>$/?8L""/W@/3N2MWO=O>=EGQK]3*6^H/AJ-]B<=]Z M"TJ#_R$\*5BS@F0W#Q-"#5@MALUHSQ;[S/6S6M?^A5IF0Z*"FS@MP"I[YODE MG)UDS$$BC;68[-A#]J%-9:D0=GV,5%[(PBLT-+G[-W>GO$W8+RS>SH8D;)8_ M>@I!.JM'.56T-9N^WCDKZMAY CZUX9Y0_.CS;?:I()OX#,8>,8&\.]QX MW8N@B#N_MB7JFN#Q.,*7#KRV^M9\\/QBYM./G.)W>>S>AXCJ\!Y8^VO=_G?; MB +E(/PSQL% 2Y+6A1(D?2JP/DC'WY12-#-?FZBT#GFT&K]XNKQ!X1? M(,,:F8^TB ?UJ!]1'*3<9MKIV%^#P9;Y?YPM7C#4V66HW.A9[OG0'729I0H\ MFRV*XER#56 [0-X _G;N0*NQEU6&\=+K@%]#VYD;:ZOQ\=U!Q8R0W?@=16*M MPB;F;%FQL?!HO=UA\D,,;P0BA1="T-_\*VJ^@ M\;OMVM;88&YK_].L-I[)22OT&(&59@O.-L!8/I,4(=@S(I6Z#:Y7$8Y24*>K M@[VD9VZDJ,$,,LP."]&K0A@AS.P:=D+6E2HW1PY#+ M;&+V9H%[$O,-.0'BXI#"F"?]0$"'()\3Q7ANBL/TJ=I?UV=)H?M'H[1FQP@[ MR,%TBK >V5B'T$,[ON(YQY;Y*N4!R?)+3][MN(G7$[U]7JYG=I$9]]-IW^-# MP*AQ5=.CB!--[274!:W_)B:&XD5[\7[Z)QP@I M1Y+T1"?EE.E\ 37:*IN6\AV4W*-"R-EB54"&4TZISJ<\)ZE3P2M1M"I*KL6Z M+<2EZD;^PZ6J_XM+@;/#4!0%4@E7:1T+$/6YXKKG@9&$?GM\']63S7N6MA3S MR2W$_01XB_KX/WQ*Q.(?G_+_GWSJ#1V8K5F"X6]Y0HR*)?8_C*I89@%+DGW5 M.8&93:$#@IECAM4(\NKA.&BUXPT>"-RE R+@;I[W+#AS@0Y$HQRWYY$#G12A M9A^H,#,) E5X5H@6N'G-":,)/3V"))^L> ')-_/;B0[ M7&ROBSG?(&VK=7](C$>*7%U>=A4>H:J%[&:_1@>NCT03Q.OA@Q8+W>C ^-7"^QFP:M(9UX/0'UJD^&MF-!,TPX&@'8J8V\=4;WX?FU]_7(GYRD62@_&G_:X*N MJ,%AIU)BJ79STQEG.0V9XI\8PH['L6E/&8;$2NTZ,T)\<^Z+3ZV)V:@3P0\( M_,W(Z$-87..YH@=.31+XQ4G;<=MK*"=[TS_/'!ZE.CPT2WVG?SH)6?%DPH-? ML^=W8551X[F)@X-GKGMZ4_.7*RO8%;Q0SG0 &4U-,$:J@"VR\-G<+-%_7[ZA M]8TV20^/8HT(YLDF/>V'TFJ7/D]O_+1G2KM\B\%I?.E%MX%]<(@D,@SWK>KI MGL.-\LJ<]< ?3?-4[+GU'>8P?_'VDPQM+$,?QI>#3YS;K5X!SC MB,)5?KG]AV$"DP;">#-)T=5\P2P=>'%["]GG5 MM-,DN&OP1P8GIJJY_$YV=X,-C/Z\_C0./6H2O)PB-]\?/YG_^?R(2 #RNO^# MRQ$*%;;Z345#@<<$GEW^J>FZG4)\3YK#>4YAB6T$R;C\JMH& DO[I:>RV0\C M>Y.5_>Z[7SHU9O]8*O+K(/(W9MV2K Q%HVQ_O7 6&5'O_V:09'HK9A1WOX-O M=:7B7&\S.&PP [7DT+%5D6MIQDDF/7:$WR2,&DK%UNFPMX<:*Q?!&VR"W0'C MTS^M_A-#5L&OS6'MB1&'\!]HYADG];WW_O7NV^[/-!3$?A44E6==%^7P,+X& MZQ^CB#B2SP54S(X6XG>0OVM<)CE3F)H$*T;9D8W) S_W^6*E7/:#4MMB11-BQJHO*]>M^^4\ MT]>Y@0S:+6N OD=9_IO*2#9\9L_=E&21/?WK<67P07H8NDSD8^??5 HP; MEN2(G$JAG= TV>K"8W_\Y#=LJSYYZV$&)?]\"AWKWIOCARB%LXG-H$#7_X_@?7[). MH[?CZD>(<=0]Z&^Q,23;S6)?HA4;-JPNO9_8FSX"6[-1!J_^CL\;/"A)_0 ) MAD*)?\U=9C:1="63. ;1<%-JV!X7QXH_2B^&=E$C2ZR<=3Q9YM)'[&V6@C<] MG'IGOKY.2-W_#LIC\#90;%UIPG BF<#FG)[MC$]\X1_@>'-\(N816\VD+#\+ M2^_[)I&0Y2&Y6X>_.+I1#6]_] 6]H2YM3P1C9]^MVP? /:.--D21*Z3W2Q1N M1Z(^3R+P@OE MOP!NMT4RIP.5Z1&HRRM^#4J8*/-PHY%I_D6C6R-'46,5?O8L6"4=^-IQR =Y MO?4@^[>/D*_U/K)!3H]VIW_AN>4=F572V[[U750BI0:>6D3[#,[&PZM!BBK7 M.@<$+2>1-B'%/X1X0'QB0%2%1Q+:/=6BSXZZDB-_.^B)R56+[3YD/HAWR]Z M^@VK,+'S.\FQ>/I 2Y14YE%-;-5MO5[4++C1K\$ESS[XT/O70$(KYOZ\6_': M.Y_"HUNF^^D%DT@_C$1(1$@X<=SQ7*/O <0$X4E4UK%LV@BR(B*<;(/Z19,E M>>+L)?4(3[*(GM)?'"M3(B+F&.:#38KTZ^:]V0FVH3HH_CMYA7WWPBONK!!= M[79(71VWC*=AG9T;,F0-4B;1F+2&\XQLDJM0>0YQZBVAH5D@N&XL(L&I"ZCT MUNTZ*\)>7(AKBH%""?71EFOSU!>@NZ;JW3'9#&PS2D%G@*)OH&53XC';%J!' MO9S"?N?X]N1#!@F+=3B%#^)\QQD\(6K"27*$Q6J(???9FK_9B\MWD^^;,F3/GO.^9,[/ ,IU2#I&^"A?!G"DO M3QTX72N>+N&,L?YLR[HZ>MA%1+Q7!D?2;XXI:?L:-P_OQ]W X;U>H:^]\)1U MO8])'/Y/ZF?8^>O8H!Y?+9509$\J^$.1L7_H)/+ID;8&,,N1^+227?'] 2:= M9K6.<+6L,9V?T5>ZK:^D*!FXHL=>FNMR4?_,I?E<=#N:++) Y;O7]E.#-XX M6M8K2PLV_F0+8@W,_&>GZPI\4-[@>^#D<,8G^?T5O6NG4VF586_JPL7BTAZN M/.GI\2GF%'FW 8Z%J*N(RK9K\*1E /4:T.-O=(!";PO""[8W82CO,5/=((DK M_RMU!0,S=*#-T. $5?EDZ_]%C8T,ERUY<.G-,+""[#_PVK([ZM"EZ2.D^W$D MY+9:)_?->8VR9P+D^L((83FS4+ZMJ:#*EU>"4[\7C%A!IKFM4/1NNA:1KP,T M%8G;B=:RYGDO?(,H$?E*V=Y06C)=,Q"2>29UF.?SI[/RL;P2\9AUGCA#3Z[7 M(?E>M0.FWLDQZ[!>ACQ(+'V (8P=]57R]YT+O7PTTCJ*HHR05J8]8,RS/T9^ M&TT6F^PT4(R;]LL%' D#W] MOQ"J@%'H'Q@'N0-Z#-#RFV'QIN\WOCL&N* G#:D>C,6KN^^*X(#YEP_V"PU\ M4!/NJ^E![%T"5U@0[%P%(^M6,MQV;.A<6!6AH1=TPF_&3@1KI% 1R@+W0"6RN,0M*3&V0BMJ30A M!/PD ^>S#[-0IJT>HOJ-X11$2SYR'K)]G\@\ ]J$^^I\/48+9B:SU MUH%X&(]C@+NV1%>F$*2A_%?5I%)$LHM&?XS"[7M=9#O'VSH< M719JHCXU^[(4#?I0)@^M$,Y&1G3-LXXE/R6L1>'#.ZIR3BVK2Q$?UFFZQ+6) MH@D5B>"N1H(!5+-#2LE'K\/^BH>K:-CY;=W0.09$5S\I;;='M&C3%1&M\DN] M#1^:+Y$'-IA_?,62>(9/\3V)"U(#2/44]5X/8U)ZF8\/[(V 8XVVGOE1?J.I M+/[[]CI_)PX4^]!;%TECR&8L#SVT>?GH27;1A@:FM"EO!OQL=F;^V?R#RIG9 MNR))-Y<=^>WY??@?BH1QG%21WQ M1W+[IH)4@KOE7\%SM;OYY[_M29_I"9[<%*=1!2QB)ZW,=;T\/ 2-E"IJ'WS@ M=OW\81%P2BPS#)L")DMQXE.]*0'P&1TE(CG-;>A/'7V 0#5)7'$OPJOQW3R:=RPR#JG"'-)2#[;^:<\#6RBO3*K2AB?71JET?<9::F&P M^ H(50E,Y98W(2K3T!G?8%(8'9%/%7]4FB1Z*Q^1GE]S/^%]B(?*A\O' .81 M>@^6D(5=1)D&-A_-=$_J2&UR%FO>QB>^/X7G78,B#L&,,GL\N#+?:J'AV$UU'O1DN@4K=SK3)07'I_*MP?HRL=(APB_]'&[)QEC>%1)FE M\@ \"/GG?VBW7V%G5=:A1S'2WYTA@KZ@+Y"C*:W"U\K&JQH*BOUDY?YH-AA] MLGV5MJO7,CQ&VDY9Q#^(T>W MG>JC.+[)_*+X=MOG9_%0/UIM'5 %BB@OC@&MJD2VCH73^S%-UD1@I,7, MVX#+9QO"0Y+%6)-.#;%9)&;!;T^8=5WR(J'!0R/%D=EH'@6/BJ/9L=/%43EW@P;Z/OONW0,H01A M@JWBI%ZL(872?NBH;"U*OJ_Z]<$K5C5SDW4 M4@;)*H,DL[JHPD"C=G\\;9VJ[__P&-#\-6$$Z]!#7I-M>W[S^4I^8(>$2\D; MS&;H=ZXHA:H?KJR4AO%F0 (\AH;<1K!O^T[H)TZZ*CT1J/C@EA&1:5W_KUC9^PW.H M<]W0PE5R>X8Z&%\@MC+]E^'IG.Z<;+W\0U!YDTE3#!0J0 MKM$"['Z!6_&X4$ M.O,'N?CP/.4T>PB,0U@N5-=0N11Q7E1NSF<$VF3[E@?",K+MDK%0>&IUB6Q& ML<=-<[%P9Q&DYD67S.BS029M:++J*,F5;$[4;(/+#5&E2VU?SO..X?>AUVXT M^&K="!2S=IZ/;[\=:2%NH$$60/IB&K4!NHQ>!D990X066%]4DQ4;GU& M+5:/8E(&+\ MY &!-4:352'=532P;F,TO7-3](-L_H>VKNNH'6E)T5FK?4T*A/$Y"3H;?0%\ ML0K!#3,)_LI4*OSH_2A"^_TP(IO)PG-@&E17B &]CVZ MO+]#O2F/):_"FY!$.NN5A^8=>H_=Q;:3'T_[07WQ"E3=>TK. @4U4&V^0Y0! MO!6(\?],\8!W9[*04[\?WJJ)JMJ'4EX,Z,9M!\7_X0AJ?53*G6GM7Z/'LY6Z M#"Q';/,O>$M8TO9INSNQP_<$:=(TMMH4QM)ZQOWZY"0DHK=I.20PIU'X_PSU.@S=*9PI M=?N!)XJZP]EU#14M;C8H'AK3:D"+*5@!K&.VU9Z"-7.CV]M,2YN3J)/R?^A9M9DMXFO_W#EC/"YT5C!0XU M2?$,Z87H?0QZTM_?\:> ,-_6-HUID9F.C,CUN&'6571EB=9[:PL9]T'YB$=8 MK75IG096S>IK0 \,](.4:)RY^:B1$DY(7+[?' )IDJR53/)A^)C/6 @X5J6: M0*[PN@13',]M[18N<)E,"\'^SIQ5GZ&/?1 *-5E$D"4/?@*C2+UR"<0<7-S$ MSJ';O"@FPG0_;LX.?AVKK2.!:,ES8!X7_TP5) 9TV$A5/S)]>?14(&WACHW* MN]V.(!TT(Z0D!V[R?WH&^:MO>@DHWS MR/#BM31!J8)BJ=I#I86-(Q0Z?0V/)8#;5&1]?\#LR*X0SW?B?XC:29P3AH=8 M4B1C"!%8-]!_$^:RR%BY1D2A7KXK,N+5],HM_.>5*6:6OV)BP0)D$@B_"4[_ZS MF'Q8NN8(D.]"C^P_TV5+;K,=]_ADN9/V3QW

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

X\)HJH4M077)S M<0:UR0$E%CITG%5AZ3ITH0 ST;'L.>.B=?[A.9HZJV+;"P'/PFL/=70 KY.T M,KKW!RX$$;.6KEPDZSQ/$%30$ U3/BB?BFC=XO88+;W!:1^-SP80?P

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

0QP9#B*H1R6%YI^D\2ZM?+ M*KWKVL#!FH.:4SAXL]"P,CU$\U!)W"OMZ=2%V@+GD:XFD^EO6 D4 M>R=F3$G&-7_7:LQ#)_?&ONA[U#$:0]4=.$(W^@.N+K779V&Q'I$H.B MB2/E#<7@*6 =;ABEYQB%&RQ >(B@3D X"E8>;_W94W$]H7!_R=X5Q^7^4UZ" MDYF!C8'\LLCKB#)&-J*8['3R 3G87\ #F>3&Z!A[-SBTX^) M7D2A:Z5/%+EVTC %WGH.3&?.@[4H>'K.G^[]4;WYWU%A/Y^9AIE[,-;(C M;H<[2 U U-.INI'4^N=D^>T>\XO;W"]NR^KJBE_]KE.K')=%U5UA18$J48#S M1D*0,@3'R>X-UZ;=DI$7S_'D9YLM1#]$CDO@' M^'*&Q$,Q7O#1D(P\:I/(^N%@ M69 ^^1DF9U4\I(;/X0P_5X&LM#O8"_/SGQS\R7A+ MK@_Q!JR=S2*E.INO3E/0@<"F4@#IG(RUIB^GUMN,AW@#7J7U+@7]H7S^-INO MEIRL*U'2>N;K7?&_G?[$Q7+=5K+*KVC-#E#M42$;P,#%+V4D93.'/Y M.1 VH:23H&%?P-Q*NAY4.SVX%8_TR&G)*08Q!42V 113$6*=4%")Q"SHX"TH66;>"*,B:LR)Y82*W M;@M[^>VP6P%JR';8;;3; ;)79::O0OH7YFL7Z7)F0@A5I!Q8\:D^45N2J;"0 MOS[=YQ7$7T,%"1=[HB.4FIO M#.3D(T6)!L&)8*%X'S@/0>?4NE3R04+&37!U@[?]E=0%TN8_9O.PQ%>SZ?UC MPV3V(I*#XXLG/YOH!\\S@G DJ5+_$%L7\3U)T+AYH(Z0UTII'2#PS\__J$NQ MIRN'Y2N2N&HF(B[OVW!+Q.=L@$>/H +S$'R(]!>3F0_)8VR].F%3VL8=^=,- M+@=191<0_3)?)5=_/7C@4"J)UFDP3JG*3:8#%P20'"TW)1AK6J>OGJ9HW)D6 M'<&QF=K&KN2\3CV\)K/_=3:?_.]P-1906W)@BR;R&85YBHB'&$ED):$S.O < M4-W&WR,9PZ>^,H[3-UZ>IJW8>\7/Q2GC46HKBX" =:X014NUBU[4&$GQ:#(F MW&R XM/?&3'7UTZ3F^!C![%V<,U=G:X;!^AR\)3.BI%=!,/I\"A5(D11IT_E MPD+DFF[PUO4:CU/3(8QV4?AL$.F/;6G>S:9?'^:B.+0%I81HL,A&UY1L9F4<_,>(=-0 P&HJS ^.RX38A3,DE%'5:IAP[>J=KKK22@9G*NK X0OX%0D(1H>K8K! M!7N(,N#CWA.V%4+VVA.VC;IZPN*-K53\,E'BQ!LL"=L%XUT"BYQP8K#;% [!9[^CYP2IL&1+U+?*Z2S M5B7AFQ>!/$Y.)V73HX!K%XUT *YKQ^3QHL)W5_U.F$H)3" )K;[!,B7 )>\@ M>JF4HDB;J]9]]%L1.$X2?WP/;S@M=@#1NRS=?HXX^4[2GOQOS*]GB^6J#/K4 M9AF%Q03H!*\38=C:88F:N*2X3?'0^I%]6QK'O88'A,O=@HXA=;<[-F?+<'8( M;*9T_KWV"F#^QWRV6/PYG6,XJPS7KI=76&9S_!+^.I6:%>Y0@_"ZWD76@K/. MUK6&@AQN;7WSUZ#X@&TW+_9?93IVLQUS;0V0>M0%""CN%$Q3A+7 MG$.169'H@PRZ=?M2$\+'+5/I']J[:WE[:/LUM*?XM1+R93"$WVRCN2F%TV1% M"29GD$;452"ZD&Q= 4S!.,>B#ZIU\FA3VL8M6QD/ITUTU><(UL]?/KS^7__Q MX=UO;SY]?O/__OGVR_^W1R_;X[^L09?:AI0VZC_[O)RE?WV;G1&D%V_^?3Y9 M_GH_6^)50Y%BF&2AJ"GS.FX)I88H*?"F6+X$KG14V'H'Y=,4[6V>KHWOA^4W MG+^>?2=%?66$E%JTA6SI6RH<"(04!6DJM+) M"G*2_^M\S=T%5X+%&'U,X%?OC6@BN(!D^&-)(I&[XR3)LR@J.0_.)P/*R#KK,C(PY*V*H")C=VL_]_?W M'R9E7+-U.$^_@2+ZQ-/%\7.ASM:6$60)D6Y[^BDPC2"3R'4"C&.J]7#H1XD9 MV==OH>KGX;.#W/L#T.4E;DK647B02B<2#<_@C,Q0N+:HN$/6?"[>@X1T!YQ= ME/PT=':0> >PV=!.7S]/I,2$4(F#9Y6_Q!3Q5P=4&>3,>:NS;/[*LR6-XSI1 M![OY!E5=#]#\\/KMR7(YG\3S9176E]G'E0(H2/Y0OH2_;LZ55"FI:*T&%ES= M(F$00LP(/F1$(82/JOF*5R*/$C"Z;(027N3VV?V[5(R,KJ$4?B^COY?TNQD]_M01O)39QUKP1^I[ M0*RG+"1N4J;P6]7R #J1M5"@0!3%\LR99K;U$^:>)(\SK/'P_.5]^ MJ_WUF$^^S\ZG2WX:A W:QP).1D_A(M?D\7@+T4KEHS6)0LDA#.SSI!U%S-T& MKT,HJ^,:RX_O3M[?F*J_XOX5\9VKD$G"JV^\^:O^N-<^@=T_UJI&1P)%5 RVB]]H($8L&G[_1 M\;^G@I.SU:^DGSZ4NNKCZ[0>N[7QKSU2%[FUE*- QQ78D /Y0XD\JZ0+<"F% M8Q&3D\W%- 0C8Q=8-/%(ABZ3OU3#25Z%Y"AB MC;8DD$7G6(3.&ELGUY\D:%P@-E/[9G#:00<= *H>L0^EMB!=%BV:'#BSOD9D MG"X*[@4X9D@TTGN)W,MT=]M/@PG;=XCH$CB[*/C>F.Q]I-T!7#Z1)NK8D9-I M_JV."9G]6)5TKUWMJWK$))-AI@Y0)@%):6M+G*TOITX9$I[BK6/?#<@:-T\S M'*1::Z0#D'W&L[.:1<(ISL,9,7:2OT^FD^K(+B<_\3*PNV!.%<5UE:MZ3:[K M5UR\_?XC3.:K6?+3=?[J@CL>.#FCT8/@FJRXD"11S04494K0HJ@4-IM6O/6G MQVV8;H^N RB@ PO7)C*ZSI(&KK6UTH,MI8'V;\XG(Y3;[PPKP%+*F 0HK@7(H%DH_&F2!I4$ MUN'L$NB?9 H$N>5,"IWNSC=XQ$7=YJLC9Z(;JGIV"+EW8-@^(4EGDJJ]KNQ< MFF>9-<5O6D-2-E96#,1B$I2@2D)6,)C6K9@/4S*RG]@>40T%WY,]NJ#_=Q+A ME?6O?'V\+,8X"]-3']$F63(QQ^G25YQ#%%Z"CRY8R9+C/FQMDS;Y\LCC\ Y@ MEYK+OP/;]+#<3I.4'I7-4!PFXD)Y"+4J5Z%WREG),VO>.O<@)2,/KQO.-C40 M?+/AMB/539VDY>3G9/GK('53=S]VT+JI)SD]3-V4+2&H6HMGO2#_7M67BSK+ M#+4N/);@I&CM;1RJ;NJ14SJ?A^G7]8C_5[^N_YV/X=CNXD=>47[;W.^&C M)6%!D'4034H>Z%;AX)2H0F4!7?-LW$T">JE[.B@([J;;=M9(!W#:77#7;$]S M=6W?A^]7DP-\-#F[#(:IU1!,#Q$#!U68DB'[X$W[19'M^1BY>71W6&V6?SN< MCCO ^9U8_\_I9+GX]/G/B[=,78I2F.NL.$7.M#6! C+C@7-T3HADA&Y=T/ D M05TF\0Z(EZ<3-7LHKP,D/BO=QX1[G8SG/B0;+=U1]:)2045PY"Q!M'4_5 @! MQ<'MZ[-4]_+XMF>CR_?H8SXM^T)E MWZUN79R7-W_]F,Q7_\VU$+07UC*44(2J(WAK$D]Q SP+C,4RFV+SP23MV>CR MI?V8S\N^4'D1Y^6^4ZI5BA$9@@F*+ECO.9 2!%D0Y)AL-JD[7VRWV$7_G[-R M()AT,M"MH1#^B9.OW^@,G_S$>?B*;_[">9K4<4N3A%5GY5)G1=IBI0/)9:TV MR[4"R3I(JAC+)!?:-2]=.#B71QKW=)="&P)4+R $VE!"IYRA*:0N"@5%W4T; M,WCE,Y"7*R@R1!%5\P&?AV'MQ:3B!D'X. =R*[@=3_+NT;>W!U,R3PHH9.5- M("5&E2@7$Q!@LDLUE'I&KQ4%H2.W&7%(]/-M_0=F,<7D\L\B@,Z) "/X8 V0[JTB^,X MR./<&Z[DUZ.UTL MY^".W];+5O'/.MA#@F;DVH(R051>">8G&O3 %N4DQ9Z9Q8 M-^_@.W%XI'[LR(G5X<%TS)?>YM*Y>.A!7I2-J8#A=5.$M(8BZXA@$^X'4]:=6?QW$Y\G2H*EYT("=)JFW0FZ00=&<2@ MDI*9_)?X#M15^)_[G2WY5];?D[4@]SI=T"/< VW%7I#TKF8M$\PWA1.D+SRE![;\F9Z%. MFT6G@(!V3O2+.E+.HS[0>Z%G\>[KGO(TEI?,F@,EDR5=A"U M22!5%B)S+U"EHSF-NT2*_:5(7])9W =N?Y\$Z9V<\LJE_XV,R>]A,O_/<':. M-Q6MH]$I,0^%' E0=+S 2R2S%K2T.CKI2C=/&L.(X$COV*-)L0X&QQ<=<&XN MOE,D'0N=,E@A/"A#!MMY:Z%XY=%P:[GJIEVC(=\O/G,[W,'IT ALA>*_7=;W M>?$5:9(*+@+WDH'2F"!H;L%'5&@4!H\'+[4]%/,O/F_\ BS!D'A^T8[ [63@ M\X)CQMG@4H&D&"<[2D"(PBD@3,CHB\BHCC4UW<80''/N^@48@B'Q_*(-P8TB MZPW,I[+,9C*:6[ LU[5RR8%CM7H4 ^/&&8&VFS[80V<$CCE#_P+._D H;IK='VC9 MROLP7R^);K)-Y=YO:[HNY6E:#[,/!;,UWGF*^0HCV"9'^C>>',$2G28?4!?6 MW(*"KV12F'.33OX/Q;[$/9!G/#[4/91KT= M^#RWUR3D;*.)MH#5V9/9U@JY#V0H$3^Y#V48C'C2*0J';QL^LCWH6P%JT/L0]E&QQW@ M_-:&RHM%&B:(E?CHJ!=!]X^Q$$6V4++QV2OG(F^]0OL!,CI_6AT<&[.VBNH M:PW*3').1EBN0*1:;.5M)B?)>\BI&.]9TD9U4RGT[J5M/-G'&3BP[H\9[3L^ M5DH90O 4)FB7#:@0$+ROX@E&:.N+C*&UU3XPBYW?"(T1/.@0^[9P&GO[^QW M!,;7\=$"_#;3IYP[$4OT@$(2SQXU>$9GW#F7HLPVX]VAVJUQ?9N@(ZV5&!/. M>VBT%ZIRB#%AX-P2RP&ZE'^ES>".@'4&\S M% _T('V9GIB5&G>LY4\2^;Z.6IJ\4F_VB:9/USMP=9CW;"_J\@[T$%D-ZW0= M.1<#@RQ",)ES[[7YF[YG:Z_8VZNW@ZK_]S!40B[!)@4VU'YI90Q8_6M"&(%64%:[YKKT7^9Z]%0B> M?,_>1B,=P&F0]ZR@:_FKXQ#<:JV?<>"]4Q"BYMP4K%O,_L][]E;OV5O!ZA#O MV=OHN .MG=66@?H:Q!/%JNYE70E*6DYJ!@=U)H!J&-]M,E6F]A-T\R+>^'> MQSTXL.Z/&>U7KXPW8N(W?_W M,3\V^3G)%,@_"DLD8Q*U$'D M[51$=,"$Z8 MFFOA9&VTD"IU\Z:]*5.=V_[&*&UU2 :!S$L[0Y\FBW_]/D=\.R4"<;%<"40( M%VTF"01;&V]BH>C;Y@2,%^^BL19C-T,9-F7JZ)_!NSE#>T/FI9VA2Z/RG[,S M^C5GD^6OE4BX-ERQY$ :0PH3-1_D3U?8H>9NOHW]^[.4<-8-/+ M2=KEY?4ID7S!^7=^RJ/5.CD))KH$JBBR+MEGX)SB.)E]$'J0N&80;H[^>7[O M?/R\ MQ_OFCE]J\,S9@L=&KYUOPGPZF7Y=?,3Y"G/7/92.69&4@@CP8[2T>^&\^P4ZX)/TZM>ZSN7U65@LUFD,Z= 9%QEDXP4H$QA$ M4U-G=.J+1*E9;O[(NRV1XX;!37#S^%OE$(KJP#VX_53AE76^+@+P,=$=DJIO M$X($;IW%+#TKKG5"O3;XS:2[P V@[PW>)F9$=R!"I[^4E,\@6L% MZ+7.5C)7RL%3@T?^]K@5K [Q]KB-CCO ^>//6-:1]++0$'4QY->Z#+'NU S: MJZQ4Y"8T]T;^1F^/6^%DX[?';92VQXJ--D. /R$Y,),:2:T8^7,Z62X^??[S M@A7OK+?("]C )2CN&'A?"F@C&#=)R.Q:%VH\25#G^=M#8["=\D;'X4G^K_/% M3FF-*=9A;W2\C(H)C M3$ Q*$AT!G-H753Y$!TCNX##J7W66 <=X.A:.)_K\G2Z#19__LAAB:1IQLP% M4U$69FV,8*VJXX(M^1"*;@69LTV&LR1%Z\>BC0@;%VG[Z_^NQ6JNC X0]J"I MOT[3Y007;TK! MM/PP78GH[OE<38D^1:5QM?,I%DW',B0.7GD/R3B=1 Q*Y=9U"KO0.6YD.@88 M!]=F;P;O9+F<3^+YJB,WY+!HV1&:VRNN5R-Y8?#OB_,JV7HEV%Q' M(=0[(6F#H+R4X*4OY+"0A^UTU#$=!*>;DSSN!7]H$SJ0*CM +ODL\U5J/YQ= M>$;/ K%K9 $7O0#A S,V9>Y2 MZSS0GB1W:'.'@M=L/%T?"[3O/_'?J X]46)Y(*'8ID%198$(K?TM\A<-D4K M:UK;Y?VI'M>[[1[@[33> <8?\:H>D_>IBUBT=1ID[0W5&AVG_V<4/.FPGTWS!W)N/GZ^+[X,US"9&\06O M21BIP2M6P(=L2TBH%+]3)OG(>.+-OSEN)]< SNR0,N_ ZCW(&9V]E+"4 "G7 M1]U"T:/G7 &3#*T()O+4NI+G04+&<3 '5?DF3^!;R;^+7-)=-BXSM-8:C4X[ M( .KR <(&D(=%QQES,DCNGL6J#F0MDFC-W?EQH32+CHXRB;0D^ERDN^]9@W7 M"OKT]X9O"-V"WZ';0EV(CCGRE&0(]3TP6@B&H&8MZ53?45MW4_5 ME(.^BGUV0MSC#:4'5W$'KMZ>/+_Z]? O6-4Q.Q:M-XJ15H2M/17U.2,FH"!* M98Q,V=!ZUO. [/32"7MXE-ZM".X$,MV>GIO+*(OES)//GH.K;I9'")E+G;;)M=;YQR^LV"N@BCO^,T\EL7K<-+"Y9H).&S"OPSFI06GEP M.4@P/.?,K+)2MWZWN4?$N,\P@V)G/X%W8'V>[K75-A?KDP>6=2;8BT+.A\P@ MN?;&AR+ISQJC9_]&Z<&>1 9%4CM%=&&)'MS/'1FS0FJPG&RJ0J;!<53@DE'* M%#2>E2'OLRTP--@3Q^%NLAV$WH$]VJ[_%DLIB0 M.O3'OY/' ,/Q'X*3[]4NG"J.F0N=(&E&?G6V'%:+Q^D.RS'3X?__V[NV[L9Q MY/R>_X*$($&">,DY;K>[QTFW[=B:R>;)!U>9&5KTDI2WG5\?0!?;DBB*%]! M[_3#S+'L5J%07Z%0-P!8V4ZL6&'U#IG5_$'*("??1GK)H79V=\NQER\ MW4#%0@_%*=XL=4:L#ZK.Z(_/6<7SHEJ^*U4GVA>53'$0,"@!TEL]H AQ@%E, M4LJT9T%L-S^UL&/A#,#F2.Y:P8UKL]1J??TDRQ4ZU2>IBE*^LB"K[]FBT&OC M9?L8RME"[%)9/V[[7=8/A?[+L]RX^J\29$H$,8X$2&4: ,0$!"2-I5XQ"D<) MQ%%$)C@2\]'3=&M1;6EPPPD"K_7% T=B@(@^ZQ^J.N/W(>.Q_L\<&4(:&@21 M22$U%ER'SM1,EVAKI:7.F>T[.X9SZS:1^Q=8 $.TXN?4_XL?6L!:8[(%+5]6 MPICY%K%[*G$*!W*YM\0U],FOY\61HAZQW$ MF.3U![T]A*%>1BF(5U>@:3D %F("8LH85)0S:?TQ[U,\N6V-F4K'K"+A9R;W M_/IJ=GGU]>)JIG^ZN_Q\<7LVN[R^.O_M[/;KQ=W7L\NKN]N+N]GM[^KJ MZ^8/9U>?KV>_Z7_,M2M398:'6YGK!2C.'V@YE]57FBTJNA"KVR-'Y(@_E#\+ MV6=W\K24U[XNYW21_=]JXMJ:5D6>B?5"7HB;=T*Y5E^TO[C@&+NX[7P^)%!NTAZ MX&#L3,A,8S6I2I;/Z^?KE$)0";VA!6% S%,2!*1*>TXLE5)101EGMOV+$RSY MC6$PA4@^,S*=EE2UD5;V;TWKAH$A%@>FG3)BY M3R5D(#6O_A'SJB"6J4HBVR;F""N^=/)/NW?9P,%3=3(_EG)[R@;1-&&Q$B#D M3 $4F#*KX@D(B5)!R**(A+:;J$\RY=9"68&^@SH-Q\'U'O8EES_T#&8Z=*=/ M("4"S-.UHD >GJ-1@!)0^D#.7^33I']K"V4?S3D!%H M%E.(U@/CT^(,?GMM7X4A-V_B2A"'YF2"$N9B3):"A(=8.XD81BSXN.#LFV^] M\:!UV\5Y7CRR;+'-N)CC*UKP)O>2B4TEY?TEO^"\9BF,8"[WZ* 1(Q% O2V'N;]);0T0%CV/;Z:X/FIJW(>1 MG3RR%_ND(!ZLFP.Y:X]'P#0UURP*96XNCJ$"J7DKE09<>SX21\+ZI7B'7+B- M-R;7QI%B]T!Q&M930]EG-3,]#9G$$0$1B?220.:XH.0,8,1XJMVBF%JO]';G MSNV6[\+LV8#)=2QRQ Z;^J)I&ML5Z[KV>+8I.][K<"-4YCYVKMUR/4^L%QH1 M&(2"Q2&-41#3H%.H,H()MYT&DVG=AV+37P?)6@<7M M PWIDNK3R[M/FT!6B1!+JM=Y9 +959XC(2F "8HQEA!#8MO;[,OC/T,301]] M/-Y$, &F'KFR^ZE?(1&% :> Q*:!/<4!8$1/(\4TAB'B+"5H(K]U2/7E SH' MIL"_8PFF#QB>ZM1NLCA!*A8J)("PF +$.0>,(Z8_AYVMXA?M(23"_H M>Y=@^N#@.NQIK1.(5 =O)$3 O+5ACDY2O?Y2!%@0<BT8 M(#P/]IQ3;5A<(AC%*0=)**2>CDP!11*""-(HA0(%^M<>=D1^0%?)!_@U-L'Q M0->.-W1!$@0A#4*]:(R0L-2K$,<80)8D:6QBC<#VK>T_:5MD+\@[MT7VD;\' MBG2]D+/L4N4:K]0$R%>4TS22.<,*AL MWW%[BB=?>RE[05],B(-#O:K*^OZF+(06S75YI]=:QM>KC6**TRB2 ")FZFLL M #1"IMS&11(JF:BHDUW2 [S3(?WI37^.C>U+6\F$VYP5L?NA-J8:L9E!M5U8 M$:,A"1(@N&DGEGIAT=@0 3<&QPZFAPHR4L"N ZR+ MO]V9_Q*]B_9T MT5'/8A_%&-MU8>$LW;.>P5S>T5Q6-Z7>H+[3IS><^%B D3 F"B M;0I*F ZL690"(B@-H:(1)*33GGQR*.\2H>,4;P+Y>F!?FSJ.[FD<"J%"KK<< M\UXY6YT[9-JE24)!XC!F7$Y[ F'-A]O0<#++-5KD'JA-C]9)2>*4H1 #',00 M(!XK0(B2(#97.?((2AS;SJQ;[G"=S"O\R,W1!CS_E!<<;5WS0C4M3'<]AMWX M%?L^N'B@9L?+AA1C MA;!,0928@S^APH"%!.G%&2(>H"2- MN[PT]:L>\%>>>*?1_Y>Z!(KZ_L2I,H M6'"Y;9*+4,K#, 6)HDR;=Q$"@A #5(=[/%!A$B';:G2$%5_K\[V /O:V\0BI M>Z \)AEIG(%W?0;;AYH5)2:M9*Z+CP$B#&I3G2@@XX1AEC 98ML'08XRXS:M M-XT"V9&\!RK4Z?1BJ"-[B#@%>@FD ,52SPD%TNS^"@4)YDC8?KS,V@4C7ERC M-9'G- PAW[1N,YG;(L^_%.4_:"GNM:Q@I)0$2 J3RHKTTH1*Z$44!CP53*]3 MVP]:G6#)6U=JH ZT*=E(0#S5KWN(8,2Y8B Q;>(U#VP/#?T996GT_*XE=FB6J["BWO.E-[FF01) MI,-O;3&]M#!Z;] MU#PV_HE6)BQY-$]PK0 S[];0ZN&>4"R4<1T1,H>".0M &HL4D!A'E(8T4I'M MK'A?'CW:]J9PP">%S-W.$XQ"(EI#I!!$/$(:4X1C;;E'M MQ>!8,V//^;)KW>,_0/;]M%PX!N VF+OL5883K6@S77FX40"QZDVFX!%9FM$0<8 MD%3"U?O!"4P$9K0M5#NM!.]'<[,OC(:KL" [U\;_Y,5HH4@B@"$SA[DQ 03! M%*1$D2 6(:&PVTD[_^Z<&P=:KZOENDK0M2J<:5')Y]7N>*V^9[FLZF*Q=I3# M)(XQYSH$)S@ 2& *6*HE%.D%PJF16-3M_:?C8[BM UG#24T,.]A!<;'U0H.M8:SF&,R2BE<;@U6,3RM%P,$ZI5F?-8_Y<63^; J M0\R7N?GNR^L$7\,B$H@P3"2(@M71XC0")(@@D E1090$A$2JO\IT'=X[71J" M^U%MF@0$#QH8#DSS6WTK4$D2I!@!Y=P'HM^J5&.A<+T+?LOJ;+Z"Y$[6=;ZRQ.N+62Y^/$F^ M>H;FDSPS?2!2?-$R7KV#QJG8AR+B6O/.BUS_JE@_F//N?J#7W7[;?6:F>RNYU/],?*<_LL?E MXSUB:12JA&L/(S1]2:8%34D) BRP"))$NR'=W+ Q7'@6\%G0O0_#Q(,MM>6( MR7:AF9_AO:!!@HB(@#2/.B!B[I1-4O. )F0)))A ,FF3>PMOGGEL=C;828#Q M3>&VO=A10@G"4($0:;.-S/7:*0Y2K1(ZE,%(Q!1->WB^1P=\_#,KTA"!NV_R MVRE%2"[6Y%>;_RQ[- 4WF'E+K7W- MW9[OKR+\]/+V;S9;VXJ]-8]Z&'-_2$X7[_H_[*[%25BT8:%SNA]C1:JE,B'VR-HN<):)<+D3UG8DGS5;?D&*#V2+D- MRMIE7IP2@.NEE.=O?%4G$SL=%E$306<('9%YT4T 'E2-WE))[8MF2,9ME[;; M8+G3*FH5BG6P/KIAJ7E6^Q>-3YF4=*_N.WG0ZZ=W5YY.F&S>&&Z?ROU ]>@L>M<.3-/NH7=T M,T/[T<"6 MN$>M320^0';QH^2KE_?&X_1&JA,X'I36#B;O R)?]0Y0?Z:U_$*SJ=/ZPF-_P<6;O!.E.T+FML743CJ]->9?K MMVMG)16F;_6=3[;+^9NND^6O'TGV56:27[[RS/,_K8J"!'$&C^IKL$5U<4 M6F?L$(G_*!:T?J"+N[Q89(T)F2- -'[17;='5QS:YNL0AANZS'^CE>F3[[,: M&K[FKI&C*P3'Y^H0@,^T?,F_TN4\[[4A-'S-74-&5P".S]5=0^J!G&PDZK*R=PN*];]\F#,Z2<8=,J[494 M_*I(-T0?=L*#XX0]P*JE0GU2('_IWHY)G/:N:^B#NCI^-4UT5,7O=9F;-R2K M:S4KA8;/3HM?"UEG*MIO"SXM&.<;L>'*1NENEY*S>+.OB]0P?5\@F67U:.]U MAY2S"'0@*#L"<(S*[3*7,& Q-$Z#*)YJ.?[$QS&:S@+5?CB=$(ECP*Z*Q128 MM9!U=FJ@'VRG!>.% 5SQI85G2HH6C. ..6?G H88PB9!>&0,9^7CHK9K"]^1 M='8&8+@I/!2(7Y;0$F#'J3KKTQIE![V#;1LPE(_9@EJTA/L4W75H#;&&1^3A M!5:?E^6*,0L@O9)RUZ(U!)U]"7@!R[N>OOG\[)EF^=AVQS:Z[OJUA@#6*AM? MVWXNRM5YUXGNX3JD;J7)YP33%GI[;B4OGF7YBDQ!^E8A< M@?+KX.^O&E;?*/E*%C9 V:7D=1_JT8E[M*_(VF((W$K8F5$;ZAET$9-KDS>? MUYM)C3YDMDO*68EQ*%K-HG",SY:A!.PW@K%XY%-4^8G.,\/6RUC9^L"U64?/,2U#ACVV<<9[532PAW$:*' ML/^1%?E*S-?JM^)1GINGO\J7;_0?4V#?.IB[:JQ-#>@B3P_50,_X[TN:9RKC M&^YG],Y;I. MR\BCJD A*QT7WLJ_+[/RU:[8,IK_XR]+4+Z.9YJ@Z@7GURL(#3&Q67/26G95VT3-Q]DX]FZ%\?[5K\X M+^YD+LU#]QL=&EVZ:*;H;B,9AE>K7%S'*9H5\>K47RN5<4WWR\+.6CM-W9T) M'(9E9WFYMIE2EE_+8OET655+BXBVT776G3O4CIZ6D6N+^F!NA!2OC-I"L8VN ML[[K13*N V43*6H.#5>V3.,QFL[Z90<"=T(VKMW.;6;X['ENS38>)>JN MU76HEWE"/!ZAM^+LG86P"6(3;7=]JA:P;!&6#Z;TE57K!O4H97<=IF/LZBE! MN>ZL^/LRJU_,TWAK4>KPYG%]LV.F-#-2S]86NCV'2JD6P;JA+A7N:,!8G1]T^2A^3$SWR2_[(#>=8Q.>/N4?>HI M/.\6^77]8-YKFW1]-X_1"6J?$E<]A>=Z55.VS&GY+:MJBZ7NXU0[P>E3.NND M@%P#>&A91M_]VTRR4[>"3\FL=M$XS_QOC;]] $_1[H2D3ZFLCL)R".FR G-* MG^Y?'?=O1=76KZ5HQ59,;+ZX03*OJ^UOWB!MIMT)1%\26*WB<>[M['G>8Y=? M(\%.M3+J2SP'R] M4&/W_:";(L]X)JN;LN"[G(^\7:-E&"M7;72=AH5[-XX/=: I P^RGJ8_ZLCM MAKQX3]K62ZFGJ3L\"-H9M]TSNQWEY?PH=1.?5T6]8=6.">\^BK.37%9Q;I'? M]!9]\P?S/T8K^>__\O]02P,$% @ 4X"G6-;6BN[D!P J2T !8 !P M8W)X+3,S,3(P,C1X97@S,3$N:'1M[5IM;]LV$/Z^7\&E6)< MF,[=E[L-$#7 MID"PK=NR OLX4.+)(D*)FDC9\7[][H[R2V)[L]>N=9?V0VJ)Y/%(/O?<0XJ7 MJ<_,U64*4EU]=?EULRE>V[C*(/V6):ZE'J M1;?=[8G?;'FGQS*4>^T-7,WL7!Z'Y\MC[N0RLFIZ=:GT6&CUXD!#][QW&EUT M^W!ZVDL@/N^K=GS2[4:=JAC?-3 R\.,ITW4Z#^![UNZZQ? M^.%$*Y\..NWV-P=<]>HRL;G'_DIL'WX&,RO&/-S[IC1ZE ]X2 >AZ:PXML:6 M@V=M_C>DDF8B,VVF@V_?Z0R<> L3<6LSF7_;<#)W30>E3D)%I_\$] G=X\=) M>CV>H=CG&$H_W./>VL]#J[N MD9OK)_;5]>V[FSO?B&50N)H&DC\X.2T^._#ZE^!=,7-(0-!YPI!,&AB'/8_F>N= MULSMC]_[\,'$='LT"302= MYQ>=X1'B[&)WG*UA_L]DV;M[MNS?28>+C_7G-ET8'< MHFA ^U+G0N934>6^K #]1QG!B@)Q($6&3Z661B0RQE>EL)GVPMM0;Z5"#H@5 M)\LI5B?8H#= 7$["#9+= UJW"88VRF1#1=GH:G!M23SP6H M(!*=(Q0(58NE;R!*L3H6ETOE.D^0O:37:$?GL:D4VD1X+:US Z&IB?$*1 IS$<@7B*_W58&7)VS3V2STS^$H_!(1CI]%5X=L4U-^C@/B*:> M!-'A$M #\,BKW;I,5KM,L$L:^^- P!HD1OZ=!MT!W&?=O0+WH3S:&W2W6[T. M380"A[LF7&!.K?^,PP9E_5A6;OLFE'XC$/.>0D*W58D&D/_&VC&K8BW(V0[M M3Q9\O,SI)1C)T*PS^@)4C9KOJ5 C-Z,OSAJM^!3$59'32LM2TP!TT!V<97*R M5#G2 AS3CH4#<[!U@ YYY'QJ5*!0UG%E)*4.'!8[L= 4V"(HE&5AA;\BH(K( M[M@>U YL3M#]_ $?[0W@.Q>M\]XJX+Q M-!7S'\$ D@15K1[C KHUZG0N;;;@\_"X7K RL+$A6Q*!\AHR\5HJ#X?"V=<:YHDB'9DQ4>U:\=Q,PA\ M;$(G*GDU]^LH>)5*-Q>Y\T!J+#B/*'@9S OZ(SCN('E65/;<-8E*V]O2S54&OT"36::] M!_B;!!-9U#%4KC3ZQT8.$?+(YX[R!?Y/>G\6I_!'I=%]CLDJC_FHY>C+QO'3 MJPLZ,R-%JQ&2M*FG@P+^.J!KA3#?P$U WE'*#XJ2DSYK83X_GIV?[83,>J\5 MCEG6T*14V-#!G"4WHKA6T-@$H8A"MQ%TAT/1X:HLPPWCG\"#J;/3VI/&)ZDI M]G!G1](A*9&(&H@/8.Y$A/%W@1J*C9!Y=3ZV9@R4?G,YJC]OE#7=0E88.P4L MG:0V<*Q\ '0$Y@?1)JV5A=\&%/OYI=OS9K5V(<) @K*)GAA9.!C,?@PQ5Q5& M3@VVQ ET'&E/!03]7#Y!&'XOJ>R,5%ZZQ]1E=%/,Z4 M5[..ZULD+;Y%X%YT9CX39I1!Z/.-ALC\^L/CZSVN,5<[O8AX# M]>C??V"95LK )QK8CW(JSAI\Y>K]1A;B?J_&]OQ9#[F/_XHWMR_??L]W3JZO M'PQT2Y"V!>N+#[CLWA8??%ZVG)8'UU#,Q,BYH=&WM6EUO&[<2?>^O8!W4,M9+6$NN26YDM5?WQER]6%+:F0D-U&NDP='NR2'0_+, MF4,N+W-?J*O+'+BX^N[R^V:3_632J@#M66J!>Q"LR]G/!8[J57<#6W7(R-F5Y="3I@4;PYDTNVU MS[OMDXO3Y*S+SY+1!20IM,_2\Z3#DW/X;^< FV+UV,;YF8(W!X74S1RH_WXW M:?5.2S^82N'S?J?=_M=!J'IUF1GML3^+[>//:&;-F(<'W^1*CG4_#.D@-IT7 MIT89VW_5#O\&5-+,>"'5K/_#G2S L?FX/J'AN/:-1U8F<6*3OX%Z!.Z M%QZGT>4>VE%2PWP(G825/'9[L\,ISC#8_[G'W8T> M1U?WR,W-$WM]\?GLW_/7]'GG[K$G],LX,&^PZYU:AQ;G/P#+D@N!C-94D/G^R1F:#$LOMQ':7Y/)>@47"-6&.JTQ0Y]#NSUJ_,D:0]N82R= MMUS[\*(S.$(T73QC 0^V;" MH /:H$Q ^UQJQO6,5=K;"M!_% Y!0R .."OPR4JN6,93?&69*:1GWL1Z:Q4T M(%8W$NT(W6J*H$V$5XKZ]Q :$IBO!+1 M0< FP"NU1&X-&O>D:PP.(-%4BZN3-KWKXT5';W#)5WCY:0DEJG-W U[FK51'1CLDSB8UC<(>,6 M HP0%G*D@):; 6)WI*3+J3I5*Y!JB6[I64B7*N,J;$"JM24'@:\<. M$3X"$(\1(S+-S>@A'\9&,=$Y%?'44;$I2Q#HB MFGIB1(UV6VWF6&7=+8GP8"UB QLEEI?D)P]Y*] OF$3;$WV%RR<%SV=?C0V4,M,T/) M1HP^@WM)2I@TK2R!9"5O;[!:&.>Q*1T9HRV7HJ'Z?"R><6UHDB':D16?U*X= MQ\T@A&,3.E'1U<*OH^A5SMU"Y!"?AN@ $1)-F(\Z"@ZC.4)_4;'SU% MGR4B]FR7>?I_L!7,2_HC.#Y#\JRI[(5K')6V-]8M5$9X M@2:+0GH/\ \)9F10QU"YD.A?,'*(D$<^=Y0O\'_2^_,XA3\KB>Z'F*QT&HY: MCKYM'+^\NJ S,U*T$B%)FWHZ* A?!V2M$!8;N"GP>TKY45&&I!^T<#@_GI^? M/0N9]5XK'K-LH$DNL*&#!4MN17&MH+$)0A&%;B/J#H>BPU5%@1O&OR ,ILY. M&T\:7Z2FV,.='4F'S"(1-1 ?$+@3$1:^"]10;,3,*_7$J E0^M5\7'_>L#7= M0E$J,P,LG>8F)PI+^8=U_=&6N'>R+$7ZV7=UDERNK6TW>IL+?M'JR>M;J_[ZMR[: MVYNNFCT.$Q$G Z?;E5R_.3@Y>,(D_:1\8)TYC\39I1!Z.N-QLC\_L,*%GY\P M5D-^9XL8J$?_\0,KI! *OM# _LUGK-<(EZP^;F0Q[O=J;*]?=9'[PE]V_?/; MVU]N?@^W3&Z&[_'I+MPR>33H'0';9D%K[#\$=IRE1[=9MH^I9E!O2K+,PD$V MF[OW=2%CVYVC;VC8&0U[M^#!8E]Z["W="0(2,O9NH8!^C;O8;PAX,0@X_"U^ M&,#%7X/!T3H.CH,R?*8P?G*'N#0NW-;HQT^&$UB[5;PDVZ \V\LF?(2,6_GM M3;:)\*U7E.N_\<+T<;BH_3=02P,$% @ 4X"G6.L1>@KL! I!\ !8 M !P8W)X+3,S,3(P,C1X97@S,C$N:'1M[5EM<]HX$/Y^OV*/S/5E!AR;UP1H M9EPP4Z8II$"NO4\WPI9C38WE2B()]^MO)>$V*>%*VVM+)^&#QV:UN\^S6DG/ MV-U$+=*3;D))=/);]_=*!?H\7"YHIB 4E"@:P5*R[ +>1%2^@TIE/:K'\Y5@ M%XF"JENMPQLNWK%+8NV*J92>%'&ZA_:Y>VB2=.<\6IUT(W8)+'I68HUJV&RZ MKEL]\L+Z<:-&O 8-FY0V:TW2\L+X;Z^$KCC<^DBU2NFSTH)EE83J_.UZU6DU M":7T=;*C%9L'35?CQC"RIA1*]@PAUR6)),5206+[4#)_J&(">&9QRL+ MN85Q4I;1@H)7U:"#ZX3-F7ITX#7=3JWJ>+=AWPTXQ I3\=T1U^]$;*'N$!-![,0P&$+P->N>SX9\!_HU#@@GXH_[:-AB. M_%%OZ)\6MKUG>G8^F9[[HQG,QN =P;DS=7H.3(.>9@Y>K>&6P9^"WQ^?S8(^ MW!B^]]0*$L=NLYC!J3]Y[H^":67\]C3X"_S>3%NJN)?L$9NO7SDLBQ!BN]K* MO_^.=#?*LZ602X)Y%?_83A:ZOK8ZMJ.(!!+Q7)\5^0V/*0T5XYF9,1Z#2BA, MB9B3C,K*^#JE*_!#I2UZQLK&OD3*0N+L8*B0"L5BAFQ40C!@PB2\7A*!DY:N M8$)S+M [@P$7"XO)V1QJ98B7*:8*^2)/-8XKIA+C*NC[)1-4GVY2)UPS7:.H/2%/ M[2UF\AI/HN)I70,:+@53.F!P'28DNZ!%(;SC6AU(%A6,*; ,X2Z(J6.(\T68 M+@W+;#F$+4),F"Y)+JC4B,K:3M(4T _GG:0X3N8(4=HBQRPC6:C_QX@1,[%U M4ARU3"TAGE-ADLK/UW.--,)DTL0I"HPQ&(\DHHE8J)6$L]'O6\_HSZ^%'9Q^ MD77^"4Q%YBDM!LRYP!510;@IR25M%S>=B,D\):LVRTQ2X]19$'&!PFC.E>*+ MMA9%EWH1A21=)S'YK'FMEXZ/G9;;TI))83E55"1>JRG'J*E#%6W:ZDZMVMAJ M=1UOJ^T_H]:<>JO^_X<];E?S M:_"PPC>F,*7Q1L5ML7]\]QD9W,=5]^B@<=2!#QVX9O_MQ!8LBE+ZDXB](BMH MV5WZVYC95;=7W!X=U%L=::XPF/BCE]!WX#0(;A'=L4E=S;?T"TS[CI6YM9EN MY[3>-17/=620/&41%/!^K6X8")*],QU Z4,'[-P!>S?))F*;*'1@Y^ M@2S^.C']Y5X_7-LVFMY7:MM:[7MHVT9]N_D;M.U1M?6@;?=^3WO0MC>U;>^% M/SD-IN [, F&(WR:E6$X'.['L?93>_L^"MU>0D2*X70[4);ADWIHAWLFB#793N+LKTDP_'.9?F)7A;T)1H9;WQ*?GC=FO$ MI_O1AU7\D/S=?Y?4$L! A0#% @ 4X"G6)DY\5\D M=0$ /Y83 !$ ( ! '!C'-D4$L! A0#% @ 4X"G6%(((HI.(P !4\! !4 M ( !8HD! '!C.L 0!P8W)X+3(P M,C0P,S,Q7V1E9BYX;6Q02P$"% ,4 " !3@*=8UX\3H0QI "4; % M @ $'*P( <&-R>"TR,#(T,#,S,5]G,2YJ<&=02P$"% ,4 M" !3@*=8'A8@(Z74 0!3$ ( % @ %%E ( <&-R>"TR,#(T M,#,S,5]G,BYJ<&=02P$"% ,4 " !3@*=8%1V7U3,G 0#E8 L %0 M @ $<:00 <&-R>"TR,#(T,#,S,5]L86(N>&UL4$L! A0#% @ M4X"G6$.)QTL+MP .7L( !4 ( !@I % '!C#,Q,BYH=&U02P$"% ,4 " !3@*=8ZQ%Z"NP$ "D'P %@ M @ 'O5P8 <&-R>"TS,S$R,#(T>&5X,S(Q+FAT;5!+!08 "P + + -H" /708 ! end XML 95 pcrx-20240331_htm.xml IDEA: XBRL DOCUMENT 0001396814 2024-01-01 2024-03-31 0001396814 2024-05-06 0001396814 2024-03-31 0001396814 2023-12-31 0001396814 us-gaap:ProductMember 2024-01-01 2024-03-31 0001396814 us-gaap:ProductMember 2023-01-01 2023-03-31 0001396814 us-gaap:RoyaltyMember 2024-01-01 2024-03-31 0001396814 us-gaap:RoyaltyMember 2023-01-01 2023-03-31 0001396814 2023-01-01 2023-03-31 0001396814 us-gaap:CommonStockMember 2023-12-31 0001396814 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001396814 us-gaap:RetainedEarningsMember 2023-12-31 0001396814 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001396814 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001396814 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001396814 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001396814 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001396814 us-gaap:CommonStockMember 2024-03-31 0001396814 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001396814 us-gaap:RetainedEarningsMember 2024-03-31 0001396814 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001396814 us-gaap:CommonStockMember 2022-12-31 0001396814 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001396814 us-gaap:RetainedEarningsMember 2022-12-31 0001396814 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001396814 2022-12-31 0001396814 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001396814 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001396814 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001396814 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001396814 us-gaap:CommonStockMember 2023-03-31 0001396814 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001396814 us-gaap:RetainedEarningsMember 2023-03-31 0001396814 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001396814 2023-03-31 0001396814 pcrx:TermLoanBFacilityMember 2024-01-01 2024-03-31 0001396814 pcrx:TermLoanBFacilityMember 2023-01-01 2023-03-31 0001396814 pcrx:TermLoanAFacilityMember 2024-01-01 2024-03-31 0001396814 pcrx:TermLoanAFacilityMember 2023-01-01 2023-03-31 0001396814 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:LargestCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:LargestCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001396814 pcrx:SecondLargestCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:SecondLargestCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001396814 pcrx:ThirdLargestCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:ThirdLargestCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001396814 pcrx:ThreeLargestCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:ThreeLargestCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001396814 srt:MinimumMember 2024-01-01 2024-03-31 0001396814 srt:MaximumMember 2024-01-01 2024-03-31 0001396814 pcrx:EXPARELMember 2024-01-01 2024-03-31 0001396814 pcrx:EXPARELMember 2023-01-01 2023-03-31 0001396814 pcrx:ZILRETTAMember 2024-01-01 2024-03-31 0001396814 pcrx:ZILRETTAMember 2023-01-01 2023-03-31 0001396814 pcrx:IoveraMember 2024-01-01 2024-03-31 0001396814 pcrx:IoveraMember 2023-01-01 2023-03-31 0001396814 pcrx:BupivacaineLiposomeInjectableSuspensionMember 2024-01-01 2024-03-31 0001396814 pcrx:BupivacaineLiposomeInjectableSuspensionMember 2023-01-01 2023-03-31 0001396814 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001396814 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001396814 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001396814 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001396814 pcrx:ComputerEquipmentAndSoftwareMember 2024-03-31 0001396814 pcrx:ComputerEquipmentAndSoftwareMember 2023-12-31 0001396814 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001396814 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001396814 us-gaap:ConstructionInProgressMember 2024-03-31 0001396814 us-gaap:ConstructionInProgressMember 2023-12-31 0001396814 us-gaap:MachineryAndEquipmentMember 2024-01-01 2024-03-31 0001396814 us-gaap:ConstructionInProgressMember 2024-01-01 2024-03-31 0001396814 us-gaap:ConstructionInProgressMember 2023-01-01 2023-03-31 0001396814 srt:EuropeMember us-gaap:LeaseholdImprovementsMember 2024-03-31 0001396814 srt:EuropeMember us-gaap:LeaseholdImprovementsMember 2023-12-31 0001396814 us-gaap:DevelopedTechnologyRightsMember 2024-03-31 0001396814 us-gaap:DevelopedTechnologyRightsMember 2024-01-01 2024-03-31 0001396814 us-gaap:CustomerRelationshipsMember 2024-03-31 0001396814 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-03-31 0001396814 us-gaap:InProcessResearchAndDevelopmentMember 2024-03-31 0001396814 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001396814 us-gaap:DevelopedTechnologyRightsMember 2023-01-01 2023-12-31 0001396814 us-gaap:CustomerRelationshipsMember 2023-12-31 0001396814 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001396814 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2023-12-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2023-12-31 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:UnsecuredDebtMember 2023-12-31 0001396814 pcrx:SecuredAndUnsecuredDebtMember 2024-03-31 0001396814 pcrx:SecuredAndUnsecuredDebtMember 2023-12-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2023-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2023-03-31 2023-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2023-06-30 2023-06-30 0001396814 srt:ScenarioForecastMember pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2025-03-31 2025-03-31 0001396814 srt:ScenarioForecastMember pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2028-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2024-01-01 2024-03-31 0001396814 srt:MinimumMember pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:BaseRateMember 2024-03-31 0001396814 srt:MaximumMember pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:BaseRateMember 2024-03-31 0001396814 srt:MinimumMember pcrx:TermLoanAFacilityDueMarch2028Member pcrx:SecuredOvernightFinancingRateSOFRMember 2024-03-31 0001396814 srt:MaximumMember pcrx:TermLoanAFacilityDueMarch2028Member pcrx:SecuredOvernightFinancingRateSOFRMember 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:SecuredDebtMember 2023-01-01 2023-12-31 0001396814 pcrx:TermLoanBFacilityDueDecember2026Member us-gaap:SecuredDebtMember 2021-12-31 0001396814 pcrx:TermLoanBFacilityDueDecember2026Member us-gaap:SecuredDebtMember 2021-12-01 2021-12-31 0001396814 pcrx:TermLoanBFacilityDueDecember2026Member us-gaap:SecuredDebtMember 2023-01-01 2023-03-31 0001396814 pcrx:TermLoanBFacilityDueDecember2026Member us-gaap:SecuredDebtMember 2023-03-31 2023-03-31 0001396814 pcrx:TermLoanBFacilityDueDecember2026Member us-gaap:SecuredDebtMember 2023-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2020-07-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember pcrx:DebtRedemptionTermsPriorToFebruary32023Member 2020-07-01 2020-07-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2020-07-01 2020-07-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2024-01-01 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member pcrx:DebtRedemptionTermsOnOrAfterAugust12023Member 2023-08-01 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member pcrx:DebtRedemptionTermsOnOrAfterAugust12023Member 2023-08-01 2023-08-01 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:UnsecuredDebtMember pcrx:FlexionTherapeuticsIncMember 2017-05-02 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member 2021-12-06 2022-01-06 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:UnsecuredDebtMember 2022-01-07 0001396814 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2024-03-31 0001396814 pcrx:TermLoanAFacilityDueMarch2028Member us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2025Member us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 pcrx:ConvertibleSeniorNotesDue2024Member us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2024-03-31 0001396814 srt:MaximumMember pcrx:ConvertibleSeniorNotesDue2025Member 2024-01-01 2024-03-31 0001396814 us-gaap:EquitySecuritiesMember 2022-12-31 0001396814 pcrx:ConvertibleNotesReceivableMember 2022-12-31 0001396814 us-gaap:EquitySecuritiesMember 2023-01-01 2023-12-31 0001396814 pcrx:ConvertibleNotesReceivableMember 2023-01-01 2023-12-31 0001396814 2023-01-01 2023-12-31 0001396814 us-gaap:EquitySecuritiesMember 2023-12-31 0001396814 pcrx:ConvertibleNotesReceivableMember 2023-12-31 0001396814 us-gaap:EquitySecuritiesMember 2024-01-01 2024-03-31 0001396814 pcrx:ConvertibleNotesReceivableMember 2024-01-01 2024-03-31 0001396814 us-gaap:EquitySecuritiesMember 2024-03-31 0001396814 pcrx:ConvertibleNotesReceivableMember 2024-03-31 0001396814 pcrx:FlexionAndMyoScienceAcquisitionMember 2024-03-31 0001396814 pcrx:FlexionAndMyoScienceAcquisitionMember 2023-12-31 0001396814 pcrx:FlexionMember 2021-11-30 0001396814 pcrx:FlexionMember 2022-08-30 0001396814 pcrx:FlexionMember 2021-11-01 2021-11-30 0001396814 pcrx:FlexionMember 2024-01-01 2024-03-31 0001396814 pcrx:FlexionMember 2023-01-01 2023-03-31 0001396814 srt:WeightedAverageMember pcrx:FlexionMember us-gaap:FairValueInputsLevel3Member pcrx:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0001396814 srt:MinimumMember pcrx:FlexionMember us-gaap:FairValueInputsLevel3Member pcrx:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0001396814 srt:MaximumMember pcrx:FlexionMember us-gaap:FairValueInputsLevel3Member pcrx:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0001396814 srt:MinimumMember pcrx:FlexionMember us-gaap:FairValueInputsLevel3Member pcrx:ContingentConsiderationMember pcrx:MeasurementInputExpectedMilestonePaymentMember 2024-03-31 0001396814 pcrx:ContingentConsiderationMember 2022-12-31 0001396814 pcrx:ContingentConsiderationMember 2023-01-01 2023-12-31 0001396814 pcrx:ContingentConsiderationMember 2023-12-31 0001396814 pcrx:ContingentConsiderationMember 2024-01-01 2024-03-31 0001396814 pcrx:ContingentConsiderationMember 2024-03-31 0001396814 us-gaap:AssetBackedSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:CorporateBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:USTreasuryBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-03-31 0001396814 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001396814 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001396814 us-gaap:AssetBackedSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:USTreasuryBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2023-12-31 0001396814 us-gaap:AssetBackedSecuritiesMember pcrx:LongTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember pcrx:LongTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember pcrx:LongTermInvestmentsMember 2023-12-31 0001396814 pcrx:LongTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member pcrx:LongTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member pcrx:LongTermInvestmentsMember 2023-12-31 0001396814 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001396814 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001396814 pcrx:MajorCustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:MajorCustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:MajorCustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001396814 pcrx:MajorCustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001396814 pcrx:MajorCustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001396814 pcrx:MajorCustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001396814 pcrx:IoveraMember 2024-03-31 0001396814 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001396814 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001396814 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-03-31 0001396814 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001396814 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0001396814 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001396814 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001396814 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001396814 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001396814 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001396814 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001396814 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001396814 us-gaap:SubsequentEventMember 2024-05-07 0001396814 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0001396814 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001396814 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001396814 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001396814 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0001396814 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0001396814 pcrx:AcquisitionRelatedChargesImpairmentAndOtherMember 2024-01-01 2024-03-31 0001396814 pcrx:AcquisitionRelatedChargesImpairmentAndOtherMember 2023-01-01 2023-03-31 0001396814 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001396814 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001396814 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001396814 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001396814 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001396814 us-gaap:AccountingStandardsUpdate202006Member 2024-01-01 2024-03-31 0001396814 us-gaap:AccountingStandardsUpdate202006Member 2023-01-01 2023-03-31 0001396814 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001396814 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001396814 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001396814 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001396814 us-gaap:SeniorNotesMember 2024-01-01 2024-03-31 0001396814 us-gaap:SeniorNotesMember 2023-01-01 2023-03-31 0001396814 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001396814 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001396814 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001396814 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001396814 us-gaap:AccountingStandardsUpdate202006Member us-gaap:SeniorNotesMember 2023-01-01 2023-03-31 0001396814 pcrx:FlexionTherapeuticsIncMember 2024-01-01 2024-03-31 0001396814 pcrx:FlexionTherapeuticsIncMember 2023-01-01 2023-03-31 0001396814 pcrx:AcquisitionRelatedFeesMember 2024-01-01 2024-03-31 0001396814 pcrx:AcquisitionRelatedFeesMember 2023-01-01 2023-03-31 0001396814 pcrx:EXPARELMember 2024-02-01 2024-02-29 0001396814 us-gaap:OneTimeTerminationBenefitsMember 2024-01-01 2024-03-31 0001396814 us-gaap:EmployeeSeveranceMember 2023-12-31 0001396814 us-gaap:ContractTerminationMember 2023-12-31 0001396814 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-03-31 0001396814 us-gaap:ContractTerminationMember 2024-01-01 2024-03-31 0001396814 us-gaap:EmployeeSeveranceMember 2024-03-31 0001396814 us-gaap:ContractTerminationMember 2024-03-31 0001396814 pcrx:FortisMember 2020-10-01 2020-10-31 0001396814 2023-08-08 0001396814 pcrx:GeneQuineMember pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember pcrx:FlexionTherapeuticsIncMember 2017-02-28 0001396814 pcrx:GeneQuineMember pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMember pcrx:FlexionTherapeuticsIncMember 2017-02-01 2017-02-28 0001396814 pcrx:LaurenRikerMember 2024-01-01 2024-03-31 0001396814 pcrx:KristenWilliamsMember 2024-01-01 2024-03-31 0001396814 pcrx:JonathanSloninMember 2024-01-01 2024-03-31 0001396814 pcrx:PaulHastingsMember 2024-01-01 2024-03-31 0001396814 pcrx:PaulHastingsMember 2024-03-31 0001396814 pcrx:DarylGauglerMember 2024-01-01 2024-03-31 0001396814 pcrx:DarylGauglerMember 2024-03-31 shares iso4217:USD iso4217:USD shares pcrx:product pcrx:segment pcrx:customer pure pcrx:lease pcrx:day pcrx:trading_day pcrx:wholesaler pcrx:offeringPeriod 0001396814 --12-31 2024 Q1 false P0D 0.953 0.0139324 P301D P112D P329D P294D P360D 10-Q true 2024-03-31 false 001-35060 PACIRA BIOSCIENCES, INC. DE 51-0619477 5401 West Kennedy Boulevard, Suite 890 Tampa FL 33609 813 553-6680 Common Stock, par value $0.001 per share PCRX NASDAQ Yes Yes Large Accelerated Filer false false false 46546148 184052000 153298000 141838000 125283000 101639000 105556000 96782000 104353000 18802000 21504000 543113000 509994000 0 2410000 171804000 173927000 58626000 61020000 163243000 163243000 468936000 483258000 141057000 144485000 36542000 36049000 1583321000 1574386000 8982000 15698000 66818000 64243000 9003000 8801000 8641000 8641000 8641000 8641000 93444000 97383000 399210000 398594000 112477000 115202000 52446000 54806000 20892000 24698000 12690000 13573000 691159000 704256000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 250000000 250000000 46517410 46517410 46481174 46481174 47000 46000 989780000 976633000 -97817000 -106796000 152000 247000 892162000 870130000 1583321000 1574386000 165824000 159431000 1293000 910000 167117000 160341000 47416000 49020000 18238000 17140000 72026000 70843000 14322000 14322000 1903000 12107000 153905000 163432000 13212000 -3091000 3903000 3142000 3316000 9589000 0 -16926000 -159000 -10000 428000 -23383000 13640000 -26474000 4661000 -6938000 8979000 -19536000 0.19 0.19 -0.43 -0.43 46499000 45949000 52193000 45949000 8979000 -19536000 -108000 251000 13000 -8000 -95000 243000 8884000 -19293000 46481000 46000 976633000 -106796000 247000 870130000 36000 1000 1000 4000 4000 13151000 13151000 -95000 -95000 8979000 8979000 46517000 47000 989780000 -97817000 152000 892162000 45928000 46000 924095000 -148751000 -380000 775010000 12000 334000 334000 30000 11990000 11990000 243000 243000 -19536000 -19536000 45970000 46000 936419000 -168287000 -137000 768041000 8979000 -19536000 3463000 -7342000 18426000 19602000 681000 937000 24000 675000 0 -16926000 13151000 11990000 -3806000 11618000 73000 -23000 -3917000 -5192000 -7572000 -3086000 -897000 1926000 -6976000 2628000 3471000 -25120000 -771000 421000 49101000 19128000 2836000 6565000 56055000 49497000 43361000 126245000 0 4000000 -15530000 66183000 0 333000 4000 0 0 149550000 0 296875000 2813000 0 0 5750000 0 1163000 -2817000 -153905000 30754000 -68594000 153298000 104139000 184052000 35545000 3969000 17634000 -245000 201000 607000 2252000 DESCRIPTION OF BUSINESS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Overview</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) is the therapeutic area leader in non-opioid pain management with a stated corporate mission of providing non-opioid pain management options to as many patients as possible and redefining the role of opioids for rescue therapy only. The Company’s long-acting, local analgesic, EXPAREL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the “Flexion Acquisition”), and added ZILRETTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. In April 2019, the Company added iovera°</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience (the “MyoScience Acquisition”). The iovera° system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to targeted nerves.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker—manages and allocates resources at a consolidated level. Effective January 2, 2024, the Company appointed a new Chief Executive Officer. Consistent with the Company’s predecessor chief operating decision maker, the Company views its business as one reportable operating segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.</span></div> 3 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”), for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1396814/000139681424000030/pcrx-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “2023 Annual Report”).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements at March 31, 2024, and for the three-month periods ended March 31, 2024 and 2023, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2023 is derived from the audited consolidated financial statements included in the Company’s 2023 Annual Report. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Major Customers</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual physicians. The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Largest wholesaler</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Second largest wholesaler</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Third largest wholesaler</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of March 31, 2024</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ASU amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The new segment disclosure requirements apply for entities with a single reportable segment. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023 and interim periods thereafter, with early adoption permitted. The ASU amendment will require adoption on a retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”), for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1396814/000139681424000030/pcrx-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “2023 Annual Report”).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements at March 31, 2024, and for the three-month periods ended March 31, 2024 and 2023, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2023 is derived from the audited consolidated financial statements included in the Company’s 2023 Annual Report. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Major Customers</span></div>The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual physicians. The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented: <div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Largest wholesaler</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Second largest wholesaler</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Third largest wholesaler</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td></tr></table></div> 3 0.36 0.32 0.23 0.24 0.20 0.23 0.79 0.79 <div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Adopted as of March 31, 2024</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ASU amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The new segment disclosure requirements apply for entities with a single reportable segment. The ASU’s amendments are effective for fiscal years beginning after December 15, 2023 and interim periods thereafter, with early adoption permitted. The ASU amendment will require adoption on a retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-07 on its consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740), Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU amendment addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU’s amendments are effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.</span></div> REVENUE<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s net product sales consist of (i) EXPAREL in the U.S., the European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and (iv) sales of its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of its bupivacaine liposome injectable suspension for veterinary use. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as group purchasing organizations, or GPOs. Product revenue is recognized when control of the promised goods are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenue is recorded at the time the products are transferred to the customer.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to qualified government healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified Department of Veteran Affairs hospitals, participating GPO members and 340B entities at prices lower than the list prices charged to other customers. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers charge the Company for the difference between the product payment and the statutory selling price to the qualified entity. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are generally determined at the time of sale to the qualified government healthcare provider by customers, and the Company generally issues credits for such amounts within weeks of the customer’s notification to the Company of the sale. Reserves for chargebacks consist of credits that the Company expects to issue for units that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from <span style="-sec-ix-hidden:f-301">zero</span> to four months from the date of the transaction, and accordingly, there is no significant financing component.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   EXPAREL</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   ZILRETTA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   iovera°</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Bupivacaine liposome injectable suspension</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total net product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,824 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,431 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P4M <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregated net product sales in the periods presented as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   EXPAREL</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   ZILRETTA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   iovera°</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,001 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Bupivacaine liposome injectable suspension</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total net product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,824 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,431 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 132430000 130408000 25839000 24334000 5030000 4001000 2525000 688000 165824000 159431000 INVENTORIES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,782 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,353 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories, net are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,099 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,782 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,353 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 51608000 54099000 18764000 31215000 26410000 19039000 96782000 104353000 FIXED ASSETS<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,804 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,927 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) During the three months ended March 31, 2024, the Company disposed of $19.0 million of fully depreciated machinery and equipment associated with its 45-liter EXPAREL manufacturing process at the Thermo Fisher Scientific Pharma Services facility located in Swindon, England. The Company continues to operate its 200-liter EXPAREL manufacturing process at the same facility.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, depreciation expense was $4.1 million and $5.3 million, respectively. For the three months ended March 31, 2024 and 2023, there was $0.7 million and $1.4 million of capitalized interest on the construction of manufacturing sites, respectively.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024 and December 31, 2023, total fixed assets, net, includes manufacturing process equipment and leasehold improvements located in Europe in the amount of $34.3 million and $36.8 million, respectively. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company had asset retirement obligations of $3.9 million and $4.3 million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.</span></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets, net, summarized by major category, consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,233 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Fixed assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,804 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,927 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) During the three months ended March 31, 2024, the Company disposed of $19.0 million of fully depreciated machinery and equipment associated with its 45-liter EXPAREL manufacturing process at the Thermo Fisher Scientific Pharma Services facility located in Swindon, England. The Company continues to operate its 200-liter EXPAREL manufacturing process at the same facility.</span></div> 106670000 121773000 58835000 61826000 17223000 17186000 2543000 2543000 106987000 105905000 292258000 309233000 120454000 135306000 171804000 173927000 19000000 4100000 5300000 700000 1400000 34300000 36800000 3900000 4300000 LEASES<div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases all of its facilities, including its EXPAREL and iovera° handpiece manufacturing facility at its Science Center Campus in San Diego, California. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees has been allocated to the lease components based on a relative fair value basis.</span></div><div style="margin-bottom:10pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2022 and February 2023, the Company has been recognizing sublease income for laboratory space leased in Woburn, Massachusetts and a portion of office space leased in Burlington, Massachusetts, respectively, from leases that were assumed as part of the Flexion Acquisition. In February 2024, the lease and sublease term concluded for the laboratory space in Woburn, Massachusetts.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.81 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company’s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Minimum<br/>Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 Total operating lease expense, net is as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,628 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to operating leases is as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities, net of lease incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.81 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 3497000 3628000 494000 567000 131000 153000 3860000 4042000 3219000 3763000 P5Y9M21D P6Y7M9D 0.0701 0.0703 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company’s operating lease liabilities are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Minimum<br/>Payments Due</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total future lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,449 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9777000 12775000 12814000 12587000 10925000 16426000 75304000 13855000 61449000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. (the Company’s California operating subsidiary) from SkyePharma Holding, Inc. (now Vectura Group Limited, a subsidiary of Philip Morris International, Inc.) in 2007, the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. The goodwill balance at each of March 31, 2024 and December 31, 2023 was $163.2 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible Assets</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consists of the in-process research and development, or IPR&amp;D, and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,025 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,655)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,698)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,956 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,698)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,258 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets was $14.3 million for both the three months ended March 31, 2024 and 2023.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $43.0 million for the remaining nine months of 2024, $57.3 million each year from 2025 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.</span></div> 163200000 163200000 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consists of the in-process research and development, or IPR&amp;D, and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,025 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible Assets, Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,655)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years, 5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,698)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,956 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,698)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,258 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 590000000 155975000 434025000 P10Y5M 90000 45000 45000 P10Y 590090000 156020000 434070000 34866000 34866000 624956000 156020000 468936000 590000000 141655000 448345000 P10Y5M 90000 43000 47000 P10Y 590090000 141698000 448392000 34866000 34866000 624956000 141698000 483258000 14300000 14300000 43000000 57300000 57300000 57300000 57300000 57300000 57300000 37400000 7900000 2200000 DEBT<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A facility maturing March 2028</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% Convertible senior notes due August 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible senior notes due May 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,328 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,437 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Term Loan A Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the Company entered into a credit agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders, to refinance the indebtedness outstanding under the Company’s then-existing TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of the Company’s and any subsidiary guarantor’s assets. Subject to certain conditions, the Company may, at any time, on one or more occasion, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the TLA Term Loan were approximately $149.6 million after deducting an original issue discount of $0.4 million.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the TLA Term Loan is as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A facility maturing March 2028</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total debt, net of debt discount and deferred financing costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,477 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,202 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TLA Term Loan matures on March 31, 2028 and the TLA Credit Agreement requires quarterly repayments of principal in the amount of $2.8 million which commenced on June 30, 2023, increasing to $3.8 million commencing March 31, 2025, with a remaining balloon payment of approximately $85.3 million due at maturity. Due to voluntary principal prepayments made, the Company is not required to make further principal payments until March 2026, although the Company retains the option to do so.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TLA Credit Agreement requires the Company to, among other things, maintain (i) a Senior Secured Net Leverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no greater than 3.00 to 1.00 and (ii) a Fixed Charge Coverage Ratio (as defined in the Credit Agreement), determined as of the last day of each fiscal quarter, of no less than 1.50 to 1.00. The TLA Credit Agreement requires the Company to maintain an unrestricted cash and cash equivalents balance of at least $500.0 million less any prepayments of the 2025 Notes (as defined below) at any time from 91 days prior to the maturity date through the earlier of (i) the latest maturity date of the 2025 Notes and (ii) the date on which there is no outstanding principal amount of the 2025 Notes. The TLA Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of March 31, 2024, the Company was in compliance with all financial covenants under the TLA Credit Agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to borrow either (i) alternate base rate borrowings or (ii) term benchmark borrowings or daily simple SOFR (as defined in the TLA Credit Agreement) borrowings. Each term loan borrowing that is an alternate base rate borrowing bears interest at a rate per annum equal to (i) the Alternate Base Rate (as defined in the TLA Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 2.00% to 2.75%. Each term loan borrowing that is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. During the three months ended March 31, 2024, the Company made a $2.8 million voluntary principal prepayment. During the year ended December 31, 2023, the Company made a scheduled principal payment of $2.8 million as well as $30.6 million of voluntary principal prepayments. As of March 31, 2024, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 8.41%. </span></div><div style="margin-bottom:8pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2026 Term Loan B Facility</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a term loan credit agreement (the “TLB Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the TLB Credit Agreement (the “TLB Term Loan”) was issued at a 3.00% discount and allowed for a single-advance term loan B facility in the principal amount of $375.0 million, which was secured by substantially all of the Company’s and each subsidiary guarantor’s assets. The net proceeds of the TLB Term Loan were approximately $363.8 million after deducting an original issue discount of $11.2 million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company repaid the outstanding $296.9 million principal on the TLB Term Loan, which resulted in a $16.9 million loss on early extinguishment of debt.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the Company used the $149.6 million of net borrowings under the TLA Credit Agreement and cash on hand to repay the indebtedness outstanding under the TLB Credit Agreement and concurrently terminated the TLB Credit Agreement. The Company incurred a prepayment fee of 2.00% of the outstanding principal balance of the TLB Term Loan in connection with the termination.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2025</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company completed a private placement of $402.5 million in aggregate principal amount of its 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and August 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. The 2025 Notes mature on August 1, 2025.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2025 Notes is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% convertible senior notes due August 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total debt, net of deferred financing costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only if certain circumstances are met, including if during the previous calendar quarter, the last reported sales price of the Company’s common stock was greater than 130% of the conversion price then applicable for at least 20 out of the last 30 consecutive trading days of the quarter. During the quarter ended March 31, 2024, the conditions for conversion were not met.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000 principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company’s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the 2025 Notes had a market price o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $953</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $402.5 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company’s option).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company’s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a “make-whole fundamental change” (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the 2025 Notes are currently classified on the Company’s condensed consolidated balance sheet at March 31, 2024 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company’s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Flexion Acquisition, in May 2017, Flexion issued an aggregate of $201.3 million principal amount of 3.375% convertible senior notes due 2024 (the “Flexion 2024 Notes”), pursuant to the indenture, dated as of May 2, 2017 (the “Original Flexion Indenture”), between Flexion and Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), as trustee (the “Flexion Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the “First Supplemental Flexion Indenture” and, together with the Original Flexion Indenture, the “Flexion Indenture”). The Flexion 2024 Notes had a maturity date of May 1, 2024, were unsecured, and accrued interest at a rate of 3.375% per annum, payable semi-annually on May 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and November 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Flexion Acquisition, and in connection with a Fundamental Change Company Notice and Offer to Purchase (the “Notice”) to the holders of the Flexion 2024 Notes in accordance with the Flexion Indenture, holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights. On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, the Company offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to 100% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder’s Flexion 2024 Notes under the Flexion Indenture as well as the right to receive interest payments on the Flexion 2024 Notes.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6 million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. At March 31, 2024, the remaining principal outstanding was $8.6 million, which was repaid upon its maturity on May 1, 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 5)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A facility maturing March 2028</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% Convertible senior notes due August 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Convertible senior notes due May 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,328 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,437 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.</span></div> 112477000 115202000 0.00750 399210000 398594000 0.03375 8641000 8641000 520328000 522437000 0.03375 0.0030 150000000 149600000 400000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the TLA Term Loan is as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A facility maturing March 2028</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total debt, net of debt discount and deferred financing costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,477 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,202 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total debt composition of the 2025 Notes is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.750% convertible senior notes due August 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total debt, net of deferred financing costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,210 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 113750000 116563000 924000 988000 349000 373000 112477000 115202000 2800000 3800000 85300000 3.00 1.50 500000000 91 0.0200 0.0275 0.0300 0.0375 2800000 2800000 30600000 0.0841 0.0300 375000000 363800000 11200000 296900000 -16900000 149600000 0.0200 402500000 0.00750 0.00750 0.00750 402500000 402500000 3290000 3906000 399210000 398594000 1.30 20 30 P40D 71.78 0.325 54.17 402500000 40 1.30 20 30 1 201300000 0.03375 0.03375 1 192600000 8600000 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized interest (Note 5)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate on total debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 3311000 9350000 681000 937000 24000 675000 700000 1373000 3316000 9589000 0.0296 0.0536 FINANCIAL INSTRUMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the FASB established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company’s convertible </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior notes and its TLA Term Loan are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either an impairment or upward or downward adjustments based on observable transactions. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A facility due March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   0.750% convertible senior notes due 2025 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   3.375% convertible senior notes due 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $29.22 per share at March 31, 2024 compared to a conversion price of $71.78 per share. At March 31, 2024, as the conversion price was above the stock price, the requirements for conversion have not been met. The maximum conversion premium that could have been due on the 2025 Notes is 5.6 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(2) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity and Convertible Note Investments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,011 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,030 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,907 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recognized contingent consideration related to the Flexion Acquisition in the amount of $20.9 million and $24.7 million as of March 31, 2024 and December 31, 2023, respectively. The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3 million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5 million prior to the Company’s September 2022 decision to formally discontinue further development of Flexion’s product candidate, PCRX-301. The Company’s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended March 31, 2024, the Company recorded a gain of $3.8 million primarily due to an adjustment reflecting the probability of achieving the remaining regulatory milestone by December 31, 2030, the expiration date. During the three months ended March 31, 2023, the Company recorded a charge of $11.6 million, which was due to a decrease to the assumed discount rate based on a significant improvement in the Company’s incremental borrowing rate resulting from the TLA Credit Agreement entered into in March 2023. These adjustments were recorded within contingent consideration (gains) charges, restructuring charges and other in the condensed consolidated statements of operations. At March 31, 2024, the weighted average discount rate was 8.6%. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ranges </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Utilized as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0% to 9.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for remaining regulatory milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available-for-Sale Investments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency and government bonds with maturities greater than three months, but less than one year. Noncurrent investments consist of asset-backed securities collateralized by credit card receivables and contain maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company’s short-term investments are reported in other comprehensive income (loss). At March 31, 2024 and December 31, 2023, all of the Company’s short-term and noncurrent investments are classified as available-for-sale investments and are determined to be Level 2 instruments, with the exception of U.S. government bonds, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. The fair value of U.S. government bonds is based on level 1 trading activity. At the time of purchase, all available-for-sale investments had an “A” or better rating by Standard &amp; Poor’s. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company’s short-term and noncurrent available-for-sale investments at March 31, 2024 and December 31, 2023 (in thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, there were no investments available for sale that were materially less than their amortized cost.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects to recognize its interest receivable separate from its available-for-sale investments. At March 31, 2024 and December 31, 2023, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.1 million and $0.4 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 39%, 19% and 16%. At December 31, 2023, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 37%, 19% and 16%. For additional information regarding the Company’s wholesalers, see Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of March 31, 2024, there were $0.1 million of allowances for credit losses on its accounts receivable associated with iovera°. As of December 31, 2023, the Company did not deem any allowances for credit losses on its accounts receivable necessary.</span></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Financial Liabilities Measured at Amortized Cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A facility due March 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   0.750% convertible senior notes due 2025 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   3.375% convertible senior notes due 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $29.22 per share at March 31, 2024 compared to a conversion price of $71.78 per share. At March 31, 2024, as the conversion price was above the stock price, the requirements for conversion have not been met. The maximum conversion premium that could have been due on the 2025 Notes is 5.6 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(2) The 3.375% convertible senior notes due May 2024 matured and were repaid on May 1, 2024.</span></div> 15877000 0 0 15877000 12030000 0 0 12030000 20892000 0 0 20892000 112477000 0 113181000 0 0.00750 399210000 0 383381000 0 0.03375 8641000 0 8641000 0 29.22 71.78 5600000 0.03375 The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):<div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,011 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,877 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,030 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,907 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15877000 5315000 21192000 0 6758000 6758000 0 61000 61000 15877000 12134000 28011000 0 -104000 -104000 15877000 12030000 27907000 20900000 24700000 372300000 425500000 P60D -3800000 11600000 0.086 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ranges </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Utilized as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0% to 9.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment for remaining regulatory milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.080 0.093 0 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Fair value adjustments and accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28122000 -3424000 24698000 -3806000 20892000 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the Company’s short-term and noncurrent available-for-sale investments at March 31, 2024 and December 31, 2023 (in thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023 Investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>(Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,631 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,879 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25345000 0 38000 0 25307000 94138000 28000 51000 0 94115000 7984000 0 6000 0 7978000 9479000 0 10000 0 9469000 4974000 0 5000 4969000 0 141920000 28000 110000 4969000 136869000 9539000 1000 0 0 9540000 77941000 103000 0 0 78044000 22849000 0 29000 0 22820000 14899000 0 20000 14879000 0 125228000 104000 49000 14879000 110404000 2403000 7000 0 0 2410000 2403000 7000 0 0 2410000 127631000 111000 49000 14879000 112814000 100000 400000 3 0.39 0.19 0.16 3 0.37 0.19 0.16 100000 0 STOCKHOLDERS’ EQUITY<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net unrealized loss on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net unrealized gain on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) Net of a nominal tax benefit and $0.2 million tax expense for the three months ended March 31, 2024 and 2023, respectively. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2024, the Company announced that its Board of Directors has approved a new share repurchase program, effective immediately, which authorizes the Company to purchase up to an aggregate of $150.0 million of the Company’s outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.</span></div> <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income (loss) for the periods presented (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net unrealized loss on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Unrealized Gain (Loss) From Available-For-Sale Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net unrealized gain on investments, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Net of a nominal tax benefit and $0.2 million tax expense for the three months ended March 31, 2024 and 2023, respectively. 124000 123000 247000 -108000 -108000 13000 13000 16000 136000 152000 -523000 143000 -380000 251000 251000 -8000 -8000 -272000 135000 -137000 0 200000 150000000 STOCK PLANS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration (gains) charges, restructuring charges and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Employee stock purchase plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Awards</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2024:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Weighted Average Exercise Price (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Outstanding at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,079,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Outstanding at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Number of<br/>Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Weighted Average Grant Date Fair Value (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,991 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of stock options granted during the three months ended March 31, 2024 was $13.65 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.94%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28 years</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is lesser. During the three months ended March 31, 2024, no shares were purchased and issued through the ESPP.</span></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration (gains) charges, restructuring charges and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation from:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Employee stock purchase plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1128000 1724000 1803000 1875000 7985000 8391000 2235000 0 13151000 11990000 6729000 6464000 6210000 5250000 212000 276000 13151000 11990000 <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the three months ended March 31, 2024:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Number of<br/>Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Weighted Average Exercise Price (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Outstanding at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,079,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,397)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Outstanding at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580,264 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Number of<br/>Restricted<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Weighted Average Grant Date Fair Value (Per Share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,991 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7079748 49.40 900995 31.95 155397 46.84 245082 50.23 7580264 47.35 1364618 47.66 196974 31.53 36395 53.97 102206 47.71 1422991 45.26 13.65 The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Weighted Average Assumption</span></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.94%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28 years</span></td></tr></table></div> 0 0.0392 0.4094 P5Y3M10D 2 P6M 0.85 0 NET INCOME (LOSS) PER SHARE<div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and the purchase of shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible notes are treated under the if-converted method, adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible debt on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible debt on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.</span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive. </span></div><div style="margin-bottom:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per common share for the three mon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ths ended March 31, 2024 and 2023 (in thousands, except per share amounts):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net income (loss)—basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 convertible notes if-converted method adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Adjusted net income (loss)—diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,008 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Weighted average common shares outstanding—basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 convertible notes if-converted method adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Dilutive effect of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Dilutive effect of RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Weighted average common shares outstanding—diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Basic and diluted net income (loss) per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs, ESPP purchase options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP purchase options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,162 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The convertible senior notes were antidilutive for the three months ended March 31, 2023, in conjunction with a $1.0 million if-converted method adjustment to the numerator that adds back the interest expense associated with the convertible senior notes on a post-tax basis.</span></div> <div style="margin-bottom:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per common share for the three mon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ths ended March 31, 2024 and 2023 (in thousands, except per share amounts):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net income (loss)—basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,979 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 convertible notes if-converted method adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Adjusted net income (loss)—diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,008 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Weighted average common shares outstanding—basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computation of diluted securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2020-06 convertible notes if-converted method adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Dilutive effect of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Dilutive effect of RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Weighted average common shares outstanding—diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Basic and diluted net income (loss) per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 8979000 -19536000 1029000 0 10008000 -19536000 46499000 45949000 5608000 0 1000 0 85000 0 52193000 45949000 0.19 0.19 -0.43 -0.43 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the outstanding stock options, RSUs, ESPP purchase options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,662 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of RSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average ESPP purchase options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,162 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The convertible senior notes were antidilutive for the three months ended March 31, 2023, in conjunction with a $1.0 million if-converted method adjustment to the numerator that adds back the interest expense associated with the convertible senior notes on a post-tax basis.</span></div> 7662000 6362000 0 5608000 1230000 1137000 52000 55000 8944000 13162000 1000000 INCOME TAXES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and income tax expense (benefit) are as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Domestic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income (loss) before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,640 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s income tax expense (benefit) represents the estimated annual effective tax rate applied to the year-to-date domestic operating re</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sults adjusted for certain discrete tax items.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective tax rate for the three months ended March 31, 2024 include costs related to non-deductible stock-based compensation and non-deductible executive compensation, partially offset by tax credits and a fair value adjustment for Flexion contingent consideration. The Company’s effective tax rate for the three months ended March 31, 2023 includes costs for a fair value adjustment to Flexion contingent consideration and a valuation allowance recorded against non-U.S. results, partially offset by tax credits and stock-based compensation benefits.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company has an income tax payable balance of $1.0 million that is included in other liabilities within the condensed consolidated balance sheets.</span></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes and income tax expense (benefit) are as follows (dollar amounts in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Domestic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income (loss) before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,640 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 13657000 -27773000 -17000 1299000 13640000 -26474000 4661000 -6938000 0.34 0.26 1000000 1000000 CONTINGENT CONSIDERATION (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration (gains) charges, restructuring charges and other for the three months ended March 31, 2024 and 2023 summarized below (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related fees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contingent consideration (gains) charges, restructuring charges and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Flexion Acquisition Contingent Consideration</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024, t</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company recognized a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $3.8 million contingent consideration gain. During the three months ended March 31, 2023, the Company recorded a $11.6 million contingent consideration charge.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value.</span></div><div style="margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company initiated a restructuring plan to ensure it is well positioned for long-term growth. The restructuring plan includes: (i) reshaping the Company’s executive team, (ii) reallocating efforts and resources from the Company’s ex-U.S. and certain early-stage development programs to its commercial portfolio in the U.S. market and (iii) reprioritizing investments to focus on commercial readiness for the implementation of separate Medicare reimbursement for EXPAREL at average sales price plus 6 percent in outpatient settings beginning in January 2025 and broader commercial initiatives in key areas, such as strategic national accounts, marketing and market access and reimbursement. The Company recognized $5.5 million of restructuring charges for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to employee termination benefits, such as the acceleration of share-based compensation, severance, and, to a lesser extent, other employment-related </span></div><div style="margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">termination costs, as well as contract termination costs. The Company’s restructuring charges as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024, including the beginning and ending liability balances,</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are summarized below (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Termination Benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Termination Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made / settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) During the three months ended March 31, 2024, there was $2.2 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition-Related Fees</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized acquisition-related costs of $0.2 million and $0.5 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024 and 2023</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, primarily related to vacant and underutilized Flexion leases that were assumed from the Flexion Acquisition.</span></div> <div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration (gains) charges, restructuring charges and other for the three months ended March 31, 2024 and 2023 summarized below (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flexion contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related fees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contingent consideration (gains) charges, restructuring charges and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -3806000 11618000 5535000 0 174000 489000 -1903000 -12107000 -3800000 11600000 0.06 5500000 The Company’s restructuring charges as of <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024, including the beginning and ending liability balances,</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are summarized below (in thousands):</span><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Termination Benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Termination Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments made / settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) During the three months ended March 31, 2024, there was $2.2 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.</span></div></td></tr></table></div> 0 0 0 2567000 733000 3300000 386000 0 386000 2181000 733000 2914000 2200000 200000 500000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of its business, including those related to its patents and intellectual property, product liability and government investigations. Except as described below, the Company is not presently a party to any legal proceedings that it believes to be material, and is not aware of any pending or threatened litigation against the Company which it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyoScience Milestone Litigation</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company and its subsidiary, Pacira CryoTech, Inc. (“Pacira CryoTech”), filed a lawsuit in the Court of Chancery of the State of Delaware against Fortis Advisors LLC (“Fortis”), solely in its capacity as representative for the former securityholders of MyoScience, and certain other defendants, seeking declaratory judgment with respect to certain terms of the merger agreement for the MyoScience Acquisition (the “MyoScience Merger Agreement”), specifically related to the achievement of certain milestone payments under the MyoScience Merger Agreement. In addition, the Company and Pacira CryoTech sought general, special and compensatory damages against the other defendants related to breach of fiduciary duties in connection with the purported achievement of milestone payments under the MyoScience Merger Agreement, and breach of the MyoScience Merger Agreement and certain other agreements with the defendants. In October 2020, Fortis filed an answer and counterclaim against the Company and Pacira CryoTech seeking to recover certain milestone payments under the MyoScience Merger Agreement. The total remaining value of these milestones is $30.0 million, plus attorneys’ fees. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial was conducted in September 2023, and a decision is expected in the coming months. The Company is unable to predict the outcome of this action at this time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eVenus Pharmaceutical Laboratories Litigations</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company received a Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc., or eVenus, of Princeton, New Jersey, submitted to the FDA an Abbreviated New Drug Application, or ANDA with a Paragraph IV certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL) in the U.S. prior to the expiration of U.S. Patent No. 11,033,495 (the ‘495 patent).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company filed a patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (21-cv-19829) asserting infringement of the ‘495 patent. This triggered an automatic 30-month stay of final approval of the eVenus ANDA which expires on July 1, 2024. On January 6, 2022, eVenus filed an Answer with counterclaims to the Complaint, alleging the ‘495 patent is invalid and/or not infringed through the manufacture, sale, or offer for sale of the product described in eVenus’s ANDA submission.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received a second Notice Letter advising that eVenus submitted to the FDA an amendment to its ANDA with a Paragraph IV Certification seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (133 mg/10 mL) in the U.S. prior to the expiration of the ‘495 patent. In the second Notice Letter, eVenus also advised that it submitted a Paragraph IV Certification to the FDA seeking authorization for the manufacturing and marketing of a generic version of EXPAREL (266 mg/20 mL and 133 mg/10 mL) in the U.S. prior to the expiration of U.S. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent No. 11,179,336 (the ‘336 patent). eVenus further alleges in the Notice Letter that both the ‘495 patent and the ‘336 patent are invalid and/or not infringed.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company filed a second patent infringement suit against eVenus and its parent company in the U.S. District Court for the District of New Jersey (22-cv-00718) asserting that the 133 mg/10 mL ANDA product will infringe the ‘495 and ‘336 patents and that the 266 mg/20 mL ANDA product will infringe the ‘336 patent. This filing triggered a second automatic 30-month stay of final approval for the 133 mg/10 mL ANDA product which expires on July 1, 2024. The first and second patent infringement suits were consolidated.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, eVenus filed its first amended answer to the first amended complaint, alleging patent invalidity, non-infringement and inequitable conduct. The Company has denied the allegations in eVenus’s first amended answer. The Company has subsequently voluntarily dismissed its claims with respect to the ‘336 Patent. The trial on the remaining claim was conducted in February 2024 with a decision expected in the coming months.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company filed a third patent infringement suit against eVenus, its parent company, and Fresenius Kabi USA, LLC, in the U.S. District Court for the District of New Jersey (23-cv-2367) asserting that the 133 mg/10 mL and 266 mg/20 mL ANDA products will infringe U.S. Patent No. 11,426,348 (the ‘348 patent). In July 2023, eVenus filed its answer with claims for declaratory judgment, alleging patent invalidity, non-infringement and inequitable conduct with respect to the ‘348 patent as well as the Company’s other patents, U.S. Patent Nos. 11,278,494; 11,304,904; 11,311,486; 11,357,727 and 11,452,691. The parties have subsequently dismissed all patents other than the ‘348 patent from this litigation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is unable to predict the outcome of these litigations at this time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Development Foundation</span></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an agreement with the Research Development Foundation, or RDF, the Company was required to pay RDF a low single-digit royalty on the collection of revenues from certain products, for as long as certain patents assigned to the Company under the agreement remain valid. RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly or indirectly opposes or disputes the validity of the assigned patent rights. The Company’s ‘495 patent was issued on June 15, 2021. Thereafter, RDF asserted that the issuance of that patent extends the Company’s royalty obligations under the agreement until 2041. The Company believes that the royalty period under the agreement ended on December 24, 2021 with the expiration of its U.S. Patent No. 9,585,838. Because of the disagreement over the interpretation of the agreement, in December 2021, the Company filed a declaratory judgment lawsuit in the U.S. District Court for the District of Nevada (21-cv-02241). The lawsuit seeks a declaration from the court that the Company owes no royalties to RDF with respect to its EXPAREL product after December 24, 2021.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, the U.S. District Court, District of Nevada, granted the Company’s motion for partial summary judgment in respect to the Company’s claim for a declaration that it no longer owes royalties for EXPAREL made under the 45-liter manufacturing process as of December 24, 2021. As a result, the Company expects to receive $14.5 million from RDF, representing the royalties that the Company paid to RDF under protest after December 24, 2021 for EXPAREL made from the 45-liter manufacturing process. Once it becomes probable that the settlement amount will be received, the Company will record a settlement gain within other operating income (expense), net in the condensed consolidated statement of operations. In November 2023, the U.S. District Court, District of Nevada conducted a mediation that did not result in a settlement. During the pendency of the remaining lawsuit, the Company will continue to pay royalties associated with the 200-liter EXPAREL manufacturing process to RDF under protest. A trial is currently scheduled for September 2024. The Company is unable to predict the outcome of this action at this time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Trial Commitments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as a condition of EXPAREL approval, has required the Company to study EXPAREL for infiltration and as a brachial plexus block in pediatric patients. The Company was granted deferrals for the required pediatric trials until after the indications were approved in adults. Similarly, in Europe, the Company agreed with the European Medicines Agency, or EMA, on a Pediatric Investigation Plan as a prerequisite for submitting a Marketing Authorization Application (MAA) in the E.U. Despite the U.K.’s withdrawal from the E.U., the agreed pediatric plan is applicable in the U.K.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received notification from the FDA in October 2023 that its pediatric studies requirement had been waived for the indication of brachial plexus interscalene nerve block to produce postsurgical regional analgesia in pediatric patients. The Company is still working with the FDA, EMA and Medicines and Healthcare Regulatory Agency (MHRA) to finalize the regulatory pathways for its remaining pediatric commitments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Milestone Payments</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for information on potential contingent milestone payments related to the Flexion Acquisition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCRX-201</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PCRX-201, a novel, intra-articular gene therapy product candidate that produces the anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) treating OA pain in the knee, was added to the Company’s portfolio as part of the Flexion Acquisition in November 2021. Prior to the Flexion Acquisition, in February 2017, Flexion entered into an agreement with GQ Bio Therapeutics GmbH to acquire the global rights to PCRX-201, a gene therapy product candidate. As part of the agreement, up to an aggregate of $56.0 million of payments could become due upon the achievement of certain development and regulatory milestones, including up to $4.5 million through initiation of a Phase 2 proof of concept clinical trial and, following successful proof of concept, up to an additional $51.5 million in development and global regulatory approval milestone payments.</span></div>In February 2024, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 for the treatment of OA pain of the knee. 30000000 14500000 56000000 4500000 51500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended March 31, 2024. No trading arrangements were terminated by our directors and executive officers during the quarter ended March 31, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Arrangement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rule 10b5-1*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Rule<br/>10b5-1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of<br/>Shares to be Sold</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lauren Riker</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adopt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/5/2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To Be Determined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristen Williams</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Administrative Officer and Secretary</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adopt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To Be Determined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/28/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Slonin</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adopt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To Be Determined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/31/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Hastings</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adopt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daryl Gaugler</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adopt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2025</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">* Intended to satisfy the affirmative defense of Rule 10b5-1(c).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(1) The aggregate number of shares to be sold pursuant to each trading arrangement listed above is dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.</span></div> false false false Lauren Riker Principal Accounting Officer true 3/5/2024 Kristen Williams Chief Administrative Officer and Secretary true 3/8/2024 Jonathan Slonin Chief Medical Officer true 3/8/2024 Paul Hastings Director true 3/12/2024 1775 Daryl Gaugler Chief Operating Officer true 3/12/2024 2500

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�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�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
H%1"P:;'(EL(O8$- M;5W82EFPBE%':$J22!;*&;:3!)E($+)AV76.GRV31&]^&+*-MK=($FTC^A91 M]"!6M4#UHE-/7O0I$,839W%_=D(R#%.5M:GS<[4?(4FTE4S@XQLUH;3>I(:@]2NJG\*J8IZV!E6 M7V$:)F]5 ,"\BB)X3J@3Z P E<0G-.C<"V\=E8;F[L]J=R@ >/.#D;I[WNY* M:,%:O78*F91DUAI-M.<1ETG(998T)QBPVNQL@NQKUW/^X 4 6R%@VP* ;=31 M +Q>/H>V6KF8=21*E?9/60L2J$Y$Q"2TCA!#_ MV70^^-7_]V1ZNX?/%@LKR6 XYY: 2SU1'&,0&1C*@S-#**/2 M\A@!T5X!'2L)Z,>8U-#HI+9X^SX3^^BGES";WW)P8_RD0C&4DV9/B\.?LR4V MF40@!R%M-I#9DV;D*\[!7GQ\?^JOI+-)50'V#8'STL\VOTD_@TQ$<:@FS;U!L#&[K99U5DF/>,[9 MEXY;01#O*)"4:,J64I;]9C/-UKRDGP;ZG6&BCC ;B%O7% X+C%PLI1 <@8- M'F!X3Z,AUD0047)PO';'O3VKLCH;P/ 6^;7=!-]KPG9]Y=#=RAA0)H4!C1NF MHLA0PH41%O/DF4P8X2OO:BS3L:-2-ZK,VDV^+=J<3S MW_"7P 8R MI>P-DX3Q5#I1 FZJP0@2@F-!&)^BJUWNL8Z>QO+Z^^&IN@(J6I^J)5IG1W\^ M.OGMZ,1/"X]?88]BK%6/JE!VM1&5E0JL;C*DRTYOXT5-S5^&\\^W-N2^$6S0 M27/7 MRZJ0J*D2TEM"77'\ Z?$\>B)R!S-<7EU?W1". 5^*"&JBIZ3/#:6=W#E_:L]%U4 M-JDAO[X5[[\]()P9Q61(@LBHRLF3#,1%AJZX9ME'RK+B&]72 M;*^B^)WEUT19VHHM[SXD2S9KQA@EEB. D2U'O&",>,!/>4K2J-H51*_1U&_X M6MU)Z$05?:?F;VX]E,F4,%R,5[V9GG$!4V1%..D=4X$D;G&UE4QCP%B< ),Y M!%QMR6^6/%O_GB;=R1T5.NE&NFU>1[O)(MPV.YSD![*$="/(_1,@FSV_7E9D M!W[>.%427$87Q22$)'=$&I]*I[9,?#*(J0*F&!4BBQ/H^IK)@R M-$BC_Y:S$!9%T4%3HQ\_5;(-5K9*E6RCC9[=YYN;Y*?3FYE^B]A1>TYSA%AN M.@0B,6(D@97Q9L9F\!PD/*U5VLF+?NG=3>YX.VAU4E'$;4!D=C!.-QS,;GN$ M:4UC,)H E+DCV7%BI2Q]5((.U%G+8*,&1IOAY#D!_87<^^OT.4#V%'#?'O/1 M7S\=G!U]O DDM9?:RF@(5X"R %\&Q@5&0H3L2H>@M)H#8&484-$(B<$OP*BE& F@.$2U$:Z?OS<_O(J M'2A[#Y'UK>WCR5>8^KM**IE .B!1E[:0V7GB@Y#H."5C2BD7D,\;],9N@K'X__&^*R5B,=U8!PC,;.4@N;9B-H5#(\(V @WJGW<["_='R-K;W5$KSD*PLI!1FG( M2*POB4:=G)0H&Z"I,EY^X*S]+I%I)ZIHP.Z\DOQ93M M:Y5NEM7E(<'SRYZ.3 MB].S_1K3O?"4*F-/U]-6;>XI*AY_Y?L+TRDC#T8%RS!& K6<$!ED!%1PM($) MI=&Z55Z5:\C9UR[=/?K,__ZK1UP-_6AV O/%'"QT#& V &V,M.6>+,A$)/6) MV%(][)*B.BB>H7I3O=>IZGMZ:1U\/#4XE;71P+YWQ]%?)M._'X_1041/\PE+ M.F:EJ34D*701I%*1V,@T,2%3 9 TL(U:&.P"L-5D]>M8=8ZP2OIH"6(?AN/A M[#.D7R:3](0E;I1VGG*"@8W%4(0+XG/&\$:HU"TU>):K>D.&5KUKF6;S(618[BBL,66:QS$W&=>&\^Q\ M[3UP [+Z15LW>'B>8:^JG);Q]J#G;63)@*6E9T(Y2H@,I86N!N%9)F4R\TS4 MSD%L0%:CUFU7*&P*M1WUT@#4?O4HTS%,OS]DY[9G4YE2DCR0B#(A4G)T.AD- MQ"I+N84LY.2, MQ/ %-5]&KYDR_Y8C9T$!I2J$0%UM2*TAI]^$5M>0JJ6'OLM=#B=77Z[Q6?>^ MZCB=3_+\=Y3R+3NL7*)W@0B9#3JM2N,*X9D8+103-!LOGYP+KFR1\]J[^LU0 M=869+@3=@"GZ<#T=#^W*R"&(!?#DIDO99R4)V*%!9)YRE(S MF]UFI?-;6*+5U/2;P>K:$%720@-X.IR,,4R^CD4SBZ."2V3EEA=--3BM,5=-$ ZA:*:N/=S4;*E&5.37$ M&)V(Y$H2:YPCWI4A D$YEUQE;+U.5;_N4[_)A=U4TS+8?IE.9K-!61\V:UTF MQ>&:%)FB3XC>HE0N M&K\')"(.%WK"ST>P4-@X'5Q-IO/A/Q;?7\G\(,K,G>:>F$6'BVPC\8E94@ZZ M@N8Z.%.[%40MVAL-*>O M1<%;P]LMP3V>'GGO5NK60YG95!:9?1CD*.,(BT- M1,'ZTO4^.,&8P37[5C9ST^/PMX]0.[:8VRJBVBGY'L7U#];0 #)SG%J%Q%): M(NM /!I_8@1+7&&0;73M>IR'[V\T JT#FIT%W<"FNE(T[X>S+Y.9'\T&WG%! MRXA";M"0HFC036 ZD,ABTCE*;JI/'GV=JD;#SXZMT&Y*:;/J_4&-2XU6P.L> M5[20'@)4(,"&-E+INCI6M)MD0DFL$)S@!H20,K)0^WCZGZ4"9QO<[%R!LXU^6MX%'YSL2^K0_].<),D# MD:EI*^!6IV$8B1;*%.G M ^[PEB&'W.$R#4&;ZB=(_Q05.%M!88<*G&WTT@#4UIYD4$>ETSD3QH'%V7 M=71C()-F4GJG2;+*$QD"$%=*1OK-'0-11WZ2"+!OP7S9( MX+IH04N0)$>&TOE/ZH@^/@^V?C>8EVEI M-):J YXJ"F@ 2&M+&*R+FO(8"%.Z-'\ 36RVCAB;=&!6R 2U.[_\T+4D^P"J MFB(: %5IN#8_@_EPN@@J3L-HN&P -Z"4<9L M=G722F*:KS+9!TYU5-!F+<#'HX/SHRIE "N>5*$"8!,:*QW^+[)ZL_LV+TG: MD&PDQ@A%I'&EF:(3Q,E0JLN%17^ZBX3J;-]C_<6UK]N)Z,M'#@*7)53,)!N- MH8$4:/BD-82F%%5"K$9K7U/R"\_MUZ_=0V&/KLCM(:N6%_9]#YM3M)#XR/'E M@L.C;Z6U-?AQ.IU_1KX?_?!XG"?3JYL*X#WM02T"JIF13B32C?7)E#DA3"#1 MB'(]7 02KO6'*4):?0Y=*Y7'S0#EEBG)&< M/*?@%6[.J@N6'A+1E,':1LY[P^NB;M7, MD D@?M/,G4 MH?&+SBYZHY!2"Z(3EX[2VE<0M[,9G65)ZL)B-XDV<#GKT,\^?QA-?K_;& _B M?/AU.!_"[&,9;7#?Y)5!3!RH()HR363&SYSW9;(+LXE'5_))M6OT-B6N@>VG MCA/;C3H:V),>.UXWT[5G R:T<3IZ HQ;(FF0Q(?2V=YG&4I?E,!JU^B]3$F_ M3FY':E_K_.ZD@^:0]!<87G[&S?&@#+F[A#,HI22W/RS3V]D@"& B*$TX4P9% MEBWQ&3)^$-GX:+F!VDU%MJ6Q 0^ICOWJ5#FM@Z]T1I]!PC(H20$SK43]#O2FT#2*N+F=?@\'N.J?H7@7:CM:E MG-8[JNL'PB4 M9<%=_#X9H-R4R"7.0L([J*:'PUY M""48)!6D$*42F:E,I!$1&2PS ="KYL(JIGSMT\2MB6PJ&'DS]&VMGA\,?Q\F MU]-!H")*ERCA( M_02-_B9%@!#"NG::]FKY"8[_=G'I"W];*Z;M3_EKF+B;O MX),?IH.,;[MCSS&C_6(NG2YG.YYY8IE0Q&L( 7ABSC^9W;NBVF_[=V^$*=TP MIMY"YC^0/1NDS%D6SI"<96E76U)4 IT%KG46WHOD7)6O!D)9E3VE)"0%I;"^-'I/AB#S7@1%@54? M8KL3H1O!S_[H\*NBIG:*059P.1!0NMUF MJI0HY?'E"P]W#U^J-:=_&%SV%BUK7>W_""D;PE2H>[/_>W)V=C+-;XG\ MZ==)/,-5W]7B@>W+*#5%AYX#)R""BEB7)GORY!G9(I2AY.9S<; M9ZTZ0V],Y/]0[HKIE&7F+#-81UI9,MNHP9=$\2W3B2(3QTQL/<7P:8K&S?0? M#E$-]=)!D/C[9#I9TLW]$^_)[2:C%^U3#S^[(8D.8_!@F*MSUIBEV]XE\A6U M0$9>8XZM[74#LL=]%C@<7@^MX:,#];T7NQR+"9Z7.MJ/T1%."KP5#(+%4*+1 MBNO676S[43SN&T.O4-Y+KT>'XLM'O^"3L<5*R$IQ.JK6TOT3 X5>W*?B,BK6 MNF!G)T+'?9GH%;.[:/$XH;IZ(0S)%E:78UL?)!W+H,%1D R90F41M UQ9$N[ MW3/N8(\>7<-U:TT>)6!7+T"YV%0$"37;VAU7LJMK;Q.@95%PF;GH *\;O]$- M]F[2,URWUN-QHI7^W=.HI=(Z9[ F\SJPOP[J(Z89=\I:PY@IK7LA=Z-TW&>6 MKM&ZK1['+F5XG,7*5:KM"S\G4SR5+C#M''D8R9!,N='@0U;@HZE+ M#;PQ:B@ UN]OAK\C?CLZE&Z.KI;BNO'Q*=\X_?M\0IR$Q<#W['B?3?0<9'I"Z82LY!I7E*(4@*L04M++ ZS9PE;6FP(=3"(1!H3/1E;MA MP7$5@ERO?;A4R^.:>_7KC_!?L_GKL[!8K'=!B*P=WR7Z]!:[3LU=9.WU8*D3 )5M:HY1^5 I1P@>N:! MVQ@L6N.9DHT!NP5YO2Q\'1PTFR>E]M)@W^"\9NQ]^'ZY,+"PR)!X!&%L7>P7 M/ 2!AJ3*M%8B.>2M!T]N2>*X(!T,*IM#$F*M=-(!O%;;EFO#T"=2%U'RC;SKBQ-4&]HNF#(E)V8*!VOK M5"H7ZYZGD.J(615%S,'8UG[?1H2-6P%Z2,BUUU,'X'O>45Z\NUH09)@Q:#F" MJY/1E20N'5<&A.;<,!NS+ZW'UFU#7R_;D \=? RFPP[P^01/_YC/%HM3$313 M!@N4Y%2=S\S!*Z'!&V==CB(IWGH \7,TC>OH#8>&S0.,[573-]1.4CK_?GX6 M[CPOG/H48Y26@<>:UTK: -EW#5B24LG$(/4AFS8>IG)MH2I(IJ6R4&0B_A*%\QZCAVQ]3"QQ&7WK.LEM:1RWP^=@ M0!Q4=1W)Z-!Z%*UOZ4&@.5@C3[_0W$9U M?32>P&!R)@6A0Q@AOGZ4 MWG';>0X&VH.IM O;^D @=_]8%F&1U6D8=6^5J_4-9*68K/DS) M_M4(-T6Y3NG+S(,Q9'VC$+(._M,08Z1C5[R.3%B7?>OA0@^0,6XRNH'>[Q<7 M["?J#KRLVRRL*GV,"9R^1):R! LJ)E$7' C(.;H214B&MR]7N4O%^%C92[%/ M F5K*7>'DQO/V,FZD')]3S$*@4X+7>&%CI.73'O/-(]R6-/22S'=OCI^$C([ M"GSL]J5ZM;^;A>G)[^0%U$FBOYWC'[5>@73J+BNPK/).UEDH.I(/F&LW:N:1 M?N(.H_-9B7L^F/W&^K$[]9YQ.9O/WLR76,=K$ MC[[@)_L4F3,%I*/ 02%#\,X***IX*^A/Y=UJRD?PLL''QGVO;(^7UO+M&2_J M@A]7ZF0PBY!5S=MZ7L?(T;]G"]L;+ZJ'"K3#XF47^7;@R-2(( MEHL#Q5PPD1=.-K+.0^>UD@@5AZQELO2W"9N76C],RO(2DD_,<\$YRIQ&S:ZC)[\ M3%^HV$6)LT$DVH%!^7R/@6(M9X5<<^\]G1?D9&*S\I"RR;'D['5QC6W)/2+& M 4QK[=[MV]U+U!U@Y2&!,/+ER-LR8#)F8L%F")%.D1$^,6.Y%+;US;.K@6GN MJ R,EWW%W0%B;KMPU^]L+K-P6$0X(O30C/E61HB%KK\?D\INAT5 M^H!3NY-T.T#&;7F\G=)OQL7R4UCBYV4M)?^(\U3U\Q5/ZQ@-%6,!R6J#N/6N MY@%J&DD:)@W/WK>^F3:GKJ?(N@VJ!M),GQ.G:M% BS5=#_Z>1D4-!UF\]=@C M=L2<70X@@E"@4G%D4+0#KHM,0AC1?A7>X8H7K"F8@_%0;"2O71A#7GL=\^RY MQ91*OC?,[N]3O+"%WCV04'EA@U?2M(Z/ M.LG7M=3L\[FZ+<3< 4X>2AYE2]Y\S F82&X=ZWG'R;T7DNYLH]%RWQ@IW>3J M!L3*OJ+N "T/U(KE8)DI(M3@+]8@+==A+06\5BDGKGRPK1NN=JRZ/.@#]#Y. MRYY2[@XG-RLZLDG:"@^FKG!02*!WQ43@J&.V% (8'*):_2BJ+K?2\<95EUL( M?.PGZ$VJ IW&I"1C("U98243&6!ER7Y*J4ALRIB[LUM?7M7E-BK=MNIR&_GV M@I=7-_CY#=.*$6+)7+ D"T_"(P.;61U85A#H9I5TA?L42N$YF>T@\_3W>KJ+ M6J*FH93'!LXFY:1%:8,R*"!)L3I-S$&0PD#*5BKE,#N[67EWJW+=$^-EFW+=P::P'!8ON\AW MU#$6B_GR=/645:7S.>$TS">SE8,G#0F'%0E%LEJ4H12XS"($D46RUJ-+&V5X MZ0LW'%_ZNVNG]]&/]V1B=H^0VLAV1'.R8N""[C^GBQ^8)F6"^>( \9A*1$W> M5DG$1*B5[[JV806M4"K-/=^HI.XY@#Q&P#@.;R.ESEI+N!.8_#Z;8PJ+J_RB M2$I8RP')&U\?&Y_I\C3:V>"=DL)MM/IW0XS<_OJ( &FCT@= LH=\1T;(IS#] MNG[O"+DH'K6F^U:2,Y4Q0DP904;Z,0GG+6MA.*X^V),#LM]MLIL,>U#\59ND MS4'[&G>%^MX0+=E(##5U9',JHIZ*5JH?VPCLJ*R[ZMY!5S5K(;VS%A[]N M$(Z<9Y2Q0/)U "KJ %&P "P)A1[K:+340O$W/SI..JN9XG>67P>O*/])[DF] MW&IQY,4N(VN4#PB<&0%*>P\.'0,GR4T6%'MC\Q+GNS2,.V6S]4O;7A+N#"$7 M[C#:*&SAM8]9U3RL2>"8*>"?.)_6V:N_3Z9AFB;3KZMB_ ^_?[IA7NZ 2_<5QS;75 M"9\M8-_F@^,^H#7"QV 2'ALU]0I>Y^L752/3_ DS?O]1U5-?"M=+%]&S4)3@ MP(,N=6*/@" D!Z,#>=C.,GMWH\PCD-GD:^/.4&[ED@PCW-[1P0C :B3^$8&5<7+Z#K^&LS?3Y63Y:V7,BQ$YY<*@\D 2JF?" M&OI;QU6HIZ/PIV88+##]CZ^SG_^3?O4ZU*(?KB.L!SXX[OS^5N[0OI(<&01K MJB_.B/'<6^TCR%3SS:5$"#X:X-D;5C0O_LD]VL\CX.;7QKF+]E;7K('LQKY1 M?C_#OZHM^X;S\ //EY.T>#M-%Q9,9X6*LP0L& ZJ_B4B\96"-LAL*%EO%D4_ M]97QE+^[TF9#2+"#M-NCPQ-0BVRM KNRAIK5(1HF@_'&A1#I%Y7RA#4X]$R; MP19N#-LULYN\1RTTAX\KWR4U43)9T MIVIK44HHSM2>LUP@&DTQG(I)H5?U_QO#YU%B>BI1;H.?-G+O $"WA?/G-*Q7 M0&.^M*FG/J$U@<04VPJWT> MHZRG4_FKW"CV&23PW%G#%H!\(:$F5.-?&8 M#5@=,U=9"&4V*K=OA;PG:.WI'?0 6&REM;&S1K>9?#W[B=- L3U'MQ/58$7 M58RGD46F6(S@M+?UT-79,K% S;50R$)>)]\LA[3Y-WO*)C>/")L)^Q@PM"Z! M/F6GVJ"(N6[EEK8V8 D)(2L-4197E/+" MW&U'V I1SU.P$;[\D>.KL2*.%6V_A5^7!0A_A.7YO#XZU'Q>T"@L=PJT*G5% M0F002!B@M9#1*1;*%A5$#0G;+*/*7CPX6^BM3\R^Q]NV_]2(*'Q*Q%(,'%2J MV^(]F[>71HV0\Y19>SW$G,',+DY=O*?6&O&,9^L M87]S5/ZI\U;ZE(D9KWT=<*O!H!C-A,_%+H85Z<1%D%N)3<:N'(\),5-%,,^+-XA:#-<'7$V?Q\% M=("F?X3)=/%NMEC@XL/TS5_+R?3K^63QK7)V88I5#@630N ^$T.!28B"[FZR MS%9:C72'MT;4LT1MAJJC2N"W5<3VR/)K9$WQ:UWGTMKK_CB_O.%_1[S8%7/* M@]+:,S*\1=0IRE% -$6"-MPCUSS9N'EQ]M/?V@PP1Y%E'T*Z'1BB+18,.554 M()\0F"H(RHH 0=5S$1D+N>BLL?4*R\VIVPQI1Y%Z'U@U'8#N9J7'V\7B/$P3 M7EC;0GZ@8X8$1L>HEJT:\*J8.C(>A6>V.-=ZFO[CU&P&JJ/(Q3<6?0<@NIOY MN!J*^85PL?@V.[MQ0#Z4S\M9^A>YBPF_S"=?O^+\5%"0H51 D%R0%(M$B"P+ MX"(J)G(R1K5&VIXD;P;'HTC=CZ'$H\#LEWG(Y(/6!/ I^DR.1,W&"*[K0,=: MPJ\*X109_L,J;NP'H\^X7)[A=>W2 M#3YOM]=^PG^?DR=\:EV2PD<'FJ\&E$D-L7!B+G >@[0BQSM5M(^.6MGNRYM! M["B> H:7?,^&[P9G57UT7KA,2J>:XI&> JG5>:E+R;3RS!B2J\=#&;J[Q&V& MNJ-Z*QA&,<>!N)4?2XP))I%K\F#KXX=BP4&PRM5]X5E0_Q;/)UI;"/<_P^.?_^8?IZ]OW[;+J*I$Z#=$G'(L!I M1%#21/!&,3"".1U08>%\HPMTM^]O!J^C>$XXE!8Z,&V?OY%T5V?D-'*E4J1P M.UICZIP1!L$4#U%;="R@M=>Y_59+4J^^OAEZCN)M84_1]M:'_4>8_PN7:SZT M5I+91%94HB0KFCB$U8X*'I++DCE,8@<3<^,3F^'@*#+_#679XXVTNF=O3#&Z M#E1K-OJRT/%4H!7:I#IPG.(*I4H@RY@RB,QR0168\IN%=;O3L!FFCB+Q?TAM M] 6ZFYGCJT*1=4OZ[[,YW< _SM12I__$TU8'S=*^(Z7R>OH7%Y:0$YNC29]8 "]F" M2LZ"=XE!R5H(QG/4G[5KG>OG]S5S^H;Y_ QG MJU?_WW 9)F>+VV0O)M]_G#W;&_OX+_N?U]3=I?OB=]Y3_(Z4XE]+G&;,__?^ M9KD.A3B;+<[G>!()1"&1PE.(,8H$/@IRN#%G<,))<-[:K+R/_.XL]R;F^#XE M;:^=]?0PEJPW)7O@7A2H#>#@/7%8C-]E/M$ MK\1.DNX0+1=3+7-2P6B%='+('5702#)BN9,2;;NF3@84K&1/. M;QP *_N*N@.TW+Z>5Z8V%L_I?I90K*R/:[7?L&X(82Z5'*)F_NX E\9>[L9. MRX'*A?9W6O:41^^7YZ?8@LR)R+=Q-F XH&LH]8% N=<2"&M:]XH_!@M M/3FZV^OX2VSSB=S.;O9TM< M$%/$C[Y:KLSI?O6)&*CNF/ UY\ #Q.PH"/ E\+Q9!YB MNDYAFT2"0*L!A7+UE0OKWB &IECNN5:>BV'OI2M2>AH[W=J5V4W>W<'FR4Y1 M[7.PP7L0R!,HY0($YDM=.^*M+98Q.VS7V_Y-O(=^/]H*#+OW\&ZCF>XP]SK, MY[\FTZ^7$_^%SQJ#!!ZR D5G$(+E#%)(LF#ATONGMG@U*&J^14]/-]\0N-I# M^ET@:?W9];Y??#U;+!?O<7F*+!+J-0(:BCI4T+P.WLB0&0:,)C/-V\\;>)"4 MGBZ]5OC97^;[#COY8YH,>MANRR.9N%" M.ZNTKQY&':;S8 &(EL@Q(R.;6NAB%H'X,!2",K*QT0N>$F_MAF]=7W/P=HE] M +.S='>_MF;+<':8\II+;^_-7S]PNL!FE3:/_-[F13>;T#]L_8WSODX"))=8 MU()WPSU!2PGRBUG6-J+3=HBI>NWK;^Z),M*/Z>P\KYVV:B17RCJUUG!17(;( M; "5,2"K)UO?4IK2-'YSMB9"[QF<0I73@3]^D_4-9>WC$TLK' M.\5$EZR@&Y?'4F?L&P0RKAZ,,L6PP()NOD_S*7K&C\P:@ZJ9\+L#TJ6PJA]W MT<=XJHHJB2<$7R?O*.04+NB@0$95"K.>!]WZ*?Y9HL8/U@:%U+YJZ !7EX9W M=2A>AQ\3Y:EUQ0@A%# 1ZV0=(2 &07%"+L6Q))S(K3WM MYZD:/V ;Z 9LI(A^$@)WKO935NH6;;K!2W2UJ<,D.B">6-'+WH9X,OGM?$X7]GH0SJGVRDJN(T3!:]&#?OWSZ\X\W[[]\O@ZZ;Z?R MPS3_'B;S_PQGY_1GRV]X,V&R1T*A.0T-D@_#RJ51HN+JJ]?H7US!WXO K74< M=&%U@&HL$+DGK\RCYDRBS8HU-A9/T;.OB;SZW:]^O0IG]9G@\S?$Y3_FL_,? MI(GUZ[MQ,@JF#=0-W[5Z(P%9>PE2.2DTHP/)6K\G;T+7N,F*9BBY:R2;JZ2# M:. &3W]@J+*J%\"KL)@L5G6'Q@MR0HN!$#U=*J[NSC4Y@\_U93.X$G7KGNAG M2.H$7,TP\#C(]E9(3_BZ/HSUX6)]D2PNBM"L$U(2\;49APXEEXK<"HW F0A1 M*W38?+_4)G1U@[3]@? 8R%III0.D?:QY&E+-\HJY![B\*$Q,25#$Y"BN=KSF ME&MA(I,%4 NC'!H=8^O,V1;D=8*[9MBX.P1_($5U@,%+/_D3_B F,5],47F4 MO:!1"B&QEMN:.L+:T$5!W#J4EOP3IU&W-GQ;DC@N%@>#RNQP>NL EF\6R\EW MBN4_E WDZ +='R)RB$Q@/=KTDU%UJ[CP@7R74&SK;-TV](W[9G4H0 ZFL0[0 M>,.QN?KQ/R8XK\TFO^KBU+.5?R.=B"4$#RZGNE,N9(C")+IBC&:H/??)Z01G[4'P&-SVU$BGX!(7K$1CA4+K 65=IBDCG4CZ#1"3C$YX MY8H8[$J]3TXG]^@HX-I%(YV"2UZPX@,Z:34%09:<7.53@1A)1%H([6W43HG6 MX\B?(&?<.J1QP;6+1CH UP-3#] %82(:B)9<6,4Y^;&UK"%3A"V38UQ@ZS>] M'>>'# ^EH?S]/<7>'7!N-+=;+@I3*H*UB?B06D! ;R$'9I533,* M;*7C30>*;"/PL0=$;#+PPGOKI20&;"WH5,Y$LJ4^090Y!:%ES8$_5^UQY -% MME+IM@-%MI'OV'C99.!%"5P)5]OJ9,J@LM3@&7? 34P1A5"&IXWPBR"P=9[P.*8!;Z799Z37 M1?QZ;0$?L'\7\QC"V6KZXGITWFJ9X.+=U3RCA,+;P"2PXFLMFPX0Z@@T%C%$ M*XLL:KBJK]UH'K<9](#U8 =0:0=N[B=,./E9Q7;]8OM MZVJC[6U^-U8RT&E ME.K:APBI1.>,PZ2;)V4VHZR3FIV#H&4VN.HZ .2;?Y]/EK]6X>-D.<'%/R?+ M;[/SY2<,>7+VZS>LL0<)EKB^8OIB%"DFHT-6%HH7#I1A H*-Q*BWDHF%[1#(N5O2?1 U=H#751[^6J /R+.N>>7)&P]80IU:R.K.'.,@:B>X M](%%V[I6Z'FJQLTB' "!C173 =2N+I1WDQ#K(_/D:>E%C)HYSR#710?*)P/$ M; 9GHM*8E>2A]4"1+4GLI"ARC-M[2&5V@-57YPL2TV+Q>O8]$J=5<*]GTR4) MMDJ2I#@AW5[,[5CS_^N4[H:H0DX@4[&@LF,0& ^08^0\"F6L;'V![T#FR![G MD+"9'5:''9L,UTE+@\Q(+;A-HL#5&V. M8$@'4F%WX+P2\FGT@KR4Z,#&.H(QJP(NI$ANB\[1Z:!*'K9.^(J47HHD1H?= M;LKI &.?OY&H/\XGJ:;-BDV%:Y"*9U V!XB*;HY(8%#2YVAYZS#E^NN]/&6- M@*0=5=!%!OS.;ICK(K7UCPN2THHS?JJ*B$(00]+H!$H;#9%3U.4"QIB=$BFU M3G5O3%PO.>W1S5@K!8Y=C;H15ZMYQJO#1R+,,E'\+^L"" DJB0(!&0-MC*Y- MD";?;8%^I#1UVR]O!#W[HJ WO(:.<1CG6V)[/0=YDUSI8/,X=R-C\)&<#:1S MB*FI"IG">+!2X7%^V=^9@NZ,N+DVG^3/*:U$TM M5TM;;G*WJ%6UBX?_Z*+8-I!G5;@1D,C-(J_+6O F6A!9<8H@->/-AT6UI+^3 M#/H^@)IUHMT.D'WWI?]JD(Q)Y*H78%([4)8I<#X$8LIJ*Z7*0;=.4CY,R;AH M&P\9SQ1D[*"FL:/Z&U'BGJ#HM( 7+G@F?;RWNO[Y M!M,'OS3NN_7HF&JOC0[L6!N'YSHUHHLNUCI-@LT%5!8.@@X('KGFR%UVI?5[ M86,6.JG.&-L!'1$7+^98O YGZ?QL]>.GV=G9[[/Y?X=Y/E6RQ)0U!QDUZ<66 M!*ZVHV9?G,K>2V.QRS/R,#\O(6+;$:B#')H&J.GI!-T8CU:3F/>87]SF_K:H M5H)O4^A M#+8PJR$?+\$GZ_O@[ :9L6/CA@(@?>#DZ_0U_7.D1X2\1,>,!>68+Q)$D&0P MA.'@'">KX8K2))J0W&!OG(=TS(:OZ.SEY'0!E3T=LS?3?,B2EO=A7IL"?K:N M4;GW>P4\$+I C() RHY!DY'#RFP'$U0,LO64>S#E'02B^Z+A'M; MOO87>P=W]&4/TDGZ]_ED,5EI9?5:FYU#ERV@8K$:,(]=:A5Q"ZZOV M$5+&A4\++3_2]K6/R#M%3OUQCI+3,JXK$/K M[3//$C4NFIJH?@,X[:Z'T>/L,_RK7BTYB%*EX,MFL M3L-S7D&P6/?6IBQY\-E;]9P/M/GG^L/,'OJ=#2KL3N!SM3,Q1*&C!,GKV[LF MZ3A;.'#ME:=SY;CFV\!D3#@,I; '\+"#]'H8#+@>D)<$65+.(+-" I"*0XQ: M A?,:+0V)K%154#3$9&#Y8L;>B>[B[$'W5^6Q+@D8["<'/A*MLZ*&"\&#,HL M.".._$;%Q48& >FO&,>=;:N-%#]@Q_O8TCD5BJ[0:#O9D,$,>V$'D'R&E:[>G(Q=*9>0KDBB;>)8/( M2112"NN#3R+FUCO"7G[GP%: &K)S8!OMCAT)/3))Z-*Z'F?M0;#%DNIM--(!N&[(:L7,U1ZQ;,FG8%R!X+DN M?""_( 9R$SP*SE5TQ&3KI[/':!EW;GVU"IEM310 MO%6@0DTO"^*(:5=8UHJ+YBFTYZGJ#U2[Z/\96.VIC [@=<]\O_KU"J?IV_